PROGRAM

2015 

19th Annual Scientific Assembly 

PROGRAM 

September 26 – 29, 2015 

Gaylord National Harbor • National Harbor, Maryland 

Sessions Begin Saturday morning at 10:30am

NEW 

Add Corlanor ® to maximally tolerated doses of beta-blockers and help 

give appropriate patients with stable, symptomatic chronic heart failure... 

MORE HOME. LESS HOSPITAL. 

Learn how you can DO MORE with Corlanor ® to reduce the risk 

of hospitalization for worsening heart failure 1 

CorlanorHCP.com 

Indication 

Corlanor ® (ivabradine) is indicated to reduce the risk of hospitalization 

for worsening heart failure in patients with stable, symptomatic 

chronic heart failure with left ventricular ejection fraction ≤ 35%, who 

are in sinus rhythm with resting heart rate ≥ 70 beats per minute and 

either are on maximally tolerated doses of beta-blockers or have a 

contraindication to beta-blocker use. 

Important Safety Information 

Contraindications: Corlanor ® is contraindicated in patients with 

acute decompensated heart failure, blood pressure < 90/50 mmHg, 

sick sinus syndrome, sinoatrial block, 3 rd degree atrioventricular 

block (unless a functioning demand pacemaker is present), a resting 

heart rate < 60 bpm prior to treatment, severe hepatic impairment, 

pacemaker dependence (heart rate maintained exclusively by the 

pacemaker), and concomitant use of strong cytochrome P450 3A4 

(CYP3A4) inhibitors. 

Fetal Toxicity: Corlanor ® may cause fetal toxicity when administered 

to a pregnant woman based on embryo-fetal toxicity and cardiac 

teratogenic effects observed in animal studies. Advise females to use 

effective contraception when taking Corlanor ® . 

Atrial Fibrillation: Corlanor ® increases the risk of atrial fibrillation. 

The rate of atrial fibrillation in patients treated with Corlanor ® 

compared to placebo was 5% vs. 3.9% per patient-year, respectively. 

Regularly monitor cardiac rhythm. Discontinue Corlanor ® if atrial 

fibrillation develops. 

Bradycardia and Conduction Disturbances: Bradycardia, sinus 

arrest and heart block have occurred with Corlanor ® . The rate of 

bradycardia in patients treated with Corlanor ® compared to placebo 

was 6% (2.7% symptomatic; 3.4% asymptomatic) vs. 1.3% per 

patient-year, respectively. Risk factors for bradycardia include sinus 

node dysfunction, conduction defects, ventricular dyssynchrony, and 

use of other negative chronotropes. Concurrent use of verapamil or 

diltiazem also increases Corlanor ® exposure, contributes to heart rate 

lowering, and should be avoided. Avoid use of Corlanor ® in patients 

with 2 nd degree atrioventricular block unless a functioning demand 

pacemaker is present. 

Adverse Reactions: The most common adverse reactions reported 

at least 1% more frequently with Corlanor ® than placebo and that 

occurred in more than 1% of patients treated with Corlanor ® were 

bradycardia (10% vs. 2.2%), hypertension or increased blood pressure 

(8.9% vs. 7.8%), atrial fibrillation (8.3% vs. 6.6%), and luminous 

phenomena (phosphenes) or visual brightness (2.8% vs. 0.5%). 

Please see Brief Summary of full Prescribing Information 

on adjacent page. 

Reference: 1. Corlanor ® (ivabradine) Prescribing Information, Amgen. 

© 2015 Amgen Inc. All rights reserved. Not for reproduction. USA-998-106020

Corlanor ® (ivabradine) 

BRIEF SUMMARY OF PRESCRIBING INFORMATION 

Please see package insert for full Prescribing Information 

1. INDICATIONS AND USAGE 

Corlanor is indicated to reduce the risk of hospitalization for 

worsening heart failure in patients with stable, symptomatic 

chronic heart failure with left ventricular ejection fraction 

≤ 35%, who are in sinus rhythm with resting heart rate ≥ 70 

beats per minute and either are on maximally tolerated doses 

of beta-blockers or have a contraindication to beta-blocker use. 

4. CONTRAINDICATIONS 

Corlanor is contraindicated in patients with: 

• Acute decompensated heart failure 

• Blood pressure less than 90/50 mmHg 

• Sick sinus syndrome, sinoatrial block, or 3 rd degree AV block, 

unless a functioning demand pacemaker is present 

• Resting heart rate less than 60 bpm prior to treatment [see 

Warnings and Precautions (5.3)] 

• Severe hepatic impairment [see Use in Specific Populations 

(8.6)] 

• Pacemaker dependence (heart rate maintained exclusively by 

the pacemaker) [see Drug Interactions (7.3)] 

• Concomitant use of strong cytochrome P450 3A4 

(CYP3A4) inhibitors [see Drug Interactions (7.1)] 

5. WARNINGS AND PRECAUTIONS 

5.1 Fetal Toxicity 

Corlanor may cause fetal toxicity when administered to a pregnant 

woman based on findings in animal studies. Embryo-fetal toxicity 

and cardiac teratogenic effects were observed in fetuses of 

pregnant rats treated during organogenesis at exposures 1 

to 3 times the human exposures (AUC 0-24hr ) at the maximum 

recommended human dose (MRHD) [see Use in Specific 

Populations (8.1)]. Advise females to use effective contraception 

when taking Corlanor [see Use in Specific Populations (8.3)]. 

5.2 Atrial Fibrillation 

Corlanor increases the risk of atrial fibrillation. In SHIFT, the rate 

of atrial fibrillation was 5.0% per patient-year in patients treated 

with Corlanor and 3.9% per patient-year in patients treated with 

placebo [see Clinical Studies (14)]. Regularly monitor cardiac 

rhythm. Discontinue Corlanor if atrial fibrillation develops. 

5.3 Bradycardia and Conduction Disturbances 

Bradycardia, sinus arrest, and heart block have occurred 

with Corlanor. The rate of bradycardia was 6.0% per patientyear 

in patients treated with Corlanor (2.7% symptomatic; 

3.4% asymptomatic) and 1.3% per patient-year in patients 

treated with placebo. Risk factors for bradycardia include 

sinus node dysfunction, conduction defects (e.g., 1 st or 2 nd 

degree atrioventricular block, bundle branch block), ventricular 

dyssynchrony, and use of other negative chronotropes (e.g., 

digoxin, diltiazem, verapamil, amiodarone). Concurrent use 

of verapamil or diltiazem will increase Corlanor exposure, 

may themselves contribute to heart rate lowering, and should 

be avoided [see Clinical Pharmacology (12.3)]. Avoid use of 

Corlanor in patients with 2 nd degree atrioventricular block, 

unless a functioning demand pacemaker is present [see 

Contraindications (4) and Dosage and Administration (2)]. 

6. ADVERSE REACTIONS 

Clinically significant adverse reactions that appear in other 

sections of the labeling include: 

• Fetal Toxicity [see Warnings and Precautions (5.1)] 

• Atrial Fibrillation [see Warnings and Precautions (5.2)] 

• Bradycardia and Conduction Disturbances [see Warnings and 

Precautions (5.3)] 

6.1 Clinical Trials Experience 

Because clinical trials are conducted under widely varying 

conditions, adverse reaction rates observed in the clinical trials of 

a drug cannot be directly compared to rates in the clinical trials of 

another drug and may not reflect the rates observed in practice. 

In the Systolic Heart failure treatment with the I f inhibitor 

ivabradine Trial (SHIFT), safety was evaluated in 3260 patients 

treated with Corlanor and 3278 patients given placebo. The 

median duration of Corlanor exposure was 21.5 months. 

The most common adverse drug reactions in the SHIFT trial are 

shown in Table 2 [see also Warnings and Precautions (5.2), (5.3)]. 

Table 2. Adverse Drug Reactions with Rates ≥ 1.0% Higher 

on Ivabradine than Placebo occurring in > 1% on ivabradine 

in SHIFT 

Ivabradine 

N=3260 

Placebo 

N=3278 

Bradycardia 10% 2.2% 

Hypertension, blood 

pressure increased 

8.9% 7.8% 

Atrial fibrillation 8.3% 6.6% 

Phosphenes, visual 

brightness 

2.8% 0.5% 

Luminous Phenomena (Phosphenes) 

Phosphenes are phenomena described as a transiently 

enhanced brightness in a limited area of the visual field, halos, 

image decomposition (stroboscopic or kaleidoscopic effects), 

colored bright lights, or multiple images (retinal persistency). 

Phosphenes are usually triggered by sudden variations in 

light intensity. Corlanor can cause phosphenes, thought to be 

mediated through Corlanor’s effects on retinal photoreceptors 

[see Clinical Pharmacology (12.1)]. Onset is generally within 

the first 2 months of treatment, after which they may occur 

repeatedly. Phosphenes were generally reported to be of mild to 

moderate intensity and led to treatment discontinuation in < 1% 

of patients; most resolved during or after treatment. 

6.2 Postmarketing Experience 

Because these reactions are reported voluntarily from a 

population of uncertain size, it is not always possible to 

estimate their frequency reliably or establish a causal 

relationship to drug exposure. 

The following adverse reactions have been identified during 

post-approval use of Corlanor: syncope, hypotension, 

angioedema, erythema, rash, pruritus, urticaria, vertigo, 

diplopia, and visual impairment. 

7. DRUG INTERACTIONS 

7.1 Cytochrome P450-Based Interactions 

Corlanor is primarily metabolized by CYP3A4. Concomitant 

use of CYP3A4 inhibitors increases ivabradine plasma 

concentrations, and use of CYP3A4 inducers decreases them. 

Increased plasma concentrations may exacerbate bradycardia 

and conduction disturbances. 

The concomitant use of strong CYP3A4 inhibitors is 

contraindicated [see Contraindications (4) and Clinical 

Pharmacology (12.3)]. Examples of strong CYP3A4 inhibitors 

include azole antifungals (e.g., itraconazole), macrolide 

antibiotics (e.g., clarithromycin, telithromycin), HIV protease 

inhibitors (e.g., nelfinavir), and nefazodone. 

Avoid concomitant use of moderate CYP3A4 inhibitors when 

using Corlanor. Examples of moderate CYP3A4 inhibitors 

include diltiazem, verapamil, and grapefruit juice [see Warnings 

and Precautions (5.3) and Clinical Pharmacology (12.3)]. 

Avoid concomitant use of CYP3A4 inducers when using 

Corlanor. Examples of CYP3A4 inducers include St. John’s 

wort, rifampicin, barbiturates, and phenytoin [see Clinical 

Pharmacology (12.3)]. 

7.2 Negative Chronotropes 

Most patients receiving Corlanor will also be treated with a betablocker. 

The risk of bradycardia increases with concomitant 

administration of drugs that slow heart rate (e.g., digoxin, 

amiodarone, beta-blockers). Monitor heart rate in patients 

taking Corlanor with other negative chronotropes. 

7.3 Pacemakers 

Corlanor dosing is based on heart rate reduction, targeting 

a heart rate of 50 to 60 beats per minute [see Dosage and 

Administration (2)]. Patients with demand pacemakers set to 

a rate ≥ 60 beats per minute cannot achieve a target heart rate 

< 60 beats per minute, and these patients were excluded from 

clinical trials [see Clinical Studies (14)]. The use of Corlanor is 

not recommended in patients with demand pacemakers set to 

rates ≥ 60 beats per minute. 

8. USE IN SPECIFIC POPULATIONS 

8.1 Pregnancy 

Risk Summary 

Based on findings in animals, Corlanor may cause fetal harm 

when administered to a pregnant woman. There are no 

adequate and well-controlled studies of Corlanor in pregnant 

women to inform any drug-associated risks. In animal 

reproduction studies, oral administration of ivabradine to 

pregnant rats during organogenesis at a dosage providing 1 to 

3 times the human exposure (AUC 0-24hr ) at the MRHD resulted in 

embryo-fetal toxicity and teratogenicity manifested as abnormal 

shape of the heart, interventricular septal defect, and complex 

anomalies of primary arteries. Increased postnatal mortality was 

associated with these teratogenic effects in rats. In pregnant 

rabbits, increased post-implantation loss was noted at an 

exposure (AUC 0-24hr ) 5 times the human exposure at the MRHD. 

Lower doses were not tested in rabbits. The background risk 

of major birth defects for the indicated population is unknown. 

The estimated background risk of major birth defects in the U.S. 

general population is 2 to 4%, however, and the estimated risk 

of miscarriage is 15 to 20% in clinically recognized pregnancies. 

Advise a pregnant woman of the potential risk to the fetus. 

Clinical Considerations 

Disease-associated maternal and/or embryo/fetal risk 

Stroke volume and heart rate increase during pregnancy, 

increasing cardiac output, especially during the first trimester. 

Pregnant patients with left ventricular ejection fraction less 

than 35% on maximally tolerated doses of beta-blockers may 

be particularly heart-rate dependent for augmenting cardiac 

output. Therefore, pregnant patients who are started on 

Corlanor, especially during the first trimester, should be followed 

closely for destabilization of their congestive heart failure that 

could result from heart rate slowing. 

© 2015 Amgen Inc. All rights reserved. Not for reproduction. USA-998-106020, v2 05/15 

Monitor pregnant women with chronic heart failure in 3 rd 

trimester of pregnancy for preterm birth. 

Data 

Animal Data 

In pregnant rats, oral administration of ivabradine during 

the period of organogenesis (gestation day 6-15) at doses of 

2.3, 4.6, 9.3, or 19 mg/kg/day resulted in fetal toxicity and 

teratogenic effects. Increased intrauterine and post-natal 

mortality and cardiac malformations were observed at doses 

≥ 2.3 mg/kg/day (equivalent to the human exposure at the MRHD 

based on AUC 0-24hr ). Teratogenic effects including interventricular 

septal defect and complex anomalies of major arteries were 

observed at doses ≥ 4.6 mg/kg/day (approximately 3 times the 

human exposure at the MRHD based on AUC 0-24hr ). 

In pregnant rabbits, oral administration of ivabradine during the 

period of organogenesis (gestation day 6-18) at doses of 7, 14, 

or 28 mg/kg/day resulted in fetal toxicity and teratogenicity. 

Treatment with all doses ≥ 7 mg/kg/day (equivalent to the 

human exposure at the MRHD based on AUC 0-24hr ) caused an 

increase in post-implantation loss. At the high dose of 28 mg/kg/ 

day (approximately 15 times the human exposure at the MRHD 

based on AUC 0-24hr ), reduced fetal and placental weights were 

observed, and evidence of teratogenicity (ectrodactylia observed 

in 2 of 148 fetuses from 2 of 18 litters) was demonstrated. 

In the pre- and postnatal study, pregnant rats received 

oral administration of ivabradine at doses of 2.5, 7, or 

20 mg/kg/day from gestation day 6 to lactation day 20. Increased 

postnatal mortality associated with cardiac teratogenic findings 

was observed in the F1 pups delivered by dams treated at the 

high dose (approximately 15 times the human exposure at the 

MRHD based on AUC 0-24hr ). 

8.2 Lactation 

Risk Summary 

There is no information regarding the presence of ivabradine in 

human milk, the effects of ivabradine on the breastfed infant, or 

the effects of the drug on milk production. Animal studies have 

shown, however, that ivabradine is present in rat milk [see Data]. 

Because of the potential risk to breastfed infants from exposure 

to Corlanor, breastfeeding is not recommended. 

Data 

Lactating rats received daily oral doses of [ 14 C]-ivabradine 

(7 mg/kg) on post-parturition days 10 to 14; milk and maternal 

plasma were collected at 0.5 and 2.5 hours post-dose on 

day 14. The ratios of total radioactivity associated with [ 14 C]- 

ivabradine or its metabolites in milk vs. plasma were 1.5 and 

1.8, respectively, indicating that ivabradine is transferred to milk 

after oral administration. 

8.3 Females and Males of Reproductive Potential 

Contraception 

Females 

Corlanor may cause fetal harm, based on animal data. Advise 

females of reproductive potential to use effective contraception 

during Corlanor treatment [see Use in Specific Populations (8.1)]. 

8.4 Pediatric Use 

Safety and effectiveness in pediatric patients have not been 

established. 

8.5 Geriatric Use 

No pharmacokinetic differences have been observed in elderly 

(≥ 65 years) or very elderly (≥ 75 years) patients compared to 

the overall population. However, Corlanor has only been studied 

in a limited number of patients ≥ 75 years of age. 

8.6 Hepatic Impairment 

No dose adjustment is required in patients with mild or moderate 

hepatic impairment. Corlanor is contraindicated in patients with 

severe hepatic impairment (Child-Pugh C) as it has not been studied 

in this population and an increase in systemic exposure is anticipated 

[see Contraindications (4) and Clinical Pharmacology (12.3)]. 

8.7 Renal Impairment 

No dosage adjustment is required for patients with creatinine 

clearance 15 to 60 mL/min. No data are available for patients 

with creatinine clearance below 15 mL/min [see Clinical 

Pharmacology (12.3)]. 

10. OVERDOSAGE 

Overdose may lead to severe and prolonged bradycardia. In 

the event of bradycardia with poor hemodynamic tolerance, 

temporary cardiac pacing may be required. Supportive treatment, 

including intravenous (IV) fluids, atropine, and intravenous betastimulating 

agents such as isoproterenol, may be considered. 

This Brief Summary is based on the Corlanor ® Prescribing 

Information v1, 04/15 

Corlanor ® (ivabradine) 

Manufactured for: Amgen Inc. 

One Amgen Center Drive 

Thousand Oaks, California 91320-1799 

Patent: http://pat.amgen.com/Corlanor/

2015 HFSA ANNUAL SCIENTIFIC MEETING 

Table of Contents 

President’s Message ..................................................................................5 

About the HFSA ........................................................................................7 

Executive Council ......................................................................................8 

Scientific Program Committee .................................................................. 8 

General Meeting Information .....................................................................9 

Business Meeting .................................................................................... 10 

Scientific Meeting and Satellite Supporters ............................................. 12 

Continuing Education Information .......................................................... 13 

Speaker Disclosure Information .............................................................. 13 

Scientific Program Learning Objectives ..................................................14 

Abstract Reviewers ..................................................................................16 

Scientific Program and Satellite Symposium Faculty ..............................17 

Program-at-a-Glance ................................................................................22 

Special Events and Activities in the Exhibit Hall .....................................26 

Award Listing………………………………….. .....................................27 

Saturday, September 26 

Scientific Sessions and Satellite Symposia ...............................................29 

Sunday, September 27 

Satellite Symposia ....................................................................................35 

Morning Scientific Program .....................................................................36 

Noon Hour Activities ...............................................................................39 

Afternoon Scientific Program ..................................................................42 

Monday, September 28 

Satellite Symposia ................................................................................... 46 

Award Sessions……. .............................................................................. 48 

Scientific Program ................................................................................... 49 

Tuesday, September 29 

Scientific Program ................................................................................... 60 

Posters 

Poster Reception I - Saturday Poster Presenters………………........…….…65 

Poster Reception II - Sunday Poster Presenters…………….......…………..83 

Exhibit Hall 

Industry Expert Theaters ....................................................................... 100 

Clinical Trial Row ..................................................................................102 

List of Exhibitors ................................................................................ ...107 

Exhibit Hall Floor Plan .......................................................................... 108 

Exhibitor Descriptions ........................................................................... 109 

Speaker/Author Index ............................................................................ 117 

Gaylord National Harbor Meeting Rooms Floor Plan ........................... 132 

Notes ............................................................................................... ...... 135 

Dates to Remember ............................................................................... 138 

SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND 

4


President’s Message 

Dear Colleagues, 

Welcome to the 19th Annual Heart Failure Society of America Scientific Meeting. The HFSA 

Strategic Plan has articulated that our core purpose is to reduce the burden of heart failure to 

patients and society through prevention, treatment, and discovery. We have made major strides 

in this purpose in 2015. Following our core values of excellence, multidisciplinary endeavors, 

inclusiveness, integrity, innovation, and collaboration, we have continued to improve the things 

we did well and have begun a number of new initiatives. 

1. HFSA Annual Scientific Meeting. We offer thanks to the Program Committee Chairs— 

Gregg Fonarow, MD, Debra Moser, DNSc, RN, Mona Fiuzat, PharmD, and John Burnett, Jr., 

MD, who have done a great job in making the program both exciting and comprehensive. This 

year’s program has 75 educational sessions, 280 faculty, 350 posters, and nearly 50 exhibitors, 

with an anticipated attendance of more than 1,800 heart failure specialists. The program 

reflects the excitement for new medical and device therapies that have been approved in the past 

year, and is designed to provide up-to-date summaries of new therapies as well as to stimulate 

discussion. We have added a PharmD chair to the program committee to reflect the important 

contributions of Pharmacy to the practice of Heart Failure and Transplantation. The entire Program 

Committee membership also reflects the HFSA goal to include and encourage young heart 

failure practitioners in both clinical activity and research, and we give many thanks to the entire 

committee for your hard work. 

2. Publication of the Journal of Cardiac Failure and eleven education modules providing 

practical information on specific topics that are useful to patients and their families in the care 

and treatment of those with heart failure. We thank Gary Francis, MD for his outstanding work 

as the recent Editor of JCF and welcome Paul J. Hauptman, MD as our new Editor. Paul has 

an exciting vision for the journal and he encourages your ideas and contributions to JCF, and 

would love to consider your state of the art manuscripts for publication. The next iteration of 

Heart Failure Practice guidelines will be ACC/AHA/HFSA Heart Failure Guidelines and will be 

published simultaneously in JACC, Circulation, and JCF. 

3. Comprehensive Heart Failure Review Course. The Heart Failure Board Review Course 

alternates every other year with a Heart Failure Review Course with the Board Review Course 

held the year of the Advanced Heart Failure and Transplantation American Board of Internal 

Medicine Examination. The 2015 Comprehensive Heart Failure Review and Update is scheduled 

for October 22-25, 2015 in Tampa, Florida. The 2015 HF Review Course is designed 

by and for cardiologists, internists, nurses, clinical pharmacists and other health professionals 

with a special interest in heart failure. Thanks go to Barry Greenberg, MD for his long-term 

leadership spearheading this state of the art program and to his co-chairs, J. Herbert Patterson, 

PharmD and Sara C. Paul, DNP, FNP for their work in planning this year’s course. 

4. Successful Advocacy Efforts resulting in the approval of a Medicare payment reform bill 

that includes the repeal of the flawed Sustainable Growth Rate (SGR) Formula. The Advocacy 

Committee under Joe Hill’s leadership has been instrumental in the approval of HFSA’s request 

for a provider taxonomy code to designate specialists in advanced heart failure and transplant 

cardiology by the National Uniform Claim Committee (NUCC). The taxonomy code was 

approved July 1, 2015 and will be effective on October 1, 2015. See HFSA’s website for more 

information. 


5


5. Continued Research and Travel Grant Awards 

Many thanks to Medtronic for allowing HFSA to award research funds to fellows for important 

research, project assistance and travel grants. With these funds, many more Early Career heart 

failure fellows will have new opportunities to pursue their research and to attend the HFSA 

Annual Meeting and Review course. Additionally, two grants made possible by St. Jude Medical 

are available for specific research on implantable devices. See the HFSA website for more 

information. 

6. Launch of HFSA’s Quality Care Initiative – This is a multi-organizational effort to identify 

and establish benchmarks to improve the standards of quality care for those impacted by heart 

failure. The first collaboration of this kind included 18 associations involved in heart failure. 

Thanks to our founding partner, AMGEN and Silver level partner, Bayer, for their sponsorship 

of this important endeavor. Paul Heidenreich, MD and Nancy Albert, PhD, CNS chaired this 

one day symposium, which was designed to improve quality of care for heart failure patients 

through a collaborative effort. The first meeting was held in Chicago in June and four projects 

have been developed. We will be publishing a white paper early next year as the first step in 

this important initiative. Please read the HFSA Press Release HFSA Says Heart Failure is Not 

an Option for more information. 

7. Development of Patient Health Fair Day in collaboration with the American Association 

of Heart Failure Nurses (AAHFN). Patient Health Fair Days are being developed to improve 

the health and well-being of the heart failure community by connecting patients and caregivers 

to multi-disciplinary heart failure experts and resources. In collaboration with the AAHFN, the 

HFSA will host the first biannual “Patient Day” in advance of our scientific sessions. These 

meetings will be held in advance of HFSA and the AAHFN annual meetings and program 

materials will be designed to allow dissemination to our membership and will be available on 

our website. This year’s chairs are Shashank Desai, MD and Robin Trupp, PhD, ACNP-BC. 

“Patient Day” will be a five hour session for heart failure patients and their caregivers designed 

to give a broad overview of pathophysiology, standard heart failure care, and “what’s new in 

heart failure.” Patients and caregivers will be able to then select four of eight breakout sessions 

that will be designed to cover smaller topics such as diet, medications, participation in clinical 

trials, helpful tips for caregivers, and psychological aspects of heart failure. We hope to develop 

these programs for MendedHearts for presentation in their chapter meetings. Novartis will 

be awarding a national “Caregivers Award.” Thanks to St. Jude Medical, Novartis Pharmaceuticals 

Corporation and Amgen for supporting this important program for patients. 

8. Development of the HFSA Fellows Designation (to be announced at this meeting) to recognize 

significant contributions to the field of heart failure. Designation will be available to members 

who meet the criteria and have maintained continuous membership for two or more years. 

I would like to also thank Michele Blair, CEO of HFSA for her outstanding work in leading our 

organization to financial stability and for creating the organizational stability that allows all of 

these things to happen. 

Thanks so much for attending the meeting. We would love to hear your thoughts if you have 

ideas for new programs or for improvements to old ones. We are excited about this meeting and 

about the future of the HFSA in providing leadership for the care of patients with heart failure. 

Sincerely, 

JoAnn Lindenfeld, MD 


6


About the HFSA 

The Heart Failure Society of America (HFSA) represents the first organized effort by heart 

failure experts from the Americas to provide a forum for all those interested in heart failure 

research and patient care. 

The HFSA is dedicated to: 

Promoting research related to all aspects of heart failure and to providing a forum for presentation 

of basic, clinical and population-based research. 

Educating health care professionals through programs, publications, and other media in the 

areas of basic science, clinical medicine, patient management, and social, ethical and economic 

issues to enable them to diagnose and treat heart failure and concomitant medical conditions 

more effectively. 

Encouraging primary and secondary preventive measures to reduce the incidence of heart 

failure; serving as a resource for government, private industry, and health care providers to 

facilitate the establishment of programs and policies that will better serve the patient. 

Enhancing quality and duration of life in those with heart failure. 

Promoting and facilitating the formal training of physicians, scientists and allied health care 

providers in the field of heart failure. 

Society Membership Information 

Membership in the Society is open to all health care professionals with an interest in cardiovascular 

medicine. 

For information about the HFSA or to become a member, call or write: 

Heart Failure Society of America, Inc. 

6707 Democracy Blvd., Suite 925 

Bethesda, MD 20817 

Phone: 301-312-8635 

Fax: 888-213-4417 

E-mail: info@hfsa.org 

Interested participants can also visit the HFSA booth located near the Maryland C meeting 

room or visit the HFSA web site at www.hfsa.org 


7


Executive Council 

JoAnn Lindenfeld, MD - President 

Mandeep R. Mehra, MD - Vice President 

Christopher M. O'Connor, MD, FACC - Treasurer 

Sara C. Paul, DNP, FNP - Secretary 

Thomas Force, MD - Immediate Past President 

Jonathan D. Rich, MD 

Jonathan Howlett, MD, FACC 

Biykem Bozkurt, MD, PhD 

Corrine Y. Jurgens, RN, PhD 

Heather J. Ross, MD 

James E. Udelson, MD 

Javed Butler, MD, MPH 

John C. Burnett Jr., MD 

John R. Teerlink , MD 

Joseph A. Hill, MD, PhD 

Nancy M. Albert, PhD, CHFN 

Paul J. Mather, MD 

Sharon A. Hunt, MD, MACC 

Steven R. Houser, PhD 

Susan E. Ammon, NP-C, CHFN 

Jay N. Cohn, MD, MACP 

Monica R. Shah, MD 

Journal of Cardiac Failure 

Paul Hauptman, MD 

2015 Annual Meeting Program Committee 

Co-Chairs: 

John C. Burnett, Jr., MD 

Mona Fiuzat, PharmD 

Gregg Fonarow, MD 

Debra Moser, DNSc, RN 

Members 

Larry Allen, MD, MHS 

Amrut V. Ambardekar, MD 

Barry A. Borlaug, MD 


Sheryl L. Chow, PharmD 

Patricia M. Davidson, PhD, MEd, RN, FAAN 

Victoria Vaughan Dickson, RN, PhD 

Mark Drazner, MD, MSc 

Peter M. Eckman, MD 

James C. Fang, MD 

Adrian F. Hernandez, MD 

James Louis Januzzi, MD 

Mariell Jessup, MD 

David A. Kass, MD 

Terry A. Lennie, PhD 

W. Robb MacLellan, MD 

Kenneth B. Margulies, MD 

Gina Mentzer, MD 

Shawn M. Merhaut, MSN, CNP 

Christopher Newton-Cheh, MD, MPH 

Peter S. Pang, MD 

Lisa D. Rathman, MSN, CRNP 

Joseph G. Rogers, MD 

Douglas B. Sawyer, MD, PhD 

Sanjiv J. Shah, MD 

Julie A. Shinn, MA 

Jeffrey M. Testani, MD, MTR 

Orly Vardeny, PharmD 

David J. Whellan, MD, MHS 

Clyde W. Yancy, MD, MSc 

The Program Chairs and members of the 2015 Scientific 

Program Committee wish to thank all members, past attendees, 

and others who submitted session proposals for this year's 

meeting. All were given serious consideration, and many were 

included, whole or in part, in the final program. In part, as a 

result of these proposals, many new speakers will be featured 

in this year's meeting. A call for proposals for 2016 will go 

out in October. 


8

General Meeting Information 

Meeting Location 


All meeting activities will be held in the Gaylord National Harbor Convention Center and Hotel. See page 132 for a floor 

plan of meeting rooms. 

CME Accreditation/Registration 

Heart Failure Society of America 

6707 Democracy Blvd. 

Suite 925 


Phone: 301-312-8635 

Fax: 888-213-4417 

Email: info@hfsa.org 

Registration Hours 

Friday, September 25.........................12:00 PM – 5:00 PM 

Saturday, September 26.......................7:00 AM – 5:00 PM 

Sunday, September 27.........................7:00 AM – 5:00 PM 

Monday, September 28........................7:00 AM – 5:00 PM 

Tuesday, September 29........................7:00 AM – 10:00 AM 

Included in Registration Fee 

The registration fee includes meeting materials, admission to scientific sessions, satellite symposia, receptions (some invitation 

only), exhibits and activities in the Exhibit Hall, and complimentary food events. 

Meeting Sessions Online 

In response to requests from previous attendees, HFSA will provide the scientific sessions online free-of-charge for 2015 

meeting attendees for 30 days following the meeting. Sessions also will be available for purchase for reference throughout 

the year. See the Sessions OnDemand desk located outside the Exhibit Hall. 

Opening Reception 

The opening reception (wine and hors d’ oeuvres) is Saturday, September 26, 6:00 – 8:00 PM in the Exhibit Hall (Prince 

George’s Exhibit Hall B&C). 


9


General Meeting Information (continued) 

Poster Receptions 

The first Poster Reception will be held in the Exhibit Hall in conjunction with the opening reception, Saturday evening, 

6:00 – 8:00 PM. The reception will take place from 6:00-8:00pm with posters presented from 6:30 - 7:30pm. The second 

will be on Sunday in the Exhibit Hall following Sessions. The reception will take place from 5:15 pm - 6:30 pm with posters 

presented from 5:30 pm - 6:30 pm. There will be no reception Monday. 

Food Policy 

The Physician Payment Sunshine Act, part of the Affordable Care Act, requires that manufacturers of drugs and devices 

report to CMS certain payments and items of value given to physicians. These items of value include meals at CME activities, 

such as this annual meeting. For this reason, the following food and refreshments provided at the 2015 HFSA Annual 

Scientific Meeting will be paid for out of registration fees and the HFSA operating budget: the opening reception, the poster 

receptions, early morning refreshments, and coffee breaks. 

No Smoking Policy 

HFSA and The Gaylord National Harbor prohibit smoking in all meeting and hotel areas. Thank you for your cooperation. 

Video/Photography Policy 

HFSA staff members, as well as official HFSA photographers/videographers, are the only ones authorized to photograph 

and film events and educational sessions throughout the Annual Scientific meeting and will be identified by name badges. 

The photographs and videos taken at the HFSA Annual Scientific Meeting are used exclusively by HFSA for promotional 

purposes and continuing education offerings. They may be used in the association’s publications or on its Web site, and they 

may appear in programs or other HFSA promotional materials. 

If you are at an event or session at which an HFSA photographer is present and you do not wish to be photographed, please 

identify yourself to the photographer and your request will be respected. 

Special Needs 

The HFSA strives to hold meetings that are accessible to all. Please let us know if you have special needs. Contact Nikki 

Ahmetaj, Global Meetings and Incentives at nikki@gmimeetings.com (908)-358-3082 

Annual Business Meeting 

The annual business meeting is scheduled for 7:30 AM Tuesday in Chesapeake L. 


10



Questions 

There will be an information booth staffed by HFSA in the Maryland Hallway. Please visit the HFSA booth with conference, membership 

or resource related questions. Questions about the local area, restaurants or travel should be addressed with the hotel front 

desk or concierge. Tickets for the Faculty and Fundraising dinner may be purchased at the Onsite Registration Counter outside 

Prince George’s Exhibit Hall B&C. 

Speaker Ready Room – Chesapeake F 

Saturday, September 26........................8:00 AM – 6:00 PM 

Sunday, September 27..........................6:30 AM – 6:00 PM 

Monday, September 28.........................6:30 AM – 6:00 PM 

Tuesday, September 29.........................6:30 AM – 11:00 AM 

Press Room – Price George’s Exhibit Hall B Registration Office 

Saturday, September 26........................10:00 AM – 5:00 PM 

Sunday, September 27..........................10:00 AM – 5:00 PM 

Monday, September 28..........................7:00 AM – 5:00 PM 

Tuesday, September 29...........................7:00 AM – 11:00 AM 

All late breaking presentations embargoed until they have are presented. 

Exhibit Hall Schedule 

Please visit our exhibitors and thank them for supporting the HFSA Annual Scientific Meeting. Exhibits are located in the 

Prince George’s B&C Exhibit Hall. See page 107 for a list of exhibitors and locations. 

Saturday, September 26.........................6:00 PM – 8:00 PM 

Sunday September 27.........................10:00 AM – 6:30 PM 

Monday, September 28.......................10:00 AM – 2:00 PM 

Email from the Exhibit Hall 

Email stations will be located in the Exhibit Hall for attendees to check e-mail. 

There will be a cell phone charging station next to the email station and one by the HFSA Information booth. 

WiFi 

Complimentary WiFi is available in the hotel lobby and public areas. 


11



Poster Sessions 

Posters are displayed in the Exhibit Hall from 6:00 PM Saturday through 2:00 PM Monday. Presenters will be at their posters 

6:30-7:30 PM Saturday during the Opening Reception and 5:30-6:30 PM Sunday during the Poster Reception. Posters 

range from basic science topics to clinical and outcomes studies. They represent some of the newest work being done in the 

field on heart failure. Please take advantage of this opportunity to see interesting work and to encourage new investigators. 

New this year: All posters will be presented during the times the exhibit hall is open. 

Posters on display: 

Saturday, September 26...................6:00 PM – 8:00 PM 

Sunday, September 27...................10:00 AM – 6:30 PM 

Monday, September 28 .................10:00 AM - 1:30 PM 

Presenters at their posters: 

Saturday, September 26...................6:30-7:30 PM 

Sunday, September 27.....................5:30-6:30 PM 

2015 HFSA Satellite/Scientific Program Supporting Companies 

CME Satellite Symposia: Meeting Supporters: Advertisers: 

Amgen Arbor Pharmaceuticals, LLC Amgen 

Arbor Pharmaceuticals, LLC Cytokinetics Cytokinetics 

ReardenCME Medtronic Novartis Pharmaceuticals Corporation 

Relypsa, Inc Novartis Pharmaceuticals Corporation Roche 

ResMed St. Jude Medical scPharmaceuticals 

St. Jude Medical Thoratec Corporation Thoratec Corporation 

ZS Pharma 

Hands-on Workshops: Non-CME Industry Corporate Members: 

Abiomed Expert Theaters: Amgen 

Biotronik Amgen Bayer 

Boston Scientific Novartis Pharmaceuticals Corporation Cytokinetics 

CardiacAssist Roche GE Healthcare 

HeartWare scPharmaceuticals Medtronic 

Maquet Thoratec Corporation Novartis Pharmaceuticals Corporation 

Medtronic 

St. Jude Medical 

Thoratec Corporation 

A Special Thank You: Thank you to WomenHeart, Mended Hearts, Heart Brothers and The National Minority Quality Forum 

for their work on heart failure initiatives and their collaboration with HFSA on improving quality care to patients. 


12


Continuing Education Credit Information 

Scientific Program 

Physicians: The Heart Failure Society of America is accredited by the Accreditation Council for Continuing Medical 

Education to provide continuing medical education for physicians. The Heart Failure Society of America designates this live 

activity for a maximum of 24.5 AMA PRA Category 1 Credits. 

Nurses: This Program Has Been Approved by the American Association of Critical Care Nurses (AACN) for a total of 

23.25 Contact Hours, File Number 00019357. 

Pharmacists: The CU Skaggs School of Pharmacy and Pharmaceutical Sciences is accredited by the Accreditation 

Council for Pharmacy Education as a provider of continuing pharmacy education (CPE). This program has been 

accredited for 24.25 contact hours of knowledge-based CPE, and pharmacists may earn up to 18.75 hours of credit 

due to concurrent presentations. To earn credit, participants must complete all online evaluations for programs 

attended and provide their NABP eProfile ID number and month and day of their birthdate. CE credit will be uploaded to 

CPE monitor within 60 days. 

Clinical Fundamentals I: The Immune Response in Cardiovascular Disease - 0008-9999-15-083-L01-P, Transitions in Heart 

Failure Care: It's Not Just About Hospital to Home - 0008-9999-15-084-L01-P, The Prevention of Heart Failure: Targets and 

Strategies - 0008-9999-15-085-L01-P, Excellence in Translational Science: Bench to Bedside - 0008-9999-15-086-L01-P, 

New Concepts in the Pathophysiology of HFpEF - 0008-9999-15-088-L01-P, How to Troubleshoot a VAD - 

0008-9999-15-089-L01-P, Guideline Session: Unique Heart Failure Populations: What Makes Them "Special"? - 

0008-9999-15-090-L01-P, Managing VAD Complications - 0008-9999-15-091-L01-P, Clinical Fundamentals II: FAQs 

About Heart Failure Drug Therapy - 0008-9999-15-092-L01-P, Putting the "Self" Back in Self-Care: Innovative Strategies 

to Improve Heart Failure Self-Care - 0008-9999-15-093-L01-P, Controversies in Cardio-oncology 0008-9999-15-094-L01-P, 

How to Manage Diuretic Resistance: What to Do When the Fluid Won't Come Off - 0008-9999-15-095-L01-P, What's New 

and Emerging in Heart Failure Pharmacology - 0008-9999-15-096-L01-P, Alternative Therapies for Heart Failure: Fact or 

Fiction? - 0008-9999-15-097-L01-P, Clinical Fundamentals III: Acute Heart Failure - 360 0008-9999-15-098-L01-P, Pharmacogenetics 

of Heart Failure and Transplant: Additive or Redundant - 0008-9999-15-098-L01-P 

Satellite Symposia 

Physicians: The Heart Failure Society of America is accredited by the Accreditation Council for Continuing Medical Education 

to provide continuing medical education for physicians. The Heart Failure Society of America designates each live 

activity for a maximum of 1.0/1.5 AMA PRA Category 1 Credits. 

Nurses: See satellite listings in this book or satellite handout materials for nursing credit statements. 

Presenter/Planner Disclosure Information 

The Heart Failure Society of America has a disclosure policy that requires oral presenters to disclose financial relationships 

with relevant commercial entities. 

Speaker disclosure information is available at http://www.hfsa.org/hfsa-wp/wp/disclosures2015/ Speakers also have a disclosure 

slide at the beginning of each presentation. 


13


Continuing Education Credit Information (continued) 

Scientific Program Learning Objectives 

Following this meeting, attendees will be able to: 

1. Describe the epidemiology of heart failure and implement strategies for the prevention of heart failure. 

2. Describe current knowledge about the scientific basis of heart failure. 

3. Identify the findings of basic science research and current clinical trials and describe their implications for 

current and future heart failure therapy. 

4. Implement optimal guideline-based therapeutic options for heart failure, including pharmacologic agents, non-pharmaco 

logic options, such as diet and exercise; and implantable devices. 

5. Manage comorbidities including hypertension, diabetes, depression, sleep apnea, and chemotherapy. 

6. Demonstrate awareness of psychosocial, economic, regulatory, and ethical issues in the treatment of patients with heart failure. 

7. Implement strategies for effective management of the patient with heart failure, incorporating the family, encouraging 

self-care, and employing the team approach. 

8. Outline strategies for transitioning patients from inpatient to outpatient care and for reducing hospital readmissions. 

9. Engage in performance measurement and other site-based research. 

10. Outline strategies for more effective communication with patients, families, and other health professionals. 

Specific learning objectives for the scientific session and satellite symposia are listed in the program book. 

Competencies Addressed 

The 2015 scientific program contains content that addresses the following ABMS core competencies: 

• Patient care 

• Medical knowledge 

• Interpersonal and communication skills 

• Professionalism 

• Systems-based practice 

Sessions also address the following ABIM-specified competency areas in advanced heart failure and transplant cardiology: 

• Epidemiology and risk factors 

• Pathophysiology of heart failure 

• Hemodynamics and hemodynamic monitoring 

• Heart failure and normal ejection fraction 

• Heart failure with renal dysfunction/cardiorenal syndrome 

• Diagnostic tests and procedures 

• Acute decompensation of chronic heart failure 

• Subsets of patients with heart failure, including women, the elderly, and different racial or ethnic groups 

• Heart failure comorbidities 

• Heart failure and pregnancy 

• Cardiomyopathies 

• Pharmacotherapy 

• Implantable devices 

• Heart transplant 

• Mechanical circulatory support 

• End-of-life issues 


14


Continuing Education Credit Information (continued) 

Evaluations 

An evaluation must be completed in order to receive a credit certificate for the scientific meeting or for satellite symposia. 

All evaluations will be electronic and will be formatted for smartphones, tablets and computers. They can also be accessed using 

the CE kiosks in the registration area. The evaluation form for the scientific program will be accessible during and after the meeting. 

Evaluations for satellites will be accessible after completion of each satellite. An email will be sent to attendees providing the 

website address to access evaluation forms and credit certificates. See more information about CE certificates elsewhere in this 

booklet. 

Pharmacists will be asked to complete a survey for each day of the meeting. Pharmacists who do not have the link to the surveys 

should check at the registration desk. For questions related to continuing pharmacy education, please call (303) 724-4298 or email 

sop.ContinuingEducation@ucdenver.edu 

Credit Certificates 

Physician and nursing continuing education credit certificates for the scientific meeting and for satellite symposia can be requested 

onsite using smartphones, tablets, computers or the CE kiosks in the registration area or after the meeting at the following site: 

http://ceu.experientevent.com/hfs151/. As noted above, evaluations must be completed before certificates will be issued. Certificates 

can be printed out or emailed. Pharmacists should follow ACPE procedures. For more information, go to www.hfsa.org 

under Annual Scientific Meeting > CE Credit Information. 

Certificates will be issued only to individuals registered for the annual meeting. If necessary, attendance will be verified based on information 

collected by hand-held scanners at meeting room entrances. CME credit cannot be earned with an exhibitor or guest badge. 

Meeting Content 

The 2015 HFSA Annual Scientific Meeting provides a forum for the open exchange and discussion of research results and scientific 

advancements in the field of heart failure; however, HFSA makes no representation or warranty as to the truth, originality, 

or accuracy of the information presented. Nor are the views expressed by the individual speakers necessarily the view of HFSA. 

HFSA supports the ACCME’s policy on evidence-based content and encourages faculty to adhere to these standards when preparing 

a presentation. 

Liability Statement 

Disclaimer: The Heart Failure Society of America (HFSA) cannot accept, and hereby specifically disclaims, any liability for 

death, injury, any loss, cost or expense suffered or incurred by any person if such loss is caused by, arises from or results from 

the act, default or omission of any person other than an employee or agent of HFSA. In particular, neither HFSA nor its agents 

can accept, and hereby specifically disclaims, any liability for losses arising from, caused by, or resulting from, the provision or 

non-provision of services provided by the hotels, companies, or transport operators. Neither HFSA nor its agents can accept, and 

hereby specifically disclaims, liability for losses suffered by reason of war including threat of war, riots and civil strife, terrorist 

activity, natural disaster, weather, fire, flood, drought, technical, mechanical or electrical breakdown within any premises visited 

by delegates and/or participants in connection with the meeting, industrial disputes, government action, regulations or technical 

problems that affect or may affect the services provided in connection with the meeting. HFSA is not able to warrant and does not 

warrant that a particular person will appear as a speaker. As a condition to any participation in or attendance at the Annual Scientific 

Meeting or any function associated or affiliated herewith, each attendee and participant accepts the foregoing disclaimer. 


15

2015 Abstract Reviewers 


Nancy Albert, RN, PhD 

Cleveland, OH 

Gregory Ewald, MD 

St. Louis, MO 

Stuart Katz, MD 

New York, NY 

Heather Ross, MD 

Toronto, ON 


Aurora, CO 

James Fang, MD 

Salt Lake City, UT 

Marvin Konstam, MD 

Boston, MA 

Stuart Russell, MD 

Baltimore, MD 

Amrut Ambardekar, MD 

Aurora, CO 

Gary Michael Felker, MD 

Durham, NC 

Maria Kontaridis, PhD 

Boston, MA 

Marc Semigran, MD 

Boston, MA 

Inder Anand, MD, PhD 

Minneapolis, MN 


Durham, NC 

David Lanfear, MD, MS 

Detroit, MI 

Sanjiv Shah, MD 

Chicago, IL 

Martha Biddle, PhD, APRN, CCNS 

Lexington, KY 


Los Angeles, CA 

Daniel Levine, MD 

Providence, RI 

Garrick Stewart, MD 

Boston, MA 

Burns Blaxall, PhD 

Cincinnati, OH 

Michael Givertz, MD 

Boston, MA 

Douglas Mann, MD 

St. Louis, MO 

Wilson Tang, MD 

Cleveland, OH 

Barry Borlaug, MD 

Rochester, MN 

Steven Goldman, MD 

Tucson, AZ 

Kenneth Margulies, MD 

Philadelphia, PA 

John Teerlink, MD 

San Francisco, CA 

Bikyem Bozkurt, MD, FACC 

Houston, TX 

Stephen Gottlieb, MD 

Baltimore, MD 

Paul Mather, MD 


Jeffrey Testani, MD 

New Haven, CT 

John Burnett Jr., MD 

Rochester, MN 

Barry Greenberg, MD 

La Jolla, CA 

Gina Mentzer, MD 

Lincoln, NE 

Jeffrey Teuteberg, MD 

Pittsburgh, PA 


Stony Brook, NY 

Roger Hajjar, MD 

New York, NY 

Shawn Merhaut, MSN, CNP 

Cleveland, OH 

James Udelson, MD 

Boston, MA 

Sheryl Chow, PharmD 

Pomona, CA 

Karol Harshaw-Ellis, MSN 

Durham, NC 

Leslie Miller, MD 

Tampa, FL 


Madison, WI 

Misook Chung, PhD 

Lexington, KY 

Akshay Desai, MD 

Boston, MA 

Anita Deswal, MD, MPH 

Houston, TX 

Victoria Vaughan Dickson, PhD, 

CRNP, MSN 

New York, NY 

Mark Drazner, MD 

Dallas, TX 

Shannon Dunlay, MD 

Rochester, MN 

Peter Eckman, MD 


Paul Heidenreich, MD, MS 

Palo Alto, CA 

J. Thomas Heywood, MD 

La Jolla, CA 

Tamara Horwich, MD, MS 


Sharon Hunt, MD 

Palo Alto, CA 

James Januzzi, MD 

Boston, MA 

Brian Jaski, MD 

San Diego, CA 



Alan Miller, MD 

Jacksonville, FL 

Christopher Newton-Cheh, MD, MPH 

Boston, MA 

Robert Page, II, PharmD, MSPH 

Aurora, CO 

Peter Pang, MD 

Indianapolis, IN 

Ileana Pina, MD, MPH 

New York, NY 

Lisa Rathman, MSN, CRNP 

Lancaster, PA 

Joseph Rogers, MD 

Durham, NC 

Hector Ventura, MD, FACC, 

FACP 

New Orleans, LA 

Lynne Warner Stevenson, MD 

Boston, MA 

David Whellan, MD, MHS 


Clyde Yancy, MD, MSc 

Chicago, IL 

Michael Zile, MD 

Charleston, SC 


16


Faculty 2015 HFSA Annual Scientific Meeting and Satellite Symposia 

Keith Aaronson, MD, MS 

University of Michigan 

Ann Arbor, MI 

Zoltan P. Arany, MD, PhD 

University of Pennsylvania 


Eugene Braunwald, MD 

Harvard 

Boston, MA 

Monica Colvin, MD, MS 

University of Minnesota 

Ann Arbor, MN 

Jamil Aboulhosn, MD 

University of California 


Pavan Atluri, MD 



Michael Bristow, MD, PhD 

University of Colorado 

Aurora, CO 

Leslie Cooper, MD 

Mayo Clinic 

Rochester, MN 

William Abraham, MD 

Ohio State University 

Columbus, OH 

Patricia Adams, BSN 

Duke University 

New Haven, CT 

Kirkwood Adams, MD 

University of North Carolina 

Chapel Hill, NC 

Tariq Ahmad, MD, MPH 

Yale University 

New Haven, CT 

Nancy Albert, PhD, RN, CHFN 

Cleveland Clinic 

Cleveland, OH 



Aurora, CO 

Amrut Ambardekar, MD 


Aurora, CO 

Susan Ammon, MSN, NP 

San Francisco VAMC 


Inder Anand, MD, PhD 

VA Medical Center 


Allen Anderson, MD 

Northwestern University 

Chicago, IL 

Lori Anderson, RN 

Tampa General Hospital 

Tampa, FL 

Stefan Anker, MD, PhD 

Charite Campus Virchow Klinikum 

Berlin, Germany 

Dipanjan Banerjee, MD 

Stanford University 

Palo Alto, CA 

Bradley Bart, MD 

Hennepin County Medical Center 


Arvind Bhimaraj, MD, MPH 

Methodist DeBakey Heart and 

Vascular Institute 

Houston, TX 

Martha Biddle, PhD, APRN, CCNS 

University of Kentucky 

Lexington, KY 

Robert M. Blanton Jr., MD 

Tufts Medical Center 

Boston, MA 

Burns Blaxall, PhD 

Cincinnati Children's Hospital 


Barry Bleske, PharmD 


Ann Arbor, MI 

Michale Bohm, MD, PhD 

University of Saarland 

Homburg/Saar, Germany 

Barry Borlaug, MD 

Texas Children's Hospital 

Rochester, MN 

Robert Bourge, MD 

University of Alabama 

Birmingham, AL 

Rebecca Boxer, MD, MS 


Denver, CO 

Biykem Bozkurt, MD 

Baylor College of Medicine 

Houston, TX 

John Burnett, MD 

Mayo Clinic 

Rochester, MN 


Stony Brook University 


Antonio Cabrera, MD 

Texas Children's Hospital 

Houston, TX 

Robert Califf, MD 

US Food and Drug Administration 

Silver Spring, MD 

Peter Carson, MD 

Washington VAMC 

Washington, DC 

John Chin, MD 

Sutter Medical Center 

Sacramento, CA 

Julio Chirinos, MD 

Pennsylvania Cardiovascular Institute 



Western University of Health Science 

Pomona, CA 

Misook Chung, PhD 


Lexington, KY 

John Cleland, MD 

Imperial College 

Harefield, Middlesex, UK 

Jay Cohn, MD 


Minneapolis, MD 

Paolo C. Colombo, MD 

Columbia University 

New York, NY 

Maria Rosa Costanzo, MD 

Midwest Heart Specialist - Advocate 

Heart Institute 

Naperville, IL 

William Cotts, MD 

Advocate Christ Hospital 

Oak Lawn, IL 

Patricia Davidson, PhD, Med, RN 

John Hopkins University 

Baltimore, MD 

William Dec, MD 

Massachusetts General Hospital 

Boston, MA 

Prakash Deedwania, MD 

University San Francisco California 

Fresno, CA 

Christopher deFilippi, MD 

University of Maryland 

Baltimore, MD 

Rebecca Dekker, PhD, RN, APRN 


Lexington, KY 

Cheryl Dennison Himmelfarb, 

RN, PhD 

Johns Hopkins University 

Baltimore, MD 

Eugene DePasquale, MD 



Akshay Desai, MD 

Brigham and Women's Hospital 

Boston, MA 

Victoria Dickson, PhD, CRNP, MSN 

New York University 

New York, NY 


17



Robert DiDomenico, PharmD 

University of Illinois at Chicago 

Chicago, IL 

Thomas DiSalvo, MD, MPH, MBA 

Vanderbilt University 

Nashville, TN 

Maghee Disch, MSN, RN, CNL 


Columbus, OH 

Gregory Ewald, MD 

Washington Univeristy School of 

Medicine 

St. Louis, MO 

Beth Fahlberg, PhD 

University of Wisconsin 

Madison, WI 

DeLisa Fairweather, PhD 


Baltimore, MD 

Alan Go, MD 

Kaiser Permanante 

Oakland, CA 

Lee R. Goldberg, MD, MPH 



Sarah Goodlin, MD 

Portland VAMC 

Portland, OR 

Ray Hershberger, MD 


Columbus, OH 

Thomas Heywood, MD 

Scripps Clinic 

La Jolla, CA 

Joseph Hill, MD, PhD 

Univeristy of Texas Southwestern 

Dallas, TX 

Stavros Drakos, MD, PhD 

University of Utah 


James Fang, MD 



Steven Gottlieb, MD 

University of Maryland 

Baltimore, MD 

Carolyn Ho, MD 

Brigham & Womens Hospital 

Boston, MA 

Mark Drazner, MD 

University of Texas Southwestern 

Dallas, TX 

Arthur Feldman, MD 

Temple University 


Kathleen Grady, PhD, APN, FAAN 


Chicago, IL 

Jennifer Ho, MD 

Boston University 

Boston, MA 

Daniel Dries, MD, MPH 

Temple Health 


Michael Felker, MD 

Duke Clinical Research Center 

Durham, NC 

Barry Greenberg, MD 


San Diego, CA 

Seth Hollander, MD 


Palo Alto, CA 

Dan Duprez, MD 



Gerasimos Filippatos, MD 

University of Athens 

Athens, Greece 

Roger Hajjar, MD 

Mount Sinai 

New York, NY 

Steven Houser, MD 



Jean-Bernard Durand, MD 


Houston, TX 



Durham, NC 

Michele Hamilton, MD 

Cedars Sinai Heart Institute 


Jonathan Howlett, MD 

University of Calgary 

Calgary, AB, Canada 

Peter Eckman, MD 






Joshua Hare, MD 

University of Miami 

Miami, FL 

Eileen Hsich, MD 

Cleveland Clinic Foundation 

Cleveland, OH 

Howard J. Eisen, MD 

Drexel University 


Thomas Force, MD 


Nashville, TN 

Karol Harshaw-Ellis, MSN 


Durham, NC 

Scott Hummel, MD, MS 


Ann Arbor, MI 

Uri Elkayam, MD 

University of Southern California 


Gary Francis, MD 



Paul Hauptman, MD 

St. Louis University 

St. Louis, MO 

Sharon A. Hunt, MD 


Palo Alto, CA 

David Ellison, MD 

Oregon Health Science University 

Portland, OR 

Hanna Gaggin, MD 


Boston, MA 

Paul Heidenreich, MD 


Palo Alto, CA 

Leonard Ilkhanoff 

Inova Fairfax Hospital 

Vienna, VA 

Murray Epstein, MD 

University of Miami 

Miami, FL 

Julie Gee, RN, PhD 

VA Medical Center 

Cleveland, OH 

Seongkum Heo, PhD, RN 

University of Arkansas 

Little Rock, AR 

James Januzzi, MD 


Boston, MA 

Lorraine Evangelista, RN, PhD 


Irvine, CA 

Michael Givertz, MD 

Brigham & Womens Hospital 

Boston, MA 

Adrian Hernandez, MD 


Durham, NC 





18



Susan Joseph, MD 


Houston, TX 

Marvin Konstam, MD 


Boston, MA 

Greg Lewis, MD 


Boston, MA 

Paul McKie, MD 

Mayo Clinic 

Rochester, MN 

David Joyce, MD 

Mayo Clinic 


Rajan Krishnamani, MD 

Advanced Cardiovascular Institute 

Mason, OH 

Ronglih Liao, PhD 

Brigham & Women's Hospital 

Boston, MA 

Rhondalyn McLean, MD 

Johns Hopkins Hospital 

Baltimore, MD 

Corrine Jurgens, RN, PhD 

Stony Brook University 


Teresa Kruisselbrink, MD 

Mayo Clinic 

Rochester, MN 

Peter Libby, MD 

Harvard 

Boston, MA 

John McMurray, MD 

Western Infirmary 

Glasgow, UK 

Suraj Kapa, MD 

Mayo Clinic 

Rochester, MN 

Valentina Kutyifa, MD, PhD 

University of Rochester 

Rochester, NY 

JoAnn Lindenfeld, MD 


Nashville, TN 

Dennis McNamara, MD 

University of Pittsburgh 


Navin Kapur, MD 


Boston, MA 

Bonnie Ky, MD, MSCE 


Philadelphia, PN 

Peter Liu, MD 

University of Ottawa Heart Institute 

Ontario, Canada 

Mandeep Mehra, MD 


Boston, MA 

Peter Karpawich, MD 

The Children's Hospital of Michigan 

Detroit, MI 

Neal Lakdawala, MD 


Boston, MA 

Carlin Long, MD 


Denver, CO 

Robert Mentz, MD 


Durham, NC 

David Kass, MD 


Baltimore, MD 

Carolyn Lam, MB. BS 

National Heart Centre 

Singapore 

Alan Maisel, MD 


San Diego, CA 

Marco Metra, MD 

University of Brescia 

Brescia, Italy 

Jason Katz, MD 



David Lanfear, MD, MS 

Henry Ford Hospital 

Detroit, MI 

Douglas Mann, MD 

Washington University 

St. Louis, MO 

Alan Miller, MD 

University Florida HSC 

Jacksonville, FL 

Daniel P Kelly, MD 

Sanford Burnham Prebys Medical 

Discovery Institute 

Orlando, FL 

Richard Kitsis, MD 

Albert Einstein College of Medicine 

Bronx, NY 

Dalane Kitzman, MD 

Wake Forest Baptist Health 

Winston-Salem, NC 

Liviu Klein, MD, MS 



Walter Koch, PhD 



Robb Kociol, MD 

Beth Israel Deaconess Medical Center 

Boston, MA 

Ann Laramee, MSN, APRN-BC 

University of Vermont 

Burlington, VT 

Christopher Lee, RN, PhD, FAHA 

Oregon Health & Science University 

Portland, OR 

Terry Lennie, PhD 


Lexington, KY 

Wayne C Levy, MD 

University of Washington 

Seattle, WA 

Martin LeWinter, MD 

University of Vermont 

Burlington, VT 

Connie Lewis, MD, MPH 


Nashville, TN 

Kenneth Margulies, MD 



David Markham, MD 

Emory University 

Atlanta, GA 

Martin Maron, MD 


Boston, MA 

Mathew Maurer, MD 


New York, NY 

Ernest Mazzaferri, MD 


Columbus, OH 

Peter McCullough 

Baylor University 

Dallas, TX 

Leslie Miller, MD 

Heart and Vascular Institute 

Clearwater, FL 

Wayne L. Miller, MD, PhD 

Mayo Clinic 

Rochester, MD 

Debra Moser, DNSc, RN 


Lexington, KY 

Maria Mountis, DO 


Cleveland, OH 

Matthew Movsesian, MD 

Univesity of Utah 


Wilfried Mullens, MD 

Ziekenhuis Oos Limburg Genk 

University 

Genk, Belgium 


19



Jean Nappi, PharmD 

University of South Carolina 


J. Herbert Patterson, PharmD 



Michael Rich, MD 

Washington University 

St. Louis, MO 

Andrew Sauer, MD 

University of Kansas 

Kansas City, KS 

Ali Nsair, MD 



Sara Paul, DNP, FNP 

Catawba Valley Cardiology 

Hickory, NC 

John Rickard, MD 


Baltimore, MD 

Douglas Sawyer, MD, PhD 


Nashville, TN 

Jose Nativi-Nicolau, MD 



W. Frank Peacock, MD 


Houston, TX 

Barbara Riegel, DNSc, RN 



Erik Schelbert, MD 



Matthew Needleman, MD 

Walter Reid National Military 

Medical Center 

Bethesda, MD 

Ivan Netuka, MD, PhD 

Institute for Clinical and 

Experimental Medicine 

Prague, Czech Republic 

Christopher Newton-Cheh, 

MD, MPH 


Boston, MA 

Christopher O'Connor, MD 

Inova Heart & Vascular Institute 

Falls Church, VA 

Guilherme Oliveira, MD 

University Hospitals Cas 

Medical Center 

Cleveland, OH 

Milton Packer, MD 


Dallas, TX 

Francis Pagani, MD, PhD 


Ann Arbor, MI 

Robert Page, PharmD, MSPH 


Denver, CO 

Peter Pang, MD 

Indiana University 


Bray Patrick-Lake 


Durham, NC 

Naveen Pereira, MD 

Mayo Clinic 

Rochester, MN 

Michael Petty, RN, PhD, 

CCNS, ACNS 


Richfield, MN 

Kerry Pickworth, PharmD 

Ohio State Medical Center 

Columbus, OH 

Ileana Pina, MD, MPH 

Albert Einstein College of Medicine 

New York, NY 

Sean Pinney, MD 

Mount Sinai 

New York, NY 

Bertram Pitt, MD 


Ann Arbor, MI 

Juan Carlos Plana, MD 


Cleveland, OH 

Eduardo Rame, MD 



Lisa Rathman, MSN, CRNP 

Lancaster General Health 

Lancaster, PA 

Margaret Redfield, MD 

Mayo Clinic 

Rochester, MN 

Jonathan Rich, MD 


Chicago, IL 

Jo Ellen Rodgers, PharmD 



Joseph Rogers, MD 


Durham, NC 

Heather Ross, MD 

The Toronto Hospital 

Toronto, Canada 

Henri Roukoz, MD 



Frederick Ruberg, MD 

Boston Medical Center 

Boston, MA 

Frank Ruschitzka, MD 

University Hospital Zurich 

Zurich, Switzerland 

Stuart Russell, MD 


Baltimore, MD 

Hani Sabbah, PhD 

Henry Ford Health System 

Detroit, MI 

Mitchell Saltzberg, MD 

Christiana Care Health System 

Newark, DE 

Flora Sam, MD 

Boston Medical Center 

Boston, MA 

Javier Sanz, MD 

Mount Sinai Hospital 

New York, NY 

Douglas Schocken, MD 


Durham, NC 

Marc Semigran, MD 


Boston, MA 

Ravi Shah, MD 


Boston, MA 

Sanjiv Shah, MD 


Chicago, IL 

Monica Shah, MD, MHS 

National Heart Lung & Blood 

Institute 

Bethesda, MD 

Eduard Shantsila, MD, PhD 

University of Birmingham 

Birmingham, UK 

Hiroaki Shimokawa, MD 

Tohoku University 

Sendai, Japan 

Roxanne Siemeck, MSN, APRN 

Advocated Christ Medical Center 

Oak Lawn, IL 

Marc Silver, MD 

Advocate Christ Medical Center 

Oak Lawn, IL 

Scott Solomon, MD 


Boston, MA 

Johannes-Peter Stasch, PharmD, PhD 

Bayer Pharma AG 

Wupertal, Germany 


20



Randall Starling, MD 


Cleveland, OH 

Gregg Stone, MD 


New York, NY 

Alan Storrow, MD 


Nashville, TN 

Nancy Sweitzer, MD, PhD 

University of Arizona 

Tucson, AZ 

Wilson Tang, MD 


Cleveland, OH 

Ryan Tedford, MD 


Baltimore, MD 

John Teerlink, MD 



Jeffry Testani, MD, MTR 

Yale University 

New Haven, CT 

Jeffrey Teuteberg, MD 



Christine Thompson, MS, RN, CNS 

Stanford Healthcare 

Stanford, CA 

Guillermo Torre-Amione, MD, PhD 

The Methodist Hospital 

Houston, TX 

Jeffrey Towbin, MD 

University of Cincinatti 


James Udelson, MD 


Boston, MA 

Nir Uriel, MD 

University of Chicago 

Chicago, IL 


University of Wisconsin 

Madison, WI 

Eric Velazquez, MD 


Durham, NC 

Niraj Varma, MD, PhD 


Cleveland, OH 

Hector O. Ventura, MD 

Ochsner Clinic Foundation 

New Orleans, LA 

Renu Virmani, MD, FACC 

CV Path Institute 

Gaithersburg, MD 

Rey Vivo, MD 



Joyce Wald, MD 



Mary Norine Walsh, MD 

St. Vincent Heart Center 


Paul Wang, MD 


Stanford, CA 

Alberta Warner, MD 

VA Greater Los Angeles 


Lynne Warner Stevenson, MD 


Boston, MA 

Cheryl Westlake, PhD 

Asuza University 

Azusa, CA 

Laura F. Wexler, MD 

University of Cincinatti 


David Whellan, MD, MHS 

Thomas Jefferson University 


Maria Fe White, NP 

Cedars Sinai 


James White, MD, PhD 

University of Calgary 

Calgary, AB 

Joshua Willey, MD 


New York, NY 

Susan Wingate, RN, PhD 

National Institute of Health 

Gaithersburg, MD 

Ronald Witteles, MD 


Stanford, CA 

Matthew J. Wolf, PhD 


Durham, NC 

Jia-Rong Wu, PhD, RN 



Kzuhiro Yamamoto, MD, PhD 

Tottori University 

Tottori, Japan 

Clyde Yancy, MD, MSc 


Chicago, IL 

Edward Yeh, MD 

University of Texas 

Houston, TX 

Quincy Young, PhD 

Providence Health 

Vancouver, BC, Canada 

Payman Zamani, MD 

Universit of Pennsylvania 


Faiez Zannad, MD, PhD 

Universite de Lorraine 

Vandoeuvrer, France 

Michael Zile, MD 

Medical University of South Carolina 



21


Program-at-a-Glance 

Saturday September 26 

New in 2015 Program Begins Saturday Morning 

TIME SESSION 1 SESSION 2 SESSION 3 SESSION 4 SESSION 5 HOW 

10:30-12:30 Clinical Fundamentals 

I: The Immune 

Response in Cardiovascular 

Disease 

Potomac C 

12:30-1:30 Lunch 

1:30-3:30 Recent Advances in 

the Management of 

Myocarditis 

(Joint Session with 

Myocarditis Foundation) 

Potomac D 

3:30-4:00 Break 

3:45-5:15 Satellite Symposium: 

Achieving Heart Rate 

Control: The Role of I f 

Inhibition 

(1.5 hours) 

National Harbor 2-3 

5:00-6:00 Nursing Reception 

Cherry Blossom Ballroom 

Foyer 

6:00-8:00 Exhibit Hall: 

Opening Reception 

Prince George's B-C 

7:30-8:30 Speed Mentoring 


Foyer 

8:30-10:00 Early Career Reception 


Foyer 

Transitions in Heart 

Failure Care: It’s Not 

Just About Hospital to 

Home 


The Prevention of Heart 

Failure: Targets and 

Strategies 


AHA) 

Potomac C 

Satellite Symposium: 

Contemporary and 

Future Management 

of Heart Failure in the 

African American 

Population (1.5 hours) 


Pharmacy Reception 

Cherry Blossom Ballroom Foyer 

Poster Reception 


Hemodynamics in Heart 

Failure 


SCAI) 

Potomac D 

Tool Kit for the Evaluation 

and Selection of the 

Patient for MCS 


ICCAC-VAD) 


Ask the Experts: Challenging Clinical Situations 

in MCS 


Excellence in 

Translational Science: 

Bench to Bedside 

Potomac 5-6 

Moderated Poster Session I - 6:30pm - 7:30pm 


Disposition Decision 

Making 

From the ER 


SAEM) 


Hands-on Workshop 1: 

CRT 

Potomac 1-2 


CRT (repeat) 

Potomac 1-2 


22



Sunday September 27 

TIME SESSION 1 SESSION 2 SESSION 3 SESSION 4 SESSION 5 HOW HOW 

6:30-7:30 Continental Breakfast 

7:00-8:00 Satellite Symposium 

Hyperkalemia in 

Heart Failure: 

New Data, Emerging 

Options 

Potomac C 

Satellite Symposium 

Sleep-Disordered 

Breathing in Heart 

Failure: Targeted 

Treatments for Improved 

Outcomes 



Remote Monitoring of Patients with HF: Making it Work in Practice 

Potomac D 

8:05-10:00 Awards and Plenary Session: The Economic Model of Heart Failure Care: Policy and Reform 

Maryland A-C 

10:00-10:30 Policy and Reform 

10:30-12:00 Heart Failure Trials: 

The Year in Review 

Maryland B 

12:00-1:30 Lunch Break and Poster Viewing 

12:15-1:15 How to: 

Change Behavior 

Maryland A 

1:15-1:30 Break 

1:30-3:00 Guideline Session: 

Unique Heart 

Failure Populations 

What Makes Them 

“Special?” 

Maryland B 

3:00-3:30 Break 

3:30-5:00 Late Breaking 

Clinical Trials 

Maryland B 

5:15-6:30 Exhibit Hall: 


Potomac C 

Cutting Edge 

Concepts in Device 

Therapy for Heart 

Failure 

(Joint Session with HRS) 


How to: 

Troubleshoot a 

VAD 


Cardiac Amyloidosis 

Maryland A 

Moving From the 

Problem to the 

Solution: Integrating 

a Palliative 

Approach in Heart 

Failure 

Management 

Maryland A 

Moderated Poster Session II 

5:30pm – 6:30pm 

Prince Georges B-C 

What is the Best 

Way to Measure 

Congestion in the 

Patient with Heart 

Failure? 

Potomac C 

How to: 

Opportunities in 

Early Career Nursing 

Potomac 5-6 

NHLBI Special 

Session: Heart 

Failure Clinical 

Trials – 

Strategies to 

Optimize 

Enrollment 

Maryland C 

Managing VAD 

Complications 

Maryland C 

New Concepts in 

the Pathophysiology 

of HFpEF 


How to: Cases in 

the Evaluation and 

Management of 

Right Heart Failure 

in the Patient with 

Pulmonary Arterial 

Hypertension 

Potomac C 

From Tele-Monitoring 

to Tele-Management 

and Electronic 

and Mobile-Health 

in Heart Failure 

Potomac C 

From Bench to 

Bedside: Emerging 

Therapies for the 

Failing Myocardium 

Potomac C 

Born This Way: The 

Role of Genetic 

Testing in 

Cardiomyopathy 

Potomac D 

Rapid Fire Abstracts 

Maryland C 

6:30-9:00 Faculty Reception and Fundraiser (6:30) Faculty Dinner and Fundraiser (7:30) (ticket required) 


Acute Cardiogenic 

Shock with Peripherally 

Implanted 

Devices 

10:30am - 12:30pm 

Potomac 1-2 


Acute Cardiogenic 

Shock with Peripherally 

Implanted 

Devices (repeat) 

1:30pm - 3:30pm 

Potomac 1-2 


Echo Made Simple 

for the Multidisciplinary 

Heart 

Failure Team 

10:30am - 12:30pm 

Potomac 3-4 


Echo Made Simple 

for the Multidisciplinary 

Heart Failure 

Team (repeat) 

1:30pm - 3:30pm 

Potomac 3-4 


23



Monday September 28 

TIME SESSION 1 SESSION 2 SESSION 3 SESSION 4 SESS 5 / HOW HOW 


7:15-8:15 Clinical Fundamentals II: 

FAQ’s About Heart 

Failure 

Drug Therapy 

Potomac C 


Improving Patient 

Outcomes and Reducing 

Re-Admission Rates in 

Chronic Heart Failure 

Maryland C 


RAAS and RAASi in 

Chronic Heart Failure 

Maryland A 

8:15-8:30 Break 

8:30-10:00 Case Discussion-Clinical 

Conundrums 

Maryland B 

10:00-10:30 Break 

10:30-12:00 Managing the VAD 

Outpatient 

Maryland C 

12:00-1:30 Lunch Break and Poster Viewing 

12:15-1:15 How to: 

Use Cardiac 

Rehabilitation 


Maryland C 

1:15-1:30 Break 

Nursing Research 

Award 

Maryland A 

Putting the “Self” back 

in Self-Care: Innovative 

Strategies to Improve 

Heart Failure Self-Care 


AAHFN) 

Maryland A 

Rapid Fire Abstracts 

Potomac C 

JNC Young Investigators 

Award: Clinical/ 

Integrative 

Maryland C 

Controversies in 

Cardiooncology 

Maryland D 

How to: 

Manage Diuretic 

Resistance: What to Do 

When the Fluid Won’t 

Come Off 

Maryland D 

JNC Young 

Investigators Award: 

Basic Science 

Maryland 1-2 

The “Hidden Gems” 

of Heart Failure 

Publishing 

Potomac C 

How to: 

Conduct Bedside 

Assessment in Heart 

Failure 

Maryland 1-2 

1:20-1:30 Awards Presentation - JNC Young Investigators Award: Clinical/Integrative, JNC Young Investigators Award: 

Basic Science and Nursing Research Award 

Maryland B 

Cardiovascular 

Magnetic Resonance 

Imaging for the 

Heart Failure Specialist 

Potomac C 


Advanced Troubleshooting 

with Durable 

VADs 

10:30am - 12:30pm 

Maryland 3-4 


Cardiopulmonary 

Function Testing 

10:30am - 12:30pm 

Maryland 5-6 

How to: 

How to Manage Sleep Apnea in Heart Failure 

Maryland A 

1:30-3:00 Hyde Park Session 

Maryland B 

Load, Unloading, 

Remodeling and 

Recovery 

Maryland C 

What’s New and 

Emerging in Heart 

Failure Pharmacology? 

Maryland A 


Advanced Troubleshooting 

with Durable 

VADs (repeat) 

1:30pm - 3:30pm 

Maryland 3-4 


Cardiopulmonary 

Function Testing 

(repeat) 

1:30pm - 3:30pm 

Maryland 5-6 

3:00-3:30 Break 

3:30-5:00 Debate 

Potomac C 

Alternative Therapies 

for Heart Failure: Fact 

or Fiction? 

Maryland A 

Emergency 

Management of 

VAD Patients 


ISHLT) 

Maryland C 

How to Interpret 

Biomarker Studies 

Maryland D 


24



Tuesday September 29 

TIME SESSION 1 SESSION 2 SESSION 3 SESSION 4 


7:00-8:15 Clinical Fundamentals III: 

Acute Heart Failure 360 

Maryland C 

Managing the Patient with 

Newly Diagnosed Heart Failure 

Maryland A 

The Periphery in Heart Failure: 

More Than an Innocent Bystander 

Potomac C 

8:15-8:30 Break 

8:30-9:45 Interventional Structural Devices 

for Heart Failure 

Potomac C 

Right Sided Heart Failure: 

What Do We Do When Orthopnea is 

Traded for Ascites? 

Maryland A 

Heart Failure Clinics: 

The Evidence, the Need and the 

Redesign 

Maryland C 

Interventions for 

Vulnerable Patients 

Maryland D 

9:45-10:15 Break 

10:15-11:30 Update on Peripartum 

Cardiomyopathy and Pregnancy 

Associated Heart Failure 

Maryland C 

Pharmacogenetics of Heart Failure 

and Transplant: Additive or Redundant? 

Maryland A 

New Clinical Insights 

into HFpEF 

Potomac C 

11:30 MEETING ADJOURNS 

See You Next Year in Florida! 


25



HFSA 2015 Annual Scientific Meeting 

Special Events and Exhibit Hall Activities 

Saturday September 26 

5:00 PM – 6:00 PM Nursing Reception* Cherry Blossom Ballroom Foyer 

Supported by St. Jude Medical 

5:00 PM – 6:00 PM Pharmacy Reception* Cherry Blossom Ballroom Foyer 

6:00 PM – 8:00 PM Exhibit Hall Opening Reception Exhibit Hall Prince Georges’ B-C 

6:15 PM – 7:15 PM Industry Expert Theater (see pg. 100) Exhibit Hall Prince Georges’ B-C Booth 100 

Sponsored by Novartis Pharmaceuticals 

6:30 PM - 7:30 PM Poster Reception I Exhibit Hall Prince Georges’ B-C 

6:30 PM – 7:30 PM Moderated Poster Session I Exhibit Hall Prince Georges’ B-C 

7:30 PM – 8:30 PM Speed Mentoring* Cherry Blossom Ballroom 


8:30 PM – 10:00 PM Early Career Reception* Cherry Blossom Ballroom 


Sunday September 27 

10:10 AM – 10:40 AM Industry Expert Theater (see pg. 100) Exhibit Hall Prince Georges’ B-C Booth 100 

Sponsored by Thoratec Corporation 


Sponsored by Roche Diagnostics 


Sponsored by scPharmaceuticals 


Sponsored by Amgen 

5:30 PM – 6:30 PM Poster Reception II Exhibit Hall Prince Georges’ B-C 

5:30 PM – 6:30 PM Moderated Poster Session II Exhibit Hall Prince Georges’ B-C 

6:30 PM – 7:30 PM Faculty/Fundraiser Dinner Reception Cherry Blossom Ballroom Foyer 

Supported by Thoratec Corporation 

7:30 PM – 10:00 PM Faculty/Fundraiser Dinner & Show Cherry Blossom Ballroom 

Supported by Novartis Pharmaceuticals 

Monday September 28 






Sponsored by Novartis Pharmaceuticals 


26


Tuesday September 29 

7:30 AM – 8:30 AM HFSA Business Meeting Chesapeake L 

Industry Expert Theatres are non-CME educational activities held in dedicated space in the exhibit hall. They allow industry 

experts an opportunity to provide clinical updates and educate attendees on current therapies, disease states, products and 

pipeline activities while remaining close to the action in the exhibit hall. Sessions are formatted for learning and are a great 

way to receive higher level interaction and engagement with company representatives. See page 100-101 for a full schedule of 

Industry Expert Theater sessions 

*These events by invitation only. 

Award Winners: 

Lifetime Achievement Award 

2014 Recipient: 

Gary Francis, MD – University of Minnesota Medical School 


Sidney Goldstein, MD – Wayne State University School of 

Medicine. Supported by Cytokinetics 

JNC New Investigator Integrative Physiology/ 

Clinical Award 

2014 Recipients: 

1st: Payman Zamani, MD - University of Pennsylvania 

2nd: Christopher Sparrow, MD - Washington University in St. 

Louis 


Selected at 2015 HFSA Annual Scientific Meeting 

Nursing Investigator Research Award 


1st: Carolyn Miller Reilly, RN, PhD - Emory University 

2nd: Ming Fen Tsai, MD - Chang Gung University of Science 

and Technology 



Clinical Excellence in Nursing Award 


Karol Harshaw-Ellis, MSN - Duke University Health System-Division 

of Heart Failure 


Diane Gauthier, MS, RNP-BC - Boston University School of 

Medicine 

JNC New Investigator Basic Science Award 


1st: Silvio Antoniak, PhD - University of North Carolina 

2nd (tie): Robert Baumgartner, MD - Molecular Cardiology 

Research Institute, Tufts Medical Center 

Anthony S. Fargnoli, MS - Carolinas HealthCare System 



Nursing Leadership Award 


Christopher S. Lee, RN, PhD, FAHA - Oregon Health & 

Science University 


Sandra Dunbar, RN, DSN - Nell Hodgson Woodruff School of 

Nursing Emory University. Supported by Cytokinetics 


27

2015 SESSIONS 

19th Annual Scientific Assembly 

September 26 – 29, 2015 



SATURDAY, SEPTEMBER 26 

10:30 AM – 12:30PM 

Potomac C 

Clinical Fundamentals I: The Immune 

Response in Cardiovascular Disease 

Moderators: Amrut Ambardekar, Aurora, CO 

Sharon Hunt, Palo Alto, CA 

10:30 The Nuts and Bolts of Basic Immunology 

Maria Rosa Costanzo, Naperville, IL 

10:50 Inflammation as a Pathophysiologic Mechanism 


Paolo Colombo, New York, NY 

11:10 The Role of the Immune Response in Myocarditis 

Peter Liu, Toronto, ON, Canada 

11:30 The Immunology of Cardiac Allograft Rejection 

Sharon Hunt, Palo Alto, CA 

11:50 Targeting Inflammation in the Development of 

Cardiovascular Diseaase 

Peter Libby, Boston, MA 

12:10 Panel Discussion 

12:30 Adjourn 

10:30 AM – 12:30 PM 


Transitions in Heart Failure Care: 

It’s Not Just About Hospital to Home 

Moderators: Larry Allen, Aurora, CO 

Susan Ammon, San Francisco, CA 

10:30 Post-Hospital Care Programs: Gems or Stones 

Nancy Albert, Cleveland, OH 

10:55 Coordinators versus Checklists to Achieve 

Clinical Outcomes 

Robb Kociol, Boston, MA 

11:20 Common Patient Issues Affecting Transition Care 

Mary Norine Walsh, Indianapolis, IN 

11:45 Transitioning to End-of-Life 

Ann Laramee, Burlington, VT 


12:30 Adjourn 

Learning Objective: Manage transitions in heart failure care 

with effective programs and attention to patient needs. 

Abstracts/posters of interest: 273, 112, 274, 303 

Learning Objective: Describe the role of the immune response 

in cardiovascular disease, including heart failure. 

Abstracts/posters of interest: 40, 44, 47, 55, 76, 197, 

199, 284 

29


10:30 AM – 12:30 PM 

Potomac D 

Hemodynamics in Heart Failure 

(Joint Session with SCAI) 

Moderators: Barry Borlaug, Rochester, MN 

Gregory Ewald, St. Louis, MO 

10:30 Basics of Hemodynamics in the Cath Lab 

Mark Drazner, Dallas, TX 

10:50 Hemodynamic Assessment Pre-VAD/Transplant 

James Fang, Salt Lake City, UT 

11:10 The Hemodynamics of HFpEF 

Barry Borlaug, Rochester, MN 

11:30 Hemodynamics of MCS 

Nir Uriel, Chicago, IL 

11:50 TAVR and MitraClip Hemodynamics 

Olcay Aksoy, Los Angeles, CA 


Faculty 

12:30 Adjourn 

Learning objective: Identify the role of hemodynamics in 

heart failure assessment and management. 

Abstracts/posters of interest: 181, 178, 18, 165, 151, 304 

10:30 AM – 12:30 PM 


Ask the Experts: Challenging Clinical 

Situations in MCS 

Moderators: Maria Mountis, Cleveland, OH 

Guillermo Torre-Amione, Houston, TX 

10:30 LVAD in Restrictive Cardiomyopathy 

Naveen Pereira, Rochester, MN 

10:55 LVAD in Chemotherapy-Induced Cardiomyopathy 

Guilherme Oliveira, Cleveland, OH 

11:20 LVAD in Children 

Antonio Cabrera, Houston, TX 

11:45 LVAD in Women 

Eileen Hsich, Cleveland, OH 

12:10 LVAD in Morbidly Obese Patients 

Ali Nasair, Los Angeles, CA 

12:30 Adjourn 

Learning Objective: Identify critical issues and clinically 

sound responses in the management of challenging MCS 

patients. 

Abstracts/posters of interest: 53, 219, 68, 72, 79 

30


10:30 AM – 12:30 PM 

Potomac 1-2 

Hands-On Workshop 1 

CRT: Indications, Optimization, Device 

Interrogation, Interpreting the Data, 

Troubleshooting 

(Limited enrollment, preregistration required) 

Chair: Liviu Klein, San Francisco, CA 

10:30 Start 

12:30 Adjourn 

Learning Objective: Describe indications for CRT, identify 

CRT devices, and demonstrate their use and interrogation. 

Supported by educational grants from Biotronik, Boston 

Scientific, Medtronic, and St. Jude Medical 

1:30 PM – 3:30 PM 

Potomac D 

Recent Advances in the Management of 

Myocarditis 

(Joint Session with Myocarditis Foundation) 

Moderators: Leslie T. Cooper, Jr., Rochester, MN 

Sharon A. Hunt, Palo Alto, CA 

1:30 Recent Translational Studies in Cardiovascular 

Inflammation 

DeLisa Fairweather, Baltimore, MD 

1:55 Epidemiology, Mechanisms and Prevention of 

Sudden Death in Myocarditis 

Renu Virmani, Gaithersburg, MD 

1:30 PM – 3:30 PM 

Potomac C 

The Prevention of Heart Failure: Targets 

and Strategies (Joint Session with AHA) 

Moderators: Mariell Jessup, Philadelphia, PA 

Biykem Bozkurt, Houston, TX 

1:30 Salt Control in the Population to Prevent HF 

Pro: Scott Hummel, Ann Arbor, MI 

Con: Javed Butler, Stony Brook, NY 

1:50 HTN Rx for Prevention of HF 

Clyde Yancy, Chicago, IL 

2:05 Discussion 

Hummel, Butler, Yancy 

2:15 DD: Can it be Stopped from Causing Heart Failure 

Margaret Redfield, Rochester, MD 

2:30 Biomarkers for Prediction and Prevention of 

Heart Failure – Beyond BNP 

Jennifer Ho, Boston, MA 

2:45 Nurse-Practitioner-Based Community Outreach 

to Control Lifestyle Issues Leading to Heart Failure 

Connie Lewis, Nashville, TN 


3:30 Adjourn 

Learning Objective: Outline strategies for the prevention of 

heart failure, identifying pros and cons. 

2:20 Cardiac MRI for Diagnosis and Prognosis in 

Suspected Myocarditis 

James White, Calgary, AB, Canada 

2:45 Techniques to Improve the Diagnosis Value of 

Endomyocardial Biopsy 

Suraj Kapa, Rochester, MN 


3:30 Adjourn 

Learning Objective: Describe recent advances in myocarditis 

diagnosis, prognosis, and management. 


31


1:30 PM – 3:30 PM 


Tool Kit for the Evaluation and Selection 

of the Patient for MCS (Joint Session 

with ICCAC-VAD) 

Moderators: Michael Petty, Minneapolis, MN 

Lee Goldberg, Philadelphia, PA 

1:30 New Metrics for Assessing the Progression of 

Heart Failure: More than VO 2 

! 


1:45 Who Does Poorly with MCS? INTERMACS 

and Beyond 

Lynne Warner Stevenson, Boston, MA 

2:00 Evaluating Psychosocial Risk: Is an Identified 

Caregiver Enough? 

Lori Anderson, Tampa, FL 

2:15 MCS as a Means to Evaluation Adherence: 

Expensive Test or Justifiable Alternative? 

Jeffery Teuteberg, Pittsburgh, PA 

2:30 Have We Agreed How to Assess the Right Ventricle? 

Pavan Atluri, Philadelphia, PA 

2:45 What Do We Know About Moving from ECMO 

to VAD? 

Francis Pagani, Ann Arbor, MI 

3:00 My Single Biggest Mistake on Selection 

Faculty 


Faculty 

3:30 Adjourn 

Learning Objective: Use effective strategies for the selection 

of patients for mechanical circulatory support. 


1:30 PM – 3:30 PM 

Potomac Rooms 5-6 

Excellence in Translational Science: 

Bench to Bedside 

Moderators: Thomas Force, Nashville, TN 

Peter Libby, Boston, MA 

1:30 Cellular and Molecular Mechanisms 

(sGC/pGC/cGMP/PKG) 

David Kass, Baltimore, MD 

1:45 Soluble Guanylyl Cyclase: From Biology to 

Drug Discovery 

Johannes-Peter Stasch, Wuppertal, Germany 

2:00 Particulate Guanylyl Cyclase: From Biology to 

Drug Discovery 

John Burnett, Jr., Rochester, MN 

2:15 What Genetics Have Told Us About sGC and 

pGC Pathways in CV Disease 

Christopher Newton-Cheh, Boston, MA 

2:30 sGC Therapeutics for Heart Failure and Pulmonary 

Hypertension 

Marc Semigran, Boston, MA 

2:45 Natriuretic Peptides for Acute and Chronic 

Heart Failure 

Christopher O’Connor, Falls Church, VA 

3:00 A New Paradigm in cGMP Therapeutics: 

ARNI’s, PARADIGM and Beyond 

Milton Packer, Dallas, TX 


3:30 Adjourn 

Learning Objective: Describe new findings in translational 

science and their implications for heart failure treatment. 

32


1:30 PM – 3:30 PM 


Disposition Decision Making From the ER 

(Joint Session with SAEM) 

Moderators: David Lanfear, Detroit, MI 

Alan Storrow, Brentwood, TN 

1:30 Hospital Admission – The Path of Least Resistance 

Alan Storrow, Nashville, TN 

1:50 Identifying Low-Risk and Impediments to Safe 

Discharge 

Adrian Hernandez, Durham, NC 

2:10 What Happens in an Observation Unit? 

Maghee Disch, Columbus, OH 

2:30 Optimizing Post- Discharge Care- ED and OU 

Transitions 

Karol Harshaw-Ellis, Durham, NC 

2:50 ED vs. Hospital Discharge: Should Endpoints 

Be the Same? 

Peter Pang, Indianapolis, IN 


3:30 Adjourn 

Learning Objective: Identify critical factors in effective 

heart failure disposition decisions in the ER. 

1:30 PM – 3:30 PM 

Potomac Room 1-2 

Hands-On Workshop 1 (Repeat) 

CRT: Indications, Optimization, Device 

Interrogation, Interpreting the Data, 

Troubleshooting 


3:45 PM – 5:15 PM 



Achieving Heart Rate Control: The Role 

of I f 

Inhibition 

Chair: 

John R. Teerlink, San Francisco, CA 

3:45 Opening Remarks 

John R. Teerlink, San Francisco, CA 

3:50 The Role Of Heart Rate And Conventional 

Therapies In Heart Failure 

Marco Metra, Brescia, Italy 

4:10 The Role Of I f 

Inhibition In Coronary Artery 

Disease 

Jeffrey S. Borer, Brooklyn, NY 

4:30 Targeted Heart Rate Lowering In Heart Failure: 

The Role Of I f 

Inhibition 

Michael Böhm, Homburg/Saar, Germany 

4:50 Panel Discussion with Q&A 

All Faculty 

5:10 Closing Remarks 

Learning Objectives: 

1. Discuss the potential prognostic importance of heart rate 

in cardiovascular disease 

2. Summarize current evidence-based treatment approaches 

to heart-rate reduction in HF 

3. Evaluate the effect of I f 

in 

4. Identify the appropriate clinical applicability of I f 

inhibtion 

in HF 

Supported by an educational grant from Amgen 

Chair: Liviu Klein, San Francisco, CA 

1:30 Start 

3:30 Adjourn 

Learning Objective: Describe indications for CRT, identify 

CRT devices, and demonstrate their use and interrogation. 

Supported by educational grants from Biotronik, Boston 

Scientific, Medtronic, and St. Jude Medical 

33


3:45 PM – 5:15 PM 



Contemporary and Future Management 

of Heart Failure in the African American 

Population 

Chair: 

Clyde W. Yancy, Chicago, IL 

3:45 Introduction, Program Overview and Pre-Test 


3:50 Epidemiology of Heart Failure 


4:05 Contemporary Treatment – Lessons Learned 

from GWTG-HF and Other Registries 

Gregg C. Fonarow, Los Angeles, CA 

4:30 Exploring New Treatment Paradigms for HF in 

African Americans 

Dennis McNamara, Venetia, PA 

6:00 PM – 8:00 PM 

Exhibit Hall - 


Opening Reception and Poster Reception 

Presenters at their Posters 6:30-7:30 

See Page 100-101 for a list of Industry Expert Theaters and 

other Exhibit Hall Activities. 

An exhibitor list can be found on page 107. 

Moderated Poster Session I 

6:30 Poster Professors 

John Chin, Sacramento, CA 

Thomas DiSalvo, New Haven, CT 

Martin LeWinter, Burlington, VT 

7:30 Adjourn 

4:55 Panel Discussion, Questions & Answers 

All Faculty 

5:15 Program Concludes 


1. Review the epidemiology, disease mechanisms, and 

natural history of heart failure in the African American 

population. 

2. Discuss real-world treatment experiences in African 

Americans with heart failure. 

3. Describe evolving treatment strategies for HF in African 

Americans stemming from genotypic characterization 

and ongoing treatment challenges in this population. 

Supported by an educational grant from 

Arbor Pharmaceuticals, LLC. 

34

SUNDAY, SEPTEMBER 27 

6:30 AM 

Meeting Level Foyers 

Light Breakfast 

7:00 AM – 8:00 AM 

Potomac C 


Hyperkalemia in Heart Failure: New 

Data, Emerging Options 

Chair: 

Javed Butler, Stony Brook, NY 



7:05 Potassium Homeostasis: Implications for Heart 

Failure Management 

Peter A. McCullough 

7:20 The Impact of Hyperkalemia and Renal Impairment 

on Clinical Outcomes in Heart Failure 


7:35 Emerging Management Options for Hyperkalemia: 

Where Are We Headed? 

Marvin A. Konstam, Boston, MA 

7:50 Faculty Panel Discussion 

Moderator: Javed Butler, Stony Brook, NY 

8:00 Closing Remarks 



1. Describe mechanisms of potassium homeostasis and 

pathogenesis of hyperkalemia in heart failure 

2. Define the impact of hyperkalemia and renal impairment 

on clinical outcomes in heart failure 

3. Identify current clinical challenges in treatment of acute 

and recurrent hyperkalemia 

4. Describe emerging therapies for hyperkalemia and the 

data supporting their effectiveness in patients with heart 

failure 

7:00 AM – 8:00 AM 



Sleep Disordered Breathing in Heart 

Failure: Targeted Treatment for Improved 

Outcomes 

Chair: 


7:00 Welcome and Overview 


7:05 Sleep Disordered Breathing: A Major Comorbidity 


Christopher M. O’Connor, Falls Church, VA 

7:15 Differential Diagnosis and Clinical Features of 

Obstructive and Central Sleep Apnea 

Laura Wexler, Cincinnati, OH 

7:25 Treatment Options in Comorbid Sleep Disordered 

Breathing 

Susan Joseph, Houston, TX 

7:40 How to Incorporate Clinical Care for Sleep 

Disordered Breathing in the Heart Failure 

Sara C. Paul, Hickory, NC 

7:50 Panel Discussion and Audience Q&A (All) 

8:00 Adjourn 


1. Describe the clinical significance of sleep disordered 

breathing in heart failure 

2. Describe current findings concerning sleep disordered 

breathing in heart failure and the effectiveness of available 

treatment options 

3. Make decisions about treatment strategies for heart failure 

patients with sleep disordered breathing 

4. Outline a practical approach to the evaluation and 

management of patients with heart failure and sleep 

disordered breathing. 

Supported by an educational grant from ResMed 

Supported by an educational grant from ZsPharma 

35


7:00 AM – 8:00 AM 

Potomac D 


Remote Monitoring of Patients with 

Heart Failure: Making it Work in Practice 

Chair: 

Larry A. Allen, Denver, CO 

7:00 Introduction: The Former Future of Remote 

Monitoring 

Larry A. Allen, Denver, CO 

7:05 Beyond CHAMPION: Recent Data and Updates 

on Remote PA Pressure Monitoring 

William T. Abraham, Columbus, OH 

7:15 Remote Monitoring in Context: Programmatic 

Integration, Staff Training, and Work Flow 

Margaret M. Redfield, Rochester, MN 

7:25 Boots on the Ground: Cath Lab Implications, 

Data Management, and Algorithms for Medication 

Adjustment 

Rita A. Jermyn, New York, NY 

7:35 Cases, Audience Q&A and Panel Discussion 

Faculty 

8:00 Adjourn 


1. Describe the goals and obstacles of remote monitoring of 

patients with heart failure. 

2. Discuss the how the findings of clinical trials of implantable 

hemodynamic monitoring apply to real-world practice. 

3. Outline strategies for the implementation of implantable 

hemodynamic monitoring in clinical practice. 

4. Identify patient scenarios in which implantable hemodynamic 

monitoring could affect treatment and hospitalization. 

Supported by an educational grant from St. Jude Medical 

8:05 AM- 10:00 AM 

Maryland A & C 


Michele Blair, Bethesda, MD 

8:15 Lifetime Achievement Award 

Presented by: Paul Hauptman, St.Louis, MO 

Hani Sabbah, Detroit, MI 

8:20 Clinical Excellence in Nursing Award 

Presented by: Maria Fe White, Los Angeles, CA 

8:25 Nursing Leadership Award 

Presented by: Victoria Dickson, New York, NY 

Plenary Session: 

The Economic Model of Heart Failure Care 

Moderators: JoAnn Lindenfeld, Nashville, TN 


8:30 Cardiovascular Drugs, Devices and Tobacco at 

the FDA 

Robert Califf, Silver Spring, MD 

9:05 The Evolving Economics of Heart Failure Care 

Jim Field, Washington DC 


10:00 Adjourn 

Learning Objective: Describe economic models of heart failure 

care, including the role of regulatory agencies. 

10:00 AM 



Exhibit Hall Opens 




36


10:30 AM - 12:00 PM 

Maryland Ballroom B 

Heart Failure Trials: The Year in Review 

Moderators: William Dec, Boston, MA 

Hector Ventura, New Orleans, LA 

10:30 Evaluation of ReDS 

William Abraham, Columbus, OH 

10:50 Ferric Carboxmaltose in Iron Deficient Heart Failure 

Patients: A Meta-Analysis on Individual Patient Data 

Stefan Anker, Berlin, Germany 

11:10 Randomized, Placebo-Controlled, Double-Blind 

Phase 2a Study of the Safety and Efficacy of the 

Recombinant Human Neuregulin-1 

Barry Greenberg, La Jolla, CA 

11:30 Baroreflex Activation Therapy for the Treatment 

of Heart Failure with a Reduced Ejection Fraction 



12:00 Adjourn 

Learning Objective: Outline key findings of recent key 

trials in heart failure and their potential impact on practice. 

Abstracts/posters of interest: 41, 245, 93, 252, 260, 250, 88 

10:30 AM - 12:00 PM 


Cutting Edge Concepts in Device Therapy 

for Heart Failure (Joint Session with HRS) 

Moderators: John Chin, Sacramento, CA 

JoAnn Lindenfeld, Nashville, TN 

10:30 Electricity or Catheters for HF: What is Coming 

Down the Pike? 

Paul Wang, Stanford, CA 

10:45 Individualizing Resynchronization Therapy: Is This 

the Way to Move Forward? 

Niraj Varma, Cleveland, OH 

11:00 Wearable Cardioverter Defibrillators in the Newly 

Diagnosed Heart Failure Patient: Is There a Role? 

Valentina Kutyifa, Rochester, MN 

11:15 Electrical Therapies for the Heart Failure Patient: 

When Do We Get the Palliative Team Involved? 


11:30 Atrial Fibrillation in the HF Patient: Working 

Through the Double Whammy? 

Frank Ruschitzka, Zurich, Switerland 


Faculty 

12:00 Adjourn 

Learning Objective: Identify clinical issues and new options 

in device therapy for the heart failure patient. 

37


10:30 AM - 12:00 PM 

Potomac C 

What is the Best Way to Measure Congestion 

in the Patient with Heart Failure? 

Moderators: John Cleland, Harefield Middlesex, UK 

Mark Dunlap, Cleveland, OH 

10:30 History and Physical Examination 

Mark Drazner, Dallas TX 

10:45 Patient Assessment of Congestion 

Susan Wingate, Gaithersburg, MD 

11:00 Biomarkers, Hemoconcentration and Blood 

Volume Measurements 

James Januzzi, Boston MA 

11:15 Right Heart Catheterization 

Barry Borlaug, Rochester MN 

11:30 Implantable Monitors 

J. Thomas Heywood, La Jolla, CA 


Faculty 

12:00 Adjourn 

Learning Objective: Use appropriate techniques and tools in 

the measurement of congestion in the heart failure patient. 

10:30 AM - 12:00 PM 


New Concepts in the Pathophysiology of 

HFpEF 

Moderators: Peter Carson, Washington, DC 

Dalane Kitzman, Winston-Salem, NC 

10:30 Ventricular Function and Hemodynamic 

Mechanisms in HFpEF 

Michael Zile, Charleston, SC 

10:45 Thinking Outside the Box (Thorax): Impact of the 

Vasculature and Periphery in HFpEF 

Julio Chirinos, Philadelphia, PA 

11:15 What Makes the Ventricle So Stiff? Endothelial 

Dysfunction, Fibrosis, or Both? 

Carolyn Lam, Singapore 

11:30 Stressing the System: The Role of Exercise Testing 

to Phenotype HFpEF 

Gregory Lewis, Boston, MA 


Faculty 

12:00 Adjourn 

Learning Objective: Describe new concepts in the pathophysiology 

of HFpEF and their implicaitons for practice. 

10:30 AM - 12:00 PM 

Potomac D 

Born This Way: The Role of Genetic Testing 

in Cardiomyopathy 

Moderators: Eugene DePasquale, Los Angeles, CA 

Neal Lakdawala, Boston, MA 

10:30 Dilated Cardiomyopathy: Genes and Beyond 

Jeffrey Towbin, Cincinnati, OH 

10:45 Hypertrophic Cardiomyopathy 

Carolyn Ho, Boston, MA 

11:00 ARVC 

Ray Hershberger, Columbus, OH 

11:15 Restrictive Cardiomyopathy 

Mathew Maurer, New York, NY 

11:30 Role of Genetic Counseling 

Teresa Kruisselbrink, Rochester, MN 


Faculty 

12:00 Adjourn 

Learning Objective: Outline the effective use of genetic 

testing in selected cardiomyopathies. 

Abstracts/posters of interest: 193, 48, 206 

11:00 New insights into the Molecular Mechanisms of 

HFpEF 

Flora Sam, Boston, MA 

38


10:30 AM – 12:30 PM 

Potomac 1-2 

Hands-On Workshop 2: 

Acute Management of Cardiogenic 

Shock with Peripherally Implanted 

Devices 


Chair: Navin Kapur,Boston, MA 

Co-Chair: Arvind Bhimaraj, Houston, TX 


10:30 Start 

12:30 Adjourn 

Learning Objective: Describe management goals in cardiogenic 

shock, identify percutaneous devices used in the management 

of cardiogenic shock, and demonstrate their uses. 

Supported by educational grants from Abiomed, Cardiac 

Assist, Maquet, and Thoratec. 

10:30 AM - 12:30 PM 

Potomac 3-4 

Interactive Workshop 3: 

Echo Made Simple for the Multidisciplinary 

Heart Failure Team 


Moderators: Victoria Dickson, New York, NY 

Maria Fe White, Los Angeles, CA 

10:30 Introduction to Flow, Planes and Physics of 

Echocardiography 

Alberta Warner, Los Angeles, CA 

10:55 Common and Uncommon Echo Pathologies in Heart 

Failure 

Leslie Miller, Clearwater, FL 

11:20 Case studies in Echo Imaging and Hemodynamics 

Michele Hamilton, Los Angeles, CA 

12:10 Question & Answer 

Faculty 

12:30 Adjourn 

This interactive workshop is designed to demystify echocardiographic 

imaging in heart failure patients. It is intended 

for the non-cardiologist participants of the annual HFSA 

meeting, nurses, NPs, PAs, Pharmacists, and students and 

other members of the HF Multidisciplinary team. 

Learning Objective: Describe how echocardiography 

works, interpret selected images, and describe implications 

for clinical practice. 

12:15 PM - 1:15 PM 

Maryland A 

How to Change Behavior 

Moderators: Peter Eckman, Minneapolis, MN 

Seongkum Heo, Little Rock, AR 

12:15 Using Motivational Interviewing to Promote 

Behavioral Change 

Barbara Riegel, Philadelphia, PA 

12:25 Addressing the Enviornment Challenges to 

Challenges to Changing Behavior 

Terry Lennie, Lexington, KY 

12:35 Helping Patients Engage in Effective Self-Care 

Corrine Jurgens, Stony Brook, NY 

12:45 Supporting Caregivers to Change Patient Behavior 

Misook Chung, Lexington, KY 

12:55 Roundtable 

Faculty 

1:15 Adjourn 

Learning Objective: Use proven strategies to change patient 

behavior, helping patients engage in effective self-care. 


11:45 Clinical Implications for Advanced Practice 

Nursing and Physician Assistants 


11:30 Role of Genetic Counseling 

Teresa Kruisselbrink, Rochester, MN 

39


12:15 PM - 1:15 PM 


How to Troubleshoot a VAD 

Moderators: Allen Anderson, Chicago, IL 

Rhondalyn McLean, Baltimore, MD 

12:15 What are the Critical Differences Between the 

Continuous Flow VAD’S 

Nir Uriel, Chicago IL 

12:25 What is a Ramp Study and How is One Done? 

Eduardo Rame, Philadelphia, PA 

12:35 What is the Role of Measuring Hemodynamics – 

What Does it Add? 

Dipanjan Banerjee, Stanford, CA 

12:45 Anticoagulation and Anti-Platelets: Now What? 

Randall Starling, Cleveland, OH 

12:55 How Can Imaging Help Problem Solve? 

Eric Velazquez, Durham, NC 

1:05 Frequently Asked Questions 

Faculty 

1:15 Adjourn 

Learning Objective: Identify techniques for troubleshooting 

VADs in patients with heart failure. 

12:15 PM- 1:15 PM 

Potomac 5-6 

How to: Opportunities in Early Career 

Nursing 

Moderators: Patricia Davidson, Baltimore, MD 

Sara Paul, Hickory, NC 

Early Career Leader in Heart Failure 

Christopher Lee, Portland, OR 

Early Career Clinician/Scientist in Heart Failure 

Martha Biddle, Lexington, KY 

Early Career Clinician in Heart Failure 

Karol Harshaw-Ellis, Durham, NC 

Early Career Academic Scientist in Heart Failure 

Rebecca Dekker, Lexington, KY 

Learning Objective: Discuss leadership, clinical, and scientific 

opportunities in nursing practice. 

12:15 PM- 1:15 PM 

Potomac C 

How to: Cases in the Evaluation and 

Management of Right Heart Failure in 

the Patient with Pulmonary Arterial 

Hypertension 

12:15 Assessment of Right Ventricular Function in 

Pulmonary Arterial Hypertension 

Mandeep Mehra, Boston MA 

Management of Right Heart Failure in Pulmonary 

Arterial Hypertension 

Johnathan D. Rich, Chicago, IL 

Learning Objective: Use effective management strategies for patients 

with right heart failure and pulmonary arterial hypertension. 

40


12:15 PM – 1:15 PM 

Maryland C 

Rapid Fire Abstracts I 

Moderators: John Burnett, Rochester, MN 

Matthew Wolf, Durham, NC 

12:15 Trends and Outcomes of Patients with Adult 

Congenital Heart Disease with Pulmonary 

Hypertension listed for Orthotopic Heart 

Traplantation in the United Network for Organ 

Sharing Database 

Yamini Krishnamurthy 1 , 2 , Lauren B. Cooper 3 , 2 , Di Lu 2 , 

Jacob N. Schroder 3 , Joseph G. Rogers 3 , 2 , Carmelo A. 

Milano 3 , Adrian F. Hernandez 3 , 2 , Chetan B. Patel 3 , 2 . 

1 

Duke University School of Medicine, Durham, NC; 

2 

Duke Clinical Research Institute, Durham, NC; 3 Duke 

University Medical Center, Durham, NC 

12:20 Cardiac Transplantation for Older Patients: 

Characteristics and Outcomes in the 

Septuagenarian Population 

Lauren B. Cooper 1 , Di Lu 2 , Robert J. Mentz 2 , Joseph 

G. Rogers 2 , Carmelo A. Milano 2 , G. Michael Felker 2 , 

Jacob N. Schroder 2 , Adrian F. Hernandez 2 , Chetan 

B. Patel 2 . 1 Duke University, Durham, NC; 2 Duke 

University, Durham, NC 

12:25 Obese Patients Have Improved Ten-Year Survival 

after CRT-D Implantation 

Alison L. Wand, E. Wilson Grandin, Payman Zamani, 

J. Eduardo Rame, Ralph J. Verdino. University of 

Pennsylvania, Philadelphia, PA 

12:30 Decompensated Heart Failure Admissions are 

Inaccurately Identified by Centers for Medicare 

and Medicaid Services; Administrative Data 

Zachary L. Cox 1 , 2 , Pikki Lai 1 , Connie M. Lewis 1 , 

Daniel J. Lenihan 1 . 1 Vanderbilt University Medical 

Center, Nashville, TN; 2 Lipscomb University College 

of Pharmacy, Nashville, TN 

12:35 Efficacy of LCZ696 Persists at Lower than Target 

Doses in the PARADIGM-HF trial 

Orly Vardeny 1 , Brian Claggett 2 , John J.V. McMur 

ray 3 , Milton Packer 4 , Jean Rouleau 5 , John R. 

Teerlink 6 , Michael Zile 7 , Karl Swedberg 8 , Martin 

Lefkowitz 9 , Victor Shi 9 . 1 University of Wisconsin, 

Madison, WI; 2 Brigham and Women's Hospital, Boston, 

MA; 3 University of Glasgow, Glasgow, United 

Kingdom; 4 UT Southwestern, Dallas, TX; 5 Univer 

sity of Montreal, Montreal, QC, Canada; 6 UCSF, 

San Francisco, CA; 7 MUSC, Charleston, SC; 

8 

University of Gothenburg, Gothenburg, Sweden; 

9 

Novartis Pharmaceuticals, East Hanover, NJ 

12:40 Inadequate Heart Rate Control in Ambulatory 

Patients with Systolic Heart Failure Despite 

Broad Beta Blocker Utilization: A Single Center 

Experience 

Kenneth D. Varian, Kevin Chagin, Justin L. 

Grodin, Frederik Verbrugge, Alex Milinovich, 

Michael W. Kattan, W.H. Wilson Tang. Cleveland 

Clinic Foundation, Cleveland, OH 

12:45 Remote Monitoring Program for Heart Failure 

Patients Discharged to Skilled Nursing Facilities 

to Improve Outcomes 

Mitchell T. Saltzberg 1 , Kelly A. Whitmarsh 2 , 

Alexander Cheryl 3 , Vivek K. Reddy 4 . 1 Christi 

anaCare Health System, Newark, DE; 2 Chris 

tianaCare Health System, Newark, DE; 3 Christiana 

Care Health System, Newark, DE; 4 IPC Health 

Care, Newark, DE 

12:50 Bedside Hemodynamic Profiles in Acute Decompensated 

Heart Failure: Clinical Uncertainty 

May Identify Higher Risk 

Deepa M. Gopal, John D. Groarke, Adriana Luk, 

Emer Joyce, Sachin P. Shah, Eldrin F. Lewis, Neal K. 

Lakdawala, Anju Nohria. Brigham and Women's Hos 

pital, Boston, MA 

12:55 Lack of Improvement in 30-day Readmission 

Rates for Patients Hospitalized with Heart Failure: 

Data from Get with the Guidelines-Heart Failure 

Registry 

Kristin E. Bergethon 1 , Christine Ju 1 , Adam D. 

DeVore 1 , 2 , N. Chantelle Hardy 1 , Gregg C. Fon 

arow 3 , Clyde W. Yancy 4 , Paul A. Heidenreich 5 , 6 , 

Deepak L. Bhatt 7 , 8 , Eric D. Peterson 1 , 2 , Adrian F. 

Hernandez 1 , 2 . 1 Duke Clinical Research Insti 

tute, Durham, NC; 2 Duke University School of 

Medicine, Durham, NC; 3 Ahmanson-UCLA Car 

diomyopathy Center, UCLA, Los Angeles, CA; 

4 

Northwestern University, Feinberg School of 

Medicine, Chicago, IL; 5 Veterans Affairs Palo Alto 

Health Care System, Palo Alto, CA; 6 Stanford 

University, Stanford, CA; 7 Brigham and Women's 

Hospital, Boston, MA; 8 Harvard Medical School, 

Boston, MA 

1:00 Identification of Stage D Heart Failure Patients: 

Clinical Assessment Versus ESC Heart Failure 

Association Criteria 

Mariyah Yazdani, Jeffrey S. Hedley, Ayman S. Tah 

han, Andrew A. McCue, Raghda Al-Anbari, Alanna 

A. Morris, Andrew L. Smith, Vasiliki V. Georgiopoulou, 

Andreas P. Kalogeropoulos. Emory Uni 

versity, Atlanta, GA 

41


1:05 Lung Impedance-guided Therapy of Patients 

with Chronic Heart Failure Improves Clinical 

Outcome 

Michael Shochat 1 , Avraham Shotan 1 , Mark Ka 

zatsker 1 , Ilia Kleiner 2 , Iris Dahan 1 , Aya Asif 1 , 

David Blondheim 1 , Simcha Meisel 1 . 1 Hillel Yaffe 

Heart Institute, Hadera, Israel; 2 Soroki Medical 

Center, Beer Sheva, Israel 

1:10 Rapid and Highly Accurate Prediction of Poor 

Diuretic Natriuretic Response in Patients with 

Heart Failure 

Jennifer Simon, Chukwuma Onyebeke, Susan J. 

Cheng, Jeffrey M. Testani. Yale University School 

of Medicine, New Haven, CT 

1:15 Adjourn 

Learning Objectives: Discuss findings from recent research in 

HF and their implications for research and clinical practice. 

1:30 PM – 3:00 PM 

Maryland B 

Guideline Session: Unique Heart Failure 

Populations: What Makes Them "Special"? 

Moderators: Michael Givertz, Boston, MA 

Nancy Sweitzer, Tucson, AZ 

1:30 African Americans with Heart Failure: Epidemiology 

and Genetics 

Monica Colvin, Ann Arbor, MI 

1:45 Hispanics with Heart Failure: Socioeconomics 

and Comorbidities 

Rey P. Vivo, Los Angeles, CA 

2:00 South Asians with Heart Failure: Vascular 

Function and Coronary Disease 

Eduard Shantsila, Birmingham, UK 

1:30 PM – 3:00 PM 

Maryland A 

Cardiac Amyloidosis 


Jose Nativi-Nicolau, Salt Lake City, UT 

1:30 The Cardiotoxicity of Amyloid Proteins 

Ronglih Liao, Boston, MA 

1:45 Imaging in Cardiac Amyloidosis: From ECG to 

Echocardiography to MRI 

Javier Sanz, New York, NY 

2:00 Emerging Therapies for AL Cardiac Amyloidosis 

Allen Anderson, Chicago, IL 

2:15 Emerging Disease Modifying Therapies for 

Transthyretin Cardiac Amyloidosis 

Mathew Maurer, New York, NY 

2:30 Defibrillators, Cardiac Transplantation, and 

Mechanical Support in Cardiac Amyloidosis: 

Too Little, Too Late, or Novel and Underutilized 

Marc Semigran, Boston, MA 


Faculty 

3:00 Adjourn 

Learning Objective: Describe the effective use of imaging 

to diagnose cardiac amyloidosis and identify emerging 

therapies. 


2:15 Women with Heart Failure: Hypertension and 

Remodeling 

Jennifer E. Ho, Boston, MA 

2:30 Older Adults with Heart Failure: Frailty and 

Polypharmacy 

Alan S. Go, Oakland, CA 

2:45 Roundtable Discussion 

Faculty 

3:00 Adjourn 

Learning Objective: Outline guidelines for the treatment of 

unique heart failure populations. 

Abstracts/posters of interest: 22, 20, 195, 103, 99, 265, 105, 

110, 175, 12, 118, 229, 216, 61 

42


1:30 PM – 3:00 PM 

Maryland C 

NHLBI Special Session: 

Heart Failure Clinical Trials - Strategies 

to Optimize Enrollment 

Moderators: Monica Shah, Bethesda, MD 

Eugene Braunwald, Boston, MA 



1:32 Why is Enrollment is Important in HF Trials? 

Monica Shah, Bethesda, MD 

1:42 Strategy to Optimize Enrollment – Consider 

New Models for Trials 

John McMurray, Glasgow, UK 

1:54 Strategy to Optimize Enrollment – Consider 

Randomized Registry Trials 

Gregg Fonarow, Los Angeles, CA 

2:06 Strategy to Optimize Enrollment – Partner with 

Health Systems 


2:18 Srategey to Optimize Enrollment – Engage 

Patients 

Bray Patrick Lake, Durham, NC 

2:30 Srategey to Optimize Enrollment – Test 

Protocol Feasibility 

Patricia Adams, Durham, NC 

2:40 From TIMI 1 to 61: Ten Tips on Conducting 

Clinical Trials 



Faculty 

2:58 Concluding Remarks 

Monica Shah, Bethesda, MD 

3:00 Adjourn 

Learning Objective: Describe strategies to optimize enrollment 

in heart failure clinical trials. 

1:30 PM – 3:00 PM 

Potomac C 

From Tele-monitoring to Tele-management 

and Electronic and Mobile-Health in Heart 

Failure 

Moderators: Julie Gee, Cleveland OH 

David Whellan, Philadelphia, PA 

1:30 Heart Failure Tele-Monitoring 

Larry Allen, Denver, CO 

1:50 Heart Failure Implantable Sensors 

Robert Bourge, Birmingham, AL 

2:10 E-Health / M-Health Heart Failure Management 

Nancy Albert, Cleveland, OH 

2:30 Panel Discussion: The Strengths and Concerns of 

Tele-monitoring, Tele-management and E- and 

M-health 

Faculty 

3:00 Adjourn 

Learning Objective: Identify tools for remote monitoring of 

patients with heart failure. 


1:30 PM – 3:30 PM 

Potomac 1-2 

Hands-On Workshop 2 (Repeat) 

Acute Management of Cardiogenic 

Shock with Peripherally Implanted 

Devices 


Chair: Navin Kapur,Boston, MA 

Co-Chair: Arvind Bhimaraj, Houston, TX 


1:30 Start 

3:30 Adjourn 

Learning Objective: Describe management goals in cardiogenic 

shock, identify percutaneous devices used in the management 

of cardiogenic shock, and demonstrate their uses. 

Supported by educational grants from Abiomed, Cardiac 

Assist, Maquet, and Thoratec. 

43


1:30 PM – 3:30 PM 

Potomac 3-4 

Interactive Workshop 3 (Repeat) 

Echo Made Simple for the Multidisciplinary 

Heart Failure Team 




1:30 Introduction to Flow, Planes and Physics of 

Echocardiography 

Alberta Warner, Los Angeles, CA 

1:55 Common and Uncommon Echo Pathologies in 

Heart Failure 

Leslie Miller, Clearwater, FL 

2:20 Case studies in Echo Imaging and Hemodynamics 


2:45 Clinical Implications for Advanced Practice 

Nursing and Physician Assistants 


3:10 Question & Answer 

Faculty 

3:30 Adjourn 

This interactive workshop is designed to demystify echocardiographic 

imaging in heart failure patients. It is intended 

for the non-cardiologist participants of the annual HFSA 

meeting, nurses, NPs, PAs, Pharmacists, and students and 

other members of the HF Multidisciplinary team. 

Learning Objective: Describe how echocardiography 

works, interpret selected images, and describe implications 

for clinical practice. 

3:30 PM – 5:00 PM 

Maryland B 

Late Breaking Clinical Trials 

Moderators: Gary Francis, Minneapolis, MN 


3:30 Follow-Up Results from AUMENT-HF: 

A Multicenter Randomized Controlled Clinical 

Trial of the Efficacy of Left Ventricular Augmentation 

with Algisyl-LVR in the Treatment of Heart Failure 

Douglas Mann, St. Louis, MO 

3:40 Commentary 


3:45 HeartMate 3 CE Mark Study 

Ivan Netuka, Prauge, Czech Republic 


Marvin Konstam, Boston, MA 

4:00 Neural Cardiac Therapy for Heart Failure 

(NECTAR-HF) 

Faiez Zannad, Vandoeuvre, France 


Inder Anand, Minneapolis, MN 

4:15 Aquarpheresis Versus Diuretics and Hospitalization 

for Heart Failure Trial (AVOID-HF) 




4:30 Cupid 2: A Phase2b Trial Investigating the Efficacy 

and Safety of Intracoronary Administration of 

AAV/SERCA2a in Patients with Advanced Heart 

Failure 

Barry Greenberg, La Jolla, CA 


John Burnett, Rochester, MN 

4:45 ENCORE Study 

Inder Anand, Minneapolis, MN 


Mandeep Mehra, Boston, MA 

5:00 Adjourn 

Learning Objective: Describe the results of recent clinical 

trials in heart failure and discuss their clinical implications. 

3:30 PM – 5:00 PM 

Maryland A 

Moving From the Problem to the Solution 

Integrating a Palliative Approach in Heart 

Failure Management 

Moderators: Beth Fahlberg, Madison, WI 

Sarah Goodlin, Portland, OR 

3:30 Shared Decision Making in Heart Failure: 

Making Palliative Care a Reality 

Larry Allen, Denver, CO 

3:50 Managing Breathlessness in Heart Failure 

Patricia Davidson, Baltimore, MD 

4:10 Managing Patients with Left Ventricular Assist 

Devices: Having Crucial Conversations 

Stuart Russell, Baltimore, MD 

44


4:30 Integrating Spiritual Aspects in Heart Failure Care 

Cheryl Westlake, Asuza, CA 


Kathleen Grady, Chicago, IL 

John Teerlink, San Francisco, CA 

Faculty 

5:00 Adjourn 

Learning Objective: Outline an effective palliative approach 

in heart failure management and describe specific strategies. 


3:30 PM – 5:00 PM 

Maryland C 

Managing VAD Complications 

Moderators: Monica Colvin, Ann Arbor, MI 

Joyce Wald, Philadelphia, PA 

3:30 GI Bleeding in Continuous Flow VADs 

Maria Mountis, Cleveland, OH 

3:45 Acquired Von Willebrand Syndrome in Continuous 

Flow VADs 

David Joyce, Rochester, MN 

4:00 Thrombosis in Continuous Flow VADs 


4:15 Cerebrovascular Disease in Continuous Flow 

VADs: A Neurologic Perspective 

Joshua Willey, New York, NY 

4:30 Systemic Vascular Reactivity in Continuous 

Flow VADs 

Joseph Rogers, Durham, NC 


Faculty 

5:00 Adjourn 

Learning Objective: Describe effective strategies for managing 

selected complications in HF patients with VADs. 

3:30 PM – 5:00 PM 

Potomac C 

From Bench to Bedside: Emerging Therapies 

for the Failing Myocardium 

Moderators: Michael R. Bristow, Aurora, CO 

Kenneth B. Margulies, Philadelphia, PA 

3:30 Targeting Calcium Handling Defects (with Gene 

Therapy) 

Roger Hajjar, New York, NY 

3:45 Targeting Abnormal Cardiac Metabolism 

Daniel P. Kelly, Olrando, FL 

4:00 Targeting Fibrosis in the Failing Heart 

Carlin S. Long, Denver, CO 

4:15 Targeting Pathological Hypertrophy 

Steven Houser, Philadelphia, PA 

4:30 Targeting Cell Death Pathways 

Richard Kitsis, New York, NY 

4:45 GRK2 Inhibition as an Emerging Heart Failure 

Therapy 

Walter Koch, Philadelphia, PA 

5:00 Adjourn 

Learning Objective: Identify emerging therapies for the failing 

myocardium, and discuss their implications for clinical practice. 

Abstracts/posters of interest: 208, 256, 255, 252, 182, 85, 

120, 256 

5:15 PM – 6:30 PM 




Presenters at their Posters 5:30 - 6:30 




Moderated Poster Session II 

5:30 Poster Professors 

Douglas Sawyer, Nashville, TN 

Michael Rich, St. Louis, MO 

Faiez Zannad, Vandoeuvre, France 

6:30 Adjourn 

6:30 PM - 10:00 PM 

Cherry Blossom 

Fundraising & Faculty Dinner 

(All invited to attend. Tickets available at registration desk) 

6:30 Reception 

7:30 Dinner 

8:15 Entertainment: Laughter is the Best Medicine! 

Healthcare humorist Diana Jordan 

45

MONDAY, SEPTEMBER 28 

6:30 AM – 7:15 AM 

Meeting Level Foyers 

Light Breakfast 

7:15 AM – 8:15 AM 

Maryland C 


Improving Patient Outcomes and Reducing 

Re-Admission Rates in Chronic Heart Failure 

7:15 AM – 8:15 AM 

Maryland A 


Update on RAAS Inhibition in Chronic Heart 

Failure: Real World Considerations 

Chair: 

James L. Januzzi, Jr., Boston, MA 

Chair: 

Murray Epstein, Miami FL 

7:15 Program Overview 


7:20 Heart Failure Hospitalization: The Epidemiology, 

Pathophysiology, and Diagnosis of Chronic Heart 

Failure vs. Acute Heart Failure 


7:30 Current and Emerging Therapeutics for the 

Management of Chronic Heart Failure 

Barry H. Greenberg, San Diego, CA 

7:45 Optimizing Treatment Plans, Overcoming 

Barriers to Care, and Improving Patients Outcomes 

in Chronic Heart Failure 

Ileana L. Piña, New York, NY 

8:00 Questions and Answers 

Faculty 

Learning objectives: 

1. Discuss the epidemiology, pathophysiology, and diagno 

sis of chronic heart failure and how management goals 

for chronic heart failure differs from acute heart failure 

2. Review the data on the current and emerging therapeu 

tics for the management of chronic heart failure 

3. Apply evidence based strategies to optimize pharmaco 

logical treatment, overcome barriers to care, and 

improve outcomes in patients with chronic heart failure 

Supported by an educational grant from Amgen 

7:15 Introduction 

Murray Epstein, Miami, FL 

7:20 RAAS and RAASi - State of the Art Review and 

Evolving Perspectives 

Bertram Pitt, Ann Arbor, MI 

7:35 RAASi in CHF, CKD and T2DM 

Daniel Duprez, Minneapolis, MN 

7:50 Mandated Guidelines and the Real World Clinical 

Arena 

Murray Epstein, Miami, FL 


Faculty 

8:15 Adjourn 

Learning objectives: 

1. Describe current knowledge of RAAS and RAAS inhibition 

including emerging approaches and future directions 

2. Describe the data on RAASi in specific patient populations 

including CHF patients with CKD and/or T2DM 

3. Describe current guidelines for the management of CHF 

and RAASi. 

4. Understand the gaps between mandated guidelines and 

current clinical realities 

5. Describe emerging therapeutic approaches to maintaining 

and managing RAASi therapy in patients with CHF 

Supported by an educational grant from ReardenCME made 

possible by Relypsa, Inc. 

46


7:00 AM- 8:15 AM 

Potomac C 

Clinical Fundamentals II: FAQ’s About 

Heart Failure Drug Therapy 

Moderators: Mariell Jessup, Philadelphia, PA 

Jo Ellen Rodgers, Chapel Hill, NC 

Discussion Panel: 

John Chin, Sacramento, CA 

Daniel Dries, Philadelphia, PA 

Gerasimos Filippatos, Athens, Greece 

Heather Ross, Toronto, ON, Canada 

Mark Semigran, Boston, MA 

7:00 Case 1 & FAQs: 

55-year-old male with HTN, diabetes, and history of childhood 

asthma is admitted with new onset heart failure, LVEF 

20%. He has non-critical CAD and is stable after 2 days of 

IV diuretic. His BP is now 140/90 mmHg, and his heart rate 

is 70 bpm. Renal function is normal. 

Which ACE-inhibitor would you start? 

When do you start the beta-blocker? 

When do you start the MRA? 

Which beta-blocker would you start? 

Do you follow the NT-proBNP? 

How high would the creatinine have to be before you would 

not start an ACE-I? 

Is there anyone who would start an ARB first? What if the 

patient was Asian? 

What other tests are needed before discharge? 

What do you use as discharge criteria? 

Does he need a heart failure cardiologist to follow him? 

Would you evaluate his hypertension? Would his race matter 

in this answer? 

Would you start a statin? If so, which one and at what dose? 


55-year-old woman has been followed for a dilated cardiomyopathy 

for several years by a board-certified advanced 

heart failure cardiologist and is on evidence-based therapy 

at the highest tolerated doses. She has had to stop working 

as a teacher, and is only able to do light chores at home. 

She is not volume overloaded but is profoundly fatigued. 

She has a single-lead ICD. Her BP is 90/50 mmHg, and her 

heart rate is 55 bpm. Renal function is normal. 

Would you order a VO2 max? 

Would you perform a right heart cath? 

Would you perform a left heart cath? 

Is there a role for MRI now? 

Would you order any biomarkers? If so, which ones? 

Would you admit her to the hospital? 

What hemodynamics would compel you to decrease her 

medications? 

What hemodynamics would compel you to add medicines? 

What circumstances would compel you to add an inotrope? 

What triggers do you use to initiate a transplant evaluation? 

What is your weight cut-off for transplant? How about for 

VAD? 

What is your age cut-off for transplant? 


55 year old male has a dilated cardiomyopathy for unclear 

reasons. He has refused left heart cath in the past. 

He has long standing hypertension, recent diabetes and is 

a 40 pack year cigarette smoker. He is now admitted with 

acute decompensated heart failure. He is approximately 20 

pounds increased from his last office visit weight. His BP 

is 90/50mmg, heart rate 110/min, somewhat irregular. On 

examination, he is warm and volume overloaded. Renal 

function is normal. In the emergency room, he is given 40 

IV furosemide with little urine output over the next hour. 

Would you give a higher dose of furosemide? 

Would you give a thiazide diuretic like metalozone? 

Is there a role for nesiritide? 

When would you consider invasive hemodynamic testing? 

Does he need admission? 

Does your program transplant active cigarette smokers? 

How about marijuana? 

How high would a troponin have to be before you take him 

to the cath lab? 

8:00 Additional Audience FAQs 

8:00 Adjourn 

Learning objective: Identify important decision points in 

drug therapy for heart failure, and describe effective management 

strategies. 

Abstracts/posters of interest: 102, 98, 99, 96, 97, 101, 103 

8:30 AM – 10:00 AM 

Maryland B 

Case Discussion – Clinical Conundrums 

Moderators: Sara Paul, Hickory, NC 

Lynne Warner Stevenson, Boston MA 

Panelists: 

Robert DiDomenico, Chicago, IL 

Joseph Hill, Dallas, TX 

Alan Miller, Jacksonville, FL 

Christine Thompson, Stanford CA 

Sana Al-Khatib, Durham, SC 

10:00 Adjourn 

Learning Objective: Using practice guidelines, research 

findings, and clinical experience, make management decisions 

about difficult cases in heart failure. 

47


8:30 AM – 10:00 AM 

Maryland A 

Nursing Research Award 



8:30 ASC Methylation and Expression are Associated 

with Depressive Symptoms, Anxiety, and Quality 

of Life in Heart Failure 

Brittany Butts 1 , Rebecca A. Gary 1 , Sandra B. 

Dunbar 1 , Javed Butler 2 . 1 Emory University, Atlanta, 

GA; 2 Stony Brook University, Stony Brook, NY 

8:45 Women's Experiences Being Diagnosed with 

Peripartum Cardiomyopathy 

Rebecca L. Dekker 1 , Christine H. Morton 2 , Paula 

Singleton 3 , Audrey Lyndon 4 . 1 University of Kentucky, 

Lexington, KY; 2 Stanford University, 

Stanford, CA; 3 Leeds University, Leeds, United 

Kingdom; 4 University of California San Francisco, 


9:00 Assessment of the Accuracy of the Diagnosis for 

Heart Failure in a Large Metropolitan Health Care 

System and the Impact on Readmission Rates 

Sandra Carey, Giovanna Saracino, Cara A. East, 

Paul A. Grayburn, Ravi C. Vallabhan, Kyle Bass, 

William Shutze Jr, Shelley A. Hall. Baylor Scott & 

White Health, Dallas, TX 

9:15 Right Ventricular Dysfunction is an Independent 

Predictor of Length of Stay Following Left 

Ventricular Assist Device Implantation 

Rachel Clarke, Amanda R. Vest, Linda Ordway, 

Michael S. Kiernan, David DeNofrio. Tufts Medical 

Center, Boston, MA 

9:30 An Acceptability and Feasibility Study of Decision 

Aids for Patients and Their Caregivers Considering 

Destination Therapy Left Ventricular Assist Device 

Colleen K. McIlvennan 1 , Jocelyn S. Thompson 2 , Daniel D. 

Matlock 3 , Joseph C. Cleveland 4 , Larry A. Allen 1 . 1 University 

of Colorado, Aurora, CO; 2 University of Colorado, 

Aurora, CO; 3 University of Colorado, Aurora, CO; 

4 

University of Colorado, Aurora, CO 

9:45 Using Shared Medical Appointments to Decrease 

Readmission Rates 

Donna Walker 1 , Renee Marincic 2 . 1 Euclid Hospital, 

Euclid, OH; 2 Euclid Hospital, Euclid, OH 

10:00 Adjourn 

*10-minute presentation, 5 minute discussion 

Learning Objectives: Discuss the results of recent nursing 

research and its implications for the care of patients with 

heart failure. 

8:30 AM – 10:00 AM 

Maryland C 

JNC Young Investigators Award: Clinical/ 

Integrative 

Moderators: Jay Cohn, Minneapolis, MN 


8:30 Correlation Between Coronary Sinus, Arterial 

and Venous BNP Levels in Subjects with 

Reduced Left Ventricular Systolic Function 

Zubair Shah, Arun Mahankali Sridhar, Reza Masoomi, 

Mark Wiley, Buddhadeb Dawn, Kamal Gupta. University 

of Kansas Medical Center, Kansas City, MO 

8:45 Mortality in Status 2 Patients Listed for Heart Transplantation 

in the United States: Will Understanding 

Mode of Death Help Justify Implantationof Left 

Ventricular Assist Devices Into Less Sick Patients? 

Alanna A. Morris 1 , Andreas Kalogeropoulos 1 , Anita 

Kelkar 1 , Robert T. Cole 1 , Divya Gupta 1 , Duc Nguyen 2 , 

S. Raja Laskar 1 , Andrew Smith 1 , J. David Vega 2 . 1 Emory 

University, Atlanta, GA; 2 Emory University, Atlanta, GA 

9:00 Patients With HF Show High Degrees of Moderate to 

Severe Cognitive Impairment Despite Normal 

MMSE Testing 

Deepak J. Pattanshetty, Dana Cook, Sonika Malik, Mark 

E. Dunlap. Metrohealth Campus of Case Western Reserve 

University, Cleveland, OH 

9:15 Bridging Anticoagulation After CF-LVAD Implantation 

Indra Bole 1 , Bethany Tellor 2 , Michael Nassif 3 , David 

Raymer 3 , Anjan Tibrewala 1 , Scott Silvestry 4 , Justin Vader 

3 , Shane LaRue 3 . 1 Washington University School of 

Medicine, Saint Louis, MO; 2 Washington University 

School of Medicine, Saint Louis, MO; 3 Washington 

University School of Medicine, Saint Louis, MO; 4 

Washington University School of Medicine, Saint Louis, MO 

9:30 Cardiac Rotational Mechanics as a Predictor of 

Favorable Functional and Structural Response 

After Mechanical Unloading With Cardiac Assist 

Devices in Advanced Heart Failure Patients 

Michael J. Bonios 1 , James Wever Pinzon 1 , Josef Stehlik 1 , 

Abdallah Kfoury 2 , Edward M. Gilbert 1 , Rami Alharethi 2 , 

Jose Nativi-Nicolau 1 , Craig H. Selzman 1 , Mohammad 

Alsari 1 , Bruce Reid 2 , Stephen H. McKellar 1 , Antigone 

Koliopoulou 1 , William Caine 2 , Dean Y. Li 1 , James Fang 1 , 

Stavros G. Drakos 1 . 1 University of Utah, Salt Lake City, 

UT; 2 Intermountain Medical Center, Salt Lake City, UT 

9:45 Outcomes After Cardiopulmonary Resuscitation 

Among Patients Hospitalized with Heart Failure 

Justin S. Sadhu, Michael W. Rich. Washington 

University in St. Louis, Saint Louis, MO 

10:00 Adjourn 

*10 minute presentation, 5 minute discussion 

Learning Objective: Discuss the results of recent heart failure 

research and their implications for treatment. 

48


8:30 AM – 10:00 AM 

Maryland 1-2 

JNC Young Investigators Award: 

Basic Science 

Moderators: Steven Houser, Philadelphia, PA 


8:30 Acute Blood Pressure, Renal and cGMP Responses 

to the Novel Designer Natriuretic Peptide ZD100 in 

Spontaneously Hypertensive Rats 

Alessia Buglioni 1 , Jeson S. Sangaralingham 1 , 

Gerald E. Harders 1 , Brenda K. Huntley 1 , Horng H. 

Chen 1 , 2 , John C. Burnett 1 , 2 . 1 Mayo Clinic, Rochester, 

MN; 2 Zumbro Discovery, Rochester, MN 

8:53 Oxidative Stress Induced Modulation of Platelet 

Integrin αIIbβ3 Expression and Shedding During 

Major Bleeding in Heart Failure Patients Supported 

By Continuous Flow Left Ventricular 

Assist Devices 

Nandan K. Mondal 1 , Zengsheng Chen 1 , Jun Ding 1 , 

Mike Sobieski 1 , Si Pham 2 , Steven Koenig 1 , Bartley 

P. Griffith 2 , Mark S. Slaughter 1 , Zhongjun J. Wu 1 . 

1 

University of Louisville School of Medicine, 

Louisville, KY; 2 University of Maryland School of 

Medicine, Baltimore, MD 

9:15 Rapid Restoration of Transplanted Stem Cell 

Bioenergetics By Metabolic Scaffolds That Promote 

Cell Adhesion and Provide Substrates 

Junaid Afzal, Angel Chan, Mehmet Fatih Karakas, 

Kirubel Woldemichael, Stella Vakrou, Brian 

O'Rourke, M Roselle Abraham. Johns Hopkins 

University, Baltimore, MD 

9:38 Temporal Assessment of Endothelial to Mesenchymal 

Transition as a Contributor to Fibrosis in a Mouse 

Model of Heart Failure 

Cesar Uribe, Andrea M. Cordero-Reyes, Keith 

A. Youker, Guha Ashrith, Barry H. Trachtenberg, 

Jerry D. Estep, Guillermo Torre-Amione, John P. 

Cooke, Arvind Bhimaraj. The Methodist Hospital, 

Houston, TX 

10:00 Adjourn 

8:30 AM – 10:00 AM 

Potomac C 

Cardiovascular Magnetic Resonance 

Imaging for the Heart Failure Specialist 

Moderators: Eric Velazquez, Durham, NC 

James Udelson, Boston, MA 

8:30 Introduction 

8:35 Scar Imaging in Cardiomyopathy and Heart 

Failure: "Non-Ischemic" Dilated Cardiomyopathy 

Eric Schelbert, Pittsburgh, PA 

8:50 CMR in Infiltrative and Inflammatory 

Cardiomyopathies 

Frederick Ruberg, Boston, MA 

9:05 CMR in Hypertrophic Cardiomyopathy 

Martin Maron, Boston, MA 

9:20 New Frontiers in Cardiac MR Research: Where 

Do We Go from Here? 

Ravi Shah, Boston, MA 


Faculty 

10:00 Adjourn 

Learning Objective: Describe the uses of cardiovascular MRI 

in heart failure diagnosis and management. 

Abstracts/posters of interest: 161 

10:00 AM 



Exhibit Hall Opens 




*14 minute presentation, 8- minute discussion 

Learning objective: Discuss the results and implications of 

basic science research in heart failure. 

49


10:30 AM – 12:00 PM 

Maryland C 

Managing the VAD Outpatient 

Moderators: Jason Katz, Chapel Hill, NC 

Roxanne Siemeck, Oak Lawn, IL 

10:30 Alarms and Device Malfunction: Handling the 

Calls from Home 

William Cotts, Oak Lawn, IL 

10:45 Patient and Caregiver Psychosocial Issues 

Quincy Young, Vancouver, Canada 

11:00 Using the Echocardiogram: Should Imaging Be 

Protocol Driven? 

Andrew Sauer, Chicago, IL 

11:15 Recovery Inclusive of Biomarkers 

Tarek Ahmad, Durham, NC 

11:30 How to Improve the Functional Capacity of the 

VAD Patient 

Seth Hollander, Stanford, CA 


Faculty 

12:00 Adjourn 

Learning Objective: Effectively manage VAD outpatients, 

addressing medical, psychosocial, and functional issues. 

10:30 AM – 12:00 PM 

Maryland A 

Putting the “Self” Back in Self-Care: 

Innovative Strategies to Improve Heart 

Failure Self-Care (Joint Session with 

AAHFN) 


Connie Lewis, Nashville, TN 

10:30 Why is Self-Care so Difficult? 

Corrine Jurgens, Stony Brook, NY 

10:50 Managing Medications at Home 

Kerry Pickworth, Columbus, OH 

11:10 Using Technology to Engage Patients and 

Caregivers in Self-Care 

Misook Chung, Lexington, KY 

11:30 Engaging patients with Health Literacy Barriers 

Jia-Rong Wu, Chapel Hill, NC 


Faculty 

12:00 Adjourn 

Learning Objective: Describe effective self-care and outline 

strategies for engaging HF patients in self-care. 


50


10:30 AM – 12:00 PM 

Maryland D 

Controversies in Cardio-Oncology 


Ron Witteles, Stanford, CA 

10:30 Left Ventricular Dysfunction With Herceptin- 

To Hold or Not to Hold? 

Bonnie Ky, Philadelphia, PA 

10:50 Myocardial Biopsy for Anthracycline Toxicity— 

When, How and What For? 

Jean-Bernard Durand, Houston, TX 

11:10 Tracking Cardiotoxicity with Myocardial 

Strain—What Now? 

Juan Carlos Plana, Houston, TX 

11:30 Cardioprotection in Chemotherapy Recipients 

Edward T. H. Yeh, Houston, TX 


Faculty 

12:00 Adjourn 

Learning Objective: Identify cardiotoxicity in chemotherapy 

recipients and use effective management and cardioprotective 

strategies. 

Abstracts/posters of interest: 26 

10:30 AM – 12:00 PM 

Maryland C 

The “Hidden Gems” of Heart Failure 

Publishing 

Moderators: Gary Francis, Minneapolis, MN 

Jay N. Cohn, Minneapolis, MN 

10:30 The Best of JCF 

Paul Hauptmann, St. Louis, MO 

10:43 The Best of JACC: Heart Failure 


10:56 The Best of Circulation: Heart Failure 

James Udelson, Falls Church, VA 

11:09 The Best of European Journal of Heart Failure 

Marco Metra, Brescia, Italy 

11:22 The Best of the Journal of Heart & Lung 

Transplant 

Mandeep Mehra, Boston, MA 

11:35 The Best of the Journal of Cardiovascular Nursing 

Debra Moser, Lexington, KY 

11:48 Panel Discussion/Q&A with Journal Editors – 

Challenges in Publishing, Questions 

12:00 Adjourn 

Learning Objective: Identify key research findings published 

in leading heart failure journals and discuss their implications for 

practice. 

Abstracts/posters of interest: 553, 137, 297, 448, 497, 315, 311, 

484 

51


10:30 AM – 12:30 PM 

Maryland 3-4 


Advanced Troubleshooting with Durable VADs 


Chair: Joseph Rogers, Durham, NC 

Co-Chair: Selma Mohammed, Rochester, MN 


10:30 Start 

12:30 Adjourn 

Learning Objective: Describe common or difficult issues in 

the management of VAD patients and strategies for troubleshooting. 


Supported by educational grants from Heartware and 

Thoratec 

10:30 AM – 12:00 PM 

Maryland 5-6 


Cardiopulmonary Function Testing 


Chair: Gregory Lewis, Boston, MA 

10:30 Start 

12:00 Adjourn 

Learning Objective: Describe and demonstrate the effective 

use of cardiopulmonary testing in heart failure. 

12:15 PM – 1:15 PM 

Maryland C 

How to Use Cardiac Rehabilitation in 

Heart Failure 

Ileana Pina, New York, NY 

Stuart Russell, Baltimore, MD 

David Whellan, Philadelphia, PA 


1:15 Adjourn 

Learning Objective: Describe the role of cardiac rehabilitation 

in HF and outline an effective patient program. 

12:15 PM – 1:15 PM 

Potomac C 

Rapid Fire Abstracts II 

Moderators: Joseph Rogers, Durham, NC 

Paul J. Hauptman, St. Louis, MO 

12:15 Peripheral Metabolite Pattern in Heart Failure 

Patients is an Independent Predictor of Survival 

David E. Lanfear 1 , Stephen Gardell 2 , Albert Levin 1 , 

Jia Li 1 , Keoki Williams 1 , Hani Sabbah 1 , Nicole 

Zeld 1 . 1 Henry Ford Health System, Detroit, MI; 

2 

Sanford Burnham Research Institute, Orlando, FL 

12:20 Genetic Factors Influencing B-type Natriuretic 

Peptide Mediated Production of Cyclic Guanosine 

Mono Phosphate and Blood Pressure Effects 

in Heart Failure Patients 

David Lanfear 1 , Raza Abbas 1 , Badri Padhukasahasram 1 , 

Ramesh C. Gupta 1 , David Langholz 2 , W. Wilson Tang 3 , 

L. Keoki Williams 1 , Hani N. Sabbah 1 . 1 Henry Ford 

Hospital, Detroit, MI; 2 Spectrum Health, Grand Rapids, 

MI; 3 Cleveland Clinic Foundation, Cleveland, OH 

12:25 Burden of Heart Failure and Treatment Practices 

Among Patients with HIV Infection in an Era of 

Contemporary Antiretroviral Therapy 

Sadeer G. Al-Kindi, Guilherme H. Oliveira, Chris 

T. Longenecker. University Hospitals Case Medical 

Center, Cleveland, OH 

12:30 In-Vitro Exposure of Isolated Failing Cardiomyocytes 

to Vepoloxamer (Purified Poloxamer 188) Limits 

Unregulated Calcium Entry into the Cell 

Ramesh C. Gupta 1 , Vinita Sing-Gupta 1 , Marty 

Emanuele 2 , Hani N. Sabbah 1 . 1 Henry Ford Health 

System, Detroit, MI; 2 Mast Therapeutics, Inc., San 

Diego, CA 

12:35 NEOD001 Demonstrates Cardiac and Renal 

Biomarker Responses in a Phase 1/2 Study in 

Patients with AL Amyloidosis and Persistent 

Organ Dysfunction 

Michaela Liedtke 1 , Heather Landau 2 , Ray Comenzo 

3 , David Seldin 4 , Brendan Weiss 5 , Jeffrey 

Zonder 6 , Jackie Walling 7 , Gene Kinney 8 , Martin 

Koller 8 , Morie A. Gertz 9 . 1 Stanford University 

School of Medicine, Stanford, CA; 2 Memorial 

Sloan-Kettering Cancer Center, New York, NY; 

3 

Tufts Medical Center, Boston, MA; 4 Boston 

University, Boston, MA; 5 University of Pennsylvania, 

Philadelphia, PA; 6 Karmanos Cancer Institute, 

Detroit, MI; 7 JW Consulting, Hillsborough, CA; 

8 

Prothena Biosciences, South San Francisco, CA; 

9 

Mayo Clinic, Rochester, MN 

52


12:40 A Pharmacogenetic Investigation of Intravenous 

Furosemide in Decompensated Heart Failure: A 

Meta-Analysis of 3 Clinical Trials 

Simon de Denus 1 , Jean L. Rouleau 1 , Douglas L. 

Mann 2 , Gordon S. Huggins 3 , Thomas P. Cappola 4 , 

Svati H. Shah 5 , Julianna Keleti 6 , Yassamin Feroz 

Zada 1 , Sylvie Provost 1 , Amina Bardhadi 1 , Michael 

S. Phillips 1 , Valérie Normand 1 , Ian Mongrain 1 , Marie-Pierre 

Dubé 1 . 1 Montreal Heart Institute, Montreal, 

QC, Canada; 2 Washington University School 

of Medicine, St. Louis, MO; 3 Tufts Medical Center, 

Boston, MA; 4 University of Pennsylvania, Philadelphia, 

PA; 5 Division of Cardiology, Duke University 

School of Medicine, Durham, NC; 6 National Heart, 

Lung, and Blood Institute, Bethesda, MD 

12:45 Baseline Characteristics Predict the Presence 

of Amyloid on Endomyocardial Biopsy Among 

Patients With Heart Failure With Preserved 

Ejection Fraction 

Van-Khue Ton, Aditya Bhonsale, Marc K. Halushka, 

Charles Steenbergen, Edward Kasper, Ryan 

J. Tedford, Ilan Wittstein, Kavita Sharma, Stuart 

Russell, Daniel P. Judge. Johns Hopkins Hospital, 

Baltimore, MD 

1:05 Effect of Corin Deficiency and Mutation on 

Cardiac Natriuretic Peptide Processing in the 

Intact Heart Under Cardiac Pressure-Overload 

Conditions 

Bin Xu, Temple University, Philadelphia, PA 

1:10 Telomere Integrity as a Genetic Marker of 

Effective Treatment for Advanced Heart Failure 

Cara Statz 1 , Judith Brown 2 , Aleksandra Ras 1 , Kev 

in Ballard 1 , Dharma Desai 2 , Daniel Fusco 1 , Jona 

than Hammond 1 , Jason Gluck 1 , Detlef Wencker 3 . 

1 

Hartford Hospital, Hartford, CT; 2 University of 

Connecticut, Storrs, CT; 3 University of Kansas 

Medical Center, Kansas City, KS 

1:15 Adjourn 

Learning Objective: Discuss findings from recent research 

in HF and their implications for research and clinical practice. 

12:50 Contemporary Natural History, Mechanical 

Circulatory Support Needs and Post-Transplant 

Outcomes of Patients With Myocarditis Listed 

for Heart Transplantation 

Chantal Elamm, Sadeer Al-Kindi, Mahazarin Ginwalla, 

Rodolfo Benatti, Mobolaji Ige, Mohammadkattea, 

Chang kim, Guilherme Oliveira. University 

Hospitals of Cleveland, Cleveland, OH 

12:55 Central-Line Associated Bloodstream Infections 

Related to Inpatient Pulmonary Artery Catheterization 

among Patients Waiting for Heart 

Transplantation 

Usama Daimee, Katherine Dodd, Saadia Sherazi, 

Lynn Fine, Christine Hay, Eugene Storozynsky, 

Jeffrey Alexis, Leway Chen, University of Rochester 

Medical Center, Rochester, NY 

1:00 Relevance of Changes in Serum Creatinine 

During a Heart Failure Trial of Decongestion: 

Insights From the DOSE Trial 

Meredith A. Brisco 1 , Michael R. Zile 1 , Jennifer 

Simon 2 , W.H. Wilson Tang 3 , Jeffrey M. Testani 2 . 

1 

Medical University of South Carolina, Charleston, 

SC; 2 Yale University School of Medicine, New 

Haven, CT; 3 The Cleveland Clinic Foundation, 

Cleveland, OH 

53


12:15 PM – 1:15 PM 

Maryland D 

How to Manage Diuretic Resistance: 

What to Do When the Fluid Won’t Come 

Off 

12:15 What is Diuretic Resistance? 

Wilfried Mullens, Genk, Belgium 

12:25 Increase the Dose of the Loop Diutetic 

Michael Felker, Durham, NC 

12:35 Combination Diuretic Therapy 

David Ellison, Portland, OR 

12:45 Ultrafiltration 

Bradley Bart, Minneapolis, MN 


Faculty 

1:15 Adjourn 

Learning Objective: Use appropriate options to reduce 

fluid overload in the management of patients with diuretic 

resistance. 

12:15 PM – 1:15 PM 

Maryland A 

How to Manage Sleep Apnea in Heart 

Failure 

12:15 Why is Sleep Apnea So Bad for the Heart Failure 

Patient? 

Stephan Gottlieb, Baltimore, MD 

12:25 Studies of Mask-Based Therapies in Heart Failure 

Susan Joseph, Houston, TX 

12:35 Novel Implantable Devices for Treating Sleep Apnea 

Maria Rosa Costanzo, Chicago, IL 

12:45 Patient Management 



Faculty 

1:15 Adjourn 

Learning Objective: Describe the significance of sleep 

apnea in heart failure and use effective management tools 

and options. 

12:15 PM – 1:15 PM 

Maryland 1-2 

How to Conduct Bedside Assessment in 

Heart Failure 

James Fang, Salt Lake City, UT 

Gregory Lewis, Boston, MA 

Jonahtan Howlett, Calgary, Alberta, Canada 

12:15 Adjourn 

Learning Objective: Describe key principles and strategies 

for bedside assessment in heart failure. 

54


1:20 PM – 3:00 PM 

Maryland B 

Announcement of Awards 

JNC New Investigator Award: Basic Science 

Presented by: Steven Houser, Philadelphia, PA 


JNC New Investigator Award: Clinical/Integrative 

Presented by: Jay Cohn, Minneapolis, MN 


Nursing Research Award 

Presented by: Victoria Dickson, New York, NY 

Hyde Park Session 

Moderators: Douglas Shocken, Durahm, NC 


1:30 The Big Box Approach: How Wal-Mart, Sam’s 

Club and Target Fail Clinical Trials 

Peter Carson, Washington, DC 

1:48 A New Core Measure HF 


2:06 Medicare Changes List of Quality Core Measures 

for Heart Failure After Study Finds that Computers 

Failed to Educate Patient Upon Marking a Check 

Box in the EMR for Discharge Instructions and 

Ultrasound Waves Cure Heart Failure - A Mocking 

Finding for the Get With the Guidelines Initiative 

Arvind Bhimaraj, Houston, TX 

1:30 PM – 3:00 PM 

Maryland C 

Load, Unloading, Remodeling and Recovery 

Moderators: Keith Aaronson, Ann Arbor, MI 

Douglas Mann, St, Louis, MO 

1:30 Patterns, Mechanisms, and Clinical Implications 

of Ventricular Remodeling 


1:50 Pharmacological Unloading of the Right and 

Left Ventricle: From Pathophysiology to Therapy 

Ryan Tedford, Baltimore, MD 

2:10 Mechanical Ventricular Unloading and Reverse 

Remodeling: From VAD Registries to Prospective 

Investigations 

Stavros Drakos, Salt Lake City, UT 

2:30 Types of Mechanical Unloading to Enhance 

Reverse Remodeling and Cardiac Recovery: 

From Animal Models to Clinical Applications 

Thomas Force, Nashville, TN 


Faculty 

3:00 Adjourn 

Learning objective: Describe ventricular remodeling in 

heart failure and discuss the clinical implications of pharmacological 

and device unloading. 

2:24 Perverse Incentives: Rats Tails and the Transplant 

Waiting List 

Matthew Movsesian, Salt Lake City, UT 

2:42 Are Heart Failure Doctors Chimpanzees? 

Stephen Gottlieb, Baltimore, MD 

3:00 Adjourn 

Learning objective: Discuss new insights and perspectives 

on important issues in HF research and clinical practice. 

55


1:30 PM – 3:00 PM 

Maryland A 

What’s New and Emerging in Heart Failure 

Pharmacology? 

Moderators: Mona Fiuzat, Durham, NC 

Scott Solomon, Boston, MA 

1:30 New and Emerging Drugs for Acute Heart Failure 

Milton Packer, Dallas, TX 

1:50 New and Emerging Drugs for Heart Failure 

with Reduced Ejection Fraction 


2:10 New and Emerging Drugs for Heart Failure 

with Preserved Ejection Fraction 

Orly Vardeny, Madison, WI 

2:30 What’s New and Emerging in Cell Therapy? 

Joshua Hare, Miami, FL 

2:50 Panel Discussion: Implications for Practice 

Faculty 

3:00 Adjourn 

Learning Objective: Identify new and emerging drugs in 

heart failure and their implications for practice. 

1:30 PM – 3:30 PM 

Maryland 3-4 

Hands-On Workshop 4 (Repeat): 

Advanced Troubleshooting with Durable 

VADs 


Chair: Joseph Rogers, Durham, NC 

Co-Chair: Selma Mohammed, Rochester, MN 


1:30 Start 

3:30 Adjourn 

Learning Objective: Describe common or difficult issues in 

the management of VAD patients and strategies for troubleshooting. 

Supported by educational grants from Heartware and 

Thoratec 

1:30 PM – 3:00 PM 

Maryland 5-6 

Hands-On Workshop 5 (Repeat): 

Cardiopulmonary Function Testing 


Chair: Gregory Lewis, Boston, MA 

1:30 Start 

3:00 Adjourn 

Learning Objective: Describe and demonstrate the effective 

use of cardiopulmonary testing in heart failure. 

56


3:30 PM – 5:00 PM 

Potomac C 

Debates 



3:30 Pro: Routine Genetic Screening for All Individuals 

Diagnosed with Non-Ischemic Cardiomyopathy 

Ray Hershberger, Columbus, OH 

3:45 Con: Routine Genetic Screening for All Individuals 

Diagnosed with Non-Ischemic Cardiomyopathy 

John Cleland, Harefiled Middlesex, UK 


4:15 Case Based Debate Presentation 


72-year old white female with history of heart 

failure with systolic dysfunction with a known left 

ventricular ejection fraction of 25% assessed 6 

months ago, diabetes mellitus for 10 year, and 

chronic kidney disease. She presents to the emergency 

room with progressively worsening heart 

failure signs and symptoms for 5 days. She denies 

any changes in diet or medication non-compliance. 

No symptoms of infection. No chest pain, syncope, 

or palpitations. She is currently on lisinopril 

10mg qd, carvedilol 12.5 bid, digoxin 0.125 qd, 

furosemide 40 po bid, and insulin. 

On physical examination, her vital signs included, 

blood pressure 100/68, heart rate 92, respiratory 

rate 21, O2 saturation of 94% 

JVP 10 cm 

Chest: Bilateral basilar rales 

Cardiovascular: Regular rhythm, S1+S2, 2/6 HSM LSB 

Abdomen: Liver tip palpable on deep inspiration. 

No ascites, no tenderness, no distension 

Lower extremities: Bilateral 2+ pitting edema 

4:30 She was started on furosemide 80 mg IV bid and 

home medications were continued. On day 2, she 

is feeling better and has a net negative urine output 

of 1.8 liters. Her morning labs show a serum Cr of 

2.3 mg/dl. 

Should her lisinopril be held while actively being 

diuresed and restarted at discharge? 

Opinion 1: Lynne Warner Stevenson, Boston MA 

Opinion 2: Joshua Hare, Miami, FL 

4:40 On day 5th of admission, she is feeling better and 

ambulating and the decision is made to discharge 

the patients. The intern tells you that they ordered 

BNP level with morning labs and it came back at 

1423 pg/ml. 

Should you discharge the patients or keep her 

another few days to diurese more and lower BNP 

levels? 

Opinion 1: Alan Maisel, San Diego, CA 

Opinion 2: Kirkwood Adams, Chapel Hill, NC 

4:50 The patient is ready for discharge. She lost 7 lbs. 

and is feeling good. Her vital signs are stable and 

she is ambulating. Her labs on the morning of 

discharge include sodium 136 meq/L, potassium 

4.6 meq/L, and creatinine 1.8 mgdl (eGFR 36). In 

preparation for discharge, she was placed back on 

all her usual pre-admission medications. 

Should she be started on aldosterone antagonist at 

discharge? 

Opinion 1: Adrian Hernandez, Durham, NC 

Opinion 2: Gregg Fonarow, Los Angeles, CA 

5:00 Adjourn 

Learning Objective: Outline arguments for and against 

routine genetic screening in individuals with non-ischemic 

cardiomypathy and discuss treatment options for selected 

HF cases. 

Her initial testing showed: Sodium 134 meq/L, 

K4.5 meq/L, Cr. 1.9 mg/dl, BNP 1958 pg/ml 

ECG: NSR, non-specific ST-T changes 

Chest X Ray: Prominent venous congestion 

4:20 On admission, should she be put on a strict low 

salt and fluid restriction diet? 

Opinion 1: Paul Hauptman, St. Louis, MO 

Opinion 2: W. H. Wilson Tang, Cleveland, OH 

57


3:30 PM – 5:00 PM 

Maryland A 

Alternative Therapies for Heart Failure: 

Fact or Fiction? 

Moderators: Sheryl Chow, Los Angeles, CA 

Orly Vardeny, Madison, WI 

3:30 Neutraceuticals: Hawthorn, Co-enzyme Q10, 

Omega-3’s 

Barry Bleske, Ann Arbor, MI 

3:45 High Dose Vitamins, Vitamin D 

Rebecca Boxer, Denver, CO 

4:00 Diet 

Terry Lennie, Lexington, KY 

4:15 Alternative Agents to Avoid 

Jean Nappi, Charleston, SC 

4:30 Counseling Patients about Alternative Therapies 

Robert Page II, Denver, CO 


Faculty 

5:00 Adjourn 

Learning Objective: Describe the evidence base for selected 

alternative therapies for heart failure and counsel patients 

with questions about alternative therapies. 


3:30 PM – 5:00 PM 

Maryland C 

Emergency Management of VAD Patients 

(Joint Session with ISHLT) 

Moderator: Mandeep Mehra, Boston, MA 

Sean Pinney, New York, NY 

3:30 VAD Patients with Heart Failure 

Joseph Rogers, Durham, NC 

3:50 Cardiac Arrest and Arrhythmias 

Henri Roukoz, Minneapolis, MN 

4:00 Trauma 

W. Frank Peacock, Houston, TX 

4:10 Device Failure and Malfunction 

Nir Uriel, Chicago, IL 

4:20 GI Bleeding 

Maria Mountis, Cleveland, OH 

4:30 Neurovascular Events 

Jeffrey Teuteberg, Pittsburgh, PA 


Faculty 

5:00 Adjourn 

Learning Objective: Identify management strategies for 

VAD emergencies such as GI bleeding, cardiac arrest, and 

neurovascular events. 

58


3:30 PM – 5:00 PM 

Maryland D 

How to Interpret Biomarker Studies 

Moderators: Inder Anand, Minneapolis, MN 

Deedwania Prakash, San Francisco, CA 

3:30 Overview of Biomarkers in Heart Failure 

James Januzzi, Boston, MA 

3:43 Can We Use Biomarkers to Prevent Heart Failure? 

Christopher deFilippi, Baltimore, MD 

3:56 What Have We Learned from Natriuretic 

Guided Trials 

Hanna Gaggin, Boston, MA 

4:09 Biomarkers of Cardio-Renal Syndrome 

Jeffrey Testani, New Haven, CT 

4:22 Biomarkers and Heart Failure Devices 

Tariq Ahmad, Durham, NC 

4:35 Monitoring Cancer Therapeutics Using Biomarkers 

Bonnie Ky, Philadelphia, PA 

4:48 Biomarkers and Acute Heart Failure 

G. Michael Felker, Durham, NC 

5:00 Adjourn 

Learning Objective: Describe the current role of biomarkers 

in heart failure diagnosis and management. 

59

TUESDAY, SEPTEMBER 29 

7:00 AM – 8:15 AM 

Maryland A 

Managing the Patient with Newly Diagnosed 

Heart Failure 

Moderators: David Whellan, Philadelphia, PA 


7:00 Approaches and Challenges to Making the 

Diagnosis 


7:15 Determining Etiology: Implications For Further 

Management 

Biykem Bozkurt, Houston, TX 

7:30 Initiating Therapy. Getting It Right from the Start 

Barry Greenberg, San Diego, CA 

7:45 Stratifying Risk and Preventing SCD 

Wayne Levy, Seattle, WA 

8:00 Bad News and Good News – Patient and Family 

Education For New Diagnosis 

Ann Laramee, Burlington, VT 

8:15 Adjourn 

Learning Objective: Effectively diagnose, determine etiology, 

initiate therapy and strategy risk in patients with newly 

diagnosed heart failure. 

7:00 AM – 8:15 AM 

Maryland C 

Clinical Fundamentals III: Acute Heart 

Failure 360 

Moderators: Gerasimos Filippatos, Athens, Greece 

Laura Wexler, Cincinnati, OH 

7:00 Current Concepts in the Pathophysiology of 

Acute Heart Failure 


7:15 Acute Heart Failure - Past Trials 


7:30 What’s Next in Acute Heart Faillure: Ongoing 

Trials 

John Teerlink, San Francisco, CA 

7:45 Regulations Impacting the Management of 

Acute Heart Failure 

Paul Heidenreich, San Francisco, CA 

8:00 How to Treat Acute Heart Failure- Tips from a 

Master Clinician 

Mariell Jessup, Philadelphia, PA 

8:15 Adjourn 

Learning Objective: Describe the pathophysiology of acute 

heart failure, key trial results, and clinical strategies for 

managing patients. 


60


7:00 AM – 8:15 AM 

Potomac C 

The Periphery in Heart Failure: More 

Than an Innocent Bystander 

Moderators: Michelle Hamilton, Los Angeles, CA 

Stuart Katz ,New York, NY 

7:00 Arterial Stiffness, Wave Reflections and Heart 

Failure 

Julio A. Chirinos, Boston, MA 

7:15 Systemic Arterial Vasodilation in Heart Failure: 

HFrEF vs. HFpEF 

Rajan Krishnamani, Mason, OH 

7:30 Skeletal Muscle in Heart Failure 

Dalane Kitzman, Winston-Salem, NC 

7:45 The Role of the Microcirculation in Exercise 

Intolerance in Heart Failure 

Payman Zamani, Philadelphia, PA 


Faculty 

8:15 Adjourn 

Learning Objective: Describe the role of the periphery in 

heart failure. 

8:30 AM – 9:45 AM 

Potomac C 

Interventional Structural Devices for 

Heart Failure 

Moderators: Flora Sam, Boston, MA 

Gregg Stone, New York, NY 

8:30 TAVR in Heart Failure Patients with Severe 

Aortic Stenosis 

Olcay Aksoy, Los Angeles, CA 

8:45 MitraClip for Functional Mitral Regurgitation 


Gregg Stone, New York, NY 

9:00 Percutaneous Left Ventricular Partitioning in 

Ischemic Heart Failure 

Ernest Mazzaferri, Columbus, OH 

9:15 Inter-Atrial Shunts 



Faculty 

9:45 Adjourn 

Learning Objective: Identify new interventional structural 

devices, how they function, and their roles in heart failure 

management. 

61


8:30 AM – 9:45 AM 

Maryland A 

Right Sided Heart Failure: What Do We Do 

When Orthopnea is Traded for Ascites? 

Moderators: Liviu Klien, San Francisco, CA 

Wayne Miller, Rochester, MN 

8:30 RV Dysfunction in Heart Failure: Assessment, 

Causes and Implications 

Mandeep Mehra, Boston MA 

8:45 Pulmonary Hypertension in Left Heart Disease 

Causing Right Heart Failure 

Howard J. Eisen, Philadelphia, PA 

9:00 Tricuspid Regurgitation: Mediator, Abettor or 

Barometer of Right Heart Failure? 

Barry Borlaug, Rochester, MN 

9:15 Treatment of Right Heart Failure 

Mitchell Saltzberg, Neward, DE 

9:30 Right Heart Failure and Cardiorenal Syndrome 

Jeffrey Testani, New Haven, CT 

8:30 AM – 9:45 AM 

Maryland C 

Heart Failure Clinics: The Evidence, the 

Need and the Redesign 

Moderators: J. Herbert Patterson, Chapel Hill, NC 

Marc Silver, Oak Lawn, IL 

8:30 Key Issues for the Heart Failure Clinic 

Akshay Desai, Boston, MA 

8:50 Essential Adjuncts for Chronic Heart Failure 

Management 

Ileana Pina, New York, NY 

9:10 Emerging Technology to Enhance Clinic Care 

Thomas Heywood, La Jolla, CA 


Faculty 

9:45 Adjourn 

Learning Objective: Identify key issues for the heart failure 

clinic, essential components, and strategies for success. 

9:45 Adjourn 

Learning Objective: Describe the mechanisms and presentation 

of right heart failure, its relationship to cardiorenal 

syndrome, and current treatment options. 


62


8:30 AM – 9:45 AM 

Maryland D 

Interventions for Vulnerable Patients 

Moderators: Debra Moser, Lexington, KY 

Lisa Rathman, Lancaster, PA 

8:30 Cultural Adaptation of an Educational Intervention 

Karen Vuckovi, Chicago, IL 

8:42 Addressing Education for Rural and Remote 

Heart Failure Populations 

Debra Moser, Lexington, KY 

8:54 Educational Interventions for Older Populations 

Lorraine Evangelista, Irvine, CA 

9:06 Addressing Cultural Issues in an Urban African 

American Population 

Cheryl R. Dennison Himmelfarb, Baltimore, MD 

9:18 Addressing Cultural Issues in Hispanic Populations 

Victoria Dickson, New York, NY 


Faculty 

9:45 Adjourn 

Learning Objective:Identify vulnerable patients with heart 

failure and outline strategies for cultural and educational 

issues. 


10:15 AM – 11:45 AM 

Maryland C 

Update on Peripartum Cardiomyopathy 

and Pregnancy Associated Heart Failure 


Paul McKie, Rochester, MN 

10:30 Final Outcome Status for 1st North American 

Prospective IPAC Study of PPCM/PAC: Risk 

Profile For Recovery/Non-Recovery 

Uri Elkayam, Los Angeles, CA 

10:45 Differential Diagnosis of Heart Failure in Pregnancy: 

Towards an Earlier Diagnosis/recognition 

David Markham, Atlanta, GA 

11:00 Role of Cardiac Magnetic Resonance (CMR) in 

PPCM/PAC 

Erik Schelbert, Pittsburgh, PA 

11:15 New Insights into the Mechanisms of Peripartum 

Cardiomyopathy 

Zoltan P. Arany, Cincinnati, OH 

11:30 Potential Newer Intervention Strategies in 

PPCM/PAC for Those at Highest Risk for 

Non-Recovery 

Michael M. Givertz, Boston, MA 

11:45 Adjourn 

Learning Objective: Describe the importance of early 

diagnosis and identify emerging intervention strategies in 

peripartum cardiomyopathy and pregnancy associated HF. 

63


10:15 AM – 11:30 AM 

Maryland A 

Pharmacogenetics of Heart Failure and 

Transplant: Additive or Redundant? 

Moderators: Arthur Feldman, Philadelphia, PA 

Michael Bristow, Aurora, CO 

10:15 Pharmacogenetics: Overview and Clinical Status 

Mona Fiuzat, Durham, NC 

10:25 Pharmacogenetics of Beta Blockers: Still Relevant? 

Michael Bristow, Aurora, CO 

10:38 Optimizing Use of Hydralazine and Isosorbide 

Dinitrate: What is the Evidence? 

Dennis McNamara, Pittsburgh, PA 

10:50 Genetic Contribution of Immunosuppression- 

Related Toxicity: Better than Serum Drug 

Concentration Monitoring? 

David Lanfear, Detroit, MI 

11:02 Barriers to Implementation in Practice: 

Current State of the Art 

Christopher Newton-Cheh, Boston, MA 

11:15 Putting It All Together: Panel Discussion 

Faculty 

11:30 Adjourn 

Learning Objective: Describe the relationship between 

pharmacogenetics and heart failure and transplantation and 

identify potential next steps. 

10:15 AM – 11:30 AM 

Potomac C 

International Session: 

New Clinical Insights into HFpEF (Joint 

Session with HFA of ESC and Japanese 

HF Society) 

Moderators: Hiroaki Shimokawa, Sendai, Japan 

Robert Mentz, Durham, NC 

10:15 What Exactly Is HFpEF and How Do We 

Diagnose It? 

Kazuhiro Yamamoto, Tottori, Japan 

10:27 Managing Comorbidities in HFpEF: What to Do 

with Coronary Disease and Atrial Fibrillation 

Nancy Sweitzer, Tucson, AZ 

10:39 Treating HFpEF: What Have We Learned and 

What Is Coming Next? 

Margaret Redfield, Rochester, MN 

10:51 Phenomics: How Can We Resolve the Heterogeneity 

of HFpEF? 

Sanjiv Shah, Chicago, IL 

11:03 Wave of the Future? Novel Device Therapies in 

HFpEF 

Wilfried Mullens, Genk, Belgium 


Faculty 

11:30 Adjourn 

Learning Objective: Define HFpEF and its diagnosis and 

identify current and emerging treatment options. 


64

POSTER RECEPTION I - SATURDAY (pages 65-82) 

POSTERS 

All posters will be on display Saturday at 6:00 PM - Monday at 1:30 PM 

Cardiovascular Physiology ..................................................................................................................................... 

017 

Pulse Amplitude Ratio Measured Using Finger Photoplethysmography During a Valsalva Maneuver Estimates 

Pulmonary Capillary Wedge Pressure in Heart Failure Patients 

Nisha A. Gilotra, Ryan J. Tedford, Ilan S. Wittstein, Stuart D. Russell, Harry A. Silber. Johns Hopkins Hospital, Baltimore, MD 

018 

Right Ventricular Stroke Work Index is Inversely Related to Renal Function in Patients with Left Ventricular 

Diastolic Heart Failure 

Qaiser Shafiq, Bhavana Siddegowda Bangalore, Mohamed Elamin, George Moukarbel, Samer Khouri. University of Toledo 

Medical Center, Toledo, OH 

019 

Assessment of Soluble Fms Like Tyrosine Kinase - 1 in Animal Heart Failure Models 

Muhammad Hammadah 1 , Malory Weber 1 , W.H.Wilson Tang 2 . 1 Cleveland Clinic, Cleveland, OH; 2 Cleveland Clinic, 

Cleveland, OH 

020 

Longitudinal Red Cell Distribution Width Variation in African Americans with Acute Decompensated Heart Failure 

is Associated with Increased Readmissions 

Carlos D. Davila, Mahek Shah, Kuan-Hsiang Gary Huang, Vincent M. Figueredo. Albert Einstein Medical Center, Philadelphia, 

PA 

021 

Significant Enhancement of ATP-Synthesis in Cardiomyocytes By Electric Microcurrent 

Karin Macfelda 1 , Alexander Holly 1 , Johannes Mueller 2 . 1 Medical University of Vienna, Vienna, Austria; 2 Berlin Heals, Berlin, 

Germany 

022 

Features of Transthyretin Cardiomyopathy Patients With 6 Specific Cardiac Genotypes in the THAOS Registry. 

Jennifer Schumacher, Leslie Amass, Denis Keohane, Rajiv Mundayat, Moh-Lim Ong. Pfizer Inc., New York, NY 

Cardiovascular Structure/ Imaging .................................................................................................................. 

023 

POCUS as a Tool to Estimate PCWP 

James Regan, Sirtaz Adatya, Andrew Olson, Daniel Schnobrich. University of Minnesota, Minneapolis, MN 

024 

Dilated Cardiomyopathy Causes Significant Derangement in Biventricular Mechanics Not Fully Appreciated By Simply 

Measuring Left Ventricular Ejection Fraction Alone 

Francisco Lopez-Menendez 1 , Denada Palm 2 , Angel Lopez-Candales 3 . 1 University Of Cincinnati Medical Center, Cincinnati, 

OH; 2 University Of Cincinnati Medical Center, Cincinnati, OH; 3 University of Puerto Rico School of Medicine, San Juan, 

Puerto Rico 

025 

Effect of Preload on Right Ventricular Peak Systolic Strain Which Contributes to Right Heart Failure 

Chan Seok Park. Catholic University of Korea, Seoul, Korea, Republic of 

026 

Cardiac Status of Patients Treated With Anthracyclines - A Brazilian Osteosarcoma Study 

Maria V. C. Santos, J. A. Soares, G. H. Pinto, C. R. Macedo, C. Dias, A. S. Petrilli, I. Gonçalves, O. Campos, V. A. Moisés, 

A. C. C. Carvalho. Universidade Federal de São Paulo, São Paulo, Brazil 

65

POSTER RECEPTION I - SATURDAY 

POSTERS 

027 

Estimation of Pulmonary Capillary Wedge Pressure by Echocardiography: A Simplified Approach 

Rajeev Mohan 1 , Hirsch Mehta 1 , 2 , Arvin Narula 1 , Michael Smith 1 , David Rubenson 1 , Allen Johnson 1 , J. Thomas Heywood 1 . 

1 

Scripps Clinic, La Jolla, CA; 2 San Diego Cardiac Center, San Diego, CA 

028 

Mitral Annular Motion: A Useful Echocardiographic Measure of Left Ventricular Systolic and Diastolic Function 

Francisco Lopez-Menendez 1 , Denada Palm 2 , Angel Lopez-Candales 3 . 1 University of Cincinnati Medical Center, Cincinnati, 

OH; 2 University of Cincinnati Medical Center, Cincinnati, OH; 3 University of Puerto Rico School of Medicine, San Juan, 

Puerto Rico 

029 

Echocardiographic Measurements Predictive of Left Ventricular Ejection Fraction Recovery 

Patrick Hohl 1 , Richard Pinckney 2 , Martin LeWinter 1 . 1 University of Vermont Medical Center, Burlington, VT; 2 University of 

Vermont Medical Center, Burlington, VT 

030 

Impact of Pre-transplant Cirrhotic Cardiomyopathy on Long-Term Mortality in the Liver Recipients 

Thoetchai Peeraphatdit 1 , Niyada Naksuk 2 , Chayakrit Krittanawong 2 , Charat Thongprayoon 3 , Paola Ricci 4 , Roongruedee 

Chaiteerakij 5 , Lewis R. Roberts 2 , Kyle Klarich 6 . 1 University of Minnesota, Minneapolis, MN; 2 Mayo Clinic, Rochester, MN; 

3 

Mayo Clinic, Rochester, MN; 4 Minneapolis Veterans Affairs Health Care System, Minneapolis, MN; 5 Mayo Clinic, Rochester, 

MN; 6 Mayo Clinic, Rochester, MN 

031 

Relationship of Right Ventricular Function and Respiratory Status in a Large Cohort of Duchenne 

Muscular Dystrophy 

Muddassir Mehmood 1 , Michael D. Taylor 2 , John L. Jefferies 2 , Subha V. Raman 3 , Stephanie Ambach 4 , Wojciech Mazur 5 . 

1 

Allegheny General Hospital, Pittsburgh, PA; 2 Cincinnati Children’s Hospital, Cincinnati, OH; 3 Ohio State University, Columbus, 

OH; 4 University of Cincinnati, Cincinnati, OH; 5 The Christ Hospital, Cincinnati, OH 

Biomarkers/Neurohormones/Cytokines ........................................................................................................ 

032 

Minute Ventilation-Targeted Adaptive Servo Ventilation Improves Subendocardial Injury in Acute Decompensated 

Heart Failure Patients as Assessed Through Decreases in High-Sensitivity Cardiac Troponin I 

Elizabeth Lee 1 , Matt Kawahara 1 , Trenton Gluck 1 , Boris Arbit 1 , 2 , Kathleen Sarmiento 1 , 2 , Atul Malhotra 1 , 2 , Alan Maisel 1 , 2 . 

1 

Veterans Affairs San Diego Healthcare System, San Diego, CA; 2 University of California, San Diego, La Jolla, CA 

033 

Relationship Between Serum Neuregulin Level and Subsequent Cardiac Function Among Patients with Systolic 

Heart Failure 

Ugochukwu O. Egolum, Sandip Zalawadiya, Daniel Lenihan. Vanderbilt University, Nashville, TN 

034 

The Clinical Implications of Cardiac Troponin I Measured by an “Ultrasensitive” Assay in Acute Decompensated 

Heart Failure: Insights from ASCEND-HF 

Justin L. Grodin 1 , Adrian F. Hernandez 2 , Javed Butler 3 , Marco Metra 4 , G. Michael Felker 5 , Adrian Voors 6 , John J. McMurray 7 , 

Paul W. Armstrong 8 , Randall C. Starling 1 , Christopher O'Connor 5 , W. H. Wilson Tang 1 . 1 Cleveland Clinic, Cleveland, OH; 

2 

Duke University Medical Center, Durham, NC; 3 Stony Brook University, Stony Brook, NY; 4 University of Brescia, Brescia, 

Italy; 5 Duke University Medical Center, Durham, NC; 6 University of Groningen, Groningen, Netherlands; 7 University of 

Glasgow, Glasgow, United Kingdom; 8 University of Alberta, Edmonton, AB, Canada 

66


POSTERS 

035 

Association Between Serum Ghrelin levels and Congestive Heart Failure: A Meta Analysis 

Pradyumna Agasthi 1 , Sivakanth Aloor 2 , Nchang Taka 1 , Vijaya Sena Reddy Dendi 3 , Avantika Chenna 1 , Anekwe Onwuanyi 4 . 

1 

Morehouse School of Medicine, Atlanta, GA; 2 University of Miami, Miami, FL; 3 Wright Center for Gaduate Medical Education, 

Scranton, PA; 4 Morehouse School of Medicine, Atlanta, GA 

036 

Adrenomedullin Helps Risk Stratify Patients With Pre-Clinical Diastolic Dysfunction 

Jeremy Egnatios 1 , Nick Marston 2 , Boris Arbit 3 , Elizabeth Lee 4 , Hermineh Aramin 4 , Joachim Struck 5 , Alan S. Maisel 3 . 1 University 

of California San Diego, San Diego, CA; 2 University of California San Diego and VA-San Diego Health System, San 

Diego, CA; 3 University of California San Diego and VA-San Diego Health System, San Diego, CA; 4 VA- San Diego Health 

System, San Diego, CA; 5 Sphingotec Gmbh, Berlin, Germany 

037 

Renal Biomarkers Predict Adverse Outcomes in Heart Failure with Preserved Ejection Fraction 

Aaron Singh 1 , Sheldon S. G. Lee 1 , Puay Joo Tan 2 , Huang Pei 2 , Cao Yan 3 , Carmen J. W. Kam 4 , Siang Chew Chai 1 , Tek Siong 

Chee 1 , Khim Leng Tong 1 , Gerard K. T. Leong 1 . 1 Changi General Hospital, Singapore, Singapore; 2 Changi General Hospital, 

Singapore, Singapore; 3 Changi General Hospital, Singapore, Singapore; 4 Changi General Hospital, Singapore, Singapore 

038 

Prognostic Implications of Serum Chloride Levels in Patients with Stable Heart Failure 

Justin L. Grodin, Frederik H. Verbrugge, Stanely L. Hazen, W. H. WIlson Tang. Cleveland Clinic, Cleveland, OH 

039 

Predictive Value of 1, 25-dihydroxyvitamin D to PTH(1-84) Ratios for Cardiovascular Death in Heart Failure 

Damien Gruson, Sylvie Ahn, Michel Rousseau. Cliniques Universitaires Saint Luc, Brussels, Belgium 

040 

The Presence of IgG3 Autoantibody Against β1 Adrenergic Receptors is Associated with Favorable Myocardial Recovery 

in Patients with Recent Onset Cardiomyopathy - a Post-hoc Analysis of IMAC-2 Study 

Yuji Nagatomo 1 , Dennis M. McNamara 2 , Jeffrey D. Alexis 3 , Leslie T. Cooper 4 , G. William Dec 5 , Daniel F. Pauly 6 , Richard 

Sheppard 7 , Randall C. Starling 1 , W. H. Wilson Tang 1 . 1 Cleveland Clinic, Cleveland, OH; 2 University of Pittsburgh Medical 

Center, Pittsburgh, PA; 3 University of Rochester Medical Center School of Medicine and Dentistry, Rochester, NY; 4 Mayo 

Clinic Jacksonville, Jacksonville, FL; 5 Massachusetts General Hospital, Boston, MA; 6 Truman Medical Centers, Kansas 

City, MO; 7 Jewish General Hospital, Montreal, QC, Canada 

041 

Telomere Length as a Biomarker and Potential Contributor of Heart Failure Progression 

Elizabeth Silver 1 , Aleksandra Ras 1 , Christine Cosgrove 1 , Patricia Sheiner 1 , Jason Gluck 1 , Detlef Wencker 2 , Cara Statz 1 . 1 Hartford 

Hospital, Hartford, CT; 2 University of Kansas Medical Center, Kansas CIty, KS 

042 

Minute Ventilation-Targeted Adaptive Servo Ventilation Reduces Kidney Injury In Patients With Acute Decompensated 

Heart Failure 

Matt Kawahara 1 , Boris Arbit 1 , 2 , Elizabeth Lee 1 , Trenton Gluck 1 , Kathleen Sarmiento 1 , 2 , Atul Malhotra 1 , 2 , Alan Maisel 1 , 2 . 

1 


043 

Urinary Angiotensinogen is Increased in Human Heart Failure 

Seethalakshmi Iyer, Denise Heublein, Sherry Benike, John C. Burnett Jr.. Mayo Clinic, Rochester, MN 

044 

Serum Concentrations of Heme Oxigenase-1 are Reduced in Patients with Acute Heart Failure and Preserved Ejection 

Fraction 

Paulino Alvarez 1 , Andrea M. Cordero-Reyes 1 , Keith A. Youker 1 , Javier Amione-Guerra 1 , Cesar Uribe 1 , Arvind Bhimaraj 1 , Barry 

Trachtenberg 2 , Guha Ashrith 2 , Vijay Nambi 3 , Guillermo Torre-Amione 2 , Jerry D. Estep 4 . 1 The Methodist Hospital, Houston, 

TX; 2 The Methodist Hospital, Houston, TX; 3 Baylor College of Medicine, Houston, TX; 4 The Methodist Hospital, Houston, TX 

67


POSTERS 

Molecular Biology/Genetics/Cell Therapy ...................................................................................................... 

045 

Presence of Endothelial to Mesenchymal Transition in End Stage Human Myocardial Samples-documentation in 

Human Heart Failure for the First Time 

Cesar Uribe, Andrea M. Cordero-Reyes, Keith A. Youker, Barry H. Trachtenberg, Guha Ashrith, Jerry D. Estep, Guillermo 

Torre-Amione, Erik E. Suarez, John P. Cooke, Arvind Bhimaraj. The Methodist Hospital, Houston, TX 

046 

Hypoxia Inducible Factor (HIF) Adaptation After Mechanical Circulatory Unloading of the Heart. A Gene Expression 

Analysis Study of Paired Myocardial Samples. 

Paulino Alvarez, Cesar Uribe, Andrea M. Cordero-Reyes, Keith A. Youker, Guillermo Torre-Amione, Jerry D. Estep. The 

Methodist Hospital, Houston, TX 

047 

Evidence of the Presence of Autoantibodies Specific for β 1 Adrenergic Receptor in Failing Human Heart Tissue 

Yuji Nagatomo, Christine S. Moravec, W. H. Wilson Tang. Cleveland Clinic, Cleveland, OH 

048 

Carriers of Variants of Unknown Significance Have Intermediate Hypertrophic Cardiomyopathy Phenotypes 

Patrick J. Warner, Ashley A. Cronkright, Noreen Dolan, Martin Maron, Gordon S. Huggins. Tufts Medical Center, Boston, 

MA 

049 

Neuregulin/ERBB Signaling in Human Ventricular Myocardial Progenitor Cells 

Sergey Ryzhov 1 , Oleg Tikhomirov 1 , Rutwik Rath 1 , Douglas B. Sawyer 2 , 1 . 1 Maine Medical Center Research Institute, Scarborough, 

ME; 2 Maine Medical Center, Portland, ME 

Surgery/Transplantation/Devices ........................................................................................................................ 

050 

Impact of Patient Comorbidities on Post-Implant Outcomes Among Patients Receiving Ventricular Assist Devices in 

a Commercially Insured Population 

Jiang Tao, Wade Bannister, Charlotte Wu, Frank D. Irwin. Optum, Eden Prairie, MN 

051 

Predictors of Outcome Using Phase II Cardiac Rehabilitation Data in Patients With Durable, Implanted Left Ventricular 


Kathleen Morris, Jonathan Shirazi, Milena Jani, I-Wen Wang, Kathleen A. Lane, Stanley Taylor, Changyu Shen, Adnan Malik. 

IU School of Medicine, Indianapolis, IN 

052 

Heart rate and respiration during activity measured by an implanted device correlate well with those measured by a 

CPX machine 

Alan J. Bank 1 , John Chronakos 2 , Kenneth C. Beck 3 , Paji Vitoff 3 , Colleen Delaney 3 , Julie Thompson 3 , Yi Zhang 3 . 1 United 

Heart & Vascular Clinic, St Paul, MN; 2 Danbury Hospital, Danbury, CT; 3 Boston Scientific, St Paul, MN 

053 

The Safety of Right Heart Catheterization in Patients with Continuous-Flow Left Ventricular Assist Devices 

Kershaw Patel 1 , Daniel Rodgers 1 , Cory Henderson 1 , Emeka Anyanwu 1 , Savitri Fedson 1 , Gene Kim 1 , Nitasha Sarswat 1 , Colleen 

Juricek 2 , Takeyoshi Ota 2 , Valluvan Jeevanandam 2 , Gabriel Sayer 1 , Nir Uriel 1 . 1 University of Chicago, Chicago, IL; 

2 

University of Chicago, Chicago, IL 

68


POSTERS 

054 

Assessment of Pre-LVAD Laboratory Parameters to Predict Post LVAD Early Right Ventricular Failure 

Burhan Mohamedali 1 , Gardner Yost 2 , Geetha Bhat 2 . 1 Rush University Medical Center, Chicago, IL; 2 Advocate Christ Medical 

Center, Oak Lawn, IL 

055 

Induction Therapy Prior to Heart Transplantation Leads to Freedom from Antibody-mediated Rejection Without 

Increasing Infection 

Yevgeniy Brailovsky, Estefania Oliveros, Val Rakita, Vladimir Lakhter, Huaqing Zhao, Daniel Schwartz, Akira Shiose, 

Yoshiya Toyoda, Rene Alvarez, Alfred Bove, Eman Hamad. Temple University Hospital, Philadelphia, PA 

056 

Baseline Pulmonary Function and Outcomes in Patients Receiving Left Ventricular Assist Devices 

Suraj Raheja, Cristina Tita, Celeste Williams, Jeffrey A. Morgan, Hassan Nemeh, Yelena Selektor, Chetan Bhardwaj, Robert 

Brewer, Jamil Borgi, Mauricio Velez, David E. Lanfear. Henry Ford Hospital, Detroit, MI 

057 

Relationship of Baseline Right Ventricle Function with Response to Cardiac Resynchronization Therapy 

Abhishek Sharma 1 , Ajay Vallakati 2 , Sunny Goel 3 , Carl J. Lavie 4 , John Kassotis 1 , Debabrata Mukherjee 5 , Jason M. Lazar 1 . 

1 

State University of New York, Downstate Medical Center, Brooklyn, NY; 2 Metrohealth Medical Center, Case Western Reserve 

University, Cleveland, OH; 3 Maimonides Medical Center, Brooklyn, NY; 4 John Ochsner Heart and Vascular Institute, 

Ochsner Clinical School-the University of Queensland School of Medicine, New Orleans, LA; 5 Texas Tech University, El 

Paso, TX 

058 

Prophylactic Intra-Aortic Balloon Pumping before Implantation of Ventricular Assist Device Improves Perioperative 

Clinical Course and Medical Expenses in Patients with INTERMACS Profile II 

Teruhiko Imamura 1 , Koichiro Kinugawa 1 , Daisuke Nitta 2 , Masaru Hatano 2 , Osamu Kinoshita 3 , Kan Nawata 3 , Minoru Ono 3 . 

1 

Graduate School of Medicine, University of Tokyo, Tokyo, Japan; 2 Graduate School of Medicine, University of Tokyo, 

Tokyo, Japan; 3 Graduate School of Medicine, University of Tokyo, Tokyo, Japan 

059 

Clinical Characteristics of Patients with Suspected Left Ventricular Assist Device Thrombosis who Respond to Intensified 

Anticoagulation 

Demetrios G. Doukas 1 , Neelam Balasubramanian 1 , Stephanie A. Kliethermes 1 , Joseph I. Bailey 1 , Brett Dubner 1 , Edith Boyes 

1 , Jefferey P. Schwartz 2 , Alain L. Heroux 1 , Erin Coglianese 3 . 1 Loyola University Medical Center, Maywood, IL; 2 Loyola 

University Medical Center, Maywood, IL; 3 Loyola University Medical Center, Maywood, IL 

060 

Socioeconomic Status May be a Marker of Risk for Clinical Outcomes with Continuous Flow Ventricular Assist Devices 

Mustafa Ahmed 1 , Christopher Le 2 , Alexander Bolanos 3 , Juan A. Aranda, Jr 1 , Charles T. Klodell Jr 4 . 1 University of Florida, 

Gainesville, FL; 2 University of Florida, Gainesville, FL; 3 University of Florida, Gainesville, FL; 4 University of Florida, 

Gainesville, FL 

061 

Trends in LVADs and Orthotropic Heart Transplantations in the Older and Higher Comorbid Demographicsfor 

2003-2011 

Zubair Shah 1 , Arun Mahankali Sridhar 1 , Sameer Chaudhari 2 , Buddhadeb Dawn 1 , Gurusher Panjrath 3 . 1 University of Kansas 

Medical Center, Kansas city, KS; 2 Beth Israel Medical Center, Newark, Newark, NJ; 3 George Washington University School 

of Medicine and Health Sciences, Washington DC, DC 

062 

Caregiving Affects the Quality of Life of Patients and their Caregivers after Mechanical Circulatory Support 

Susan Magasi 1 , Sarah K. Buono 2 , Clyde W. Yancy 3 , Kathleen L. Grady 4 . 1 University of Illinois at Chicago, Chicago, IL; 

2 

Northwestern University, Chicago, IL; 3 Northwestern University, Chicago, IL; 4 Northwestern University, Chicago, IL 

69


POSTERS 

063 

Changes in Pulmonary Function After Left Ventricular Assist Device Implantation 

Suraj Raheja, Mauricio Velez, Chetan Bhardwaj, Jeffrey A. Morgan, Robert Brewer, Hassan Nemeh, Yelena Selektor, Celeste 

Williams, Jamil Borgi, Cristina Tita, David E. Lanfear. Henry Ford Hospital, Detroit, MI 

064 

Heart Failure Related Hospitalization and Mortality after Aortic Valve Replacement 

Vincent Chan 1 , Fraser Rubens 1 , Maria Koullick 2 , Dan Gutfinger 2 , Manya Harsch 3 , Marc Ruel 1 . 1 University of Ottawa, Ottawa, 

ON, Canada; 2 St. Jude Medical, Plymouth, MN; 3 Technomics Research, Minneapolis, MN 

065 

Invasive Hemodynamics in Severely Obese Patients Following Continuous-Flow Left Ventricular Assist Device 

Implantation 

Kershaw V. Patel 1 , Cory Henderson 1 , Emeka Anyanwu 1 , Savitri E. Fedson 1 , Gene H. Kim 1 , Nitasha Sarswat 1 , Colleen 

Juricek 2 , Takeyoshi Ota 2 , Valluvan Jeevanandam 2 , Gabriel Sayer 1 , Nir Uriel 1 . 1 University of Chicago, Chicago, IL; 2 University 

of Chicago, Chicago, IL 

066 

Safety and Long Term Outcomes of Using Beta Blockers After Heart Transplantation 

Amaninderapal S. Ghotra, Christopher Angus, John Price, Kelly McCants, Mark S. Slaughter, Allen Cheng, Andrew 

Lenneman, Emma J. Birks. University of Louisville, Louisville, KY 

067 

Reversibility of Restrictive Pulmonary Function Post Cardiac Transplantation 

Carolyn M. Rosner, Gurusher Panjrath, Ramesh Singh, Shashank S. Desai, Anthony J. Rongione. Inova Health System, Falls 

Church, VA 

068 

The Relation Between Liver Dysfunction and Gastrointestinal Bleeding in Patients with Ventricular Assist Devices 

David Lowe 1 , Georg Wieselthaler 1 , Liviu Klein 2 . 1 UCSF, San Francisco, CA; 2 UCSF, San Francisco, CA 

069 

Hemodynamic Effects of Intra-Aortic Balloon Counterpulsation in Patients with Advanced Heart Failure 

Lyanne Buiten, Vikram Paruchuri, Duc Thinh Pham, Michael Kiernan, David DeNofrio, Carey Kimmelstiel, Navin K. Kapur. 

Tufts Medical Center, Boston, MA 

070 

Elevated Right Atrial Pressure Predicts Post Heart Transplant Outcomes 

Carolyn M. Rosner, Anthony J. Rongione, Gurusher Panjrath, Palak Shah, Shashank S. Desai, Ramesh Singh. Inova Health 

System, Falls Church, VA 

071 

VNS Does Not Reduce Heart Failure Progression in a Canine High Rate Pacing Model of HF 

Avram Scheiner. Medtronic, Mounds Veiw, MN 

072 

Early Elevated Pump Power and Associated Hemolysis Amongst HeartMate II Left Ventricular Assist Devices 

Anjan Tibrewala, Michael Nassif, David Raymer, Justin Vader, Shane LaRue, Scott Silvestry, Greg Ewald. Washington 

University, St. Louis, MO 

073 

Discharge Glomerular Filtration Rate (GFR) as a Predictor of Outcomes Post Left Ventricular Assist Device Placement 



70


POSTERS 

074 

Longevity Performance of St. Jude Medical ICDs at a Single Center 

Raffaele Corbisiero 1 , Pherson Charlene 1 , Ellen Cleary 1 , Marlene Belsito 1 , David Muller 2 . 1 Deborah Heart & Lung Center, 

Browns Mills, NJ; 2 St Jude Medical, Sylmar, CA 

075 

Use of Basiliximab is Associated with Similar Outcomes Post Orthotopic Heart Transplantation: A Single Center 

Experience 

Esther Vorovich, Maria Molina, Tamara Claridge, Mary Williams, Susan Chambers, Christine Gearhart, Patricia Stutman, 

Donna Chojnowski, Wilhelmina Maslanek, Payman Zamani, Edo Y. Birati, Anjali T. Owens, Lee R. Goldberg. University of 

Pennsylvania, Philadelphia, PA 

076 

Effect of Donor Blood Transfusions on Post Heart Transplant Outcomes 

Carolyn M. Rosner, Ramesh Singh, Gurusher Panjrath, Palak Shah, Shashank S. Desai, Anthony J. Rongione. Inova Health 

System, Falls Church, VA 

077 

HeartMate II to HVAD Device Exchange: What Can We Learn? 

Kershaw V. Patel 1 , Emeka Anyanwu 1 , Colleen Juricek 2 , Viktoriya Kagan 2 , Holly Ruedlinger 2 , Whayoun Lee 2 , Takeyoshi 

Ota 2 , Gabriel Sayer 1 , Nir Uriel 1 , Valluvan Jeevanandam 2 . 1 University of Chicago, Chicago, IL; 2 University of Chicago, Chicago, 

IL 

078 

Rapid Reversal of Pulmonary Hypertension in Failing Mustard Physiology After Continuous Flow Systemic Ventricular 

Assist Device 

Joel Simon 1 , Mark Turrentine 2 , I-wen Wang 3 , Marco Caccamo 1 , W. Aaron Kay 1 . 1 Indiana University, Indianapolis, IN; 2 Indiana 

University, Riley Hospital for Children, Indianapolis, IN; 3 Indiana University, Indianapolis, IN 

079 

Anticoagulation Intensity and Thrombotic or Bleeding Outcomes in Outpatients with Continuous Flow Left Ventricular 


Michael E. Nassif, David S. Raymer, Anjan Tibrewala, Gregory A. Ewald, Shane J. LaRue, Justin M. Vader, Brain F. Gage. 

Washington University, St. Louis, MO 

Electrophysiology/Arrhythmias ............................................................................................................................. 

80 

Diagnostic Yield of a 14 Day Ambulatory ECG Recorder in Patients With Suspected Syncope 

Andrew Keibel 1 , Steven Carlson 2 , Leslie Saxon 2 , Philip Chang 2 , Rahul Doshi 2 , Jerold Shinbane 2 , Mary Huntsinger 2 . 1 Keck 

Hospital of USC, Los Angeles, CA; 2 Keck Hospital of USC, Los Angeles, CA 

81 

Impact of Non-apical Right Ventricular Lead Placement on Left Ventricular Reverse Remodeling and Inter-ventricular 

Dys-synchrony in Cardiac Resynchronization Therapy: a Meta-analysis 

Alok Saurav, Aiman Smer, Muhammad S. Azzouz, Hussam Abuissa, Claire Hunter. Creighton University Medical Center, 

Omaha, NE 

82 

Changes in Left Atrial Appendage Velocities Are Useful Indices to Predict New Onset Atrial Fibrillation Following 

Transcatheter Aortic Valve Replacement 

Tomo Ando 1 , David Slvout 2 , Cynthia Taub 2 . 1 Mount Sinai Beth Israel, New York, NY; 2 Montefiore Medical Center, Bronx, 

NY 

71


POSTERS 

83 

Subclinical Paroxysmal Atrial Fibrillation in Outpatients with Heart Failure Detected by a Novel Non-invasive Wireless 

Remote Monitoring Platform 

Lyle Olson, Virend Somers, Nancy Lexvold, Paul Friedman, Louis Schenck, Bradley Lewis, Charles Bruce. Mayo Clinic, 

Rochester, MN 

84 

Arrhythmic Outcomes in Patients following Explanation of Left Ventricular Assist Devices after Myocardial Recovery 

Amaninderapal S. Ghotra, Emma J. Birks, Zeeshan Hussain, Andrew Lenneman, Mark S. Slaughter, Rashmi U. Hottigoudar, 

Rakesh Gopinathannair. University of Louisville, Louisville, KY 

Clinical Trials ....................................................................................................................................................................... 

085 

Effects of Heart Rate Reduction in Black Patients from the SHIFT (Systolic Heart failure treatment with the If 

inhibitor ivabradine Trial) Study 

Jeffrey S. Borer 1 , Michel Komajda 2 , Ian Ford 3 , Luigi Tavazzi 4 , Fabienne Dominjon 5 , Juan Maya 6 , Yuna Wu 6 , Christophe Depre 

6 , Michael Böhm 7 . 1 State University of New York Downstate Medical Center, New York, NY; 2 University Pierre et Marie 

Curie Paris VI, Paris, France; 3 University of Glasgow, Glasgow, United Kingdom; 4 GVM Care & Research, Cotignola, Italy; 

5 

Institut de Recherches Internationales Servier, Suresnes, France; 6 Amgen Inc., Thousand Oaks, CA; 7 Universitätskliniken 

des Saarlandes, Homburg/Saar, Germany 

086 

Comparison of the Baseline Demographics of the LCZ696 PARADIGM-HF and TITRATION Studies 

Fabian Chen 1 , Alan Charney 1 , Jim Gong 1 , Victor Shi 1 , Michele Senni 2 . 1 Novartis, East Hanover, NJ; 2 Azienda Ospedaliera 

Papa Giovanni XXIII, Med.Generale 2 Cardiovascolare, Bergamo, Italy 

087 

Percutaneous Ventricular Restoration (PVR) therapy using the Parachute® Device in Subjects with Ischemic Dilated 

Heart Failure: Two Year Meta-Analysis 

William T. Abraham. The Ohio State University, Columbus, OH 

088 

The Angiotensin Receptor Neprilysin Inhibitor LCZ696 is Effective Across the Spectrum of Ejection Fraction in 

Heart Failure With Reduced Ejection Fraction 

Scott Solomon 1 , Milton Packer 2 , Michael Zile 3 , Karl Swedberg 4 , Jean Rouleau 5 , Martin Lefkowitz 6 , Victor Shi 6 , Akshay 

Desai 1 , Brian Claggett 1 , Randall Starling 7 , John J. V. McMurray 8 . 1 Brigham and Women's Hospital, Boston, MA; 2 UT Southwestern, 

Dallas, TX; 3 MUSC, Charleston, SC; 4 University of Groninger, groninger, Sweden; 5 University Montreal, Montreal, 

QC, Canada; 6 Novartis, E Hanover, NJ; 7 Cleveland Clinic, Cleveland, OH; 8 University of Glasgow, Glasgow, United Kingdom 

089 

Ivabradine Improves Symptoms and Quality of Life in Chronic Systolic Heart Failure Patients With Different Baseline 

Symptom Severity 

Christian Zugck 1 , Peter Martinka 2 , Georg Stöckl 2 . 1 Internistische Gemeinschaftspraxis im Steiner Thor, Straubing, Germany; 

2 

Servier Deutschland GmbH, München, Germany 

090 

Effect of Comorbidities and Risk Factors on Outcomes and Ivabradine’s Effects in Patients With Chronic Systolic 

Heart Failure in the SHIFT Trial 

Michael Böhm 1 , Jeffrey S. Borer 2 , Ian Ford 3 , Michel Komajda 4 , Michele Robertson 3 , Luigi Tavazzi 5 , Karl Swedberg 6 . 1 Universitätskliniken 

des Saarlandes, Homburg/Saar, Germany; 2 State University of New York Downstate Medical Center, New 

York, NY; 3 University of Glasgow, Glasgow, United Kingdom; 4 University Pierre et Marie Curie Paris VI, Paris, France; 

5 

Maria Cecilia Hospital, Cotignola, Italy; 6 University of Gothenburg, Göteborg, Sweden 

72


POSTERS 

091 

Trials are Needed to Evaluate Nutrition Interventions for HF: Analysis of the Federal Nutrition and HF Research 

Portfolio 

Patrice Desvigne-Nickens 1 , Karen Regan 2 , Rebecca Costello 3 , Abby Ershow 4 . 1 National Heart, Lung, and Blood Institute, 

Bethesda, MD; 2 National Institutes of Health, Bethesda, MD; 3 National Insitutes of Health, Bethesda, MD; 4 National Institutes 

of Health, Bethesda, MD 

092 

Remote Wireless Telemonitoring Combined with Health Coaching (Tele-HC) to Lower Readmission Rates for Patients 

with Acute Decompensated Heart Failure 

Lyle Olson, Shaival Kapadia, Nancy Lexvold, Virend Somers, Paul Friedman, Louis Schenck, Bradley Lewis, Rickey Carter, 

Charles Bruce. Mayo Clinic, Rochester, MN 

093 

Probenecid Improves Cardiac Function in Patients With Heart Failure. Interim Analysis of the Re-Prosper Hf Trial 

Mark Gilbert, Nathan Robbins, Ginger Conway, Mohamed Effat, Jack Rubinstein. University of Cincinnati, Cincinnati, OH 

094 

Post Hoc Analysis of a Multicenter, Randomized, Controlled Study in Patients with Chronic Heart Failure: Factors 

Associated with Clinical Composite Response Improved by Adaptive-Servo Ventilation Therapy 

Shin-ichi Momomura 1 , Yoshihiko Seino 2 , Yasuki Kihara 3 , Hitoshi Adachi 4 , Yoshio Yasumura 5 , Hiroyuki Yokoyama 6 . 1 Saitama 

Medical Center, Jichi Medical University, Saitama, Japan; 2 Nippon Medical School Chiba Hokusoh Hospital, Chiba, 

Japan; 3 Hiroshima University Graduate School of Biomedical & Health Sciences, Hiroshima, Japan; 4 Gunma Prefectural 

Cardiovascular Center, Gunma, Japan; 5 Osaka National Hospital, Osaka, Japan; 6 National Cerebral and Cardiovascular Center, 

Osaka, Japan 

095 

Cracking the NNT Code: Effect of Ivabradine on Recurrent Hospitalizations 

Jennifer K. Rogers 1 , Adrian Kielhorn 2 , Jeffrey S. Borer 3 , Ian Ford 4 , Stuart J. Pocock 1 . 1 London School of Hygiene and 

Tropical Medicine, London, United Kingdom; 2 Amgen Inc., Thousand Oaks, CA; 3 State University of New York Downstate 

Medical Center, New York, NY; 4 University of Glasgow, Glasgow, United Kingdom 

Cardiovascular Pharmacology ............................................................................................................................... 

096 

The Anti-aldosterone Effects of Torsemide Do Not Lead to Detectable Improvement in Potassium Losses in Patients 

Treated for Decompensated Heart Failure 

Chukwuma Onyebeke, Jennifer Simon, Susan J. Cheng, Jeffrey M. Testani. Yale University School of Medicine, New Haven, CT 

097 

Bucindolol Prevents Atrial Flutter via the Beta-1 389 Arg/Gly Adrenergic Receptor Polymorphism 

Ryan Aleong 1 , Amrut Ambardekar 1 , Gordan Davis 2 , Michael R. Bristow 1 . 1 University of Colorado, Aurora, CO; 2 ARCA 

Biopharma, Westminster, CO 

098 

The use of Intravenous Iron Therapy in Iron Deficient Patients with Heart Failure with Reduced Ejection Fraction: 

Decrease Hospitalizations and Improve in Symptoms and Quality of Life - A Meta-Analysis of Randomized Clinical 

Trials 

Abel Casso Dominguez 1 , Georges E. El-Hayek 1 , Elizabeth Contreras 2 , Arpit Shah 1 , Saurav Chatterjee 1 , Marrick Kukin 1 . 

1 

Mount Sinai St. Luke's-Roosevelt Hospital, New York, NY; 2 Instituto Tecnologico de Santo Domingo, Santo Domingo, 

Dominican Republic 

099 

Beta Blocker Survival Benefit in Heart Failure is Associated with ADRB1 Ser49Gly Genotype 

David E. Lanfear, Edward L. Peterson, Nicole Zeld, Karen Wells, Hani N. Sabbah, Keoki Williams. Henry Ford Health 

System, Detroit, MI 

73


POSTERS 

100 

Evaluation of a Sirolimus / Tacrolimus-Minimization Strategy in Heart Transplant Recipients: Can We Avoid Further 

Nephrotoxicity? 

William L. Baker 1 , Ashley M. Gale 1 , Jason A. Gluck 2 , Joseph A. Radojevic 2 , Lynn F. O'Bara 2 , Andrea D. Murphy 2 , James 

Dougherty 3 , Spencer T. Martin 4 . 1 University of Connecticut School of Pharmacy, Storrs, CT; 2 Hartford Hospital, Hartford, 

CT; 3 Hartford Hospital, Hartford, CT; 4 Hartford Hospital, Hartford, CT 

101 

Role of β-Blockers in Patients with Heart Failure with Preserved Ejection Fraction: A Meta-Analysis 

Daniel Marks, Ajay Vallakati, Siddharth Reddy, Mark Dunlap. Metrohealth Medical Center, Cleveland, OH 

102 

Differential Prognostic Effect of Lipophilic Versus Hydrophilic Statins in Heart Failure Patients: A Meta-Analysis of 

Randomized Controlled Trials 

Hidekatsu Fukuta, Nobuyuki Ohte. Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan 

103 

Ability to Achieve Target Doses of an Evidence-based Heart Failure Treatment Regimen in an Advanced Heart Failure 

Clinic at a Tertiary Care Facility 

A. Modany 1 , C. Walter 1 , M. Clarke 2 , J. Klootwyk 3 , K. Stollar 4 , George G. Sokos 2 . 1 Allegheny General Hospital, Pittsburgh, 

PA; 2 Allegheny General Hospital, Pittsburgh, PA; 3 Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA; 4 Mylan 

School of Pharmacy, Duquesne University, Pittsburgh, PA 

Epidemiology/ Prevention ......................................................................................................................................... 

104 

Prognostic Impacts and Temporal Changes of Post-Traumatic Stress Disorder after the Great East Japan Earthquake 

in Patients with Heart Failure -A Report from the CHART-2 Study- 

Takeo Onose, Yasuhiko Sakata, Masanobu Miura, Soichiro Tadaki, Ryoichi Ushigome, Takeshi Yamauchi, Kenjiro Sato, 

Kanako Tsuji, Ruri Abe, Kotaro Nochioka, Jun Takahashi, Satoshi Miyata, Hiroaki Shimokawa. Tohoku University Graduate 

School of Medicine, Sendai, Japan 

105 

Clinical Profiles and Prognostic Factors in the Elderly Patients with Heart Failure in Japan 

-A Report from the CHART-2 Study- 

Kenjiro Sato, Yasuhiko Sakata, Satoshi Miyata, Masanobu Miura, Soichiro Tadaki, Ryoichi Ushigome, Takeshi Yamauhi, 

Takeo Onose, Kanako Tsuji, Ruri Abe, Kotaro Nochioka, Jun Takahashi, Hiroaki Shimokawa. Department of Cardiovascular 

Medicine, Tohoku University Graduate School of Medicine, SENDAI, Japan 

106 

Effect of Weight Loss on Renal Function in Overweight and Obese Patients with Heart Failure 

Marjan Motie, Lorraine Evangelista. University of California Irvine, Irvine, CA 

107 

Follow up of Patients Unable to Receive Indicated Device Therapy Under the Care of an Advanced Heart Failure 

Program in a Developing Country. 

Feras Bader 1 , 2 , Guirgis Gabrah 2 , Medhat Soliman 2 , Khalid Zakariea 2 , Smitha Varghese 2 , Sonia Kuruvilla 2 , Ameena Alsayed 2 , 

Fawzia Alkandari 2 , Mustafa Ridha 2 . 1 University of Utah, Salt Lake City, UT; 2 Dabbous Cardiac Center- Adan Hospital, Kuwait 

City, Kuwait 

74


POSTERS 

108 

The Association of Hemoglobin A1c with Short-term Outcomes in Patients who Have Heart Failure with Preserved 

Ejection Fraction and Diabetes: Results from Korean Acute Heart Failure Registry 

Hyo-In Choi, Min-Seok Kim, Jae-Joong Kim. Asan Medical Center, Seoul, Korea, Republic of 

109 

Death Analysis of a Cohort of Blood, Lymphatic Cancer and Breast Cancer Patients Who Have Developed Heart 

Failure Following Cancer Treatment. 

Robyn A. Clark 1 , Alexandra McCarthy 2 , Munir H. Chowdhury 1 , Narelle Berry 1 , Shahid Ullah 3 , Bogda Koczwara 4 , John Atherton 

5 , David Roder 6 . 1 Flinders University, Adelaide, Australia; 2 Queensland University of Technology, Brisbane, Australia; 

3 

Flinders University, Adelaide, Australia; 4 Flinders University, Adelaide, Australia; 5 University of Queensland, Brisbane, 

Australia; 6 University of South Australia, Adelaide, Australia 

110 

Pericardial Involvement in a Cohort of HIV Infected African Americans in Post HAART Therapy Era_a Changing 

Trend 

Puvanalingam Ayyadurai, Sridhar Chilimuri. Bronx Lebanon Hospital Center, New York, NY 

Quality of Care/Outcomes ......................................................................................................................................... 

111 

Association of HbA1c With Hospitalization Among Patients With Heart Failure and Diabetes 

Saul Blecker, Hannah Park, Stuart Katz. NYU School of Medicine, New York, NY 

112 

Risk Factors for Smoking Re-Abuse Following Heart Transplantation 

Jonathan Dunn, Rady Ho, Paul Mather. Thomas Jefferson University Hospital, Philadelphia, PA 

113 

Achy Breaky Heart - Quality of Life Changes with Progressing Congestive Heart Failure 

Tristan Cordier 1 , Lane Slabaugh 2 , Gilbert Haugh 2 , Diana Cusano 2 , Vipin Gopal 2 , George Andrews 2 , Andrew Renda 2 . 1 Humana, 

Inc., Atlanta, GA; 2 Humana, Inc., Louisville, KY 

114 

Centers for Medicare and Medicaid Services’ Heart Failure Report is Not Representative of a Hospital’s Heart Failure 

Population 

Zachary L. Cox 1 , 2 , Pikki Lai 1 , Connie M. Lewis 1 , Sahar Torabi 2 , Daniel J. Lenihan 1 . 1 Vanderbilt University Medical Center, 

Nashville, TN; 2 Lipscomb University College of Pharmacy, Nashville, TN 

115 

Can the Braden Scale or the Morse Fall Scale Predict Mortality in Hospitalized Patients With Heart Failure? 

Victoria V. Dickson 1 , Matthew Carazo 2 , Tina Sadarangani 1 , Sundar Natarajan 2 , Caroline Blaum 2 , Stuart D. Katz 2 . 1 NYU, New 

York, NY; 2 NYU, New York, NY 

116 

Evolution of the Advanced Heart Failure Nurse Coordinator Role 

Julie Webster, Blaine Ney, David A. Dean. Piedmont Heart, Atlanta, GA 

75


POSTERS 

117 

Heart Failure Readmissions Reduction Intervention Positively Affects Readmissions for HFrEF But not HFpEF 

Milena Jani 1 , Joanna Kingery 2 , Irmina Gradus-Pizlo 1 , Azam Hadi 1 , Marco Caccamo 1 , Jose Finet 1 , Adnan Malik 1 . 1 Indiana 

University School of Medicine, Indianapolis, IN; 2 IU Health, Indianapolis, IN 

118 

Health Care Goals, Communication, and Knowledge Among Older ICD Recipients 

Yaw Adjei-Poku 1 , Michelle Samuel 1 , Diane Engorn 2 , Daniel Habtemariam 2 , Matthew R. Reynolds 3 , Susan L. Mitchell 2 , 

Daniel B. Kramer 1 . 1 Beth Israel Deaconess Medical Center, Boston, MA; 2 Hebrew SeniorLife Institute for Aging Research, 

Boston, MA; 3 Harvard Clinical Research Institute, Boston, MA 

119 

High Prevalence of Heart Failure (HF) Knowledge Deficits in Hospitalized Chronic Heart Failure Patients-a Single 

Center Retrospective Analysis of Quality Data Showing a Need for Better CMS Core Measures 

Michael Pudlo, Sarah Homer, Carl Daniel, Susan Bionat, Andrea Creamer, Sayali Ketkar, Arvind Bhimaraj. Houston Methodist 

Hospital, Houston, TX 

120 

Heightened Platelet Re-activity Assessed by Increase in Mean Platelet Volume is Associated With Poor Outcomes in 

Stable Heart Failure Patients 

Muhammad Hammadah 1 , Danielle M. Brennan 2 , Stanley L. Hazen 2 , W.H.Wilson Tang 2 . 1 Cleveland Clinic, Cleveland, OH; 

2 

Cleveland Clinic, Cleveland, OH 

121 

Nursing Home Readmissions Reduced Using a Novel Heart Failure Protocol 

Noah Moss 1 , Rekha Bhandari 2 , Jeffrey Bander 1 . 1 Mount Sinai Medical Center, New York, NY; 2 The Allure Group, Brooklyn, 

NY 

122 

Causes and Avoidability of Hospital Readmissions post-Left Ventricular Assist Device Implantation: A One-Year 

Analysis 

Kavita Sharma, Albert J. Hicks, Natasha Gill, Damon Duquaine, Gerin R. Stevens, Ryan J. Tedford, Daniel P. Judge, Ilan S. 

Wittstein, Glenn M. Whitman, Ashish S. Shah, Stuart D. Russell. Johns Hopkins Hospital, Baltimore, MD 

123 

Predictors of Post-Discharge Mortality in Acute Hospitalized Heart Failure 

Larisa G. Tereshchenko 1 , Marcus Vollmer 2 , Silviu Dovancescu 3 , Xiaozhen Chen 4 , Niels Otani 5 , Jiri Sklenar 1 . 1 Oregon Health 

and Science University, Portland, OR; 2 University of Greifswald, Greifswald, Germany; 3 Philips Research, Aachen, Germany; 

4 Mortara Instrument, Milwaukee, WI; 5 Rochester Institute of Technology, Rochester, NY 

124 

Using a Risk Model to Predict 30-Day Readmission After Implantable Cardioverter Defibrillator 

Sandra Oliver-McNeil 1 , Thomas N. Templin 2 , David E. Haines 1 . 1 Beaumont Health, Royal Oak,MI, Royal Oak, MI; 2 Wayne 

State University, Detroit, MI 

125 

Caregivers’ Perceptions of Illness Severity in Advanced Heart Failure 

Judith E. Hupcey, Lisa A. Kitko. The Pennsylvania State University, University Park, PA 

126 

Remote Specialty Therapeutic Management Enhances Patient-Centered Heart Failure Care in a Rural Community 

Setting 

Harleen Singh 1 , Jessina C. McGregor 1 , Cindy L. Quale 2 , Kelsie W. Flynn 1 , Samaneh Zhian 1 , Matt Atkinson 1 , Kayla E. Ruhl 1 , 

Kate H. Unterberger 1 , Greg C. Larsen 2 . 1 OSU/OHSU College of Pharmacy, Portland, OR; 2 Portland Veterans Affairs Health 

Care System, Portland, OR 

76


POSTERS 

127 

A Markov Model-based Monte Carlo Simulation to Assess Variation in Financial Burden and Health Outcomes for 

Cardiac Implantable Electronic Devices Based on Device and Patient Characteristics 

Juergen A. Klenk 1 , Arnold J. Greenspon 2 , Edmund C. Lau 3 , Jasmine Patel 4 , Jordana K. Schmier 1 , Pamela M. McMahon 5 . 1 Exponent, 

Inc., Alexandria, VA; 2 Thomas Jefferson University, Philadelphia, PA; 3 Exponent, Inc., Menlo Park, CA; 4 Exponent, 

Inc., Philadelphia, PA; 5 Exponent, Inc., Natick, MA 

128 

Increased risk of Cerebrovascular Death in Patients with Chemotherapy-Induced Cardiomyopathy 

Emile Mehanna, Sadeer G. Al-Kindi, Mobolaji Ige, Sachin Kumar, Mohammad Kattea, Chantal ElAmm, Salil Deo, Rodolfo 

D. Benatti, Mahazarin Ginwalla, Soon J. Park, Guilherme H. Oliveira. Advanced Heart Failure & Transplant Center, Harrington 

Heart & Vascular Institute, University Hospitals Case Medical Center, Case Western Reserve University School of 

Medicine, Cleveland, OH 

129 

Sex Differences in the Management and Outcomes of Heart Failure with Preserved Ejection Fraction in Patients 

Presenting to the Emergency Department with Acute Heart Failure 

Reka Zsilinszka 1 , Peter Shrader 2 , Adam D. DeVore 3 , Natalie C. Hardy 2 , Robert J. Mentz 3 , Peter S. Pang 4 , W. Frank Peacock 5 , 

Gregg C. Fonarow 6 , Adrian F. Hernandez 3 . 1 Duke University School of Medicine, Durham, NC; 2 Duke Clinical Research 

Institute, Durham, NC; 3 Duke Clinical Research Institute, Duke University Medical Center, Durham, NC; 4 Indiana University 

School of Medicine, Indianapolis, IN; 5 Baylor College of Medicine, Durham, TX; 6 Ahmanson-University of California, 

Ronald Reagan-UCLA Medical Center, Los Angeles (UCLA) Cardiomyopathy Center, Los Angeles, CA 

130 

Temporal Trends of Digoxin Use in Patients Hospitalized with Heart Failure: Analysis From the American Heart 

Association Get With The Guidelines - Heart Failure Registry 

Nish Patel 1 , Conrad Macon 1 , Christine Ju 2 , Phillip Schulte 2 , Adrian F. Hernandez 2 , Deepak L. Bhatt 3 , Javed Butler 4 , Clyde W. 

Yancy 5 , Gregg C. Fonarow 6 . 1 University of Miami Miller School of Medicine, Miami, FL; 2 Duke Clinical Research Institute, 

Durham, NC; 3 Brigham and Woman's Hospital Heart & Vascular Center, Boston, MA; 4 Stony Brook School of Medicine, 

Stony Brook, NY; 5 Northwestern University, Chicago, IL; 6 Ronald Reagan-UCLA Medical Center, Los Angeles, CA 

131 

Pediatric Versus Adult Heart Failure Related Emergency Department Visits in the United States 

Joseph W. Rossano 1 , Erika J. Mejia 1 , Kimberly Y. Lin 1 , Eduardo Rame 2 , Matthew J. O'Connor 1 , J. Willaim Gaynor 1 , Stephen 

J. Paridon 1 , Robert E. Shaddy 1 . 1 Children's Hospital of Philadelphia, Philadelphia, PA; 2 University of Pennsylvania, Philadelphia, 

PA 

132 

Assessment of Pre-LVAD Hemodynamics to Predict Post LVAD Early RV Failure 



133 

Patient Experience With Light Chain Amyloidosis: A Survey From the Amyloidosis Research Consortium 

Isabelle Lousada 1 , Ray Comenzo 2 , Heather Landau 3 , Spencer Guthrie 4 , Giampaolo Merlini 5 . 1 Amyoidosis Research Consortium, 

Inc., Boston, MA; 2 Tufts Medical Center, Boston, MA; 3 Memorial Sloan-Kettering Cancer Center, New York, NY; 

4 

Prothena Biosciences, South San Francisco, CA; 5 Fondazione IRCCS Policlinico San Matteo and University of Pavia, 

Pavia, Italy 

134 

Need to Elicit Patient Preferences for Information About Limited Prognosis in Heart Failure 

Arden O'Donnell, Kristen Schaefer, Michelle Young, Kayley Walsh, Adam Porter, Lynne Stevenson, Akshay Desai. Brigham 

and Women's Hospital, Boston, MA 

77


POSTERS 

135 

Prediction of Post-Discharge Outcomes for Patients Hospitalized with Heart Failure: Results from PROTECT 

Mitchell A. Psotka 1 , John R. Teerlink 1 , Karen Chiswell 2 , John G. Cleland 3 , Gad Cotter 4 , Beth A. Davison 4 , Michael M. 

Givertz 5 , Marco Metra 6 , Piotr Ponikowski 7 , Adriaan A. Voors 8 , Daniel M. Bloomfield 9 , Christopher M. O'Connor 2 . 1 University 

of California San Francisco & San Francisco VA Medical Center, San Francisco, CA; 2 Duke Clinical Research 

Institute, Duke University Medical Center, Durham, NC; 3 National Heart & Lung Institute, Royal Brompton & Harefield 

Hospitals, Imperial College, London, United Kingdom; 4 Momentum Research, Durham, NC; 5 Brigham and Women's Hospital, 

Boson, MA; 6 University of Brescia, Brescia, Italy; 7 Medical University, Clinical Military Hospital, Wroclaw, Poland; 

8 

University Medical Center Groningen, Groningen, Netherlands; 9 Merck Research Laboratories, Rahway, NJ 

136 

Combining Psychosocial Dysfunction and Renal Dysfunction in Predicting Outcomes in Patients With Heart Failure: 

Is There a Link? 

Ashvarya Mangla 1 , Burhan Mohamedali 2 , Rami Doukky 3 , 4 , Elizabeth Avery 5 , DeJuran Richardson 6 , 7 , Lynda H. Powell 6 . 

1 

Rush University Medical Center, Chicago, IL; 2 Rush University Medical Center, Chicago, IL; 3 Rush University Medical 

Center., Chicago, IL; 4 John H. Stroger,Jr. Hospital of Cook County, Chicago, IL; 5 Rush University Medical Center, Chicago, 

IL; 6 Rush University Medical Center, Chicago, IL; 7 Lakeforest College, Lakeforest, IL 

137 

Heart Failure Readmissions Reduction: Implementation and Results Based on Provider Group 

Milena Jani 1 , Joanna Kingery 2 , Irmina Gradus-Pizlo 1 , Azam Hadi 1 , Marco Caccamo 1 , Jose E. Finet 1 , Adnan Malik 1 . 1 Indiana 

University School of Medicine, Indianapolis, IN; 2 IU Health, Indianapolis, IN 

138 

Correlation Between Conduction Times and Electrode Distance in CRT Patients 

Pedram Kazemian 1 , Raffaele Corbisiero 1 , Ashish Shah 1 , David Muller 2 . 1 Deborah Heart & Lung, Browns Mills, NJ; 2 St 

Jude Medical, Sylmar, CA 

139 

Improving Medication Safety, in High Risk Patients After Discharge 

Elaine I. Kim. Baylor Elder House Calls and Transitional Care, Dallas, TX 

140 

Heart Failure Hospitalizations and 30 Day Readmissions for Quadripolar and Bipolar CRT-D Systems: Results From 

a US Single Center Study 

Raffaele Corbisiero 1 , Pedram Kazemian 1 , Rupinder Bharmi 2 , Riddhi Shah 2 , David Muller 2 . 1 Deborah Heart & Lung Center, 

Browns Mills, NJ; 2 St Jude Medical, Sylmar, CA 

141 

Nurse Practitioner Run Heart Failure Bridge Clinic Reduces Readmission Rates 

Kimberly Cuomo, Stuart Russell, Johana Almansa, Abby Cummings, Hetal Rupani, Arati Kotadia. Johns Hopkins, Baltimore, 

MD 

142 

Timing of Diuretic Administration and Length of Stay in Patients with Acute Decompensated Heart Failure 

Lisa M. Fleming 1 , Kenneth Mukamal 2 , Jeffrey Testani 3 , Edward Ullman 4 , Gail Piatkowsky 2 , Steven Horng 4 , Robb Kociol 2 . 

1 

Tufts Medical Center, Boston, MA; 2 Beth Israel Deaconess Medical Center, Boston, MA; 3 Yale University Medical Center, 

New Haven, CT; 4 Beth Israel Deaconess Medical Center, Boston, MA 

143 

Cardiac Resynchronization Therapy and Kidney Function: The One Year Cardio-Renal Connection 

Raffaele Corbisiero 1 , David Muller 2 , Rebecca Armbruster 1 , Kalyan Obalampalli 1 . 1 Deborah Heart & Lung Center, Browns 

Mills, NJ; 2 St Jude Medical, Sylmar, CA 

78


POSTERS 

144 

Nurse-practitioner-run, Sub-acute Rehabilitation Program for Heart Failure Reduces Hospital Readmission Rates 

by Half 

Tracy L. Lanoza. Rutgers University, Newark, NJ 

145 

Psychosocial Risk Assessment in Patients Receiving Ventricular Assist Devices Does not Correlate with Outcomes 

Lauren Freid, Estefania Oliveros, D. Schwartz, Yoshiya Toyoda, Akira Shiose, Alfred Bove, Rene Alvarez, Eman Hamad. 

Temple University Hospital, Philadelphia, PA 

146 

Prevalence of Advanced Heart Failure Utilizing the Latest Published Definitions Yields Higher Than Previously Published 

Data 

Andrea Creamer, Sarah Homer, Michael Pudlo, Carl Daniel, Susan Bionat, Arvind Bhimaraj. Houston Methodist Hospital, 

Houston, TX 

147 

Is Depression Causing the Heart Failure Patient's Readmission? 

Katherine Lalor. Lee Memorial Health System, Fort Myers, FL 

Clinical Care ......................................................................................................................................................................... 

148 

Constrictive Pericarditis in a Post Cardiac Transplant Patient 

Ugochukwu O. Egolum. Vanderbilt University, Nashville, TN 

149 

Etiology, Characteristics and Clinical Outcomes in High Output Heart Failure: A 15 Year Experience 

Yogesh N. V. Reddy, Vojtech Melenovsky, Barry A. Borlaug. Mayo Clinic, Rochester, MN 

150 

Heart Failure Nurses: Triumph With Titration 

Carolyn Devens, Tiffany Berg, Kathleen Miner, Laurie Bicknese. Mayo Clinic Rochester, Rochester, MN 

151 

Inferior Vena Cava Dilatation Predicts Mortality and Worsening Renal Function in Patients With Chronic Heart 

Failure 

Abdul Hafidz Muhammad Iqbal, Bayan Soujeri, Hawkey Sean, Daniel Levin, Muhammad Zaid Iskandar, Graham Stewart, 

Joanne Sloan, Chim Lang. University of Dundee, Dundee, United Kingdom 

152 

CMS Readmission Risk Score Predicts Poor Outcomes at Hospitalization 

Evelyn Dean 1 , Omima Ali 2 , Kevin F. Kennedy 1 , Anthony Magalski 3 , Bethany A. Austin 3 . 1 Saint Luke's Mid America Heart 

Institute, Kansas City, MO; 2 University of Missouri-Kansas City, Kansas City, MO; 3 Saint Luke's Mid America Heart Institute, 

Kansas City, MO 

153 

Heart to Heart: An Innovative Hospice Program for Heart Failure Patients 

Abigail Newton 1 , Martha Hager 2 , Ronetta Marhoover 1 , Patricia Pletke 2 , Stephen Rennyson 1 . 1 Centra Health, Lynchburg, VA; 

2 

Centra Health, Lynchburg, VA 

154 

Experience of a Newly Established Multidisciplinary Heart Failure Clinic at a VA Hospital 

Christina W. Rivers, Angela C. Ross, Nina Giustino, Lonnie Edwards, Siobhan Martin. Edward Hines,Jr. VA Hospital, Hines, 

IL 

79


POSTERS 

155 

Inpatient Diuretic Dose as a Predictor of Mortality and Re-Admission in Heart Failure 

Katherine Picel, Peter Eckman. University of Minnesota, Minneapolis, MN 

157 

Increased Risk of LVAD Thrombosis in Patients With a Previous History Thromboembolic Event 

Scott Lundgren. Univeristy of Nebraska Medical Center, Omaha, NE 

158 

Non-Invasive Bioelectrical Impedance for Predicting Clinical Outcomes in Outpatients with Heart Failure 

Kristin J. Lyons, Michelle K. Bischoff, Gregg C. Fonarow, Tamara B. Horwich. University of California Los Angeles, Los 

Angeles, CA 

159 

Role of Iron Chelation Therapy in Cardiac Hemosiderosis: A Case Series 

Abdullah AlMasoud, Ahmad Younes, Sadeer AlKindi, Chantal Elamm, Guilherme Oliveira, Robert Schilz, Jane Little, Mahazarin 

Ginwalla. University Hospitals Case Medical Center, Cleveland, OH 

160 

Delayed Presentation of Amiodarone Induced Thyrotoxicosis Following Heart Transplant 

LaVone Smith, Jamie Kennedy, Anthony McCall, Jennifer Kirby, Sula Mazimba. University of Virginia, Charlottesville, VA 

161 

Incremental Diagnostic and Clinical Utility of Endomyocardial Biopsy Over Cardiac Magnetic Resonance Imaging 

Alone in Patients with Unexplained Heart Failure 

Nisha A. Gilotra 1 , Mosi K. Bennett 2 , Van-Khue Ton 1 , Nicole Minkove 1 , Adam Shpigel 1 , Nishant Shah 1 , Kristina Montemayor 

1 , Allison Hays 1 , Marc K. Halushka 1 , Stuart D. Russell 1 . 1 Johns Hopkins Hospital, Baltimore, MD; 2 Minneapolis Heart 

Institute, Minneapolis, MN 

162 

Heart Failure Preserved Ejection Fraction Patients Benefit From Heart Failure Reduced Ejection Fraction Guidelines 

Gregg Steahr, Linda Kelly, Meredith Moore, Brenda Hott. Northside Hospital, Cumming, GA 

163 

Reevaluating Cardiopulmonary Exercise Testing Modality in Resynchronized Heart Failure Patients: Relevance of 

Heart Rate-Adaptive Pacing. 

Livia Goldraich, Heather J. Ross, Farid Foroutan, Juarez Braga, Mike Walker, Sean Balmain, Michael A. McDonald. University 

of Toronto, Toronto, ON, Canada 

164 

A New Training Pathway for Advanced Heart Failure/Cardiac Transplant Fellows: Sleep-Disordered Breathing Management 

Adam Pleister 1 , Rami Khayat 1 , Robin Germany 2 , William Abraham 3 . 1 The Ohio State University Wexner Medical Center, 

Columbus, OH; 2 Respicardia, Inc, Minnetonka, MN; 3 The Ohio State University Wexner Medical Center, Columbus, OH 

165 

Agreement between Pulmonary Capillary Wedge Pressure and Left Ventricular End Diastolic Pressure in Heart 

Transplant Subject; A Single Center Experience 

Abbas Bitar 1 , Farah Ammous 2 , Andrew Lenneman 1 , Greg Bell 1 , Allen Cheng 3 , Mark Slaughter 4 , Emma Birks 1 . 1 University of 

Louisville, Louisville, KY; 2 University of Louisville, Louisville, KY; 3 University of Louisville, Louisville, KY; 4 University 

of Louisville, Louisville, KY 

80


POSTERS 

166 

Sleep Quality, Fatigue, and Quality of Life in New York Heart Failure Associate Class II and III Heart Failure Individuals 

Jihane Hajj 1 , Hansie Mathelier 1 , Longjian Liu 2 , Brian Drachman 1 , Carol Patton 2 , Michael Dreher 3 . 1 Penn Presbyterian Medical 

Center, Philadelphia, PA; 2 Drexel University, Philadelphia, PA; 3 College of New Rochelle, westchester, NY 

167 

Health Status Trajectories Among Outpatients with Heart Failure 

Kelsey Flint 1 , Larry Allen 1 , 2 , Sarah Schmiege 3 , John Rumsfeld 1 , 4 , 2 , David Bekelman 1 , 4 , 2 . 1 University of Colorado, Aurora, 

CO; 2 Colorado Cardiovascular Outcomes Research Consortium, Denver, CO; 3 Colorado School of Public Health, Aurora, 

CO; 4 VA Eastern Colorado Health Care System, Denver, CO 

168 

Reduction in Heart Failure Readmissions Using Mobile Technology 

Thompson Boyd III 1 , Shelley Hankins 2 , Farhan Hasni 2 , Theresa Rowe 3 , Diane Snipas 3 , Cassandra Demastus 3 , Sandra Zimmerman 

3 , Ruth Stabler 3 , Howard J. Eisen 2 . 1 Hahnemann University Hospital, Philadelphia, PA; 2 Drexel University College 

of Medicine, Philadelphia, PA; 3 Hahnemann University Hospital, Philadelphia, PA 

Management Strategies, Adherence/ Self Care .................................................................................... 

169 

Device-Measured Rapid Shallow Breathing With Exertion Worsens Prior to Heart Failure Decompensation 

Seth Rials 1 , Bela Merkely 2 , Roy Gardner 3 , Viktoria Averina 4 , Robert Sweeney 4 , Yi Zhang 5 , Qi An 4 , John Boehmer 6 . 1 Grant 

Medical Center, OhioHealth, Columbus, OH; 2 Semmelweis University Heart Center, Budapest, Hungary; 3 Golden Jubilee 

National Hospital, Glasgow, United Kingdom; 4 Boston Scientific, St. Paul, MN; 5 B, St. Paul, MN; 6 Penn State Milton S. 

Hershey Medical Center, Hershey, PA 

170 

Remote Dielectric Sensing (ReDS)- Guided Patient Management of Ambulatory Heart Failure Patients Reduces 

Rehospitalization Rates 

William T. Abraham 1 , Offer Amir 2 , Jean Marc Weinstein 3 , Aharon Abbo 4 , Tuvia Ben Gal 5 . 1 Ohio State University, Columbus, 

OH; 2 Baruch Padeh Medical Center, Tiberias, Israel; 3 Soroka Medical Center, Beer Sheva, Israel; 4 Sensible Medical 

Innovations Ltd., Kfar Neter, Israel; 5 Rabin Medical Center, Petah Tikva, Israel 

171 

Learning Style, Health Literacy, and 90-Day Health Care Utilization in Heart Failure Patients 

Cheryl Westlake 1 , Kris Sethares 2 . 1 Azusa Pacific University, Azusa, CA; 2 University of Massachusetts, North Dartmouth, 

MA 

172 

Heart Failure Readmission Reduction Through Care Coordination 

Deborah J. Fenner 1 , Sanjeev K. Gulati 2 , Meghan E. Emig 3 . 1 Carolinas HealthCare System, Charlotte, NC; 2 Carolinas Health- 

Care System, Charlotte, NC; 3 Carolinas HealthCare System, Charlotte, NC 

173 

Home Telehealth Done in an Integrated Disease Management Program Results in Substantial Cost Savings and Reduction 

in Healthcare Utilization. 

Michael G. Dickinson 1 , Kevin L. Vos 2 . 1 Spectrum Health, Grand Rapids, MI; 2 Spectrum Health, Grand Rapids, MI 

174 

Motivational Interviewing to Improve Self-care for Patients with Chronic Heart Failure: MITI-HF Randomized 

Controlled Trial 

Ruth M. Masterson Creber 1 , Megan Patey 2 , Christopher S. Lee 3 , Barbara Riegel 2 . 1 Columbia University, New York, NY; 

2 

University of Pennsylvania, Philadelphia, PA; 3 Oregon Health & Sciences University, Portland, OR 

81


POSTERS 

175 

Symptomatology and Coping Resources Predict Self-Care in Older Patients with Heart Failure 

Lucinda J. Graven 1 , Joan S. Grant 2 , Glenna Gordon 1 . 1 Florida State University, Tallahassee, FL; 2 University of Alabama at 

Birmingham, Birmingham, AL 

176 

Hospital Readmission Rates Among Disadvantaged Heart Failure Patients Enrolled in Outreach Program 

Kira McClinton, Marisue Garganta, Marc Lato, Linda Martin, Susan Kilby, Anantharam Kalya. St. Joseph's Hospital and 

Medical Center, Phoenix, AZ 

82

POSTER RECEPTION II - SUNDAY (pages 83-98) 

POSTERS 

All posters will be on display Saturday at 6:00 PM - Monday at 1:30 PM 

Cardiovascular Physiology ................................................................................................................................... 

178 

Pulmonary Artery Proportional Pulse Pressure Predicts Adverse Clinical Outcomes in Group 1 Pulmonary 

Hypertension (Analysis of the NIH Pulmonary Hypertension Registry) 

Sula Mazimba 1 , James Bergin 1 , Jamie L. W. Kennedy 1 , Jose A. Tallaj 2 , Elizabeth Gay 3 , Mohammad Abuannadi 1 , Andrew 

Mihalek 3 , Kenneth C. Bilchick 1 . 1 University of Virginia, Charlottesville, VA; 2 University of Alabama at Birmingham, Birmingham, 

AL; 3 University of Virginia, Charlottesville, VA 

179 

Renal Dysfunction Has Limited Role in the Genesis of Diuretic Resistance in Heart Failure 

Chukwuma Onyebeke, Jennifer Simon, Susan J. Cheng, Jeffrey M. Testani. Yale University School of Medicine, New Haven, 

CT 

180 

Exercise Oscillatory Breathing is Associated With Ventricular Tachycardia, Atrial Fibrillation and Cardiomyopathy 

in Contemporary Patients Undergoing Metabolic Stress Testing 

Antonio L. Perez, Timothy Engelman, W.H. Wilson Tang. Cleveland Clinic, Cleveland, OH 

181 

Indices of Pulsatile and Resistive Afterload and Load-Dependent and Independent Right Ventricular Dysfunction 

in HFrEF 

E. Wilson Grandin 1 , Gregory S. Troutman 1 , Payman Zamani 1 , Jeremy A. Mazurek 1 , Anjali Vaidya 1 , Pavan Atluri 2 , Ryan J. 

Tedford 3 , Paul Forfia 4 , Kenneth B. Margulies 1 , J. Eduardo Rame 1 . 1 University of Pennsylvania, Philadelphia, PA; 2 University 

of Pennsylvania, Philadelphia, PA; 3 Johns Hopkins, Baltimore, MD; 4 Temple University, Philadelphia, PA 

182 

Therapeutic Insights for Heart Failure: In Vivo Comparison Between a Guanylyl Cyclase Receptor A and a Novel 

Guanylyl Cyclase Receptor B Activator 

S. Jeson Sangaralingham, Gerald E. Harders, Tomoko Ichiki, John C. Burnett Jr. Mayo Clinic, Rochester, MN 

183 

Improvements in Left Atrial Appendage Velocities Following Transcatheter Aortic Valve Replacement 

Tomo Ando 1 , Cynthia Taub 2 , David Slovut 3 . 1 Mount Sinai Beth Israel, New York, NY; 2 Montefiore Medical Center, Montefiore, 

NY; 3 Montefiore Medical Center, Bronx, NY 

184 

Diuretic-Induced Sodium Output is Highly Variable Between Patients Treated for Heart Failure But More Closely 

Associated With Hemoconcentration Than Fluid or Weight Loss 

Jennifer Simon, Susan J. Cheng, Chukwuma Onyebeke, Jeffrey M. Testani. Yale University School of Medicine, New Haven, 

CT 

Cardiovascular Structure/ Imaging .................................................................................................................. 

185 

Systolic Ejection Time is an Independent Predictor of Incident Heart Failure in a Community Based Cohort Free of 

Heart Failure 

Tor Biering-Sørensen 1 , Gabriela Querejeta Roca 1 , Sheila Hegde 1 , Amil Shah 1 , Brian Clagett 1 , Thomas H. Mosley 2 , Kenneth R. Butler 

2 , Scott D. Solomon 1 . 1 Brigham and Women’s Hospital, Boston, MA; 2 University of Mississippi Medical Center, Jackson, MS 

186 

Right Ventricular Outflow Tract Doppler Envelope Notching Predicts Pulmonary Vascular Resistance in Patients with 

Advanced Liver Disease 

Marcella Manicardi 1 , 2 , Jana Svetlichnaya 1 , Van Selby 1 , Munir Janmohamed 1 , Francis Yao 1 , John Roberts 1 , Teresa De Marco 1 . 

1 

University of California, San Francisco, CA; 2 Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy 

83

POSTER RECEPTION II - SUNDAY 

POSTERS 

187 

Association of 4-Tiered Classification of Left Ventricular Hypertrophy With Adverse Cardiovascular Outcomes in the 

General Population 

Sonia Garg 1 , James de Lemos 1 , Colby Ayers 1 , Michel Khouri 2 , Ambarish Pandey 1 , Jarett D. Berry 1 , Ronald M. Peshock 1 , 

Mark H. Drazner 1 . 1 UT Southwestern, Dallas, TX; 2 Duke University, Durham, NC 

188 

Improved Anemia as a Predictor of Reverse Remodeling and Prognosis Following Kidney Transplantation in Patients 

with Cardiac Dysfunction 

Nael Hawwa 1 , Kevin Shrestha 2 , Muhammad Hammadah 2 , Daniel Yeo 3 , Richard Fatica 4 , W. H. Wilson Tang 1 . 1 Cleveland 

Clinic, Cleveland, OH; 2 Cleveland Clinic, Cleveland, OH; 3 Tan Tock Seng Hospital, Singapore, Singapore; 4 Cleveland Clinic, 

Cleveland, OH 

189 

Multicenter Experience of Technetium Pyrophosphate Scanning for Diagnosing TTR Cardiac Amyloid: A Revival in 

Nuclear Cardiology 

Adam Castano 1 , Martha Grogan 2 , Geoffrey B. Johnson 3 , Angela Dispenzieri 4 , Frederick L. Ruberg 5 , John L. Berk 6 , Edward J. 

Miller 7 , Mathew S. Maurer 1 , Sabahat Bokhari 8 . 1 Columbia University Medical Center, New York, NY; 2 Mayo Clinic, Rochester, 

MA; 3 Mayo Clinic, Rochester, MN; 4 Mayo Clinic, Rochester, MN; 5 Boston University Amyloidosis Center, Boston, MA; 

6 

Boston University Amyloidosis Center, New York, NY; 7 Boston University School of Medicine, Boston, MA; 8 Columbia 

University Medical Center, New York, NY 

190 

Echocardiographic Predictors of Heart Failure in Hypertrophic Cardiomyopathy Secondary to Hypertension 

Manminder Bhullar 1 , Manmeet Singh 1 , Amarbhir Bhullar 2 , Amir Najafi 2 , Robert Ferdman 2 , Chandra Katikireddy 1 . 1 UCSF 

Fresno, Fresno, CA; 2 UCSF Fresno, Fresno, CA 

191 

Improvement in Left Atrial Appendage Velocities Following Transcatheter Aortic Valve Replacement is Associated 

with Better Outcome in Patients with Severe Aortic Stenosis 

Tomo Ando 1 , David Slovut 2 , Cynthia Taub 2 . 1 Mount Sinai Beth Israel, New York, NY; 2 Montefiore Medical Center, Bronx, 

NY 

192 

Potential Utility of Longitudinal Radial Strain Imaging in the Routine Assessment of Patients on Mechanical Circulatory 

Support: A Feasibility Study 

Saad S. Ahmad, Angel Lopez Candales. University of Cincinnati, Cincinnati, OH 

193 

Cluster Analysis in Idiopathic Dilated Cardiomyopathy (IDC): Opportunity to Define Pathogenesis? 

Monica P. Revelo 1 , Eliza B. Hammond 2 , Greg L. Snow 3 , Stavros G. Dakros 4 , Kim M. Molina 5 , Dylan V. Miller 6 , Edward M. 

Gilbert 4 , Elizabeth H. Hammond 7 , Abdalah G. Kfoury 8 . 1 University of Utah Health Care System, Salt Lake City, UT; 2 North 

Carolina School of Science and Mathematics, Durham, NC; 3 Statistical DataCenter, LDS Hospital, Intermountain Healthcare, 

Salt Lake City, UT; 4 University of Utah Health Care System, Salt Lake City, UT; 5 Primary Childrens Hospital, Salt Lake 

City, UT; 6 Intermountain Medical Center, Salt Lake City, UT; 7 LDS Hospital, Intermountain Healthcare, Salt Lake City, UT; 

8 

Intermountain Medical Center, Salt Lake City, UT 

Biomarkers/Neurohormones/Cytokines ........................................................................................................ 

194 

Hyponatremia Patterns During Hospitalization for Acute Heart Failure 

Frederik H. Verbrugge 1 , Justin L. Grodin 1 , Wilfried Mullens 2 , David O. Taylor 1 , Randall C. Starling 1 , W.H. Wilson Tang 1 . 

1 

Cleveland Clinic, Cleveland, OH; 2 Ziekenhuis Oost-Limburg, Genk, Belgium 

84


POSTERS 

195 

Metabolomic Patterns in Heart Failure Patients Vary Across Demographic and Clinical Factors 

David E. Lanfear 1 , Hani N. Sabbah 1 , Albert M. Levin 1 , Yun Wang 1 , Ruicong She 1 , Jia Li 1 , Keoki Williams 1 , Stephen Gardell 2 , 

Nicole Zeld 1 . 1 Henry Ford Health System, Detroit, MI; 2 Sanford Burnham Research Institute, Orlando, FL 

196 

Prognostic Role of Serum Chloride Levels in Acute Decompensated Heart Failure 

Justin L. Grodin 1 , Jennifer Simon 2 , Rory Hachamovitch 1 , Yuping Wu 3 , Gregory Jackson 4 , Meghana Halkar 5 , Randall C. Starling 

1 , Jeffrey Testani 6 , W. H. Wilson Tang 1 . 1 Cleveland Clinic, Cleveland, OH; 2 Yale University School of Medicine, New 

Haven, CT; 3 Cleveland State University, Cleveland, OH; 4 Medical University of South Carolina, Charleston, SC; 5 Cleveland 

Clinic, Cleveland, OH; 6 Yale University School of Medicine, New Haven, CT 

197 

Novel Protein Glycan Inflammatory Biomarkers Predict Adverse Events in Heart Failure with Preserved Ejection 

Fraction 

Jacob P. Kelly 1 , 2 , Wynn G. Hunter 3 , Robert W. McGarrah III 1 , 4 , Damian Craig 4 , Carol Haynes 4 , Eric J. Velazquez 1 , 2 , G. 

Michael Felker 1 , 2 , Adrian F. Hernandez 1 , 2 , Christopher B. Newgard 4 , Svati H. Shah 1 , 1 , William E. Kraus 4 , 1 . 1 Duke University 

Medical Center, Durham, NC; 2 Duke Clinical Research Institute, Durham, NC; 3 Duke University School of Medicine, 

Durham, NC; 4 Duke Molecular Physiology Institute, Durham, NC 

198 

Hypochloremia is Strongly and Independently Associated with Mortality in Patients with Chronic Heart Failure 

Jennifer Simon 1 , Chukwuma Onyebeke 1 , Susan J. Cheng 1 , Justin Grodin 2 , W. H. Wilson Tang 2 , Jeffrey M. Testani 1 . 1 Yale 

University School of Medicine, New Haven, CT; 2 The Cleveland Clinic, Cleveland, OH 

199 

Elevated Plasma Interleukin-6, Endothelin-1, and Matrix Metalloproteinase-9 in Heart Failure Patients are Associated 

With the Need for Advanced Therapies and Mortality 

Eitan A. Friedman 1 , Ugochukwu O. Egolum 1 , David C. Shisler 1 , John A. Todd 2 , Joel Estis 2 , Niamh Nolan 2 , Adnan Shah 2 , 

Daniel J. Lenihan 1 . 1 Vanderbilt University, Nashville, TN; 2 Singulex, Inc., Alameda, CA 

200 

Big-Endothelin-1 Transpulmonary Capillary Gradient is Increased in HFpEF, not Endothelin-1 

Bhavana Siddegowda Bangalore, Qaiser Shafiq, Mohamed Elamin, Samer Khouri. University of Toledo, Toledo, OH 

201 

Clinical Characteristics of Survivors and Non-Survivors with Immunoglobulin Light Chain (AL) Cardiac Amyloid 

Heart Failure 

Usman Tahir 1 , John S. Kim 1 , Lawreen Connors 2 , Flora Sam 3 . 1 Boston University Medical Center, Boston, MA; 2 Boston University 

School of Medicine, Boston, MA; 3 Boston University Medical Center, Boston, MA 

202 

Early Improvement Of Dyspnea And Neurohormonal Status Using Minute Ventilation-Targeted Adaptive Servo Ventilation 

In Acute Heart Failure 

Boris Arbit 1 , 2 , Matt Kawahara 1 , Elizabeth Lee 1 , Trenton Gluck 1 , Kathleen Sarmiento 1 , 2 , Atul Malhotra 1 , 2 , Alan Maisel 1 , 2 . 

1 


203 

Elevated Hepatocyte Growth Factor is Associated With Worse Prognosis in Cardiac Amyloidosis 

Eitan A. Friedman, Kelsey Tomasek, Yan Ru Su, Douglas B. Sawyer, Daniel J. Lenihan. Vanderbilt University, Nashville, TN 

204 

Plasma Aldosterone and Heart Failure in the General Community 

Alessia Buglioni, Valentina Cannone, Jeson S. Sangaralingham, Christopher G. Scott, Richard J. Rodeheffer, John C. Burnett. 

Mayo Clinic, Rochester, MN 

85


POSTERS 

Molecular Biology/Genetics/Cell Therapy ..................................................................................................... 

206 

MicroRNA-130a Regulation of Desmocollin2 in a Novel Model of Arrhythmogenic Cardiomyopathy 

Stefan Mazurek, Tyler Calway, Cynthia Harmon, Gene H. Kim. University of Chicago Medicine, Chicago, IL 

208 

Induced Pluripotent Stem Cell Derived Cardiomyocyte Scaffold Improves Electro-Mechanical Coupling and Left 

Ventricular Function in Rats With Heart Failure 

Jordan J. Lancaster 1 , Elizabeth Juneman 1 , Pablo Sanchez 1 , Kyle Weigand 1 , Talal Moukabary 1 , Nicole Lahood 1 , Joseph J. 

Bahl 1 , Steven Goldman 2 . 1 Sarver Heart Center, Tucson, AZ; 2 Southern Arizona VA Health Care System, Tucson, AZ 

209 

Bone Marrow Stem Cell Derived Cardiomyocyte Precursors Differentiated on Nanofiber Scaffolds Attenuate Scar 

Formation in a Rat Model of Myocardial Infarction 

Edward D. Marks, Arun Kumar. University of Delaware, Newark, DE 

Surgery/Transplantation/Devices ........................................................................................................................ 

210 

Right Vagus Nerve Stimulation With a Novel Self-Sizing 

Cuff Electrode Improves Left Ventricular Function in Dogs With Heart Failure 

Hani N. Sabbah 1 , Mengjun Wang 1 , Kefei Zhang 1 , Ramesh C. Gupta 1 , Maxime Lemonnier 2 , Andrew Khair 2 , Melanie Mallemeester 

2 , Christine Henry 2 . 1 Henry Ford Health System, Detroit, MI; 2 Sorin Group, Clamart, France 

211 

Impact of Pulmonary Function Tests on Outcomes in Patients after Left Ventricular Assist Device Implantation 

Amaninderapal S. Ghotra 1 , Zeeshan Hussain 1 , Nirmanmoh Bhatia 2 , Rafael Perez 1 , Allen Cheng 1 , Mark S. Slaughter 1 , Andrew 

Lenneman 1 , Emma J. Birks 1 . 1 University of Louisville, Louisville, KY; 2 Vanderbilt University, Nashville, TN 

212 

Region and Insurance Status Impacts LVAD Utilization for Patients Listed for Heart Transplantation 

Anita A. Kelkar, Yi-An Ko, Andreas Kalogeropoulos, Andrew L. Smith, David Vega, Alanna A. Morris. Emory University School 

of Medicine, Atlanta, GA 

213 

Fifteeen Years of Cardiac Resynchronization Pacing for Heart Failure Among Congenital Heart Patients: Direct 

Contractility not Guidelines Determines Responders 

Peter P. Karpawich, Yamuna Sanil, Neha Bansal, Kathleen Zelin. The Children's Hospital of Michigan, Wayne State University, Detroit, MI 

214 

Preoperative Iodine-123 Meta-Iodobenzylguanidine Imaging is a Novel Predictor of Left Ventricular Reverse Remodeling 

during Left Ventricular Assist Device Treatment 

Teruhiko Imamura 1 , Koichiro Kinugawa 1 , Daisuke Nitta 2 , Masaru Hatano 2 , Osamu Kinoshita 3 , Kan Nawata 3 , Minoru Ono 3 . 

1 

Graduate School of Medicine, University of Tokyo, Tokyo, Japan; 2 Graduate School of Medicine, University of Tokyo, Tokyo, 

Japan; 3 Graduate School of Medicine, University of Tokyo, Tokyo, Japan 

216 

The Impact of Frailty in an Elderly Population on Outcomes After Destination Therapy LVAD Placement: The Greater 

New York Geriatric Cardiology Consortium 

Deena S. Goldwater 1 , Victoria V. Dickson 2 , Cecilie Gjerde 2 , Jeff Goldsmith 3 , Nathan E. Goldstein 4 , Evelyn M. Horn 5 , Anu Lala 2 , Gordon 

R. Reeves 6 , Alex Reyentovich 2 , Melana Yuzefpolskaya 7 , Mathew S. Maurer 7 , Sean P. Pinney 1 . 1 Icahn School of Medicine at Mount Sinai 

Hospital, New York, NY; 2 New York University School of Medicine, New York, NY; 3 Columbia Mailman School of Public Health, New 

York, NY; 4 Icahn School of Medicine at Mount Sinai Hospital, New York, NY; 5 Weill Cornell Medical College, New York Presbyterian 

Hospital, New York, NY; 6 Thomas Jefferson University, Philadelphia, PA; 7 Columbia University Medical Center, New York, NY 

86


POSTERS 

217 

Insights into the Failing Fontan Circulation: Impact of Dominant Ventricular Morphology on Ventricular-Arterial 

Coupling in Adults with Fontan Circulation 

Hirofumi Saiki, Benjamin W. Eidem, Martha Grogan, Margaret M. Redfield. Mayo Clinic, Rochester, MN 

218 

Preoperative Risk Model for Prediction of Pump Thrombosis in LVADs 

David Raymer, Michael Nassif, Anuradha Godishala, Christopher Sparrow, Eric Novak, Vaiibhav Patel, Shane LaRue, Gregory 

Ewald, Justin Vader. Washington University / Barnes-Jewish Hospital, St. Louis, MO 

219 

Durable Bi-ventricular Support in INTERMACS 1 Patients Using the Heartware HVAD System in the Right Atrial 

Position 

Hao Tran, David Cork, Eric Adler, Victor Pretorius. University of San Diego, California, La Jolla, CA 

220 

A Single, Non-Academic Experience with Use of ECPR 

Peter Barrett, Vivek Rajagopal, Erin Sheffield, Lynn Pfaender, Julie Webster, Andrew Boyle, David Dean. Piedmont Heart, 

Atlanta, GA 

221 

Impact of Pre-Transplant Ventricular Assist Device Implantation on Adult Heart Transplant Outcomes in a Commercially 

Insured Population 

Wade Bannister, Charlotte Wu, Jiang Tao, Frank D. Irwin. Optum, Eden Prairie, MN 

222 

Transvenous Stimulation of Cardiac Autonomic Inputs Improves Subacute Canine Hemodynamics 

Michael Cuchiara, Scott Purcell, Jean Darnieder, Michael Romero, Stephen Masson. NeuroTronik, Durham, NC 

223 

Cognitive Improvement After Left Ventricular Assist Device Implant 

Michelle M. Hudson 1 , Mary E. Haines 1 , Thomas A. Schwann 2 , George V. Moukarbel 3 , Samer Khouri 4 , Allison Meyers-Fabian 

1 , Mark R. Bonnell 2 . 1 University of Toledo Medical Center, Toledo, OH; 2 University of Toledo Medical Center, Toledo, 

OH; 3 University of Toledo Medical Center, Toledo, OH; 4 University of Toledo Medical Center, Toledo, OH 

224 

Prevalence and Correlation of Non Functional Tricuspid Regurgitation to Right Ventricular Failure in Patients with CF-LVADs 

Cesar Y. Guerrero-Miranda 1 , Omar Saeed 1 , Anna Koulova 2 , Julia Shin 1 , Snehal R. Patel 1 , David D’Alessandro 3 , Daniel Goldstein 

3 , Ulrich Jorde 1 , Daniel Sims 1 . 1 Montefiore Medical Center - Albert Einstein College of Medicine, Bronx, NY; 2 Mt Sinai 

St Lukes-Roosevelt Hospital, New York, NY; 3 Montefiore Medical Center - Albert Einstein College of Medicine, Bronx, NY 

225 

Health Literacy as a Predictor of Adverse Outcomes after Implantation of Left Ventricular Assist Device 

David Raymer, Justin Vader, Anne Platts, Michael Nassif, Scott Silvestry, Gregory Ewald, Shane LaRue. Washington University 

/ Barnes-Jewish Hospital, St. Louis, MO 

226 

Smoking is Associated With Pump Thrombosis After Left Ventricular Assist Device Implantation 

Vaiibhav Patel 1 , Michael Nassif 2 , David Raymer 2 , Brian Pierce 1 , Justin Vader 2 , Greg Ewald 2 , Shane LaRue 2 . 1 Washington 

University, Saint Louis, MO; 2 Washington University, Saint Louis, MO 

227 

Long Term Support of Acute, Refractory Cardiogenic Shock with an Extracorporeal, Continuous Flow Ventricular 

Assist Device: A Seven Year Experience 

James M. Meza 1 , Yamini Krishnamurthy 2 , Laura Blue 1 , Jacob Schroder 1 , Chetan B. Patel 3 , Carmelo A. Milano 1 , Mani A. 

Daneshmand 1 . 1 Duke University Medical Center, Durham, NC; 2 Duke University School of Medicine, Durham, NC; 3 Duke 

University Medical Center, Durham, NC 

87


POSTERS 

228 

Normalization of Hemodynamics Following LVAD Implantation May be Related to Improved Long Term Outcome 

Emeka C. Anyanwu 1 , Kershaw Patel 1 , Cory Henderson 1 , Savitri E. Fedson 2 , Gene H. Kim 2 , Nitasha Sarswat 2 , Colleen 

Juricek 2 , Takeyoshi Ota 3 , Valluvan Jeevanandam 3 , Gabriel Sayer 2 , Nir Uriel 2 . 1 University of Chicago Medicine, Chicago, IL; 

2 

University of Chicago Medicine, Chicago, IL; 3 University of Chicago Medicine, Chicago, IL 

230 

Development of a Preoperative Risk Model that Predicts Gastrointestinal Bleeding after Implantation of Continuous-Flow 

LVADs 

Christopher T. Sparrow, Michael E. Nassif, David S. Raymer, Paul M. Lavigne, Eric Novak, Shane J. LaRue, Joel D. Schilling, 

Gregory A. Ewald, Justin M. Vader. Washington University in Saint Louis, St. Louis, MO 

231 

Diagnosis of Left Ventricular Assist Device (LVAD) Pump Thrombosis Using Fibrin-Specific 99mTc Imaging Agent 

Gregory A. Ewald, Grace Cui, Michael Scott, Michael E. Nassif, Shane J. LaRue, Justin M. Vader, David S. Raymer, Walter 

Akers, Scott Silvestry, Akinobu Itoh, Samuel Achilefu, Gregory Lanza. Washington University, St. Louis, MO 

232 

Clinical Outcomes Associated with INTERMACS Defined Right Ventricular Failure After LVAD Implantation 

Brian R. Pierce 1 , David Raymer 2 , Anuradha Godishala 1 , Christopher Sparrow 2 , Michael Nassif 2 , Shane LaRue 2 , Gregory 

Ewald 2 , Justin Vader 2 . 1 Barnes-Jewish Hospital, Saint Louis, MO; 2 Barnes-Jewish Hospital, Saint Louis, MO 

233 

Impact of Cytomegalovirus on Survival After Heart Transplant: analysis of 20,000 Patients from the UNOS Registry Data 

Guha Ashrith, Ahmed Daoud, Larry D. Teeter, Javier Amione-Guerra, Andrea M. Cordero-Reyes, Edward Gravis, Barry H. 

Trachtenberg, Arvind Bhimaraj, Osama A. Gaber, Scott Scheinin, Guillermo Torre-Amione, Jerry D. Estep. The Methodist 

Hospital, Houston, TX 

234 

Heart Transplant Donor Characteristics Associated with Worse Outcomes Differ Between Patients who are Bridged 

Continuous Flow LVAD and Non-bridged Patients: an Analysis of the UNOS Registry 

Guha Ashrith, Larry D. Teeter, Javier Amione-Guerra, Edward A. Gravis, Barry H. Trachtenberg, Arvind Bhimaraj, Osama 

A. Gaber, Brian Bruckner, Guillermo Torre-Amione, Jerry D. Estep. The Methodist Hospital, Houston, TX 

235 

Scripted Nurse Visits: A Resource-efficient Palliative Care Model for Destination VADs 

Mary E. Moyer, James Kirkpatrick, Nina O'Connor. Hospital of the University of Pennsylvania, Philadelphia, PA 

236 

Diabetic Patients Experience Delayed Improvement in Renal Function Post CF-LVAD Implantation 

Allison P. Levin 1 , Mustafa A. Pamirsad 1 , Jenni Nguyen 1 , Snehal Patel 1 , Omar Saeed 1 , Daniel Sims 1 , David A. D'Alessandro 1 , 

Daniel Goldstein 2 , Ulrich P. Jorde 1 . 1 Montefiore Medical Center, Bronx, NY; 2 Montefiore Medical Center, Bronx, NY 

238 

Is Education the Key to Success? Association of Formal Education and Outcomes in Left Ventricular Assist Devices 

Brent C. Lampert 1 , Robert S. D. Higgins 2 , Gary Phillips 3 , Sitaramesh Emani 1 , Sakima Smith 1 , Bryan A. Whitson 2 , Ahmet 

Kilic 2 , Ayesha K. Hasan 1 , Jeffrey J. Teuteberg 4 . 1 The Ohio State University Wexner Medical Center, Columbus, OH; 2 The 

Ohio State University Wexner Medical Center, Columbus, OH; 3 The Ohio State University, Columbus, OH; 4 University of 

Pittsburgh Medical Center, Pittsburgh, PA 

239 

Structural and Functional Echocardiographic Responses to Left Ventricular Assist Device Implantation: Focus on 

the Right Ventricle 

Kunal N. Bhatt, Raghda Al-Anbari, Alanna A. Morris, Andrew L. Smith, Vasiliki V. Georgiopoulou, J. David Vega, Andreas 

P. Kalogeropoulos. Emory University, Atlanta, GA 

88


POSTERS 

Electrophysiology/Arrhythmias ............................................................................................................................. 

240 

Optimizing Quadripolar Leads to Reduce Heart Failure Hospitalizations 

Alvaro ManriqueGarcia, Vidya Thandra, Samer A. De Oliveira, Judith Mackall, Harish Manyam. University Hospitals Case 

Medical Center, Cleveland, OH 

241 

Safety of Left Atrial Appendage Closure in Patients with Low Ejection Fraction 

Sameer Gafoor 1 , Vivek Reddy 2 , Jonathan Halperin 2 , Shephal Doshi 3 , Maurice Buchbinder 4 , Petr Neuzil 5 , Kenneth Huber 6 , 

Brian Whisenant 7 , Saibal Kar 8 , Vijay Swarup 9 , Mathew J. Price 10 , David Holmes 11 , Nicole Gordon 12 , Horst Sievert 1 . 1 Cardio- 

Vascular Center Frankfurt, Frankfurt, Germany; 2 Mount Sinai Hospital, New York City, NY; 3 Pacific Heart Institute, Santa 

Monica, CA; 4 San Diego Cardiovascular Associates, San Diego, CA; 5 Na Homolce Hospital, Prague, Czech Republic; 6 St. 

Luke's Health System, Kansas City, MO; 7 Intermountain Health Care, Salt Lake City, UT; 8 Cedars-Sinai Hospital, Los Angeles, 

CA; 9 Arizona Heart Rhythm Center, Phoenix, AZ; 10 Scripps Health, San Diego, CA; 11 Mayo Clinic, Rochester, MN; 

12 

Boston Scientific, St. Paul, MN 

242 

High Prevalence of Sub-clinical Cerebral Infarctions in Patients with Heart Failure with Preserved Ejection Fraction 

Rebecca J. Cogswell 1 , Faye L. Norby 2 , Rebecca F. Gottesman 3 , Lin Y. Chen 1 , Scott D. Solomon 4 , Amil M. Shah 4 , Alvaro 

Alonso 2 . 1 University of Minnesota, Minneapolis, MN; 2 University of Minnesota, Minneapolis, MN; 3 Johns Hopkins, Baltimore, 

MD; 4 Brigham and Woman's Hospital, Boston, MA 

243 

The Success of ICD-delivered ATP Therapy in Heart Failure Patients with Ventricular Tachycardia 

Dalia Giedrimiene 1 , Danette Guertin 2 , Jeffrey Kluger 2 . 1 University of Saint Joseph, West Hartford, CT; 2 Hartford Hospital, 

Hartford HealthCare, Hartford, CT 

244 

"Permissive ICD Programming for LVAD Patients" 

Dominique Williams, MD 1 , Praveen Rao, MD 2 , Michael Nassif, MD 2 , Eric Novak, MS 2 , Sarah Sandberg, MD 2 , Shane LaRue, 

MD 2 , Daniel Cooper, MD 2 , Justin Vader, MD 2 . 1 Washington University School of Medicine, Saint Louis, MO; 2 Washington 

University School of Medicine, Saint Louis, MO 

Clinical Trials ..................................................................................................................................................................... 

245 

Ranolazine Increases Exercise Capacity in Heart Failure with Preserved Ejection Fraction (HFpEF) 

Payman Zamani 1 , Denise Barnard 2 , Annette Contasti 3 , Daniel Blanchard 2 , Ottar Lunde 2 , Johanna Schandera 2 , Melanee 

Schimmel 2 , Roxana Ghashghaei 2 , Barry Greenberg 4 . 1 Hospital of the University of Pennsylvania, Philadelphia, PA; 2 UC San 

Diego, San Diego, CA; 3 Sharp Memorial Hospital, San Diego, CA; 4 UC San Diego, San Diego, CA 

246 

Normalization of Serum Potassium With Sodium Zirconium Cyclosilicate (ZS-9) in Patients With Heart Failure 

Prakash Deedwania 1 , Ileana L. Piña 2 , Henrik S. Rasmussen 3 , Philip T. Lavin 4 , Bhupinder Singh 3 , Alex Yang 3 , Peter A. Mc- 

Cullough 5 . 1 University of California at San Francisco, San Francisco, CA; 2 Albert Einstein COM/Montefiore Medical Center, 

Bronx, NY; 3 ZS Pharma, Inc., Coppell, TX; 4 Boston Biostatistics Research Foundation, Framingham, MA; 5 Baylor University 

Medical Center, Baylor Heart and Vascular Institute, Baylor Jack and Jane Hamilton Heart and Vascular Hospital, Dallas, 

TX 

89


POSTERS 

248 

Abstract: Prognostic Implications of Achieving an N-Terminal Pro-B-Type Natriuretic Peptide Level


POSTERS 

Epidemiology/ Prevention ........................................................................................................................................ 

262 

Coronary Artery Calcium as a Predictor of Incident Heart Failure with Preserved Ejection Fraction: Results from the 

Multi-Ethnic Study of Atherosclerosis (MESA) 

Kavita Sharma 1 , Haitham Ahmed 1 , Zeina Dardari 1 , Michael G. Silverman 2 , Clyde W. Yancy 3 , Moyses Szklo 4 , Joseph Yeboah 

5 , Stuart D. Russell 1 , Roger S. Blumenthal 1 , Michael J. Blaha 1 . 1 Johns Hopkins Hospital, Baltimore, MD; 2 Brigham 

and Women's Hospital, Boston, MA; 3 Northwestern University, Feinberg School of Medicine, Chicago, IL; 4 Johns Hopkins 

Hospital, Baltimore, MD; 5 Wake Forest University, Salem, NC 

263 

Efficacy of Preemptive Beta Blockers for Prevention of Cardiotoxicity in Patients Undergoing Hematopoietic Stem 

Cell Transplantation 

Chang H. Kim 1 , Sadeer Al-Kindi 1 , Ana CDAH de Souza 2 , Joyce Njoroge 2 , Marwan Qattan 3 , Brian D. Hoit 3 , Ann Liner 3 , 

Jamie Wilson 3 , Basem William 4 , Marcos de Lima 4 , Guilherme H. Oliveira 3 . 1 University Hospitals Case Medical Center, 

Cleveland, OH; 2 Case Western Reserve University, Cleveland, OH; 3 University Hospitals Case Medical Center, Cleveland, 

OH; 4 University Hospitals Seidman Cancer Center, Cleveland, OH 

264 

The Prevalence of Iron Deficiency in Patients with Heart Failure with Preserved Ejection Fraction and its Association 

with Elevated Pulmonary Pressure, Reduced Exercise Capacity and Quality of Life 

Tarek Bekfani 1 , Pierpaolo Pellicori 2 , Nicole Ebner 3 , Daniel- A. Morris 1 , Anja Sandek 1 , Wolfram Doehner 1 , John-G Cleland 2 , 

Mitja Lainscak 4 , Stefan-D Anker 3 , Stephan von Haehling 3 . 1 Charité University Hospital, Berlin, Germany; 2 University of 

Hull, Hull, United Kingdom; 3 University Medical Center Goettingen, Goettingen, Germany; 4 General Hospital Celje, Celje, 

Slovenia 

265 

Abnormal EKG Finding Associated with Presence and Severity of Sleep Apnea in Hispanic Patients with Obesity and 

Diastolic Dysfunction 

Johanna P. Contreras, Peter Montan, Eliscer Guzman. Mount Sinai Hospital, New York, NY 

266 

Prognostic Implications of Visit-to-visit Blood Pressure Variability in the Patients with Heart Failure 

Ju-Hee Lee, Sang Min Kim, Sang Yeub Lee, Jang-Whan Bae, Kyung-Kuk Hwang, Dong-Woon Kim, Myeong-Chan Cho. 

Chungbuk National University Hospital, Cheongju, Korea, Republic of 

267 

Circulating cGMP Levels in the General Population: Relationship with Cardiovascular and Renal Diseases 

Valentina Cannone 1 , Christopher G. Scott 2 , Kent R. Bailey 2 , Denise M. Heublein 1 , Margaret M. Redfield 1 , Richard J. Rodeheffer 

3 , Johannes-Peter Stasch 4 , John C. Burnett Jr. 1 . 1 Cardiorenal Research Laboratory, Mayo Clinic, Rochester, MN; 

2 

Division of Biostatistics, Mayo Clinic, Rochester, MN; 3 Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN; 

4 

Bayer, Wuppertal, Germany 

268 

The Renal-Cardio Connection and the Development of HFpEF : A Population Based Study 

Amit K. Jain 1 , Christopher G. Scott 2 , Horng H. Chen 3 . 1 Mayo Clinic and Foundation, Rochester, MN; 2 Mayo Clinic and 

Foundation, Rochester, MN; 3 Mayo Clinic and Foundation, Rochester, MN 

269 

The Role of Aspirin in the Prevention of Coronary Allograft Vasculopathy in Cardiac Transplant Patients 

Lane B. Benes 1 , Tiana L. Riley 2 , Catherine M. Murks 2 , Gabriel T. Sayer 2 , Savitri E. Fedson 2 , Nir Y. Uriel 2 , Gene H. Kim 2 . 

1 

University of Chicago, Chicago, IL; 2 University of Chicago, Chicago, IL 

91


POSTERS 

Quality of Care/Outcomes ......................................................................................................................................... 

270 

A Multi-State Model to Predict Heart Failure Hospitalizations and All-Cause Mortality in Outpatients With Heart 

Failure 

Jenica N. Upshaw, Marvin A. Konstam, Gordon S. Huggins, Farzad Noubary, David M. Kent. Tufts Medical Center, Boston, 

MA 

271 

Impact of Sociodemographic and Clinical Risk Factors on Hospitalisation Rates Among Ambulatory Patients with 

Heart Failure and Preserved Ejection Fraction 

Vasiliki V. Georgiopoulou 1 , Gregory Burkman 1 , Raghda Al-Anbari 1 , Nikolaos Spilias 1 , Taylor A. Lebeis 1 , Kanwal Farooq 1 , 

Mariyah Yazdani 1 , Lampros Papadimitriou 2 , Andrew L. Smith 1 , Javed Butler 2 , Andreas P. Kalogeropoulos 1 . 1 Emory University, 

Atlanta, GA; 2 Stony Brook University, Stony Brook, NY 

272 

Making a Case for the Heart Failure ICU - Differences in Characteristics and Care Between Critically Ill Cardiac 

Patients With and Without Heart Failure 

Jason N. Katz 1 , Anthony Peters 2 , Sarah Waters 2 , Ian Hollis 3 , Brian C. Jensen 1 . 1 University of North Carolina, Chapel Hill, 

NC; 2 University of North Carolina, Chapel Hill, NC; 3 University of North Carolina, Chapel Hill, NC 

273 

Trends in the Use of Guideline-based Therapies Among Dialysis Patients Hospitalized with Heart Failure: Findings 

from Get With The Guidelines-Heart Failure 

Ambarish Pandey 1 , Harsh Golwala 2 , Adam DeVore 3 , Di Lu 4 , George Madden 5 , Deepak L. Bhatt 6 , Philip Schulte 4 , Paul Heidenreich 

7 , Clyde Yancy 8 , Adrian Hernandez 4 , Gregg C. Fonarow 9 . 1 University of Texas Southwestern Medical Center, Dallas, 

TX; 2 University of Louisville School of Medicine, Louisville, KY; 3 Duke Clinical Research Institute, Durham, NC, Durham, 

NC; 4 Duke Clinical Research Institute, Durham, NC, Durham, NC; 5 University of Oklahoma School of Medicine, Oklahoma 

City, OK; 6 Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA; 7 Stanford 

University, Palo Alto, CA; 8 Northwestern University, Chicago, IL; 9 Ronald Reagan-UCLA Medical Center, Los Angeles, CA 

274 

Healthcare Costs in the Last Six Months of Life among Patients with Heart Failure 

Jason P. Swindle 1 , Engels N. Obi 2 , Stuart J. Turner 3 , Patricia A. Russo 4 , Cori J. Blauer-Peterson 1 , Lynn A. Wacha 1 , Aylin 

Altan 1 . 1 Optum, Inc., Eden Prairie, IL; 2 Rutgers University, Piscataway, NJ; 3 Novartis Pharmaceuticals Corporation, East 

Hanover, NJ; 4 DataMed Solutions, Washington, DC 

275 

Impact of Pulmonary Artery Pressure Monitoring on All-cause 30-day HF Readmissions and Associated Centers for 

Medicare and Medicaid Services Hospital Readmissions Reduction Program Penalty 

Philip B. Adamson 1 , Rupinder Bharmi 2 , Nirav Dalal 2 , William T. Abraham 3 . 1 St. Jude Medical, Austin, TX; 2 St. Jude Medical, 

Sylmar, CA; 3 Ohio State University Heart Center, Columbus, OH 

276 

Heart Failure is Associated With Worse Quality of Life and Survival But Similar Stroke Risk in Atrial Fibrillation 

Tharian S. Cherian 1 , Peter Shrader 2 , Gregg C. Fonarow 3 , Larry A. Allen 4 , Eric D. Peterson 2 , Jonathan Piccini 2 , Laine Thomas 

2 , Peter R. Kowey 5 , Paul Burton 6 , Bernard J. Gersh 7 , Kenneth W. Mahaffey 1 . 1 Stanford University, Stanford, CA; 2 Duke 

University Medical Center, Durham, NC; 3 University of California, Los Angeles, CA; 4 University of Colorado, Denver, CO; 

5 

Institute for Medical Research, Wynnewood, PA; 6 Janssen Pharmaceuticals, Inc, Titusville, NJ; 7 Mayo Clinic, Rochester, 

MN 

92


POSTERS 

277 

A New Measure of Healthcare Resource Utilization in Heart Failure: Development and Content Validity Evaluation 

Miyeon Jung, Marita Titler, Penny Riley, Barry Bleske, Susan J. Pressler. University of Michigan, Ann Arbor, MI 

279 

Vascular Reactivity Analysis in Patients with Continuous Flow Left Ventricular Assist Devices (CF-LVADs) - the Role 

of Endothelial Function in Continuous Flow Physiology 

Cesar Uribe, Keith A. Youker, Barry H. Trachtenberg, Guha Ashrith, Jerry D. Estep, Guillermo Torre-Amione, Brian A. 

Bruckner, John P. Cooke, Arvind Bhimaraj. The Methodist Hospital, Houston, TX 

280 

Grip Strength Assessment and Early Outcomes in Hospitalized Acute Decompensated Heart Failure: A Prospective 

Study 

Emer Joyce, Deepa M. Gopal, Adriana Luk, John D. Groarke, Sachin P. Shah, Garrick C. Stewart, Michael M. Givertz, 

Mandeep R. Mehra. Brigham and Women's Hospital, Boston, MA 

281 

Utilization of Aldosterone Receptor Antagonists at Discharge in Patients Hospitalized With Heart Failure and a 

Reduced Ejection Fraction 

Chris Domenico, Ed Lau, Karen Yiu, John Lindsley, Michael Moranville. Johns Hopkins Hospital, Baltimore, MD 

282 

Pre-operative Pulmonary Function Tests and Outcomes After Heart Transplantation 

Usama Daimee, Heather McGrane-Minton, Todd Massey, Leway Chen, Matthew Kottmann. University of Rochester Medical 

Center, Rochester, NY 

284 

Efficacy and Safety of Anti-thymocyte Globulin for the Treatment of Acute Cellular Rejection in Orthotopic Heart 

Transplant 

Stacy Crow, Samir J. Patel, Kyle L. Dawson, Andrea M. Cordero-Reyes, Arvind Bhimaraj, Barry H. Trachtenberg, Guha 

Ashrith, Jerry D. Estep. The Methodist Hospital, Houston, TX 

285 

Pulmonary Artery Pressure Guided Heart Failure Management During a ‘Real-World’ Clinical Setting Follow-Up 

Period Demonstrated Even Greater Improvement in Clinical Outcomes Than That Achieved in the CHAMPION 

Randomized Controlled Trial 

Philip B. Adamson 1 , John Henderson 2 , Greg Ginn 2 , Susan Neville 2 , William T. Abraham 3 . 1 St. Jude Medical, Austin, TX; 2 St. 

Jude Medical, Atlanta, GA; 3 Ohio State University Medical Center, Columbus, OH 

287 

Detectable Cardiac Troponin I Predicts Adverse Cardiac Events and Heart Failure Hospitalizations in Stable Heart 

Failure Outpatients 

Muhammad Hammadah 1 , Vasiliki Georgiopoulou 2 , Andreas Kalogeropoulos 2 , Javed Butler 3 , W.H.Wilson Tang 4 . 1 Cleveland 

Clinic, Cleveland, OH; 2 Emory University, Atlanta, GA; 3 Stony brook, Stony brook, NY; 4 Cleveland Clinic, Cleveland, OH 

289 

Predicting Likelihood of 30-Day Readmission After Heart Failure Hospitalization Using Readily Available Electronic 

Health Record Data 

Cheryl Bartone, Eugene Chung, Santosh Menon, Gregory Egnaczyk, Thomas O'Brien. The Christ Hospital, Cincinnati, OH 

291 

Survival and Implantable Cardioverter-Debrillator Deactivation in End-Stage Congestive Heart Failure Patients 

Lillian C. Man 1 , Loheetha Ragupathi 2 , Paul Mather 3 . 1 Jefferson University Hospital, Philadelphia, PA; 2 Jefferson University 

Hospital, Philadelphia, PA; 3 Jefferson University Hospital, Philadelphia, PA 

93


POSTERS 

292 

No Increase in Mortality Seen with β-blocker Treatment in 

Heart Failure Patients with Cocaine Use 

Peter Nguyen 1 , 2 , Hassan Kamran 1 , Saifullah Nasir 1 , Wenyaw Chan 1 , 2 , 3 , Biykem Bozkurt 1 , 2 , 4 . 1 Baylor College of Medicine, 

Houston, TX; 2 Winters Center For Heart Failure Research, Houston, TX; 3 University of Texas School of Public Health, 

Houston, TX; 4 Micheal E. Debakey Veterans Affairs Medical Center, Houston, TX 

293 

Risk Predictors for 30 day Readmission & Length of Stay 

Joseph Ingrassia 1 , Richard Soucier 2 , Melissa Woiciechowski 1 , Penny Cyr 2 , Rebecca Crowell 2 . 1 University of Connecticut, 

Farmington, CT; 2 St. Francis Hospital and Medical Center, Hartford, CT 

294 

Elevated Total Bilirubin on Admission is a Marker of Worse 30- and 180-Day Outcomes for Patients With Acute HF: 

Insights From ASCEND-HF 

Marc Samsky 1 , Allison Dunning 1 , Phillip Schulte 1 , Adam DeVore 1 , Robert Mentz 1 , Chetan Patel 1 , Randall Starling 2 , John 

Teerlink 3 , Wilson Tang 2 , Paul Armstrong 4 , Justin Ezekowitz 4 , Marco Metra 5 , Adriaan Voors 6 , John McMurray 7 , Javed Butler 8 , 

Christopher O'Connor 1 , Adrian Hernandez 1 . 1 Duke University, Durham, NC; 2 Cleveland Clinic, Cleveland, OH; 3 University 

of California, San Francisco, San Francisco, CA; 4 University of Alberta, Edmonton, AB, Canada; 5 University of Brescia, 

Brescia, Italy; 6 University Medical Center Groningen, Groningen, Netherlands; 7 University of Glasgow, Glasgow, United 

Kingdom; 8 Stony Brook University, Stony Brook, NY 

295 

Elevated Transpulmonary Gradient is a Predictor of Survival in Patients with WHO Group II Pulmonary Hypertension 

Treated with Continuous-flow Left Ventricular Assist Devices (CF-LVAD) 

Javier Amione-Guerra 1 , Andrea M. Cordero-Reyes 1 , Arvind Bhimaraj 1 , Barry H. Trachtenberg 1 , Guillermo Torre-Amione 1 , 2 , 

Jerry D. Estep 1 , Guha Ashrith 1 . 1 The Methodist Hospital, Houston, TX; 2 Tecnológico de Monterrey, Monterrey, Nuevo León, 

Mexico 

296 

Race, Gender and Clinical Characteristics Do Not Predict Outcomes in End-Stage Heart Failure Patients Requiring 

Inotropes 

Charles D. Nicolais, Reema R. Bhatt, Lauren M. Freid, Eman A. Hamad, Rene J. Alvarez, Alfred A. Bove, Daniel R. 

Schwartz. Temple University Hospital, Philadelphia, PA 

297 

Elevated Heart Rate in Patients with Heart Failure with Reduced Ejection Fraction: Associations with One-Year 

Survival and Costs 

Adam D. DeVore 1 , Phillip J. Schulte 2 , Robert J. Mentz 1 , N. Chantelle Hardy 2 , Jacob P. Kelly 1 , Eric J. Velazquez 1 , Juan 

F. Maya 3 , Adrian Kielhorn 3 , Harshali Patel 3 , Shelby D. Reed 2 , Adrian F. Hernandez 1 . 1 Duke University Medical Center, 

Durham, NC; 2 Duke Clinical Research Institute, Durham, NC; 3 Amgen, Inc., Thousand Oaks, CA 

298 

OptiVol Impedance Threshold Crossing Predicts Patients with Higher Mortality or Hospitalization Risk Among 

Medicare Recipients 

Jason Brown 1 , 2 , Kenneth Bilchick 3 , Alvaro Alonso 2 , Eduardo Warman 1 . 1 Medtronic PLC, Minneapolis, MN; 2 University of 

Minnesota, Minneapolis, MN; 3 University of Virginia, Charlottesville, VA 

299 

How do Patients with Ventricular Assist Devices Die?_A Look at End of Life Outcomes 

Esther S. Pak 1 , Eva Laverty-Wilson 2 , Christyna Zalewski 3 , Wald Joyce 4 , Pavan Atluri 2 , Eduardo Rame 1 , James N. Kirkpatrick 

4 . 1 Hospital of the University of Pennsylvania, Philadelphia, PA; 2 Hospital of the University of Pennsylvania, Philadelphia, 

PA; 3 Hospital of the University of Pennsylvania, Philadelphia, PA; 4 Hospital of the University of Pennsylvania, 


94


POSTERS 

300 

Medical Management of Patients with the HeartMate II Left Ventricular Assist Devices. A Single Center Experience 

Adam F. Burdorf, John Um, Eugenia Raichlin, Eric Rome, Jason Darrah, Sara Varnado, Brian Lowes. University of Nebraska 

Medical Center, Omaha, NE 

301 

The Relationship Between Glucose Variability and In-Hospital Mortality in Patients With Acute Heart Failure Syndrome: 

Data From the Korean Acute Heart Failure (KorAHF) Registry 

Jaewon Oh 1 , Seok-Min Kang 1 , Eun-Seok Jeon 2 , Jae-Joong Kim 3 , Sang Hong Baek 4 , Myeong-Chan Cho 5 , Shung Chull 

Chae 6 , Dong-Ju Choi 7 , Byung-Su Yoo 8 , Byung-Hee Oh 9 . 1 Yonsei University College of Medicine, Seoul, Korea, Republic 

of; 2 Sungkyunkwan University College of Medicine, Seoul, Korea, Republic of; 3 University of Ulsan College of Medicine, 

Seoul, Korea, Republic of; 4 Catholic University of Korea College of Medicine, Seoul, Korea, Republic of; 5 Chungbuk National 

University College of Medicine, Cheongju, Korea, Republic of; 6 Kyungpook National University College of Medicine, 

Daegu, Korea, Republic of; 7 Seoul National University Bundang Hospital, Seongnam, Korea, Republic of; 8 Yonsei University 

Wonju College of Medicine, Wonju, Korea, Republic of; 9 Seoul National University Hospital, Seoul, Korea, Republic of 

302 

Heart Failure Supportive Care: Integrating Mortality Risk Modeling Into Heart Failure Care to Impact Outcomes 

Mitchell T. Saltzberg 1 , Roshni Guerry 2 , Kelly A. Whitmarsh 3 , Carolyn Moffa 1 , Lisa Keichline 4 . 1 ChristianaCare Health System, 

Newark, DE; 2 ChristianaCare Health System, Newark, DE; 3 ChristianaCare Health System, Newark, DE; 4 ChristianaCare 

Health System, Newark, DE 

303 

Inverse Changes in Quality of Life for Patients and Caregivers After Implantation of a Ventricular Assist Device 

Julie T. Bidwell, Christopher S. Lee. Oregon Health & Science University, Portland, OR 

Clinical Care ......................................................................................................................................................................... 

304 

Trends in use of Swan-Ganz Catheter Among Patients with Acute Decompensated Heart Failure Hospitalization in 

United States, 2004 -2012: Did the ESACPE Trial Make a Difference? 

Ambarish Pandey 1 , Neetika Garg 2 , Nilay Kumar 3 . 1 University of Texas Southwestern Medical Center, Dallas, TX; 2 Beth 

Israel Deaconess Medical Center, Boston, MA; 3 Cambridge Health Alliance/Harvard Medical School, Cambridge, MA 

305 

Minute Ventilation-Targeted Adaptive Servo Ventilation Protects Renal Function In Acute Decompensated Heart 

Failure Patients 

Matt Kawahara 1 , Trenton Gluck 1 , Elizabeth Lee 1 , Boris Arbit 1 , 2 , Kathleen Sarmiento 1 , 2 , Atul Malhotra 1 , 2 , Alan Maisel 1 , 2 . 

1 


306 

Prevalence of Heart Failure in Different Sickle Cell Variants by Age, Gender, and Systolic Dysfunction 

Sadeer Alkindi, Abdallah Almasoud, Ahmad Younes, Chantal Elamm, Rodolfo Benatti, Guilherme Oliveira, Robert Schilz, 

Jane Little, Mahazarin Ginwalla. University Hospitals Case Medical Center, Cleveland, OH 

307 

Increased Risk of Heart Block in Patients with Cardiac Amyloidosis on Amiodarone 

Sadeer Alkindi, Abdullah Almasoud, Ahmad Younes, Chantal Elamm, Rodolfo Benatti, Guilherme Oliveira, Mahazarin Ginwalla. 

University Hospitals Case Medical Center, Cleveland, OH 

308 

Predictors of Early and Late Heart Failure Post-orthotopic Liver Transplantation 

Mohammad A. Al-Ani, Forat G. Lutfi, Ameet P. Patel, Vikas Kullar, Angela Dolganiuc, Juan R. Vilaro, Roberto J. Firpi-Morell, 

Mustafa M. Ahmed. University of Florida, Gainesville, FL 

95


POSTERS 

309 

Correlates of Spirometery to Invasively Measured Pulmonary Arterial Hemodynamics in Advanced Chronic Heart 

Failure 

Mohammad Alasaad 1 , Justin Grodin 1 , Vijay Ngarajan 2 , W.H. Wilson Tang 1 . 1 Cleveland Clinic Foundation, Cleveland, OH; 

2 

University of Virginia, Charlottesville, VA 

310 

The Importance of Defining Red Blood Cell Mass in the Management of Volume Overload Chronic Systolic Heart 

Failure 

Wayne L. Miller. Mayo Clinic, Rochester, MN 

313 

Identifying a Strong Association Between Physical and Affective Symptom Clusters in Heart Failure 

Quin E. Denfeld 1 , James O. Mudd 2 , Shirin O. Hiatt 1 , Jill M. Gelow 2 , Christopher V. Chien 2 , Christopher S. Lee 1 , 2 . 1 Oregon 

Health & Science University, Portland, OR; 2 Oregon Health & Science University, Portland, OR 

314 

Pre-discharge Bedside Exercise Gas Exchange Measurements Predict 30 Day Heart Failure Patient Readmissions 

Gregory D. Lewis 1 , Ashley Dress 1 , Gregory A. Ewald 2 , Jean Flanagan 2 , Peter Eckman 3 , Aaron Eisman 1 , Jennifer Nelson 3 , 

Dean MacCarter 4 , Abraham Kocheril 5 . 1 Massachusetts General Hospital, Boston, MA; 2 Washington University, St. Louis, 

MO; 3 Universtiy of Minnesota, Minneapolis, MN; 4 Shape Medical Systems, St. Paul, MN; 5 University of Illinois, Champaign, 

IL 

315 

Case Series Defining Role of External Chest Compressions (ECC) in Patients with Ventricular Assist Device (VAD) 

Bhaskar Arora, Jonathan Hammond, Nicole Chomick, Tari Devoe, Nicole Huhn, Jason Gluck. Hartford Hospital, Hartford, CT 

317 

Prognostic Value of a 6-Minute Walk Test in Patients Undergoing Percutaneous Coronary Intervention: A Prospective 

Study. 

Bhavin C. Patel 1 , Siddharth A. Wayangankar 1 , Udho Thadani 1 , Pedro Lozano 1 , Faisal Latif 1 , Daniel Zhao 2 , Cheuk Leung 2 , 

Tarun W. Dasari 1 . 1 University of Oklahoma Health Sciences Center, Oklahoma City, OK; 2 University of Oklahoma Health 

Sciences Center, Oklahoma City, OK 

318 

Peripartum Cardiomyopathy Network: Medication and Device Therapy Use in the First Year 

Kismet Rasmusson 1 , Dennis McNamara 2 , Deborah Budge 1 , Abdallah Kfoury 1 , Uri Elkayam 3 , Michael Givertz 4 , Richard 

Sheppard 5 , Greg Ewald 6 , Eileen Hsich 7 , Kalgi Modi 8 , Rami Alharethi 1 . 1 Intermountain Heart Institute, Salt Lake City, UT; 

2 

Univesity of Pittsburgh, Pittsburgh, PA; 3 University of Southern California, Los Angeles, CA; 4 Brigham and Women's 

Hospital, Boston, MA; 5 Jewish General, Montreal, QC, Canada; 6 Washington University, St. Louis, MO; 7 Cleveland Clinic, 

Cleveland, OH; 8 Louisiana State University, Shreveport, LA 

320 

The Impact of Sleep Apnea Syndrome Post Cardiac Transplantation 

Sandra Carey. Baylor Scott & White Health, Dallas, TX 

321 

Pharmacotherapy for VAD Thrombus: Response Rates and Financial Impact of Anticoagulant Strategies 

Lynne Sylvia 1 , Frank Massaro 1 , David DeNofrio 2 , Michael Kiernan 2 . 1 Tufts Medical Center, Boston, MA; 2 Tufts Medical 

Center, Boston, MA 

96


POSTERS 

323 

Is the Nutritional Risk Index Useful in Advanced Heart Failure Patients? 

Gardner Yost 1 , Burhan Mohamedali 2 , Geetha Bhat 1 . 1 Advocate Christ Medical Center, Oak Lawn, IL; 2 Rush University 

Medical Center, Chicago, IL 

Management Strategies, Adherence/ Self Care .......................................................................................... 

324 

Student Heart Failure Intervention Project: A Pilot Study of Population Analytics and Outreach 

William B. Reichert 1 , Gerard Hoatam 1 , Emily Schmidt 1 , Michael Leher 1 , Arathi Gorur 1 , Anna Jones 1 , Anantharam Kalya 2 , 

Priya Radhakrishnan 2 . 1 Creighton University School of Medicine, Omaha, NE; 2 St. Joseph's Hospital and Medical Center, 

Phoenix, AZ 

325 

Predicting Absolute Risk for Unplanned Cardiovascular Readmissions in Adults With Chronic Heart Failure 

Vasiliki Betihavas 1 , Steven A. Frost 2 . 1 Sydney University, Sydney, Australia; 2 University of Western Sydney, Sydney, Australia 

326 

Reasons for Heart Failure Hospitalization: Nonadherence versus 

Worsening Heart Failure 

Nisha A. Gilotra, Adam Shpigel, Ike S. Okwuosa, Ruth Tamrat, Deirdre Flowers, Stuart D. Russell. Johns Hopkins Hospital, 

Baltimore, MD 

327 

Feasibility of Remote, Non-Invasive, Wireless, Continuous Real-Time Monitoring of Heart Rate in Heart Failure 

Patients 

Lyle Olson, Nancy Lexvold, Virend Somers, Paul Friedman, Louis Schenck, Bradley Lewis, Charles Bruce. Mayo Clinic, 

Rochester, MN 

328 

Effect of Telemanagement in Patients Discharged to a Nursing Facility After Heart Failure (HF) Hospitalization. 

Santosh G. Menon 1 , Mindy Brewer 2 , Kim Barrows 2 , Tashua Woods-Stroup 2 , Heather Overbeck 3 , Amy Dadosky 4 , Maureen 

Corl 4 , Ken Bertke 4 , Natasha Hiles 1 , Tracy Preidt 4 , Stacey Arnold 1 , Kathleen Daly 1 , Eugene Chung 1 . 1 Ohio Heart and Vascular 

Center, Cincinnati, OH; 2 Brookwood Retirement Community, Cincinnati, OH; 3 The Christ Hospital, Cincinnati, OH; 4 The 

Christ Hospital, Cincinnati, OH 

329 

Myers Briggs Type Indicator and Outcomes in Heart Failure Patients 

Ike S. Okwuosa, Nisha A. Gilotra, Adam Shpigel, Ruth Tamrat, Deirdre Flowers, Kimberly Skarupski, David Yousem, Stuart 

D. Russell. Johns Hopkins Hospital, Baltimore, MD 

330 

The Relationships of Fatigue and Depression to Hospitalizations and Gender Differences in Patients with Heart Failure 

Seongkum Heo, Jean McSweeney, Pao-Feng Tsai, Songthip Ounpraseuth. University of Arkansas for Medical Sciences, 

Little Rock, AR 

97


POSTERS 

331 

Impact of a Community-Based Heart Failure Disease Management Program 

Gregg Steahr, Linda Kelly, C. Meredith Moore, Brenda Hott. Northside Hospital, Cumming, GA 

332 

Heart Failure Patients With Dyspnea Had Higher Device-Based Respiratory Rate Than Those Without 

Roy S. Gardner 1 , Bela Merkely 2 , Pier Lambiase 3 , Yi Zhang 4 , Qi An 4 , Viktoria Averina 4 , Robert Sweeney 4 , Scott Wehrenberg 5 . 

1 

Golden Jubilee National Hospital, Glasgow, United Kingdom; 2 Semmelweis University Heart Center, Budapest, Hungary; 

3 

The Heart Hospital, London, United Kingdom; 4 Boston Scientific, St Paul, MN; 5 Boston Scientific, St Paul, MN 

333 

The Wisconsin Pharmacy Quality Collaborative - A Statewide Network of Community Pharmacists to Improve Heart 

Failure Outcomes 

Joseph Rinka 1 , Orly Vardeny 2 , Claudius Mahr 3 , Stacey M. Gardiner 4 , Erika M. Horstmann 5 . 1 Concordia University Wisconsin 

School of Pharmacy, Mequon, WI; 2 University of Wisconsin-Madison, Madison, WI; 3 University of Washington, Seattle, 

WA; 4 Medical College of Wisconsin, Milwaukee, WI; 5 The Pharmacy Society of Wisconsin, Madison, WI 

Late Breaking Clinical Trials ..................................................................................................................................... 

335 

Phase IIb safety and efficacy study of BAY 94-8862 in subjects with worsening chronic heart failure and left ventricular 

systolic dysfunction and either type 2 diabetes mellitus with or without chronic kidney disease or moderate chronic kidney 

disease alone (ARTS-HF) 

Gerasimos Filippatos, Stefan D. Anker, Michael Böhm, Mihai Gheorghiade, Lars Køber, Henry Krum, Aldo P. Maggioni, 

Piotr Ponikowski, Adriaan A. Voors, Faiez Zannad, So-Young Kim, Christina Nowack, Giovanni Palombo, Peter Kolkhof, 

Nina Kimmeskamp-Kirschbaum, Alexander Pieper, and Bertram Pitt 

336 

Ferric Carboxymaltose in Iron Deficient Heart Failure Patients: A Meta-Analysis on Individual Patient Data 

Anker SD, Comin-Colet J, Filippatos G, Kirwan BA, Ruschitzka F, Arutjunov GP, Motro M , Mori C, Moneuse P, Pocock 

SJ, van Veldhuisen DJ, Ponikowski P 

337 

Evaluation of ReDS-guided Patient Management in Ambulatory Heart Failure Patients At-Risk for Rehospitalization 

ReDS-HF Study 

William T Abraham, Tuvia Ben Gal, Jean Marc Weinstein, Aharon Abbo, Offer Amir 

98

2015 19th Annual Scientific Assembly 

EXHIBIT HALL 

September 26 – 29, 2015 



EXHIBIT HALL ACTIVITIES 

Saturday, September 26, 6:00 PM – 8:00 PM 

Exhibit Hall Opening Reception 

Saturday, September 26, 6:30 PM – 7:30 PM 

Poster Reception and Moderated Poster Sessions 

Sunday, September 27, 5:30 PM – 6:30 PM 

Poster Reception and Moderated Poster Sessions 

Industry Expert Theaters 

Industry Expert Theatres are non-CME educational activities 

held in dedicated space in the exhibit hall. They allow 

industry experts an opportunity to provide clinical updates 

and educate attendees on current therapies, disease states, 

products and pipeline activities while remaining close to the 

action in the exhibit hall. Sessions are formatted for learning 

and are a great way to receive higher level interaction 

and engagement with company representatives. 

Educational activities held in the exhibit hall do not provide 

continuing education credit. 

Saturday, September 26 

6:15 PM – 7:15 PM 

Exhibit Hall 

Targeting Neurohormones in Heart 

Failure: The Potential Role of Endogenous 

Compensatory Peptides 

Faculty: 

Milton Packer, MD 

Description: 

In heart failure (HF), the renin-angiotensin system (RAS) 

has been difficult to control possibly because of its predilection 

to escape from suppression during long-term treatment. 

Several endogenous compensatory peptides (ECPs) can act 

as biological antagonists of the RAS, but their activity is 

diminished in HF, presumably because of various factors 

such as naturetic peptide desensitization, decreased vascular 

reactivity, and a marked increase in ECP degradation. This 

program will review the physiologic role of these ECPs and 

the evidence suggesting their diminished activity as well as 

their importance in HF. 

Sunday, September 27 

10:10 AM – 10:40 AM 

Exhibit Hall 

Make a Move Sooner: Results from the 

ROADMAP Study Comparing LVAD to 

Medical Management 

Faculty: 

Jerry D. Estep, MD, FACC – Houston Methodist Hospital 

Joseph Rogers, MD – Duke University School of Medicine 

Description: 

Learn how to apply the latest clinical results from the 

ROADMAP study to your practice. Understand the risk and 

benefits of LVAD therapy for non-inotrope dependent advanced 

heart failure patients. Learn why the study supports 

the use of HeartMate II ® in this patient population. 



12:10 PM – 1:10 PM 

Exhibit Hall 

NT-proBNP in Latest Heart Failure 

Treatment 

Faculty: 

Tariq Ahmad, MD, MPH 

Description: 

Over the past several years, the clinical utility of testing for 

natriuretic peptides has been increasingly recognized. This 

program will include analytical and clinical considerations 

of NT-proBNP testing as it relates to patient care. Faculty 

will also discuss how NT-proBNP can supplement your 

judgement in the management of heart failure patients. 

Sponsored by Roche 

Sponsored by Novartis Pharmaceuticals Corporation 

100


Industry Expert Theaters (continued) 

3:10 PM – 3:40 PM 

Exhibit Hall 

Furosemide 2.0: A Convenient Alternative 

to Intravenous Furosemide Treatment 

Faculty: 

Pieter Muntedam, MD 

Description: 

scPharmaceuticals is developing furosemide for subcutaneous 

delivery by means of a patch pump. In order to be given 

subcutaneously, a buffered formulation was developed with 

a neutral pH ( 7 . 4 as compared to commercial furosemide 

which is alkaline with a pH of around 9 . 0 ). The company is 

developing a patch pump for convenient administration of 

80 

mg. This wold provide "iv-like" diuresis without the need 

for iv. Theere are several intended uses: In the pre-acute 

patients who do need more than oral alone can provide; in 

the post-acute patient to reduce length of stay and; avoidance 

of need for iv placement. It is not indicated for use in 

emergency situations. 

Sponsored by scPharmaceuticals 

5:15 PM – 6:15 PM 

Exhibit Hall 

A New Treatment Approach for Patients 

With Chronic Systolic Heart Failure 

Faculty: 



Monday, September 28 

8:30 AM – 9:30 AM 

Exhibit Hall 

A New Treatment Approach for Patients 

With Chronic Systolic Heart Failure 

Faculty: 

Vasilios Papademetriou, MD 

10:10 AM – 10:40 AM 

Exhibit Hall 

Navigating Patient Conversations: Tough 

Choices with Advanced Heart Failure 

Therapies 

Faculty: 

Larry Allen, MD, MHS – University of Colorado 

Sean Pinney, MD – Mount Sinai Medical Center 

Description: 

Learn how to address the most challenging patient conversations 

when speaking with advanced heart failure patients 

about LVAD therapy. Discuss case studies highlighting 

best practices and techniques to help the conversation be as 

effective as possible. 


12:10 PM – 1:10 PM 

Exhibit Hall 

New Heart Failure Treatment Approved: 

Highlights of Prescribing Information 

Faculty: 

Javed Butler, MD - Stony Brook University 

Barry Greenberg, MD - University of California, San Diego 

Description: 

Join Dr. Javed Butler and Dr. Barry Greenberg as they 

present information on a new heart failure medication at 

the Novartis Product Theater. Presentation topics will cover 

indication and usage, dosage and administration, dosage 

forms and strengths, warnings and precautions, adverse 

reactions, clinical pharmacology, mechanism of action, 

clinical studies, and how supplied/storage and handling. 

This presentation provides a thorough review of the clinical 

profile for this new heart failure medication. 

Sponsored by Novartis Pharmaceuticals Corporation 


101


2015 Clinical Trial Row Program Descriptions 

These posters will be on display in the Exhibit Hall from 

Saturday evening through Monday afternoon. Representatives 

will be at posters 6:30 PM – 7:30 PM Saturday and 

5:30 PM – 6:30 PM on Sunday during the poster receptions. 

These are trials in the planning, recruiting, or follow-up 

states. 

Trial Name: A Genotype-Directed Comparative Effectiveness 

Trial of Bucindolol and Toprol-XL for Prevention 

of Symptomatic Atrial Fibrillation/Atrial Flutter in 

Patients with Heart Failure 

Acronym: GENETIC-AF 

Sponsor: ARCA biopharma 

Program Description 

GENETIC-AF is a Phase 2B/3, double-blind, comparative 

effectiveness study evaluating bucindolol vs. metoprolol on 

the time to first event of symptomatic AF/AFL in HFREF 

patients who are at high risk of AF/AFL recurrence. This 

genotype-directed study is enrolling patients with the beta-1 

389 Arg/Arg adrenergic receptor (~50% of U.S. population) 

GENETIC-AF is currently enrolling patients for the Phase 

2B stage of the trial, and site identification for Phase 3 is 

ongoing. 

Trial Name: DISCOVERY: A Study Examining the 

Prevalence of TTR Mutations in Subjects Suspected of 

Having Cardiac Amyloidosis 

Acronym: DISCOVERY 

Sponsor: Alnylam Pharmaceuticals 


DISCOVERY is a prospective, international, observational 

study examining the prevalence of transthyretin (TTR) mutations 

in subjects who may have cardiac amyloidosis. 

Trial Name: A Phase 3 Multicenter, Multinational, 

Randomized, Double-Blind, Placebo-Controlled Study 

to Evaluate the Efficacy and Safety of ALN TTRSC in 

Patients With Transthyretin (TTR) Mediated Familial 

Amyloidotic Cardiomyopathy (FAC) 

Acronym: ENDEAVOUR 

Sponsor: Alnylam Pharmaceuticals 


ENDEAVOUR is a phase 3, randomized, double-blind, 

placebo-controlled, global study designed to evaluate the 

efficacy and safety of revusiran (ALN TTRSC), an investigational 

GalNAc-siRNA conjugate, in patients with 

transthyretin (TTR)-mediated Familial Amyloidotic Cardiomyopathy 

(FAC). The co-primary endpoints of the study are 

the change compared to baseline in 6-minute walk distance 

(6-MWD) and the percent reduction in TTR burden between 

placebo and revusiran treated patients at 18 months. 

Trial Name: Safety of Repeat Doses of IV Serelaxin in 

Subjects With Chronic Heart Failure 

Acronym: RELAX-REPEAT 

Sponsor: Novartis Pharmaceuticals 


A prospective, double-blind, multicenter study evaluating 

the safety of repeat 48h IV serelaxin dosing in subjects with 

chronic heart failure 

Evaluating the safety of repeat 48 hour IV serelaxin dosing 

through the detection of anti-serelaxin antibodies and any 

related adverse events. 

Trial Name: RELAX-AHF-ASIA 

Acronym: CRLX030A2302 



Multicenter, randomized, double-blind, placebo controlled 

phase III study to evaluate the efficacy, safety and tolerability 

of a 48h intravenous infusion of 30 μg/kg/day serelaxin 

when added to standard therapy in Asian patients with 

acute heart failure. 

102


Clinical Trial Row Descriptions (continued) 

Trial Name: Efficacy, safety and tolerability of serelaxin 

when added to standard therapy in acute heart failure 

patients 

Acronym: RELAX-AHF-2 



A randomized, double-blind, placebo-controlled phase III 

study to evaluate the efficacy, safety and tolerability of serelaxin 

when added to standard therapy in acute heart failure 

patients 

Trial Name: Randomized, Double-Blind, Placebo 

Controlled Study of the Short Term Clinical Effects of 

Tolvaptan in Patients Hospitalized for Worsening Heart 

Failure with Challenging Volume Management 

Acronym: SECRET of CHF 

Sponsor: Cardiovascular Clinical Science Foundation 


This is a randomized, Double-Blind, Placebo-Controlled 

Study looking at the Short Term Clinical Effects of Tolvaptan 

in Patients Hospitalized for worsening heart failure with 

challenging volume management. 

Trial Name: Chronic Oral Study of Myosin Activation to 

Increase Contractility in Heart Failure (COSMIC-HF): 

A Double-blind, Randomized, Placebo-controlled, Multicenter, 

Dose Escalation Study 

Acronym: COSMIC-HF 

Sponsor: Amgen, Inc. 


COSMIC-HF is a multicenter, randomized, double-blind, 

placebo-controlled, dose-escalation study designed to select 

an oral modified-release formulation and dose of omecamtiv 

mecarbil (OM) for chronic twice daily dosing in patients 

with heart failure and left ventricular systolic dysfunction 

and to characterize the pharmacokinetics of OM over 20 

weeks of treatment. 

Trial Name: A Multicenter, International, Phase 3, 

Double-blind, Placebo-controlled, randomized study to 

evaluate the Efficacy, Safety and Tolerability of Daily 

Oral Dosing of Tafamidis Meglumine 20 mg or 80 mg 

in Comparison to Placebo in Subjects Diagnosed with 

Transthyretin Cardiomyopathy 

Acronym: ATTR-ACT 

Sponsor: Pfizer 


Phase 3, Double-blind, Placebo-controlled, Randomized 

Study to Evaluate Daily Oral Dosing of Tafamidis Meglumine 

20 mg or 80 mg Compared with Placebo in Subjects 

Diagnosed with Transthyretin Cardiomyopathy (TTR-CM) 

Trial Name: Sensible Medical Innovations Lung Fluid 

Status Monitor Allows Reducing Readmission Rate of 

the Heart Failure Patients- a randomized controlled 

study 

Acronym: SMILE 

Sponsor: Sensible Medical Innovations Inc. 


The SMILE study is designed as a prospective, randomized, 

controlled, multi-center trial. Patients will be enrolled 

during an index hospitalization for acutely decompensated 

Heart Failure (ADHF) and will be followed for a minimum 

of 3 months or a maximum of 9 months (until the last patient 

has completed the 3 month follow-up). Patients will be 

blinded to the ReDS readings value. 

The Remote Dielectric Sensing (ReDS) device provides 

non-invasive measurement of lung fluid content. It comprises 

a wearable vest with the embedded sensors and a 

bedside console. A measurement reading is provided with 

90 seconds. Results are shared with the treating physician 

via a secured web portal. 

103



Trial Name: Study of Efficacy and Safety of LCZ696 in 

Heart Failure Patients NYHA Class II-IV with Preserved 

Ejection Fraction 

Acronym: PARAGON-HF 

Sponsor: Novartis 


Heart failure with preserved ejection fraction(HFpEF) is 

prevalent and carries dire consequences. No pharmacologic 

therapy have shown benefit in HFpEF. Sacubitril/valsartan 

has been shown to be superior to enalapril for the reduction 

of cardiovascular (CV) death and HF hospitalization in 

patients with HFrEF. The objective of the PARAGON-HF 

trial is the compare sacubitril/valsartan to valsartan in 

reducing CV death and total HF hospitalizations in patients 

with HFpEF. 

Reducing the rate of the cv 

Trial Name: Baroreflex Activation Therapy for Heart 

Failue Pivotal Trial 

Acronym: BeAT-HF 

Sponsor: CVRx, Inc. 


The Barostim BeAT-HF Pivotal study is a prospective, 

randomized, controlled trial of Baroreflex Activation Therapy 

in patients with reduced ejection fraction HF. Subjects 

will be randomized in a 1:1 ratio to receive a device plus 

optimal medical management or to receive optimal medical 

management alone. The primary efficacy endpoint is a 

demonstrated reduction between the two arms in events of 

cardiovascular mortality or worsening HF that leads to hospitalization, 

cardiac assist device or heart transplantation. 

Trial Name: Effect of GS-6615 on Exercise Capacity in 

Subjects With Symptomatic Hypertrophic Cardiomyopathy 

Acronym: LIBERTY-HCM 

Sponsor: Gilead Sciences, Inc. 


Randomized, double-blind, placebo-controlled study to 

evaluate the effect of GS-6615 (a potent and selective 

inhibitor of the cardiac late sodium current) on exercise 

capacity and quality of life in participants with symptomatic 

hypertrophic cardiomyopathy (HCM). The primary objective 

is to assess the change in exercise capacity in subjects 

with symptomatic HCM, as measured by the change in Peak 

VO2 from baseline to week 24. 

Trial Name: The AdaptResponse trial 

Acronym: The AdaptResponse trial 

Sponsor: Medtronic PLC 


AdaptResponse is an event-driven worldwide randomized 

trial that will compare patient and healthcare system outcomes, 

including mortality, hospitalizations and intervention 

for worsening heart failure, in heart failure patients who receive 

a cardiac resynchronization therapy (CRT) pacemaker 

or CRT-defibrillator with the AdaptivCRT® feature enabled 

versus patients receiving standard CRT. Three-thousand 

patients with a CRT indication, Left Bundle Branch Block 

(Strauss criteria), normal AV conduction, 

LVEF 35%, NYHA class II, III, or IV despite optimal 

medical therapy will receive CRT and be followed for a 

minimum of 24 months to assess superiority of the AdaptivCRT® 

feature. 

104



Trial Name: C-Pulse System: A Heart Assist Device 

Clinical Study 

Acronym: COUNTER HF 

Sponsor: Sunshine Heart, Inc. 


Sunshine Heart is sponsoring a prospective, multi-center, 

randomized trial to assess the safety and efficacy of the 

C-Pulse System. The purpose of the study is to determine 

whether the use of the C-Pulse as a treatment for patients 

in moderate to severe heart failure has demonstrated safety 

and efficacy, such that the C-Pulse System merits Food and 

Drug Administration (FDA) approval to market the device 

in the United States. 

Trial Name: ALLogeneic Heart STem Cells to Achieve 

Myocardial Regeneration 

Acronym: ALLSTAR 

Sponsor: Capricor, Inc. 


Randomized, Double-Blind, Placebo-Controlled Phase I/II 

Study of the Safety and Efficacy of 

Intracoronary Delivery of Allogeneic Cardiosphere-Drived 

Cells in Patients with a Myocardial 

Infarction and Ischemic Left Ventricular Dysfunction. 

Trial Name: Adjuvant Allogeneic Immuno-modulatory 

Progenitor Cell Therapy to Mitigate Incomplete Revascularisation 

in Coronary Artery Bypass Grafting 

Patients with Narrow Coronary Arteries, Bifurcation 

and Trifurcation. 

Acronym: Heartcel 

Sponsor: Cell Therapy Limited 


The inherent cardiac anatomical abnormalities of narrow 

coronary arteries, bifurcation and trifurcation, confers a 

high risk (P



Trial Name: Biased Ligand of the Angiotensin receptor 

Study in Acute Heart Failure 

Acronym: BLAST-AHF 

Sponsor: Trevena, Inc. 


BLAST-AHF is a Phase 2b, international, randomized, 

multicenter, double-blind, placebo-controlled, dose ranging 

study to explore the efficacy of TRV027 in patients hospitalized 

for acute decompensated heart failure. TRV027 

is a beta-arrestin biased ligand of the angiotensin II type 

1 receptor (AT1R) that competitively inhibits G-protein 

activation by angiotensin II, while activating AT1R-specific 

beta-arrestin recruitment. 

Trial Name: Autologous Bone Marrow Mononuclear 

Cells Using the CardiAMP Cell Therapy in Patients 

with Post MI Heart Failure 

Acronym: CardiAMP Heart Failure Trial 

Sponsor: BioCardia Inc. 


The CardiAMP trial is a prospective, multi-center, randomized, 

sham-controlled, patient and evaluator-blinded 

pivotal study comparing the CardiAMP Cell Therapy to a 

Sham treatment. It is a comprehensive therapeutic for the 

treatment of ischemic systolic heart failure, that includes 

a companion diagnostic, and is comprised of (i) a cell 

potency screening test, (ii) a point of care cell processing 

platform, and (iii) a biotherapeutic delivery system. 

106


Exhibitor Listing with Booth Numbers 

Abiomed, Inc. Booth #416 

Advanced Cardiothoracis Consultants, LL Booth #411 

AltaThera Pharmaceuticals Booth #417 

American Heart Association/American Stroke Association Booth #312 

Amgen Booth #501 

Amyloidosis Foundation Booth #615 

Arbor Pharmaceuticals, LLC Booth #310 

CardiacAssist, Inc Booth #612 

CareDx, Inc. Booth #607 

Coram CVS/Specialty Infusion Services Booth #412 

Cytokinetics, Inc. Booth #307 

DAXOR Corporation Booth #414 

Elsevier Booth #516 

Fresenius Medical Care - UF Complete Booth #415 

GeneDX Booth #413 

Heart Failure Society of America 

Maryland Hallway 

Heart Genomics, LLC Booth #616 

HeartWare, Inc. Booth #606 

Inova Heart and Vascular Institute Booth #207 

Integrated Sensing Systems, Inc. Booth #716 

Janssen Pharmaceuticals, Inc. Booth #709 

Lifemed USA Booth #317 

Medtronic, Inc. Booth #314 

Millar, Inc. Booth #712 

Miller Pharmacal Group Booth #513 

Myocarditis Foundation Booth #613 

NeuMedx Booth #611 

Novartis Pharmaceuticals Corporation Booth #301 

OnTrack to Health Booth #514 

Option Care Booth #710 

Prompt Care Home Infusion, LLC Booth #515 

Relypsa, Inc Booth #707 

ResMed Booth #407 

Roche Diagnostics Booth #511 

scPharmaceuticals Booth #617 

Sensible Medical Innovations Booth #313 

Shape Medical Systems, Inc. Booth #614 

Society of Cardiovascular Patient Care Booth #711 

Soleo Health Booth #517 

St. Jude Medical Booth #701 

The American Association of Heart Failure Nurses Booth #806 

Thoratec Corporation Booth #510 

Wolters Kluwer Health Booth #714 

ZOLL Booth #507 

ZS Pharma Booth #715 

107

IDF 

EC 

MACH. 

34 33 

IDF 

N710 

45 

N710 

45 

N710 

45 

N710 

45 


Service 

Desk 

CLINICAL TRIAL ROW 

Internet 

Station 

Late 

Breaking 

Breaking 

Abstracts 

Posters 

121 

521 

317 

416 417 

516 517 

616 617 

716 

314 

414 415 

514 515 

614 615 

714 715 

312 

313 

412 413 

513 

612 613 

712 

310 

411 

510 511 

611 

710 711 

709 

207 

307 

407 

507 

606 607 

707 

806 

Product 

Theater 

301 

501 

701 

100 

10'-10" 

CHARGING STATION 

10'-10" 

CHARGING STATION 

5' 

5' 

ENTRANCE ENTRANCE ENTRANCE ENTRANCE 

M W 

M 

W 

108


Exhibitor Descriptions 

Abiomed, Inc.…………………………………..……416 

22 Cherry Hill Drive 

Danvers, MA 01923 

978-646-1487 

Lillian Garcia Palmer 

lpalmer@abiomed.com 

Website: www.abiomed.com 

Abiomed is a pioneer and global leader in healthcare technology and innovation, 

with a mission of RECOVERING HEARTS AND SAVING 

LIVES. The Company’s portfolio of products and services offer healthcare 

professionals an array of choices across a broad clinical spectrum. 

The Company’s flagship Impella device just recently received FDA 

approval, stating that use of Impella® 2.5 for elective and urgent high 

risk PCI is safe and effective 

Advanced Cardiothoracis Consultants, LLC...............411 

12155 Golden Bluff Ct 

Indianapolis, IN 46235 

317.823.9274 

Renee Lassinger 

reneelassinger@actc4solutions.com 

www.actc4solutions.com 

Utilizing over 40 years of clinical expertise in cardiothoracic, thoracic 

transplant/organ replacement, and advanced heart failure ACTC can 

evaluate financial and clinical aspects for programs to increase efficiencies. 

Whether a new or well established program, hospital, or insurer 

let ACTC assist you in maintaining financial viability and sustaining 

growth in today’s challenging healthcare market. 

AltaThera Pharmaceuticals…....................………….417 

200 S. Wacker Dr. Ste. 3100 

Chicago, IL 60606 

312.445.8924 

Patricia Dunnigan 

pdunnigan@altathera.com 

Website: www.alththera.com 

AltaThera Pharmaceuticals is a specialty pharmaceutical company 

focused on critical care therapies to address the unmet medical needs 

of patients with severe, and often rare disorders for which few effective 

treatments are available. 

American Heart Association/American 

Stroke Association……..................………....………...312 

7272 Greenville Avenue 

Dallas, TX 75231 

901-605-7055 

Kathryn Waggoner 

kathryn.waggoner@heart.org 

Website: www.heart.org 

As the leading organization working to build healthier lives, free of 

cardiovascular diseases and stroke, the American Heart Association 

is committed to providing medical professionals tools and resources 

to improve quality of care for patients. 

Amgen…………...................................……………….501 

One Amgen Center Drive 

Thousand Oaks, CA. 91320 

805.313.2743 

Brian Lotterman 

blotterman@amgen.com 

Website: www.amgen.com 

Amgen is committed to unlocking the potential of biology 

for patients suffering from serious illnesses by discovering, 

developing, manufacturing and delivering innovative human 

therapeutics. A biotechnology pioneer since 1980, Amgen has 

reached millions of patients around the world and is developing 

a pipeline of medicines with breakaway potential. 

Amyloidosis Foundation……………………………615 

7151 North Main Street #2 

Clarkston, MI. 48436 

248.922.9610 

Mary O'Donnell 

meo1256@aol.com 

Website: www.amyloidosis.org 

Amyloidosis Foundation is a non profit whose mission is to support patients 

and families while promoting research, education and awareness. 

Arbor Pharmaceuticals…………...........……….....…310 

6 Concoure Parkway, Suite 1800 

Atlanta, GA. 30328 

404.418.5305 

Wendy Yong 

wyong@arborpharma.com 

Website: www.arborpharma.com 

Arbor Pharmaceuticals, headquartered in Atlanta, Georgia, is a specialty 

pharmaceutical company currently focused on the cardiovascular, 

hospital and pediatric markets as well as generics through its Wilshire 

division. Visit www.arborpharma.com or send email inquiries to info@ 

arborpharma.com. 

109


Exhibitor Descriptions (continued) 

CardiacAssist, Inc…………………………………...612 

240 Alpha Drive 

Pittsburgh, PA 15238 

412.963.7770 

Jill Kuhn 

marketing@tandemheart.com 

Website: www.tandemhear.com 

CardiacAssist, Inc. is the inventor of the world’s most versatile temporary 

cardiopulmonary bypass device, The TandemHeart® pump. 

Our small pump puts the power of bypass in the palm of your hand by 

providing up to 90% of native cardiac power output. The TandemHeart 

can be used in a variety of configurations (surgical, percutaneous 

cardiac support, percutaneous respiratory support) when paired with 

our PROTEK line of cannulae. Visit our booth to learn more about our 

latest innovations, PROTEK Duo and Voyager Vest. 

CareDx, Inc………………………………………….414 

3260 Bayshore Boulevard 

Brisbane, CA. 94005 

415.287.2313 

Jamie Autorino 

jautorino@caredxinc.com 

Website: www.caredxinc.com 

CareDX, Inc. is dedicated to improving the lives or organ transplant 

patients through noninvasive diagnostics. By combining 

the latest advances in genomics and bioinformatics technology, 

CareDx strives to stay at the forefront of organ transplant surveillance 

solutions. 

Coram CVS/Specialty Infusion Services………..….412 

555 17th Street, Suite 1500 

Denver, CO. 80202 

800.CORAMHC 

Chelsea Riscoe 

chelsea.riscoe@coramhc.com 

Website: www.coramhc.com 

Coram, a division of CVS Health, is a leading national provider 

of specialty home infusion services. With more than 85 branches 

and over 65 infusion suites, Coram offers both national presence 

and comprehensive local coverage. Coram’s 30+ years of clinical 

expertise and commitment to positive outcomes has earned it a 

reputation for excellence nationwide. 

Cytokinetics, Inc. …………………………………...307 

280 South Grand Ave 

South San Francisco, CA 94080 

Joanna Goldstein 

jgoldstein@cytokinetics.com 

Website: www.cytokinetics.com 

Cytokinetics, a biopharmaceutical company, is focused on discovering, 

developing and commercializing first-in-class muscle activators as potential 

treatments for debilitating diseases in which muscle performance 

is compromised and/or declining. 

DAXOR Corporation…………………...…………..414 

350 Fifth Avenue, Suite 7120 

New York, NY 10118 

212-244-0555 

Tina Lake 

rdunn@daxor.com 

Website: www.daxor.com 

Daxor Corporation’s BVA-100® Blood Volume Analyzer is a 

semi-automated instrument patented for direct measurement of blood 

volume, red cell and plasma volume. The system utilizes the Volumex® 

injection kit for a multi-sample blood volume. Measurement of blood 

volume is applicable for hypertension, CHF, transfusion, ICU/CCU, 

anemia, orthostatic hypotension and syncope. 

Elsevier Publishing …………………………….....…516 

1600 John F. Kennedy Blvd. 

Philadelphia, PA 19103 

215-235-3795 

Matthew Breen 

m.breen@elsevier.com 

Website: www.elsevierhealth.com 

Elsevier is a world-leading provider of information solutions that enhance 

the performance of science, health, and technology professionals, 

empowering them to make better decisions, and deliver better care. 

Fresenius Medical Care- UF Complete…..…………415 

920 Winter Street 

Waltham, MA. 02451 

781-699-4126 

Lisa Caso 

lisa.caso@fmc-na.com 

Website: www.fmcna.com 

UFComplete: A Complete Fluid Management Program for Heart Failure 

Patients. We provide ultrafiltration (UF) and post-discharge home 

monitoring services to improve outcomes in patients suffering from 

heart failure and fluid overload. Specifically, we address the pending 

challenges all hospitals face in reducing readmission rates for Heart 

Failure and Fluid Overload. 

110



GeneDx ...............................................………..……….…...413 

481 Edward H Ross Dr 

Elmwood Park, NJ 07407 

800-229-5227 x 8205 

Marianne Sansing 

msansing@genedx.com 

Website: www.genedx.com 

GeneDx is highly respected laboratory specializing in genetic 

testing for inherited disorders. GeneDx offers sequencing and deletion/duplication 

testing for inherited cardiac disorders, mitochondrial 

disorders, neurological disorders, inherited cancer disorders, 

prenatal disorders and rare genetic disorders. GeneDx also offers 

whole exome sequencing, next-generation and microarray-based 

testing. Visit www.GeneDx.com or email GeneDx@GeneDx.com 

Inova Heart and Vascular Institute .............................207 

3300 Gallows Rd 

Falls Church, VA 22042 

703.776.3022 

Gail Walters 

gail.walters@inova.org 

Website: www.inova.org 

Inova Heart and Vascular Institute, headquartered on the Inova 

Fairfax Medical Campus, is one of the most complete, 

technologically-advanced cardiovascular centers in the 

U.S., providing the full spectrum of diagnostic, therapeutic, 

surgical and interventional cardiac services, including 

Heart Failure, Heart/Lung Transplantation, and Genomics 

Research through Inova’s new Center for Personalized 

Medicine. 

Heart Genomics, LLC………………………………616 

523 Michigan Avenue 

Miami Beach, FL. 33139 

530-563-6488 

Joe Gutierrez 

jgutierrez@heartgenomics.com 

Website: www.heartgenomics.com 

Heart Genomics, LLC. Heart Genomics has two different 

expression profiling diagnostic tests (“HeartGen5YP” and 

HeartGenMYO), which measure gene signatures and provide 

a highly accurate assessment of the 5 year prognosis of 

heart failure patients, as well as a highly accurate diagnosis 

of myocarditis. 

Integrated Sensing Systems, Inc ...................……..…716 

391 Airport Industrial Dr 

Ypsilanti, MI 48198 

734.547.9896 

Jessica Turner 

jturner@mems-iss.com 

Website: www.mems-iss.com 

Integrated Sensing Systems Inc., designs and manufactures MEMS 

based, implantable pressure sensors for cardiac applications. The 

TitanTM Wireless Implantable Hemodynamic Monitoring (WIHM) 

System is intended to be used as an adjunctive diagnostic tool for 

measuring and recording Left Atrium (LA) Hemodynamics, including 

rhythm, heart rate, heart rate variability, filling pressure and pressure 

waveforms, in both acute and chronic conditions. 

HeartWare .......…………………………..………….606 

500 Old Connecticut Path 

Framingham, MA. 01701 

Joanna McNamara 

jmcnamara@heartware.com 

Website: www.heartware.org 

The HVAD® Pump designed to be implanted in the pericardial 

space avoiding the more invasive surgical procedures required 

with older LVAD technologies. The HVAD Pump is commercially 

available around the world. 

Janssen Pharmaceuticals, Inc. ..................…………..709 

1000 Route 202 

Raritan, NJ 08869 

908-218-6000 

Mary Ann Gengo 

mgengo@its.jnj.com 

Website: www.janssenpharmaceuticalsinc.com 

Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & 

Johnson, provides medicines for an array of health concerns in several therapeutic 

areas, including: diabetes, mental health, and cardiovascular disease. 

111



Lifemed USA………………………….........….....….317 

7790 Victoria Cir. 

Independence, OH 44131 

800-571-9079 

Murray Maynard 

mmaynard@lifemedusa.com 

Website: www.lifemedusa.com 

LIFEMED USA is the exclusive distributor of the NICaS system, a 

bioimpedence technology that allows for the accurate measurement of 

Cardiac Output in a non-invasive manner. The NICaS system is quick, 

very easy to use and is the only system which is classified by the FDA 

as being statistically equivalent to thermodilution. We look forward to 

welcoming you to our booth and demonstrating the NICaS system. 

Medtronic, Inc…………………………....….………314 

710 Medtronic Parkway 

Minneapolis, MN 55432 

763-505-0289 

Brooke Neus 

brooke.i.neus@medtronic.com 

Website: www.medtronic.com 

Through innovation and collaboration, Medtronic improves the lives 

and health of millions of people each year. Visit booth #314/316 to 

see our solutions to help you manage any heart failure patient. Learn 

more about our technology, services and solutions at Medtronic. 

com. 

Millar, Inc………………………..…………………..712 

6001-A Gulf Freeway 

Houston, TX. 77023 

832-667-7000 

Michelle Sanders 

msanders@millar.com 

Website: www.millar.com 

Millar strives to improve patient outcomes through true hemodynamics 

data. The Millar Mikro-Cath diagnostic pressure catheter 

provides exact data unaffected by patient movement to better 

understand the cardiovascular condition. The CD Leycom Inca 

PV loop system monitors the ventricular pressure-volume (PV) 

relationship, cardiac contractile state and intra-ventricular dyssynchrony 

in real-time. 

Miller Pharmacal Group, Inc………………………513 

350 Randy Road, Suite 2 

Carol Stream, IL 60188 

800-323-2935 

Stephen Wonsil 

swonsil@millerpharmacal.com 

Website: www.millerpharmacal.com 

Miller Pharmacal's 'MG PLUS PROTEIN' (TM) magnesium supplement 

treats and prevents the hypomagnesemia caused by diuretics 

(or immunosuppressants) without causing the GI disturbances 

common with magnesium oxide. Each easy-to-swallow, glazed, 

non-enteric coated tablet contains 133 mg of elemental magnesium, 

at a fraction of the cost of SLOW-MAG (TM). 

The Myocarditis Foundation……………………….613 

3518 Echo Mountain Dr 

Vingwood, TX 77345 

281-713-2962 

Genevieve Runmore 

genevieve@myocarditisfoundation.org 

Website: www.myocarditisfoundation.org 

The Myocarditis Foundation is a 501©3 Corporation whose 

Mission is to raise awareness on Myocarditis, educate the medical 

and public communities on Myocarditis, provide research grants 

specific to Myocarditis and emotionally support families affected 

by Myocarditis. 

NeuMeDx……………………………................……..611 

2014 Ford Road, Unit G 

Bristol, PA. 19007 

215-826-9998 

James Gunnerson 

jim.gunnerson@neumedx.com 

Website: www.neumedx.com 

NeuMeDx offers a Noninvasive Cardiac Output Monitor, providing the 

clinician with real time hemodynamic parameters to aid in the management 

Heart Failure. Utilization of the PhysioFlow’s Signal Morphology-based 

Impedance Cardiography (SM-ICG) coupled with appropriate 

therapy can impact quality, cost, efficiency and clinical outcomes. 

Novartis Pharmaceuticals Corporation……….....…301 

One Health Plaza 

East Hanover, NJ. 07936 

862-778-3505 

Patti Travisano 

patti.travisano@novartis.com 

Website: www.novartis.com 

Novartis Pharmaceuticals is dedicated to discovering, developing, 

manufacturing and marketing prescription drugs that help meet our 

customers’ medical needs and improve their quality of life. 

112



OnTrack to Health…………………………………..514 

23896 N. Lakeshore Drive 

Glenwood, MN 56334 

320-634-0117 

Ronald Luetmer 

ronl@ontrack2health.com 

Website: www.ontrack2health.com 

OnTrack enables patients to self-manage their heart failure by leveraging 

mobile devices, providing an accurate, real-time view of medication 

adherence, self-care activities, and vital signs; viewable to patients, 

providers, and caregivers. With OnTrack, patients take ownership of 

their health. 

Option Care .....................................................................710 

1411 Lake Cook Rd, MS#L109 

Deerfield, IL 60015 

847-964-8033 

Rian Enriquez 

rian.enriquez@walgreens.com 

Website: www.walgreens.com 

Option Care is a leading provider of home infusion services. 

It has a staff of more than 1,700 clinical experts and provides 

comprehensive support to treat a broad range of acute and chronic 

conditions. Option Care provides service through its 90 infusion 

pharmacies and 100 alternate treatment sites nationwide. 

Prompt Care Home Infusion, LLC. ....……………..515 

51 Terminal Ave 

Clark, NJ 07066 

866-776-6782 

Kathy Larson 

kathy.larson@promptcare.net 

Website: www.promptcare.net 

PromptCare Home Infusion provides a full range of home 

infusion therapies and utilizes a customized innovative team 

approach to support our Stage D heart failure patients and 

their caregivers on Inotropic infusions to improve each patient’s 

quality of life. We achieve this through early screening 

and personalized ongoing patient follow up. 

Relypsa, Inc. .............................................……………..707 

100 Cardinal Way 

Redwood City, CA 94063 

650-421-9355 

Jeffrey Garland 

rbyrne@relypsa.com 

Website: www.relypsa.com 

Relypsa, Inc. is a biopharmaceutical company whose 

mission is to improve patients’ lives through the discovery, 

development and delivery of therapeutics that leverage 

polymer science and other novel approaches. The company’s 

lead product candidate, which has completed Phase 

3 clinical trials, is being developed for the treatment of 

hyperkalemia. Hyperkalemia is a life-threatening condition 

defined as abnormally elevated levels of potassium in the 

blood, which can present chronically and acutely. More 

information is available at www.relypsa.com 

ResMed ..................................................................……..407 

9001 Spectrum Center Blvd. 

San Diego, CA 92123 

858-836-5000 

Jennifer Terchek 

jennifer.terchek@resmed.com 

Website: wwww.resmed.com 

ResMed changes lives by developing medical equipment for treating 

and managing sleep-disordered breathing and respiratory disorders. 

Through 25 years of innovation, we have pioneered solutions to 

improve the health of those suffering from these conditions while 

raising awareness about the consequences of untreated sleep-disordered 

breathing 

Roche Diagnostics ................................................……..511 

9115 Hague Rd. 

Indianapolis, IN 46250 

317.440.3613 

Bethany Diacou 

bethany.diacou@roche.com 

Website: www.roche.com 

Roche is a leader in research-focused healthcare with combined 

strengths in pharmaceuticals and diagnostics. We are the world’s largest 

biotech company with truly differentiated medicines in oncology, 

virology, inflammation, metabolism and CNS. Roche is also the world 

leader in in-vitro diagnostics, tissue-based cancer diagnostics and a 

pioneer in diabetes management. 

113



scPharmaceuticals ....................................................…..617 

131 Hartwell Ave., Ste. 215 

Lexington, MA 02421 

781-301-6706 

Katherine Taudvin 

ktaudvin@scpharma.com 

Website: www.scpharmaceuticals.com 

scPharmaceuticals is developing Furosemide 2.0 – a novel formulation 

of furosemide for subcutaneous delivery for use with a proprietary patch 

pump as a new option for the management of fluid overload in heart 

failure. Furosemide 2.0 would provide “iv-like” diuresis without the 

need for iv, reducing the resources and costs associated with intravenous 

or intramuscular administration 

Sensible Medical Innovations ................................…..313 

54 W. Yale Loop 

Irvine, CA 92604 

909-895-9800 

Erez Brem 

erez.b@sensible-medical.com 

Website: www.sensible-medical.com 

The Leader in Absolute Lung Fluid Measurement. Sensible has developed 

a wearable thoracic fluid status monitor for non-invasive measurement 

and monitoring of lung fluid, for patients with fluid management 

problems such as patients living with heart failure, taking diuretic 

medication or recovering from a coronary artery disease related event. 

Shape Medical Systems, Inc. ................................…....614 

MedTech Center 

5000 Township Parkway 

St. Paul, MN 55110 

Steve Anderson 

sanderson@shapemedsystems.com 

Point-of-care based cardiopulmonary light exercise testing system 

that determines the likely source and severity of unexplained dyspnea, 

assists in optimizing HF therapy, and reduces ADHF-related related to 

ADHF. Delegable, quick, easily interpreted and attractively reimbursed 

test. 

Society of Cardiovascular Patient Care ......................711 

6161 Riverside Drive 

Dublin, OH 43107 

614-408-1303 

Colleen Smith 

csmith1@scpc.org 

Website: www.scpc.org 

The Society of Cardiovascular Patient Care assists facilities in their 

efforts to create cardiovascular centers of excellence that delivers quality 

care and patient satisfaction in a cost sensitive environment. SCPC offers 

hospitals the support needed to effectively reduce variations of care and 

bridge existing gaps in treatment. www.scpc.org 

Soleo Health ...............................................................…..517 

950 Calcon Hook Rd, Ste. 19 

Sharon Hill, PA 19079 

888-244-2340 

Jeanne Warsing 

jwarsing@soleohealth.com 

Website: www.soleohealth.com 

Soleo Health is an innovative national provider of home and alternate-site 

specialty infusion. Our team of experienced clinicians provides 

exceptional care in managing complex disease states through comprehensive 

pharmacy, nursing, education, and therapy management 

programs. 

St. Jude Medical……………………………………..701 

6300 Bee Cave Road, Building 2, Suite 100 

Austin, TX 78746 

512.286.4092 

Rachel Stroik 

rstroik@sjm.com 

Website: www.sjm.com 

St. Jude Medical is a global medical device manufacturer dedicated 

to transforming the treatment of some of the world’s most expensive 

epidemic diseases by creating cost-effective medical technologies that 

save and improve lives of patients globally. Clinical focus areas include 

cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. 

Visit sjm.com. 

114


The American Association of Heart Failure Nurses….…..806 

1120 Route 73, Ste 200 

Mt. Laurel, NJ 08054 

856-642-4425 

Clare MacNab 

cmacnab@ahint.com 

Website: www.ahint.com 

The American Association of Heart Failure Nurses (AAHFN) is a specialty 

organization dedicated to advancing nursing education, clinical 

practice and research to improve heart failure patient outcomes. We 

serve as the interface for sharing ideas, translating research findings into 

practice and setting priorities for the future. 

The Heart Failure Society of America, Inc. (HFSA) ..........Lvl 2 

6707 Democracy Blvd. Ste. 925 


Patrick McGary 

info@hfsa.org 

Website: www.hfsa.org 

The Heart Failure Society of America, Inc. (HFSA) represents the first 

organized effort by heart failure experts from the Americas to provide 

a forum for all those interested in heart function, heart failure, and 

congestive heart failure (CHF) research and patient care. 

Thoratec Corporation.............………………………510 

6035 Stoneridge Drive 

Pleasanton, CA 94588 

925-847-8600 

Cory Ferreira 

Kay.gonzales@thoratec.com 

Website: www.thoratec.com 

Thoratec is a world leader in therapies to address advanced-stage heart 

failure. The company's products include the HeartMate II® LVAS 

(Left Ventricular Assist Systems) and Thoratec® VAD (Ventricular 

Assist Device) with more than 20,000 devices implanted in patients 

suffering from heart failure. Thoratec also manufactures and distributes 

the CentriMag® & PediMag®/PediVAS®, product lines. 

Wolters Kluwer Health………………………......….714 

Two Commerce Square 

2001 Market Street 

Philadelphia, PA 19103 

215-521-8300 

Joey-Rose Jester 

joey-rose.jester@wolterskluwer.com 

Website: www.wolterskluwer.com 

Wolters Kluwer Health is a global rovider of information, business 

intelligence and point-of-care solutions. Brands include Lippincott 

Williams & Wilkins, a leading international publisher of medical 

books, electronic media and journals including Circulation: Heart 

Failure (online journal). We offer specialized publications and software 

for physicians, nurses, students and clinicians. 

ZOLL ……………………..….....……....…...…..….507 

121 Gamma Road 

Pittsburgh, PA 15238 

412-968-3413 

Kathryn Boyle 

kboyle@zoll.com 

Website: www.zoll.com 

ZOLL® LifeVest® wearable defibrillator protects patients at risk 

of sudden cardiac arrest, during a patient’s changing condition and 

when permanent SCA risk has not been established. The LifeVest 

provides patients constant monitoring, immediate protection, and 

peace of mind. 

ZS Pharma .............................………....…...…...…….715 

8-5 Veterans Blvd., Suite 200 

Redwood City, CA 94063 

650-670-8733 

Megan Clifford 

mclifford@zspharma.com 

Website: www.zspharma.com 

ZS Pharma is a publicly traded biopharmaceutical company. ZS 

Pharma recently submitted a New Drug Application to the FDA for 

its lead product candidate, ZS-9, a new therapeutic option for the 

treatment of hyperkalemia. 

115

2015 19th Annual Scientific Assembly 

THANK YOU 

September 26 – 29, 2015 




Faculty/Author Index (Numbers preceded by P are poster numbers.) 

Aaronson, Keith 55 

Abbas, Raza 

52, P257 

Abbo, Aharon 

P170, P337 

Abdullah, Kazeen P101, P214 

Abe, Ruri 

P104, P105 

Abraham, M Roselle 49, 

Abraham, William 36, 44, 54, 61, P87, P164 

Abraham, William T 35, P087, P170, P275, P285, P337 

Abuannadi, Mohammad P178 

Abuissa, Hussam P81 

Achilefu, Samuel P231 

Adachi, Hitoshi P94 

Adamson, Philip P275, P285 

Adatya, Sirtaz 

P23 

Adjei-Poku, Yaw P118 

Adler, Eric 

P219 

Afzal, Junaid 49 

Agasthi, Pradyumna P35 

Ahmad, Saad 

P192 

Ahmed, Haitham P262 

Ahmed, Mustafa P060, P308 

Ahn, Sylvie 

P39 

Akers, Walter 

P231 

Al-Anbari, Raghda 41, P177, P239, P271 

Al-Ani, Mohammad P308 

Alasaad, Mohammad P309 

Aleong, Ryan 

P97 

Alexis, Jeffrey 53, P40, P286 

Alharethi, Rami 48, P318 

Ali, Omima 

P152 

Alkandari, Fawzia P107 

AlKindi, Sadeer 52, 53, P128, P159, P263, P306, P307 

Allen, Larry 

29, 36, 43, 44, 48, P167, P276 

Almansa, Johana P141 

Almasoud, Abdallah P159, P306, P307 

Alonso, Alvaro 89, 94, P242, P298 

Aloor, Sivakanth P35 

Alsari, Mohammad 48 

Alsayed, Ameena P107 

Altan, Aylin 

P274 

Alvarez, Paulino 67, P44, P46 

Alvarez, Rene 

P055, P145, P296 

Amass, Leslie 

P22 

Ambach, Stephanie P31 

Ambardekar, Amrut 29, 42, 63, P97 

Amione-Guerra, Javier P44, P233, P234, P295 

Amir, Offer 

P170, P337 

Ammon, Susan 29 

Ammous, Farah P165 

An, Qi 

P169, P332 

Ando, Tomo 

P82, P183, P191 

Andrews, George P113 

Angus, Christopher P66 

Anker, Stefan-D 37, 55, 60, P264, P335, P336 

Anyanwu, Emeka P53, P65, P77, P228 

Aramin, Hermineh P36 

Aranda, Jr, Juan P60 

Arbit, Boris 

P32, P36, P42, P202, p305 

Armbruster, Rebecca P143 

Armstrong, Paul P34, P294 

Arnold, Stacey P328 

Arora, Bhaskar P315 

Arthur, Susan 

P253 

Ashrith, Guha 

49, P45, P233, P234, P279, P284, P295 

Asif, Aya 

42, P247, P254 

Atherton, John P109 

Atkinson, Matt P126 

Atluri, Pavan 

32, P181, P299 

Austin, Bethany P152 

Averina, Viktoria P169, P332 

Avery, Elizabeth P136 

Ayers, Colby 

P187 

Ayyadurai, Puvanalingam P110 

Azzouz, Muhammad P81 

Bader, Feras 

P107 

Bae, Jang-Whan P266 

Baek, Sang Hong P301 

Bahl, Joseph 

P208 

Bailey, Joseph 

P59 

Bailey, Kent 

P267 

Baker, William P100 

Bakris, George P253 

Balasubramanian, Neelam P59 

Ballard, Kevin 53, P207 

Balmain, Sean P163 

Bander, Jeffrey P121 

Bank, Alan 

P52 

Bannister, Wade P50, P221 

Bansal, Neha 

P213 

Bardhadi, Amina 53, P259 

Barnard, Denise P245 

Barrett, Peter 

P220 

Barrows, Kim 

P328 

Bart, Bradley 54 

Bartone, Cheryl P289 

Bass, Kyle 48 

Beck, Kenneth P52 

Bekelman, David P167 

Bekfani, Tarek P264 

Bell, Greg 

P165 

Belsito, Marlene P74 

Ben Gal, Tuvia P170, P337 

Benatti, Rodolfo P128 

Benatti, Rodolfo 53, P237, P306, P307 


117



Benes, Lane 

P269 

Benike, Sherry P43 

Bennett, Mosi 

P161 

Berg, Tiffany 

P150 

Bergethon, Kristin 41, P278 

Bergin, James 

P178 

Berk, John 

P189 

Berman, Lance P253 

Berry, Jarett 

P187 

Berry, Narelle 

P109 

Bertke, Ken 

P328 

Betihavas, Vasiliki P325 

Bhandari, Rekha P121 

Bhardwaj, Chetan P56, P63 

Bharmi, Rupinder P140, P275 

Bhat, Geetha 

P54, P73, P132, P323 

Bhatia, Nirmanmoh P211 

Bhatt, Deepak 

41, P130, P273, P278 

Bhatt, Kunal 

P239 

Bhatt, Reema 

P296 

Bhimaraj, Arvind 39, 43, 49, 55, P44, P45, P119, P146, 

P233, P234, P279, P284, P295 

Bhonsale, Aditya 53, P312 

Bhullar, Amarbhir P190 

Bhullar, Manminder P190 

Bicknese, Laurie P150 

Bidwell, Julie 

40, P303 

Biering-Sørensen, Tor P185 

Bilchick, Kenneth P178, P298 

Bionat, Susan 

P119, P145 

Birati, Edo 

P75 

Birks, Emma 

P66, P84, P165, P211 

Bischoff, Michelle P158 

Bitar, Abbas 

P165 

Blaha, Michael P262 

Blanchard, Daniel P245 

Blauer-Peterson, Cori P274 

Blaum, Caroline P115 

Blecker, Saul 

P111 

Bleske, Barry 

58, P277 

Blondheim, David 42, P247, P254 

Bloomfield, Daniel P135 

Blue, Laura 

P227 

Blumenthal, Roger P262 

Boehmer, John P169 

Böhm, Michael 33, P85, P90 

Bokhari, Sabahat P189 

Bolanos, Alexander P60 

Bole, Indra 48 

Bonios, Michael 48 

Bonnell, Mark P223 

Borer, Jeffery 

33, P85, P90, P95, P250 

Borgi, Jamil 

P56, P63 

Borlaug, Barry 30, 38, 62, P149 

Borow, Kenneth P252 

Bove, Alfred 

P55, P145, P296 

Boyd III, Thompson P168 

Boyes, Edith 

P59 

Boyle, Andrew P220 

Bozkurt, Biykem 31, 60, P292 

Braga, Juarez 

P163 

Brailovsky, Yevgeniy P55 

Braunwald, Eugene 43 

Brennan, Danielle P120 

Brewer, Mindy P328 

Brewer, Robert P56, P63 

Brisco, Meredith 52, P251 

Bristow, Michael 45, 64, P97 

Brown, Jason 

P298 

Brown, Judith 

53, P207 

Bruce, Charles P83, P92, P327 

Bruckner, Brian P234, P279 

Buchbinder, Maurice P241 

Budge, Deborah P318 

Buglioni, Alessia 49, P204 

Buiten, Lyanne P69 

Buono, Sarah 

P62 

Burdorf, Adam P300 

Burkman, Gregory P271 

Burnett Jr. John 32, P43, P182, P267 

Burnett, John 

41, 44, 49, P204 

Burton, Paul 

P276 

Bushinsky, David P253 

Butler, Javid 31, 35, 48, 57, 102, P034, P130, 

P271, P287, P294 

Butler, Kenneth P185 

Butts, Brittany P78, P11, P117, P137 

Caccamo, Marco P78, P117, P137 

Caine, William 48 

Calway, Tyler 

P206 

Campos, O 

P26 

Cannone, Valentina P204, P267 

Cappola, Thomas 53 

Carazo, Matthew P115 

Carey, Sandra 

48, P320 

Carlson, Steven P80 

Carter, Rickey 

P92 

Carvalho, A 

P26 

Casso Dominguez, Abel P98 

Castano, Adam P189 

Chae, Shung Chull P301 

Chagin, Kevin 41 

Chai, Siang Chew P37 

Chaiteerakij, Roongruedee P30 


118



Chambers, Susan P75 

Chan, Angel 49 

Chan, Vincent 

P64 

Chan, Wenyaw P292 

Chang, Philip 

P80 

Charlene, Pherson P74 

Charney, Alan 

P86 

Chatterjee, Saurav P98 

Chaudhari, Sameer P61 

Chee, Tek Siong P37 

Chen, Fabian 

P86 

Chen, Horng 

49, P268 

Chen, Leway 

53, P282 

Chen, Lin 

P242 

Chen, Xiaozhen P123 

Chen, Xiongwen P256 

Chen, Zengsheng 49 

Cheng, Allen 

70, P165, P210 

Cheng, Susan 

42, P96, P179, P184, P198 

Chenna, Avantika P35 

Cherian, Tharian P276 

Cheryl, Alexander 41 

Chin, John 34, 47 

Chirinos, Julio 38, 61 

Chiswell, Karen P135 

Cho, Myeong-Chan P266, P301 

Choi, Dong-Ju P301 

Choi, Hyo-In 

P108 

Chojnowski, Donna P75 

Chomick, Nicole P315 

Chowdhury, Munir P109 

Chronakos, John P52 

Chung, Eugene P289, P328 

Chung, Misook L. 39, 50 

Chuprun, J. Kurt P256 

Clagett, Brian 

41, P88, P185 

Claridge, Tamara P75 

Clark, Robyn 

P109 

Clarke, M. 

P103 

Clarke, Rachel 48 

Cleary, Ellen 

P74 

Cleland, John 

P135 

Cleland, John-G P264 

Cleveland, Joseph 48 

Coglianese, Erin P59 

Cogswell, Rebecca P242 

Cohn, Jay N. 48, 51, 55 

Cole, Robert 48 

Colombo, Paolo 29 

Comenzo, Ray 52, P133 

Connors, Lawreen P201 

Contasti, Annette P245 

Contreras, Elizabeth P98 

Contreras, Johanna P265 

Conway, Ginger P93 

Cook, Dana 48 

Cooke, John 

49, P45, P279 

Cooper, Lauren 41 

Cooper, Leslie 31, 67, P40 

Cooper, Daniel P244 

Corbisiero, Raffaele P74, P138, P140, P143 

Cordero-Reyes, Andrea 49, 67, P45, P46, P232, P284, P295 

Cordier, Tristan P113 

Cork, David 

P219 

Corl, Maureen P328 

Cosgrove, Christine P41 

Costanzo, Maria Rosa 29, 35, 44, 54 

Costello, Rebecca P91 

Cotter, Gad 

P135 

Cox, Zachary 

41, P114 

Craig, Damian 85, P197 

Creamer, Andrea P119, P146 

Cronkright, Ashley P48 

Crow, Stacy 

P284 

Crowell, Rebecca P293 

Cuchiara, Michael P222 

Cui, Grace 

P231 

Cummings, Abby P141 

Cuomo, Kimberly P141 

Cusano, Diana P113 

Cyr, Penny 

P293 

D’Alessandro, David P224, P236 

Dadosky, Amy P328 

Dahan, Iris 

41, P254 

Daimee, Usama 53, P282 

Dakros, Stavros 84, P193 

Dalal, Nirav 

P275 

Daly, Kathleen P328 

Daneshmand, Mani P227 

Daniel, Carl 

P119, P146 

Daoud, Ahmed P233 

Dardari, Zeina P262 

Darnieder, Jean P222 

Darrah, Jason 

P300 

Dasari, Tarun 

P317 

Davila, Carlos 

65, P20 

Davis, Gordan P97 

Davison, Beth 

P135 

Dawn, Buddhadeb 48, P61 

Dawson, Kyle 

P284 

de Denus, Simon 53 

de Lemos, James P187 

de Lima, Marcos P263 

De Marco, Teresa P186 


119



De Oliveira, Samer P240 

de Souza, Ana 

P263 

Dean, David 

P116, P220 

Dean, Evelyn 

P152 

Dec, G. William 37, 67, P40 

Deedwania, Prakash 59, P246 

Dekker, Rebecca 40, 48 

Delaney, Colleen P52 

Demastus, Cassandra P168 

Dendi, Vijaya 

P35 

Denfeld, Quin 

P313 

Dennison Himmelfarb, Charyl 63 

DeNofrio, David 48, P69, P321 

Deo, Salil 

P128 

Depre, Christophe P85 

Desai, Akshay 

62, P88, P134, P248 

Desai, Dharma 53 

Desai, Shashank P67, P70, P76 

Desvigne-Nickens, Patrice P91 

Devens, Carolyn P150 

Devoe, Tari 

P315 

DeVore, Adam 41, P129, P273, P294, P297 

Dias, C 

P26 

Dickinson, Michael P173 

Dickson, Victoria 36, 39, 44, 48, 50, 55, 63, P115, P216 

DiDomenico, Robert 47 

Ding, Jun 49 

DiSalvo, Thomas 34 

Disch, Maghee 33 

Dispenzieri, Angela P189 

Dodd, Katherine 53 

Doehner, Wolfram P264 

Dolan, Noreen P48 

Dolganiuc, Angela P308 

Domenico, Chris P281 

Dominjon, Fabienne P85 

Doshi, Rahul 

P80 

Doshi, Shephal P241 

Dougherty, James P100 

Doukas, Demetrios P59 

Doukky, Rami P136 

Dovancescu, Silviu P123 

Drachman, Brian P166 

Drakos, Stavros 48, 55 

Drazner, Mark 30, 38, P187 

Dreher, Michael P166 

Dress, Ashley 

P314 

Dries, Daniel 47 

Dubé, Marie-Pierre 53 

Dubner, Brett 

P59 

Dunbar, Sandra 27, 48 

Dunlap, Mark 

38, 48, P101 

Dunn, Jonathan P112 

Dunning, Allison P294 

Duquaine, Damon P122 

Durand, Jean-Bernard 51 

East, Cara 48 

Ebner, Nicole 

P264 

Eckman, Peter 39, P155, P314 

Edwards, Lonnie P154 

Effat, Mohamed P93 

Egnaczyk, Gregory P289 

Egnatios, Jeremy P36 

Egolum, Ugochukwu P33, P148, P199 

Eidem, Benjamin P217 

Eisen, Howard 62, P168 

Eisman, Aaron P314 

Elamin, Mohamed P18, P200 

ElAmm, Chantal 5 3, P128, P159, P306, P307 

El-Hayek, Georges P98 

Elkayam, Uri 

63, P318 

Ellison, David 54 

Emani, Sitaramesh P238 

Emanuele, Marty 52 

Emig, Meghan P172 

Engelman, Timothy P180 

Engorn, Diane P118 

Ershow, Abby 

P91 

Estep, Jerry 49, 100, P44, P45, P46, P233, 

P234, P279, P284, P295 

Estis, Joel 

P199 

Evangelista, Lorraine 63, P106 

Ewald, Greg 30, P72, P79, P218, P225, P226, 

P230, P231, P232, P314, P318 

Ezekowitz, Justin P294 

Fahlberg, Beth 44 

Fang, James 30, 48, 54 

Farooq, Kanwal P271 

Fatica, Richard P188 

Fedson, Savitri P53, P65, P228, P269 

Feijo, Maria 

Feldman, Arthur 64, P256 

Felker, G. Michael 41, 54, 59, P34, P197 

Fenner, Deborah P172 

Ferdman, Robert P190 

Feroz Zada, Yassamin 53 

Figueredo, Vincent P20 

Fine, Lynn 53 

Finet, Jose 

P117 

Finet, Jose 

P137 

Firpi-Morell, Roberto P308 

Fiuzat, Mona 56, 64 

Flanagan, Jean P314 

Fleming, Lisa 

P142 


120



Flint, Kelsey 

P167 

Flowers, Deirdre P326, P329 

Flynn, Kelsie 

P126 

Fonarow, Gregg 34, 43, 57, P129, P130, P158, 

P273, P276 

Ford, Ian 

P85, P90, P95 

Forfia, Paul 

P181 

Foroutan, Farid P163 

Francis, Gary 27, 44, 51 

Freid, Lauren 

P145, P296 

Friedman, Eitan P199, P203 

Friedman, Paul P83, P92, P327 

Frost, Steven 

P325 

Fukuta, Hidekatsu P102 

Fusco, Daniel 53 

Gaber, Osama 

P233, P234 

Gabrah, Guirgis P107 

Gafoor, Sameer P241 

Gage, Brain 

P79 

Gaggin, Hanna 59 

Gale, Ashley 

P100 

Gao, Erhe 

P256 

Gardell, Stephen 52, P195 

Gardiner, Stacey P333 

Gardner, Roy 

P169, P332 

Garg, Neetika 

P304 

Garg, Sonia 

P187 

Garganta, Marisue P176 

Gary, Rebecca 48 

Gary Huang, Kuan-Hsiang P20 

Garza, Dahlia 

P253 

Gay, Elizabeth P178 

Gaynor, J. William P131 

Gearhart, Christine P75 

Gee, Julie 43 

Gelow, Jill 

P313 

Georgiopoulou, Vasiliki 41, 88, P271, P287 

Germany, Robin P164 

Gersh, Bernard P276 

Gertz, Morie 52 

Ghashghaei, Roxana P245 

Ghotra, Amaninderapal P66, P84, P211 

Giedrimiene, Dalia P243 

Gilbert, Edward 48, P193 

Gilbert, Mark 

P93 

Gill, Natasha 

P122 

Gilotra, Nisha 

65, P17, P161, P326, P329 

Ginn, Greg 

P285 

Ginwalla, Mahazarin 53, P128, P159, P306, P307 

Giustino, Nina 79, P154 

Givertz, Michael 42, 63, P135, P280, P318 

Gjerde, Cecilie P216 

Gluck, Jason 

53, P41, P100, P315 

Gluck, Trenton P32, P42, P202, P305 

Go, Alan 42 

Godishala, Anuradha P218, P232 

Goel, Sunny 

P57 

Goldberg, Lee 

32, P75 

Golden, Lee 

P252 

Goldman, Steven P208 

Goldraich, Livia P163 

Goldsmith, Jeff P216 

Goldstein, Daniel P224, P236 

Goldstein, Nathan P216 

Goldwater, Deena P216 

Golwala, Harsh P273 

Gonçalves, I 

P26 

Gong, Jianjian P248 

Gong, Jim 

P86 

Goodlin, Sarah 44 

Gopal, Deepa 

41, P280 

Gopal, Vipin 

P113 

Gopinathannair, Rakesh P84 

Gordon, Glenna P175 

Gordon, Nicole P241 

Gorur, Arathi 

P324 

Gottesman, Rebecca P242 

Gottlieb, Stephen 54, 55 

Gradus-Pizlo, Irmina P117, P137 

Grady, Kathleen 45, P62 

Grandin, E. Wilson 41, P181 

Grant, Joan 

P175 

Graven, Lucinda P175 

Gravis, Edward P233, P234 

Grayburn, Paul 48 

Greenberg, Barry 37, 44, 46, 60, 102, P245 

Greenspon, Arnold P127 

Griffith, Bartley 49 

Groarke, John 

41, P280 

Grodin, Justin 

41, P34, P38, P194, P196, P198, P309 

Grogan, Martha P189, P217 

Gruson, Damien P39 

Guerrero-Miranda, Cesar P224 

Guerry, Roshni P302 

Guertin, Danette P243 

Gulati, Sanjeev P172 

Gupta, Divya 48 

Gupta, Kamal 48 

Gupta, Ramesh 52, P210 

Gutfinger, Dan P64 

Guthrie, Spencer P133 

Guzman, Eliscer P265 

Habtemariam, Daniel P118 

Hachamovitch, Rory P196 


121



Hadi, Azam 

P117, P137 

Hager, Martha 

P153 

Haines, David 

P124 

Haines, Mary 

P223 

Hajj, Jihane 

P166 

Hajjar, Roger 45 

Halkar, Meghana P196 

Hall, Shelley 48 

Halperin, Jonathan P241 

Halushka, Marc 53, P161 

Hamad, Eman 

P55, P145, P296 

Hammadah, Muhammad P19, P120, P188, P287 

Hammond, Eliza P193 

Hammond, Elizabeth P193 

Hammond, Jonathan 52 

Hammond, Jonathan P315 

Hankins, Shelley P168 

Harders, Gerald 49, P182 

Hardy, N. Chantelle 41, P297 

Hardy, Natalie C. P129 

Harmon, Cynthia P206 

Harsch, Manya P64 

Harshaw-Ellis, Karol 27, 33, 40 

Hasan, Ayesha P238 

Hasni, Farhan 

P168 

Hatano, Masaru P58, P214 

Haugh, Gilbert P113 

Hauptman, Paul 36, 51, 52, 57 

Hawwa, Nael 

P188 

Hay, Christine 53 

Haynes, Carol 

P197 

Hays, Allison 

P161 

Hazen, Stanely P38, P120 

Hedley, Jeffrey 41 

Hegde, Sheila 

P185 

Heidenreich, Paul 41, 60, P273 

Henderson, Cory P53, P65, P228 

Henderson, John P285 

Henry, Christine P210 

Henry, Timothy P252 

Heo, Seongkum 39, P330 

Hernandez, Adrian 33, 41, 57, P34, P129, P130, 

P197, P294, P297, 

Heroux, Alain 

P59 

Heublein, Denise P43, P267 

Heywood, Thomas J. 38, 62, P27 

Hiatt, Shirin 

P313 

Hicks, Albert 

P122 

Higgins, Robert P238 

Hiles, Natasha P328 

Hill, Joseph A. 47 

Ho, Carolyn 38 

Ho, Jennifer 31, 42 

Ho, Rady 

P112 

Hoatam, Gerard P324 

Hohl, Patrick 

P29 

Hoit, Brian 

P263 

Hollander, Seth 50 

Hollis, Ian 

P272 

Holly, Alexander P21 

Holmes, David P241 

Homer, Sarah 

P119, P146 

Horn, Evelyn 

P216 

Horng, Steven 

P142 

Horstmann, Erika P333 

Horwich, Tamara P158 

Hott, Brenda 

P162, P331 

Hottigoudar, Rashmi P84 

Houser, Steven 45, 49, 55 

Hsich, Eileen 

30, P318 

Huang, Paul 

P252 

Huber, Kenneth P241 

Hudson, Michelle P223 

Huggins, Gordon 53, P48, P270 

Huhn, Nicole 

P315 

Hummel, Scott 31 

Hunter, Claire 

P81 

Hunter, Wynn 

P197 

Huntley, Brenda 49 

Huntsinger, Mary P80 

Hupcey, Judith P125 

Hussain, Zeeshan P84, P211 

Hwang, Kyung-Kuk P266 

Ichiki, Tomoko P182 

Ige, Mobolaji 

53, P128 

Imamura, Teruhiko P58, P214 

Ingrassia, Joseph P293 

Irwin, Frank 

P50, P221 

Ishak, K. 

P250 

Iskandar, Muhammad Zaid P151 

Itescu, Silviu 

P252 

Itoh, Akinobu 

P231 

Iyer, Seethalakshmi P43 

Jackson, Gregory P196 

Jain, Amit 

P268 

Jani, Milena 

P51, P117, P137 

Janmohamed, Munir P186 

Januzzi, James 38, 46, 59 

Jeevanandam, Valluvan P53, P65, P77, P228 

Jefferies, John 

P31 

Jensen, Brian 

P272 

Jeon, Eun-Seok P301 

Jermyn, Rita A. 36 

Jessup, Mariell 31, 47, 60 


122



Johnson, Allen P27 

Johnson, Geoffrey P189 

Jones, Anna 

P324 

Jorde, Ulrich 

P224, P236 

Joseph, Susan 35 

Joyce, David 45 

Joyce, Emer 

41, P280 

Joyce, Wald 

P299 

Jr, Charles 

P60 

Ju, Christine 

41, P130 

Judge, Daniel 

53, P122 

Juneman, Elizabeth P208 

Jung, Miyeon 

P277 

Jurgens, Corrine 39, 50 

Juricek, Colleen P53, P65, P77, P228 

Kagan, Viktoriya P77 

Kalogeropoulos, Andreas 41, 48, P212, P239, P271, P287 

Kalya, Anantharam P176, P324 

Kam, Carmen 

P37 

Kamran, Hassan P292 

Kang, Seok-Min P301 

Kansal, Anuraag P250 

Kapadia, Shaival P92 

Kapa, Suraj 31 

Kapur, Navin 

39, 43, P69 

Kar, Saibal 

P241 

Karakas, Mehmet Fatih 49 

Karpawich, Peter P213 

Kasper, Edward 53 

Kass, David 32 

Kassotis, John 

P57 

Katikireddy, Chandra P190 

Kattan, Michael 41 

Kattea, Mohammad 53, P128 

Katz, Jason 

50, P272 

Katz, Stuart 

61, P111, P115 

Kawahara, Matt P32, P42, P202, P305 

Kay, W. Aaron P78 

Kazatsker, Mark 41 

Kazatsker, Mark P254 

Kazemian, Pedram P138, P140 

Keibel, Andrew P80 

Keichline, Lisa P302 

Keleti, Julianna 53 

Kelkar, Anita 

48, P212 

Kelly, Daniel 45 

Kelly, Jacob 

P197, P297 

Kelly, Linda 

P162, P331 

Kennedy, Jamie P160, P178 

Kennedy, Jamie P178 

Kennedy, Kevin P152 

Kent, David 

P270 

Keohane, Denis P22 

Ketkar, Sayali 

P119 

Kfoury, Abdalah 48, P193, P318 

Khair, Andrew P210 

Khayat, Rami 

P164 

Khouri, Michel P187 

Khouri, Samer P18, P200, P223 

Kiatchoosakun, Songsak P248 

Kielhorn, Adrian P95, P250, P297 

Kiernan, Michael 48, P69, P321 

Kihara, Yasuki P94 

Kilby, Susan 

P176 

Kilic, Ahmet 

P238 

kim, Chang 

53, P263 

Kim, Dong-Woon P266 

Kim, Elaine 

P139 

Kim, Gene 

P53, P65, P206, P228, P269 

Kim, Jae-Joong P108, P301 

Kim, John 

P201 

Kim, Min-Seok P108 

Kim, Sang Min P266 

Kim, So-Young P335 

Kimmelstiel, Carey P69 

Kingery, Joanna P117, P137 

Kinney, Gene 52 

Kinoshita, Osamu P58, P214 

Kinugawa, Koichiro P58, P214 

Kirby, Jennifer P160 

Kirkpatrick, James P235, P299 

Kitko, Lisa 

P125 

Klarich, Kyle 

P30 

Klein, Liviu 

P68 

Kleiner, Ilia 41 

Kleiner, Ilia 

42, P254 

Klenk, Juergen P127 

Kliethermes, Stephanie P59 

Klootwyk, J. 

P103 

Kluger, Jeffrey P243 

Ko, Yi-An 

P212 

Koch, Walter 

45, 49, 55, P256 

Kocheril, Abraham P314 

Kociol, Robb 

29, 32, 39, 43, 52, 56, P142 

Koczwara, Bogda 49, P109 

Koenig, Steven 49 

Koliopoulou, Antigone 48 

Koller, Martin 52 

Komajda, Michel P85, P90 

Konstam, Marvin 35, P270 

Kotadia, Arati 

P141 

Kottmann, Matthew P282 

Koullick, Maria P64 

Koulova, Anna P224 


123



Kowey, Peter 

P276 

Kramer, Daniel P118 

Kraus, William P197 

Krishnamurthy, Yamini 41, P227 

Krittanawong, Chayakrit P30 

Krotneva, Stanmira P250 

Kukin, Marrick P98 

Kullar, Vikas 

P308 

Kumar, Arun 

P209 

Kumar, Nilay 

P304 

Kumar, Sachin P128 

Kuruvilla, Sonia P107 

Lahood, Nicole P208 

Lai, Pikki 

41, P114 

Lainscak, Mitja P264 

Lakdawala, Neal 41 

Lakhter, Vladimir P55 

Lala, Anu 

P216 

Lalor, Katherine P147 

Lambiase, Pier 53, P332 

Lampert, Brent P238 

Lancaster, Jordan P208 

Landau, Heather 52, P133 

Lane, Kathleen P51 

Lanfear, David 52, P56, P63, P99, P195 

Lang, Chim 

P151 

Langholz, David 52 

Lanoza, Tracy 

P144 

Lanza, Gregory P231 

Larsen, Greg 

48, P126 

LaRue, Shane P72, P79, P218, P225, P226, 

P230, P231, P232, P244 

Laskar, S. Raja 48 

Latif, Faisal 

P317 

Lato, Marc 

P176 

Lau, Edmund 

P127, P281 

Laverty-Wilson, Eva P299 

Lavie, Carl 

P57 

Lavigne, Paul 

P230 

Lavin, Philip 

P246 

Lazar, Jason 

P57 

Le, Christopher P60 

Lebeis, Taylor 

P271 

Lee, Christopher P174, P303, P313 

Lee, Elizabeth 

P32, P36, P42, P202, P305 

Lee, Ju-Hee 

P266 

Lee, Sang Yeub P266 

Lee, Sheldon 

P37 

Lee, Whayoun P77 

Lefkowitz, Martin 41, P88 

Leher, Michael P324 

Lemonnier, Maxime P210 

Lenihan, Daniel 41, P33, P114, P199, P203 

Lenneman, Andrew P66, P84, P165, P211 

Leong, Gerard P37 

Leung, Cheuk 

P317 

Levin, Albert 

52, P195 

Levin, Allison 

P236 

Levin, Daniel 

P151 

LeWinter, Martin 34, P29 

Lewis, Bradley P83, P92, P327 

Lewis, Connie 31, 41, 50, P114 

Lewis, Eldrin 41 

Lewis, Gregory 38, P314 

Lexvold, Nancy P83, P92, P327 

Li, Dean 48 

Li, Jia 

52, P195 

Liedtke, Michaela 52 

Lin, Kimberly 

P131 

Lindsley, John P281 

Liner, Ann 

P263 

Little, Jane 

P159 

Little, Jane 

P306 

Liu, Longjian 

P166 

Longenecker, Chris 52 

Lopez Candales, Angel P24, P28, P192 

Lopez-Menendez, Francisco P24, P28 

Lousada, Isabelle P133 

Lowe, David 

P68 

Lowes, Brian 

P300 

Lozano, Pedro P317 

Lu, Di 

41, P273 

Luk, Adriana 

41, P280 

Lunde, Ottar 

P245 

Lundgren, Scott P157 

Lutfi, Forat 

P308 

Lyndon, Audrey 48 

Lyons, Kristin 

P158 

MacCarter, Dean P314 

Macedo, C 

P26 

Macfelda, Karin P21 

Mackall, Judith P240 

Macon, Conrad P130 

Madden, George P273 

Magalski, Anthony P152 

Magasi, Susan P62 

Mahaffey, Kenneth P276 

Mahr, Claudius P333 

Maisel, Alan 

57, P32, P36, P42, P202, P305 

Malhotra, Atul P32, P42 P202, P305 

Malik, Adnan 

P51, P117, P137 

Malik, Sonika 

48, P7 

Mallemeester, Melanie P210 

Man, Lillian 

P291 


124



Mangla, Ashvarya P136 

Manicardi, Marcella P186 

Mann, Douglas 44, 53, 55, P259 

ManriqueGarcia, Alvaro P240 

Manyam, Harish P240 

Margulies, Kenneth 45, P181 

Marhoover, Ronetta P153 

Marincic, Renee 48, P16 

Marks, Daniel 

P101 

Marks, Edward P209 

Maron, Martin 49, 68, P48 

Marroquin, Oscar P252 

Marston, Nick 

P36 

Martin, Linda 

P176 

Martin, Siobhan P154 

Martin, Spencer P100 

Martinka, Peter P89 

Maslanek, Wilhelmina P75 

Masoomi, Reza 48 

Massaro, Frank P321 

Massey, Todd 

P282 

Masson, Stephen P222 

Masterson Creber, Ruth P174 

Mathelier, Hansie P166 

Mather, Paul 

P112, P291 

Matlock, Daniel 48 

Maurer, Mathew 38, 42, P189, P216 

Maya, Juan 

P85, P297 

Mayo, Martha 

P253 

Mazimba, Sula P160, P178 

Mazur, Wojciech P31 

Mazurek, Jeremy P181 

Mazurek, Stefan P206 

McCall, Anthony P160 

McCants, Kelly P66 

McCarthy, Alexandra P109 

McClinton, Kira P176 

McCue, Andrew 41 

McCullough, Peter 35, P246 

McDonald, Michael P163 

McGarrah III, Robert P197 

McGrane-Minton, Heather P282 

McGregor, Jessina P126 

McIlvennan, Colleen 48 

McKellar, Stephen 48 

McMahon, Pamela P127 

McMurray, John 41, P34, P88, P248, P294 

McNamara, Dennis 34, 64, P40, P318 

McSweeney, Jean P330 

Mehanna, Emile P128 

Mehmood, Muddassir P31 

Mehra, Mandeep 40, 44, 51, 58, 62, P280 

Mehta, Hirsch 

P27 

Meisel, Simcha 42, P254 

Mejia, Erika 

P131 

Melenovsky, Vojtech P149 

Menon, Santosh P289, P328 

Mentz, Robert 

41, 64, P129, P294, P297 

Merkely, Bela 

P169, P332 

Merlini, Giampaolo P133 

Metra, Marco 

33, 51, P34, P135, P294 

Meyers-Fabian, Allison P223 

Meza, James 

P227 

Mihalek, Andrew P178 

Milano, Carmelo 41, P227 

Milinovich, Alex 41 

Miller, Dylan 

P193 

Miller, Edward P189 

Miller, Wayne 

62, P310 

Miner, Kathleen P150 

Minkove, Nicole P161 

Mitchell, Susan P118 

Miura, Masanobu P104, P105 

Miyata, Satoshi P104, P105 

Modany, Ashley P103 

Modi, Kalgi 

P318 

Moffa, Carolyn P302 

Mohamedali, Burhan P54, P73, P132, P136, P323 

Mohan, Rajeev P27 

Moisés, V 

P26 

Molina, Kim 

P193 

Molina, Maria 

P75 

Momomura, Shin-ichi P94 

Mondal, Nandan 49 

Mongrain, Ian 53 

Montan, Peter 

P265 

Montemayor, Kristina P161 

Moore, Meredith P162, P331 

Moranville, Michael P281 

Moravec, Christine P47 

Morgan, Jeffrey P56, P63 

Morris, Alanna 41, 48, P212, P239 

Morris, Daniel- A. P264 

Morris, Kathleen P51 

Morton, Christine 48 

Mosley, Thomas P185 

Moss, Noah 

P121 

Motie, Marjan 

P106 

Moukabary, Talal P208 

Moukarbel, George P18, P223 

Moyer, Mary 

P235 

Mudd, James 

P313 

Mueller, Johannes P21 

Muhammad Iqbal, Abdul Hafidz P151 


125



Mukamal, Kenneth P142 

Mukherjee, Debabrata P57 

Mullens, Wilfried 54, 64, P194 

Muller, David 

P74, P138, P140, P143 

Mundayat, Rajiv P22 

Murks, Catherine P269 

Murphy, Andrea P100 

Nagatomo, Yuji P40, P47 

Najafi, Amir 

P190 

Naksuk, Niyada P30 

Nambi, Vijay 

P44 

Narula, Arvin 

P27 

Nasir, Saifullah P292 

Nassif, Michael 48, P72, P79, P218, P225, P226, 

P230, P231, P232, P244 

Natarajan, Sundar P115 

Nativi-Nicolau, Jose 42, 48 

Nawata, Kan 

P58, P214 

Nelson, Jennifer P314 

Nemeh, Hassan P56, P63 

Neuzil, Petr 

P241 

Neville, Susan P285 

Newgard, Christopher P197 

Newton, Abigail P153 

Ney, Blaine 

P116 

Ngarajan, Vijay P309 

Nguyen, Duc 48 

Nguyen, Jenni 

P236 

Nguyen, Peter 

P292 

Nicolais, Charles P296 

Nitta, Daisuke 

P58, P214 

Njoroge, Joyce P263 

Nochioka, Kotaro P104, P105 

Nohria, Anju 41 

Nolan, Niamh 

P199 

Norby, Faye 

P242 

Normand, Valérie 53 

Noubary, Farzad P270 

Novak, Eric 

P218, P230, P244 

Obalampalli, Kalyan P143 

O'Bara, Lynn 

P100 

Obi, Engels 

P274 

O'Brien, Thomas P289 

O'Connor, Christopher 32, 35, 43, 51, 60, P34, P135, P294 

O'Connor, Matthew P131 

O'Connor, Nina P235 

O'Donnell, Arden P134 

Oh, Byung-Hee P301 

Oh, Jaewon 

P301 

Ohte, Nobuyuki P102 

Okwuosa, Ike 

P326, P329 

Oliveira, Guilherme 30, 52, 53, P128, P159, P263, 

P306, P307 

Oliver-McNeil, Sandra P124 

Oliveros, Estefania P55, P145 

Olson, Andrew P23 

Olson, Lyle 

P83, P92, P327 

Ong, Moh-Lim P22 

Ono, Minoru 

P58, P214 

Onose, Takeo 

P104, P105 

Onwuanyi, Anekwe P35 

Onyebeke, Chukwuma 42, P96, P179, P184, P198 

Ordway, Linda 48 

O'Rourke, Brian 49 

Ota, Takeyoshi P53, P65, P77, P228 

Otani, Niels 

P123 

Ounpraseuth, Songthip P330 

Overbeck, Heather P328 

Owens, Anjali 

P75 

Packer, Milton 32, 41, 56, P88, P248 

Padhukasahasram, Badri 52 

Pak, Esther 

P299 

Palm, Denada 

P24, P28 

Pamirsad, Mustafa P236 

Pandey, Ambarish P187 



Pang, Peter 

33, P129 

Panjrath, Gurusher P61, P67, P70, P76 

Papadimitriou, Lampros P271 

Paridon, Stephen P131 

Park, Chan Seok P25 

Park, Hannah 

P111 

Park, Soon 

P128 

Paruchuri, Vikram P69 

Patel, Ameet 

P308 

Patel, Bhavin 

P317 

Patel, Chetan 

41, P227, P294 

Patel, Harshali P250, P297 

Patel, Jasmine 

P127 

Patel, Kershaw P53, P65, P77, P228 

Patel, Nish 

P130 

Patel, Samir 

P284 

Patel, Snehal 

P224, P236 

Patel, Vaiibhav P218, P226 

Patey, Megan 

P174 

Pattanshetty, Deepak 48 

Patton, Carol 

P166 

Pauly, Daniel 

P40 

Peacock, W. Frank 58, P129 

Peeraphatdit, Thoetchai P30 

Pei, Huang 

P37 

Pellicori, Pierpaolo P264 

Perez, Antonio P180 


126



Perez, Rafael 

P211 

Perin, Emerson P252 

Peshock, Ronald P187 

Peters, Anthony P272 

Peterson, Edward P99 

Peterson, Eric 

41, P276 

Petrilli, A 

P26 

Pfaender, Lynn P220 

Pham, Duc Thinh P69 

Pham, Si 49 

Phillips, Gary 

P238 

Phillips, Michael 53 

Piatkowsky, Gail P142 

Piccini, Jonathan P276 

Picel, Katherine P155 

Pierce, Brian 

P226, P232 

Piña, Ileana 

46, 52, 62, P246 

Pinckney, Richard P29 

Pinney, Sean 

58, 86, 101, P216 

Pinto, G 

P26 

Pitt, Bertram 

46, 48, 55, P253 

Platts, Anne 

P225 

Pleister, Adam P164 

Pletke, Patricia P153 

Pocock, Stuart P95 

Ponikowski, Piotr P135 

Porter, Adam 

P134 

Powell, Lynda 

P136 

Preidt, Tracy 

P328 

Prescott, Margaret P248 

Pressler, Susan P277 

Pretorius, Victor P219 

Price, John 

P66 

Price, Mathew P241 

Provost, Sylvie 53 

Psotka, Mitchell P135 

Pudlo, Michael P119, P146 

Purcell, Scott 

P222 

Qattan, Marwan P263 

Quale, Cindy 

P126 

Querejeta Roca, Gabriela P185 

Radhakrishnan, Priya P324 

Radojevic, Joseph P100 

Ragupathi, Loheetha P291 

Raheja, Suraj 

31, P56, P63 

Raichlin, Eugenia P300 

Rajagopal, Vivek P220 

Rakita, Val 

P55 

Raman, Subha P31 

Rame, Eduardo 40, 41, P131, P181, P299 

Rao, MD, Praveen P244 

Ras, Aleksandra 53, P41 

Rasmussen, Henrik P246 

Rasmusson, Kismet P318 

Rath, Rutwik 

P49 

Raymer, David 48, P72, P79, P218, P225, P226, 

P230, P231, P232 

Reddy, Siddharth P101 

Reddy, Vivek 

41, P241 

Reddy, Yogesh P149 

Redfield, Margaret 31, 36, 64, P217, P267 

Reed, Shelby 

P297 

Reeves, Gordon P216 

Regan, James 

P23 

Regan, Karen 

P91 

Reichert, William P324 

Reid, Bruce 48 

Renda, Andrew P113 

Rennyson, Stephen P153 

Revelo, Monica P193 

Reyentovich, Alex P216 

Reynolds, Matthew P118 

Rials, Seth 

P169 

Ricci, Paola 

P30 

Rich, Michael 45, 48 

Richardson, DeJuran P136 

Ridha, Mustafa P107 

Riegel, Barbara 39, P174 

Riley, Penny 

P277 

Riley, Tiana 

P269 

Rinka, Joseph 

P333 

Rivers, Christina P154 

Robbins, Nathan P93 

Roberts, John 

P186 

Roberts, Lewis P30 

Robertson, Michele P90 

Rodeheffer, Richard P204, P267 

Roder, David 

P109 

Rodgers, Daniel P53 

Rogers, Jennifer P95 

Rogers, Joseph 41 

Rome, Eric 

P300 

Romero, Michael P222 

Rongione, Anthony P67, P70, P76 

Rosner, Carolyn P67, P70, P76 

Ross, Angela 

P154 

Ross, Heather 

47, P163 

Rossano, Joseph P131 

Rouleau, Jean 

41, 53, P88, P248 

Rousseau, Michel P39 

Rowe, Theresa P168 

Rubens, Fraser P64 

Rubenson, David P27 

Ruberg, Frederick P189 


127



Rubinstein, Jack 49, P93 

Ruedlinger, Holly P77 

Ruel, Marc 

P64 

Ruhl, Kayla 

P126 

Rumsfeld, John P167 

Rupani, Hetal 

P141 

Russell, Stuart 44, 52, 53, P17, P122, P141, 

P161, P262, P326, P329 

Russo, Patricia P274 

Ryzhov, Sergey P49 

Sabbah, Hani 

36, 52, P99, P195, P210 

Sadarangani, Tina P115 

Sadhu, Justin 48 

Saeed, Omar 

P224, P236 

Saiki, Hirofumi P217 

Sakata, Yasuhiko P104, P105 

Saltzberg, Mitchell 41, 68, P302 

Sam, Flora 

38, 61, P201 

Samsky, Marc 

P294 

Samuel, Michelle P118 

Sanchez, Pablo P208 

Sandberg, Sarah P244 

Sandek, Anja 

P264 

Sangaralingham, Jeson 49, P182, P204 

Sanil, Yamuna P213 

Santos, Maria 

P26 

Saracino, Giovanna 48 

Sarmiento, Kathleen P32, P42, P202, P305 

Sarswat, Nitasha P53, P65, P228 

Sato, Kenjiro 

P104, P105 

Saurav, Alok 

P81 

Sawyer, Douglas 45, P49, P203 

Saxon, Leslie 

P80 

Sayer, Gabriel 

P53, P65, P77, P228, P269 

Schaefer, Kristen P134 

Schandera, Johanna P245 

Scheiner, Avram P71 

Scheinin, Scott P233 

Schenck, Louis P83, P92, P327 

Schilling, Joel 

P230 

Schilz, Robert 

P159, P306 

Schimmel, Melanee P245 

Schmidt, Emily P324 

Schmiege, Sarah P167 

Schmier, Jordana P127 

Schnobrich, Daniel P23 

Schroder, Jacob 41, P227 

Schulte, Philip P130, P273, P294, P297 

Schumacher, Jennifer 65, P22 

Schumacher, Sarah P256 

Schwann, Thomas P223 

Schwartz, Daniel P55, P145, P296 

Schwartz, Jefferey P59 

Scott, Christopher P204, P267, P268 

Scott, Michael P231 

Sean, Hawkey 

P151 

Seino, Yoshihiko P94 

Selby, Van 

P186 

Seldin, David 52 

Selektor, Yelena P56, P63 

Selzman, Craig 48 

Senni, Michele P86 

Sethares, Kris 

P171 

Shaddy, Robert P131 

Shafiq, Qaiser 

P18, P200 

Shah, Adnan 

P199 

Shah, Amil 

P185, P242 

Shah, Arpit 

P98 

Shah, Ashish 

P122, P138 

Shah, Mahek 

P20 

Shah, Nishant 

P161 

Shah, Palak 

P70, P76 

Shah, Riddhi 

P140 

Shah, Sachin 

41, P280 

Shah, Svati 

52, 53, P197 

Shah, Zubair 

48, P61 

Sharma, Abhishek P57 

Sharma, Kavita 52, P122, P262 

She, Ruicong 

P195 

Sheffield, Erin P220 

Sheiner, Patricia P41 

Shen, Changyu P51 

Sheppard, Richard P40, P318 

Sherazi, Saadia 52 

Shi, Victor 

41, P86, P88, P248 

Shimokawa, Hiroaki P104, P105 

Shin, Julia 

P224 

Shinbane, Jerold P80 

Shiose, Akira 

P55, P145 

Shirazi, Jonathan P51 

Shisler, David 

P199 

Shochat, Michael 42, P254 

Shotan, Avraham 42, P254 

Shpigel, Adam P161, P326, P329 

Shrader, Peter 

P129, P276 

Shrestha, Kevin P188 

Shutze Jr, William 48 

Sibulo Jr, Antonio P248 

Siddegowda Bangalore, Bhavana P18, P200 

Sievert, Horst 

P241 

Silber, Harry 

P17 

Silver, Elizabeth P41 

Silverman, Michael P262 

Silvestry, Scott 48, P72, P225, P231 


128



Simon, Jennifer 42, 53, P96, P179, P184, P196, P198 

Simon, Joel 

P78 

Sims, Daniel 

P224, P236 

Sing-Gupta, Vinita 52 

Singh, Aaron 

P37 

Singh, Bhupinder P246 

Singh, Harleen P126 

Singh, Manmeet P190 

Singh, Ramesh P67, P70, P76 

Singleton, Paula 48 

Skarupski, Kimberly P329 

Sklenar, Jiri 

P123 

Slabaugh, Lane P113 

Slaughter, Mark 49, P66, P84, P165, P211 

Sloan, Joanne 

P151 

Slovut, David 

P82, P183, P191 

Smer, Aiman 

P81 

Smith, Andrew 41, 48, P212, P239, P271 

Smith, LaVone P160 

Smith, Michael P27 

Smith, Sakima P238 

Snipas, Diane 

P168 

Snow, Greg 

P193 

Soares, J 

P26 

Sobieski, Mike 49 

Sokos, George P103 

Soliman, Medhat P107 

Solomon, Scott 56, P88, P185, P242, P248 

Somers, Virend P83, P92, P327 

Soucier, Richard P293 

Soujeri, Bayan P151 

Sparrow, Christopher 27, P218, P230, P232 

Spilias, Nikolaos P271 

Squire, Iain 

P248 

Sridhar, Arun 

48, P61 

Stabler, Ruth 

P168 

Starling, Randall 40, P34, P40, P88, P194, P196, P294 

Stasch, Johannes-Peter 32, P267 

Stasiv, Yuri 

P253 

Statz, Cara 

53, P41 

Steahr, Gregg 

P162, P331 

Steenbergen, Charles 53 

Stehlik, Josef 48 

Stevens, Gerin P122 

Stevenson, Lynne 32, 47, 57, P134 

Stewart, Garrick P280 

Stewart, Graham P151 

Stöckl, Georg 

P89 

Stollar, K. 

P103 

Storozynsky, Eugene 53 

Struck, Joachim P36 

Stutman, Patricia P75 

Su, Yan Ru 

P203 

Suarez, Erik 

P45 

Svetlichnaya, Jana P186 

Swarup, Vijay 

P241 

Swedberg, Karl 41, P88, P90, P248 

Sweeney, Robert P169, P332 

Swindle, Jason P274 

Sylvia, Lynne 

P321 

Szklo, Moyses P262 

Tadaki, Soichiro P104, P105 

Tahhan, Ayman 41 

Tahir, Usman 

P201 

Taka, Nchang 

P35 

Takahashi, Jun P104, P105 

Tallaj, Jose 

P178 

Tamrat, Ruth 

P326, P329 

Tan, Puay Joo 

P37 

Tang, W. H. Wilson 41, 52, 53, P19, P34, P38, P40, 

P47, P120, P180, P188, P194, 

P196, P198, P287, P294, P309 

Tao, Jiang 

P50, P221 

Taub, Cynthia 

P82, P183, P191 

Tavazzi, Luigi 

P85, P90 

Taylor, David 

P194 

Taylor, Michael P31 

Taylor, Stanley P51 

Tedford, Ryan 

52, P17, P122, P181 

Teerlink, John 

41, 60, P135, P294 

Teeter, Larry 

P233, P234 

Tellor, Bethany 48 

Templin, Thomas P124 

Tereshchenko, Larisa P123 

Tesmer, John 

P256 

Testani, Jeffrey 42, 53, 59, 62, P96, P142, P179, 

P184, P196, P198 

Teuteberg, Jeffrey 32, 58, P238 

Thadani, Udho P317 

Thandra, Vidya P240 

Thomas, Laine P276 

Thompson, Jocelyn 48 

Thompson, Julie P52 

Thongprayoon, Charat P30 

Tibrewala, Anjan 48, P72, P79 

Tikhomirov, Oleg P49 

Tita, Cristina 

P56, P63 

Titler, Marita 

P277 

Todd, John 

P199 

Tomasek, Kelsey P203 

Ton, Van-Khue 53, P161 

Tong, Khim Leng P37 

Torabi, Sahar 

P114 

Torre-Amione, Guillermo 49, P44, P45, P46, P233, P234, 


129



P279, P295 

Toyoda, Yoshiya P55, P145 

Trachtenberg, Barry 49, P44, P45, P233, P234, P279, 

P284, P295 

Tran, Hao 

P219 

Traverse, Jay 

P252 

Troutman, Gregory P181 

Tsai, Pao-Feng P330 

Tsuji, Kanako 

P104, P105 

Turner, Stuart 

P274 

Turrentine, Mark P78 

Ullah, Shahid 

P109 

Ullman, Edward P142 

Um, John 

P300 

Unterberger, Kate P126 

Upshaw, Jenica P270 

Uribe, Cesar 

49, P44, P45, P46, P279 

Uriel, Nir 

30, 40, 58, P53, P65, P77, P228, P269 

Ushigome, Ryoichi P104, P105 

Vader, Justin 48, P72, P79, P218, P225, P226, 

P230, P231, P232 

Vader, MD, Justin P244 

Vaidya, Anjali 

P181 

Vakrou, Stella 49 

Vallabhan, Ravi 48 

Vallakati, Ajay P57, P101 

Vardeny, Orly 

41, 56, 58, P333 

Varghese, Smitha P107 

Varian, Kenneth 41 

Varnado, Sara 

P300 

Vega, David 

48, P212, P239 

Velazquez, Eric 40, 49, P197, P297 

Velez, Mauricio P56, P63 

Verbrugge, Frederik 41, P38, P194 

Verdino, Ralph 41 

Vest, Amanda 48 

Vilaro, Juan 

P308 

Vinereanu, Dragos P248 

Vitoff, Paji 

P52 

Vollmer, Marcus P123 

von Haehling, Stephan P264 

Voors, Adriaan P34, P135, P294 

Vorovich, Esther P75 

Vos, Kevin 

P173 

Wacha, Lynn 

P274 

Walker, Donna 48 

Walker, Mike 

P163 

Walling, Jackie 52 

Walsh, Kayley P134 

Walter, C. 

P103 

Wand, Alison 41 

Wang, I-Wen 

P51, P78 

Wang, Mengjun P210 

Wang, Yun 

P195 

Warman, Eduardo P298 

Warner, Patrick P48 

Waters, Sarah 

P272 

Wayangankar, Siddharth P317 

Weber, Malory P19 

Webster, Julie 

P116, P220 

Wehrenberg, Scott P332 

Weigand, Kyle P208 

Weinstein, Jean P170 

Weir, Matthew P253 

Weiss, Brendan 52 

Wells, Karen 

P99 

Wencker, Detlef 52, P41 

Westlake, Cheryl P171 

Wever Pinzon, James 48 

Whisenant, Brian P241 

Whitman, Glenn P122 

Whitmarsh, Kelly 41, P302 

Whitson, Bryan P238 

Wieselthaler, Georg P68 

Wiley, Mark 48 

William, Basem P263 

Williams, Celeste P56, P63 

Williams, Keoki 52, P99, P195 

Williams, Mary P75 

Williams, Dominique P244 

Wilson, Jamie 

P263 

Wittstein, Ilan 

52, P17, P122 

Woiciechowski, Melissa P293 

Woldemichael, Kirubel 49 

Woods-Stroup, Tashua P328 

Wu, Charlotte 

P50, P221 

Wu, Yuna 

P85 

Wu, Yuping 

P196 

Wu, Zhongjun 49 

Xu, Bin 

52, P255 

Yamauchi, Takeshi P104, P105 

Yan, Cao 

Yancy, Clyde 

41, P37, P62, P130, P262, P273 

Yang, Alex 

P246 

Yao, Francis 

P186 

Yasumura, Yoshio P94 

Yazdani, Mariyah 41, P271 

Yeboah, Joseph P262 

Yeo, Daniel 

P188 

Yiu, Karen 

P281 

Yokoyama, Hiroyuki P94 

Yoo, Byung-Su P301 

Yost, Gardner 

P54, P73, P132, P323 

Youker, Keith 

49, P44, P45, P46, P279 


130



Younes, Ahmad P159, P306, P307 

Young, Michelle P134 

Yousem, David P329 

Yuzefpolskaya, Melana P216 

Zakariea, Khalid P107 

Zalawadiya, Sandip P33 

Zalewski, Christyna P299 

Zamani, Payman 41, P75, P181, P245 

Zeld, Nicole 

52, P99, P195 

Zelin, Kathleen P213 

Zhang, Kefei 

P210 

Zhang, Yi 

P52, P169, P332 

Zhao, Daniel 

P317 

Zhao, Huaqing P55 

Zhian, Samaneh P126 

Zhu, Weizhong P256 

Zile, Michael 

41, 52, P88, P248 

Zimmerman, Sandra P168 

Zonder, Jeffrey 52 

Zsilinszka, Reka P129 

Zugck, Christian P89 


131

Hotel Overview 



132


Prince George's Exhibition Hall 

Convention Center Level 1 

Ballrooms & Chesapeake Conference Rooms 



133


National Harbor Conference Rooms 


Hotel within a Hotel 

Hotel Meeting Space Level 2 


134


Notes 


135


Notes 


136


Notes 


137


Notes 

SEPTEMBER 26-29 

NATIONAL HARBOR, MARYLAND 

138


2015-2016 Calendar ........................................................................................................................................................ 

HFSA Dates to Remember 

3rd Biennial Comprehensive 

Review and Update Course 

October 22-25, 2015 

Sheraton Tampa East 

Tampa, FL 

 

September 17-20, 2016 

Gaylord Palms 

Orlando, FL 

 

September 16-19, 2017 

Gaylord Texan 

Grapevine, TX 

Review 

Course 

October 2015 

S M T W T F S 

1 2 3 

4 5 6 7 8 9 10 

11 12 13 14 15 16 17 

18 19 20 21 22 23 24 

25 26 27 28 29 30 31 

November 2015 

S M T W T F S 

1 2 3 4 5 6 7 

8 9 10 11 12 13 14 

15 16 17 18 19 20 21 

22 23 24 25 26 27 28 

29 30 

December 2015 

S M T W T F S 

1 2 3 4 5 

6 7 8 9 10 11 12 

13 14 15 16 17 18 19 

20 21 22 23 24 25 26 

27 28 29 30 31 

January 2016 

S M T W T F S 

1 2 

3 4 5 6 7 8 9 

10 11 12 13 14 15 16 

17 18 19 20 21 22 23 

24 25 26 27 28 29 30 

31 

February 2016 

S M T W T F S 

1 2 3 4 5 6 

7 8 9 10 11 12 13 

14 15 16 17 18 19 20 

21 22 23 24 25 26 27 

28 29 

March 2016 

S M T W T F S 

1 2 3 4 5 

6 7 8 9 10 11 12 

13 14 15 16 17 18 19 

20 21 22 23 24 25 26 

27 28 29 30 31 

April 2016 

S M T W T F S 

1 2 

3 4 5 6 7 8 9 

10 11 12 13 14 15 16 

17 18 19 20 21 22 23 

24 25 26 27 28 29 30 

May 2016 

S M T W T F S 

1 2 3 4 5 6 7 

8 9 10 11 12 13 14 

15 16 17 18 19 20 21 

22 23 24 25 26 27 28 

29 30 31 

June 2016 

S M T W T F S 

1 2 3 4 

5 6 7 8 9 10 11 

12 13 14 15 16 17 18 

19 20 21 22 23 24 25 

26 27 28 29 30 

July 2016 

S M T W T F S 

1 2 

3 4 5 6 7 8 9 

10 11 12 13 14 15 16 

17 18 19 20 21 22 23 

24 25 26 27 28 29 30 

31 

August 2016 

S M T W T F S 

1 2 3 4 5 6 

7 8 9 10 11 12 13 

14 15 16 17 18 19 20 

21 22 23 24 25 26 27 

28 29 30 31 

Note: meeting starts on Saturday 

Annual 

Scientific 

Meeting 

September 2016 

S M T W T F S 

1 2 3 

4 5 6 7 8 9 10 

11 12 13 14 15 16 17 

18 19 20 21 22 23 24 

25 26 27 28 29 30 

SEPTEMBER 26-29 

NATIONAL HARBOR, MARYLAND 

139

ENTRESTO (sacubitril and valsartan) tablets, for oral use 

Initial U.S. Approval: 2015 

BRIEF SUMMARY: Please see package insert for full prescribing information. 

WARNING: FETAL TOXICITY 

• When pregnancy is detected, discontinue ENTRESTO as soon as possible 

(5.1) 

• Drugs that act directly on the renin-angiotensin system can cause injury 

and death to the developing fetus (5.1) 

1 INDICATIONS AND USAGE 

1.1 Heart Failure 

ENTRESTO is indicated to reduce the risk of cardiovascular death and 

hospitalization for heart failure in patients with chronic heart failure (NYHA 

Class II-IV) and reduced ejection fraction. 

ENTRESTO is usually administered in conjunction with other heart failure 

therapies, in place of an ACE inhibitor or other ARB. 

4 CONTRAINDICATIONS 

ENTRESTO is contraindicated: 

• in patients with hypersensitivity to any component 

• in patients with a history of angioedema related to previous ACE inhibitor 

or ARB therapy [see Warnings and Precautions (5.2)] 

• with concomitant use of ACE inhibitors. Do not administer within 36 hours 

of switching from or to an ACE inhibitor [see Drug Interactions (7.1)] 

• with concomitant use of aliskiren in patients with diabetes [see Drug 

Interactions (7.1)]. 

5 WARNINGS AND PRECAUTIONS 

5.1 Fetal Toxicity 

ENTRESTO can cause fetal harm when administered to a pregnant woman. 

Use of drugs that act on the renin-angiotensin system during the second 

and third trimesters of pregnancy reduces fetal renal function and increases 

fetal and neonatal morbidity and death. When pregnancy is detected, consider 

alternative drug treatment and discontinue ENTRESTO. However, if 

there is no appropriate alternative to therapy with drugs affecting the reninangiotensin 

system, and if the drug is considered lifesaving for the mother, 

advise a pregnant woman of the potential risk to the fetus [see Use in 

Specific Populations (8.1)]. 

5.2 Angioedema 

ENTRESTO may cause angioedema. In the double-blind period of 

PARADIGM-HF, 0.5% of patients treated with ENTRESTO and 0.2% of 

patients treated with enalapril had angioedema [see Adverse Reactions 

(6.1)]. If angioedema occurs, discontinue ENTRESTO immediately, provide 

appropriate therapy, and monitor for airway compromise. ENTRESTO must 

not be re-administered. In cases of confirmed angioedema where swelling 

has been confined to the face and lips, the condition has generally resolved 

without treatment, although antihistamines have been useful in relieving 

symptoms. 

Angioedema associated with laryngeal edema may be fatal. Where there is 

involvement of the tongue, glottis or larynx, likely to cause airway obstruction, 

administer appropriate therapy, e.g., subcutaneous epinephrine/ 

adrenaline solution 1:1000 (0.3 mL to 0.5 mL) and take measures necessary 

to ensure maintenance of a patent airway. 

ENTRESTO has been associated with a higher rate of angioedema in Black 

than in non-Black patients. 

Patients with a prior history of angioedema may be at increased risk of 

angioedema with ENTRESTO [see Adverse Reactions (6.1)]. ENTRESTO 

should not be used in patients with a known history of angioedema related 

to previous ACE inhibitor or ARB therapy [see Contraindications (4)]. 

5.3 Hypotension 

ENTRESTO lowers blood pressure and may cause symptomatic hypotension. 

Patients with an activated renin-angiotensin system, such as volumeand/or 

salt-depleted patients (e.g., those being treated with high doses of 

diuretics), are at greater risk. In the double-blind period of PARADIGM-HF, 

18% of patients treated with ENTRESTO and 12% of patients treated with 

enalapril reported hypotension as an adverse event [see Adverse Reactions 

(6.1)], with hypotension reported as a serious adverse event in approximately 

1.5% of patients in both treatment arms. Correct volume or salt 

depletion prior to administration of ENTRESTO or start at a lower dose. If 

hypotension occurs, consider dose adjustment of diuretics, concomitant 

antihypertensive drugs, and treatment of other causes of hypotension (e.g., 

hypovolemia). If hypotension persists despite such measures, reduce the 

dosage or temporarily discontinue ENTRESTO. Permanent discontinuation 

of therapy is usually not required. 

5.4 Impaired Renal Function 

As a consequence of inhibiting the renin-angiotensin-aldosterone system 

(RAAS), decreases in renal function may be anticipated in susceptible 

individuals treated with ENTRESTO. In the double-blind period of 

PARADIGM-HF, 5% of patients in both the ENTRESTO and enalapril groups 

reported renal failure as an adverse event [see Adverse Reactions (6.1)]. 

In patients whose renal function depends upon the activity of the reninangiotensin-aldosterone 

system (e.g., patients with severe congestive heart 

failure), treatment with ACE inhibitors and angiotensin receptor antagonists 

has been associated with oliguria, progressive azotemia and, rarely, acute 

renal failure and death. Closely monitor serum creatinine, and down-titrate 

or interrupt ENTRESTO in patients who develop a clinically significant 

decrease in renal function [see Use in Specific Populations (8.7) and Clinical 

Pharmacology (12.3) in the full prescribing information]. 

As with all drugs that affect the RAAS, ENTRESTO may increase blood urea 

and serum creatinine levels in patients with bilateral or unilateral renal 

artery stenosis. In patients with renal artery stenosis, monitor renal function. 

5.5 Hyperkalemia 

Through its actions on the RAAS, hyperkalemia may occur with ENTRESTO. 

In the double-blind period of PARADIGM-HF, 12% of patients treated with 

ENTRESTO and 14% of patients treated with enalapril reported hyperkalemia 

as an adverse event [see Adverse Reactions (6.1)]. Monitor serum potassium 

periodically and treat appropriately, especially in patients with risk factors 

for hyperkalemia such as severe renal impairment, diabetes, hypoaldosteronism, 

or a high potassium diet. Dosage reduction or interruption of 

ENTRESTO may be required [see Dosage and Administration (2.1) in the 

full prescribing information]. 

6 ADVERSE REACTIONS 

Clinically significant adverse reactions that appear in other sections of the 

labeling include: 

• Angioedema [see Warnings and Precautions (5.2)] 

• Hypotension [see Warnings and Precautions (5.3)] 

• Impaired Renal Function [see Warnings and Precautions (5.4)] 

• Hyperkalemia [see Warnings and Precautions (5.5)] 

6.1 Clinical Trials Experience 

Because clinical trials are conducted under widely varying conditions, 

adverse reaction rates observed in the clinical trials of a drug cannot be 

directly compared to rates in the clinical trials of another drug and may not 

reflect the rates observed in practice. 

In the PARADIGM-HF trial, subjects were required to complete sequential 

enalapril and ENTRESTO run-in periods of (median) 15 and 29 days, 

respectively, prior to entering the randomized double-blind period comparing 

ENTRESTO and enalapril. During the enalapril run-in period, 1,102 patients 

(10.5%) were permanently discontinued from the study, 5.6% because of 

an adverse event, most commonly renal dysfunction (1.7%), hyperkalemia 

(1.7%) and hypotension (1.4%). During the ENTRESTO run-in period, an 

additional 10.4% of patients permanently discontinued treatment, 5.9% 

because of an adverse event, most commonly renal dysfunction (1.8%), 

hypotension (1.7%) and hyperkalemia (1.3%). Because of this run-in 

design, the adverse reaction rates described below are lower than expected 

in practice. 

In the double-blind period, safety was evaluated in 4,203 patients treated 

with ENTRESTO and 4,229 treated with enalapril. In PARADIGM-HF, patients 

randomized to ENTRESTO received treatment for up to 4.3 years, with a 

median duration of exposure of 24 months; 3,271 patients were treated for 

more than one year. Discontinuation of therapy because of an adverse event 

during the double-blind period occurred in 450 (10.7%) of ENTRESTO 

treated patients and 516 (12.2%) of patients receiving enalapril. 

Adverse reactions occurring at an incidence of ≥5% in patients who were 

treated with ENTRESTO in the double-blind period are shown in Table 1. 

Table 1: Adverse Reactions Reported in ≥5% of Patients Treated with 

ENTRESTO in the Double-Blind Period 

ENTRESTO Enalapril 

(n = 4,203) (n = 4,229) 

% % 

Hypotension 18 12 

Hyperkalemia 12 14 

Cough 9 13 

Dizziness 6 5 

Renal failure/acute renal failure 5 5 

In the PARADIGM-HF trial, the incidence of angioedema was 0.1% in both 

the enalapril and ENTRESTO run-in periods. In the double-blind period, the 

incidence of angioedema was higher in patients treated with ENTRESTO 

than enalapril (0.5% and 0.2%, respectively). The incidence of angioedema 

in Black patients was 2.4% with ENTRESTO and 0.5% with enalapril [see 

Warnings and Precautions (5.2)]. 

Orthostasis was reported in 2.1% of patients treated with ENTRESTO compared 

to 1.1% of patients treated with enalapril during the double-blind 

period of PARADIGM-HF. Falls were reported in 1.9% of patients treated 

with ENTRESTO compared to 1.3% of patients treated with enalapril.

Laboratory Abnormalities 

Hemoglobin and Hematocrit 

Decreases in hemoglobin/hematocrit of >20% were observed in approximately 

5% of both ENTRESTO- and enalapril-treated patients in the doubleblind 

period in PARADIGM-HF. 

Serum Creatinine 

Increases in serum creatinine of >50% were observed in 1.4% of patients 

in the enalapril run-in period and 2.2% of patients in the ENTRESTO 

run-in period. During the double-blind period, approximately 16% of both 

ENTRESTO- and enalapril-treated patients had increases in serum creatinine 

of >50%. 

Serum Potassium 

Potassium concentrations >5.5 mEq/L were observed in approximately 4% 

of patients in both the enalapril and ENTRESTO run-in periods. During the 

double-blind period, approximately 16% of both ENTRESTO- and enalapriltreated 

patients had potassium concentrations >5.5 mEq/L. 

7 DRUG INTERACTIONS 

7.1 Dual Blockade of the Renin-Angiotensin-Aldosterone System 

Concomitant use of ENTRESTO with an ACE inhibitor is contraindicated 

because of the increased risk of angioedema [see Contraindications (4)]. 

Avoid use of ENTRESTO with an ARB, because ENTRESTO contains the 

angiotensin II receptor blocker valsartan. 

The concomitant use of ENTRESTO with aliskiren is contraindicated in 

patients with diabetes [see Contraindications (4)]. Avoid use with aliskiren 

in patients with renal impairment (eGFR

LCZ696 is 

Now Approved as... 

vISIT uS AT BooTh 301! 

visit www.EntrestoHCP.com Learn more about ENTrEsTo request samples 

please see Brief Summary of prescribing Information, including Boxed wArNING, on previous pages.

LCZ696 is 

Now Approved as... 

vISIT uS AT BooTh 301! 

visit www.EntrestoHCP.com Learn more about ENTrEsTo request samples 

please see Brief Summary of prescribing Information, including Boxed wArNING, on previous pages. 

ENTREsTO is a trademark of Novartis aG. 

Novartis Pharmaceuticals Corporation 

East Hanover, New Jersey 07936-1080 © 2015 Novartis 8/15 ETr-1320770

PROGRAM

Create successful ePaper yourself

Delete template?

Save as template?